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Adult mesenchymal stem cells (MSC) are multipotential cells which can differentiate 
into various cell types thus giving them utility in tissue engineering regenerative 
medicine and cell-based therapies. Use of allogeneic MSC offers the prospect of 
―off-the-shelf‖ tissue engineered products and tailor-made ―designer‖ therapies with 
huge benefits to patients and industry. However, their immunological properties are 
poorly defined and this has hampered their potential clinical utility. Recent studies 
have suggested that allogeneic MSC are immunoprivileged in addition to possessing 
immunosuppressive properties. Interestingly, dermal fibroblasts (DF) have also been 
suggested to be functionally similar to MSC although their immunological properties 
are controversial. 
This study sought to systematically investigate the immunomodulatory properties of 
allogeneic MSC, namely (i) immunosuppression and (ii) (immunogenicity of 
allogeneic MSC before and after differentiation using an allogeneic mouse model 
which employed two genetically distinct strains; Balb/c (H2 d) and C3H (H2 k) 
which are used as responder (recipient) and stimulator (donor) respectively. 
Immunosuppressive properties were investigated using adaptations of the one-way 
mixed lymphocyte reaction (MLR) while the immunogenicity was tested using the 
lymphocyte transformation assays (LTA). DF were similarly tested for comparison. 
MSC and DF were successfully isolated from the bone marrow and abdominal skin 
respectively of Balb/c and C3H mice, expanded and characterised by flow cytometry. 
MSC expressed MHC I, Sca-1, CD29, CD44, CD90.2 and CD105 but not MHC II, 
CD11b, CD34, CD45, CD80 and CD86. In contrast to MSC, DF were negative for 
CD29, CD44 and CD105. Both MSC and DF successfully differentiated into 
adipocytes, chondrocytes and osteocytes in the tri-lineage test; the benchmark test for 
stem cells. 
Various parameters including medium changes, cell viability following mitotic 
inactivation of stimulator cells, type and concentration of serum for medium 
supplementation, responder to stimulator cell ratio and total cell numbers were tested 
to determine appropriate conditions for carrying out the MLR and LTA.  
With regard to the immunosuppressive properties, both syngeneic and allogeneic 
MSC significantly suppressed one-way MLR and two-way MLR. DF also exhibited 
similar suppressive potency. In LTA, allogeneic, but not syngeneic MSC stimulated 
Balb/c lymphocyte proliferation. Interestingly, both syngeneic and allogeneic DF 
failed to stimulate lymphocyte proliferation. 
Following chondrogenic differentiation, both syngeneic and allogeneic MSC and DF 
suppressed one-way MLR, albeit with reduced potency. With regard to their 
immunogenicity, allogeneic MSC and DF, but not syngeneic MSC and DF 
significantly stimulated lymphocyte proliferation. 
Therefore, it was concluded that both allogeneic MSC and DF possess 
immunosuppressive properties before and after differentiation. Undifferentiated and 
differentiated allogeneic MSC and differentiated DF however, may not be 
immunoprivileged. Thus the clinical utility of allogeneic MSC may be limited by 
their immunogenicity.  
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1. CHAPTER ONE: INTRODUCTION 
1.1. Stem cells 
Stem cells are broadly defined as clonogenic cells that can undergo self-renewal and 
differentiation along multiple lineage pathways capable of forming functional 
tissues. The existence of stem cells has been known for a long time as cells 
associated with tissue repair. They are classified into two broad categories namely 
embryonic and adult according to the source of tissue from which they are derived. 
Also, stem cells can be classified according to their differentiation hierarchy as 
totipotent, pluripotent, multipotent and unipotent. 
Totipotent stem cells are cells capable of differentiating into any cell type. They are 
derived from fertilised oocytes within the first three days of zygote formation at the 
8-cell stage after which they lose some of their differentiation capacity such as the 
ability to form extra-embryonic tissue. After loss of totipotency, these embryonic 
cells develop into cells that form the inner cell mass (ICM) of the growing blastocyst 
which goes on to form the foetus and the outer extra-embryonic tissue (trophoblast) 
which form supporting structures such as the placenta and yolk sac (Ringe et al., 
2002; Tesar et al., 2007; Choumerianou et al., 2008).  
Pluripotent stem cells possess the capacity to differentiate into any cell of the three-
germ layers namely the ectoderm, mesoderm and endoderm but are not able to form 
cells of the trophoblast. They are cells derived from the ICM of the embryo within 5-
14 days post fertilisation and are therefore known as embryonic stem cells (ESC). 
Further differentiation of the ESCs in the maturing foetus gives rise to specialised 
tissues and organs; the endoderm forming the inner layers such as the gastrointestinal 
and respiratory tracts, endocrine organs, urinary tract and the auditory system while 
ectodermal development gives rise to the outer layers such as the skin and the 
nervous system. The mesoderm layer develops into cells and tissues of the middle 
layer (mesenchyme) such as the bone, fat, cartilage, skeletal and smooth muscles 
(Roobrouck et al., 2008).  
Adult mesenchymal tissues harbour multipotential stem cells commonly known as 
mesenchymal stem cells (MSC) whose differentiation potential is limited to the 




formation of mesodermal cell lineages typically adipocytes, chondrocytes and 
osteoblasts. These cells were initially identified in the bone marrow but are now 
known to be distributed in other mesenchymal tissues. Many adult tissues are now 
known to be sources of multipotent stem cells that usually bear the name of the tissue 
from which they are derived from such as adipose-derived stem cells obtained from 
fat tissue and neural stem cells derived from brain tissue (Dazzi & Horwood, 2007; 
Choumerianou et al., 2008).   
Unipotent stem cells, commonly known as precursor cells, are cells derived from 
specific tissues with the ability to differentiate into a single cell type of that tissue 
such as smooth muscle precursor cells that generate smooth muscle tissue. Generally, 
the description of precursor cells as ‗stem cells‘ is controversial since the latter term 
has come to describe undifferentiated cells that at least display multipotency. 
Precursor cells however are differentiated but do display clonogenic properties which 
make them useful in tissue repair (Körbling & Estrov, 2003).  
1.1.1 Pluripotent stem cells  
Pluripotent stem cells generally refer to naturally occurring ESC derived from 
developing embryos. Lately, adult cells genetically manipulated to become 
pluripotent, known as induced-pluripotent stem (iPS) cells, also belong to this 
category. 
1.1.1.1. Embryonic stem cells (ESC) 
ESC are derived from the in vitro culture of cells derived from the ICM of vertebrate 
blastocysts. They were initially isolated from mouse embryos in 1981 (Evans & 
Kaufman, 1981; Martin, 1981) and almost nearly two-decades later from donated 
pre-implantation human embryos obtained from in vitro fertilisation procedures  
(Thomson et al., 1998). At this time, a sudden surge in interest into their potential 
application in cell replacement therapies and modelling of human development and 
disease ensued. This was in light of earlier evidence that mouse ESC injected into 
host blastocyst contributed to the development of all the tissues of the three-germ 
layers of the adult mice (Beddington & Robertson, 1989; Nagy et al., 1990).  
The standard test that demonstrates ESC pluripotency is the ability to form well 
differentiated teratoma-like masses after subcutaneous, intramuscular or 




intratesticular injection into immunodeficient adult mice (Lensch et al., 2007). 
Suspension cultures of human or mouse ESC generate spontaneous cystic cell 
aggregates called embryoid bodies which contain cells of the three germ layers 
(Muller & Lengerke, 2009).  
Despite the significant potential of ESC for providing cell-based therapies, clinical 
application has been hampered by ethical and religious concerns from the wider 
society and only recently, two on-going clinical trials using human ESC-derived 
retinal pigment epithelial (RPE) cells have been initiated by Advanced Cell 
Therapies (ACT), an American company. In one of the studies for the treatment of 
dry-age related muscular degeneration, these cells were first shown to stave-off and 
even reverse disease progression in animal models. The first results from the phase I-
II trials suggested that the cells had not caused any adverse immunological effects 
and appeared to improve vision four months post transplantation (Schwartz et al., 
2012). The other study is the first UK-sanctioned ESC-clinical trial which 
commenced in November 2011 at Moorfields Eye hospital in London and uses 
ACT‘s RPE for the treatment of patients with Stargardt‘s muscular dystrophy which 
causes blindness. Although promising, these trials are still at phase I-II and their 
efficacy remains under investigation. Another clinical trial by an American company 
Geron, which used ESC-derived oligodendrocyte progenitor cells to restore spinal 
cord function in patients with spinal cord injuries was discontinued in November 
2011 despite having been previously reported to be promising in preliminary studies 
(http://www.eurostemcell.org/story/clinical-trials-news-january-2012-update).  
1.1.1.2. Induced-pluripotent stem cells (iPS) 
iPS are defined as adult somatic cells that have been genetically re-programmed to an 
embryonic stem cell-like state by forced expression of genes and factors that are 
thought to be responsible for maintaining pluripotency (Jaenisch & Young, 2008; 
Nishikawa et al., 2008). Whether iPS and ESC differ in any clinically significant 
way remains unknown but the development of this type of stem cells was born out of 
the need to generate genetically equivalent patient-specific (isogenic) cells for use in 
cell therapies without the risk of rejection which would otherwise necessitate use of 
immunosuppressive therapy and histocompatibility testing (Muller & Lengerke, 
2009).  




There are several methods for achieving genetic re-programming of mature cells 
namely somatic cell nuclear transfer (SCNT), direct somatic cell nuclear 
reprogramming (SCNR), parthenogenesis and cell fusion  
1.1.1.2.1. iPS by somatic cell nuclear transfer (SCNT) 
The process of SCNT or therapeutic cloning involves the transfer of a somatic cell-
derived nucleus into an enucleated oocyte to generate pluripotent cells that are 
genetically matched to the nucleus donor. The idea that the contents of an enucleated 
oocyte contain factors that are sufficiently capable of directing development of a 
complete organism was pioneered in the 1950s and 1960s and demonstrated in frogs 
(Briggs & King, 1952; Gurdon, 1962). This approach was later used in mammalian 
oocytes accompanied with nuclear transfer from somatic cells with the resulting 
artificial zygotes cultured under growth supporting conditions. Cell division and 
blastocyst formation ensued and whole organisms were produced following uterine 
transplantation This approach has been successfully used in many species including 
mouse, bovine and rabbit models (Cibelli, 2007) to produce fully developed 
offspring that are able to mature to adulthood as was demonstrated by ‗Dolly‘ the 
famous sheep in 1996 (Wilmut et al., 2007). Notwithstanding the ethical issues 
surrounding application of this technology to humans, the difficulty of obtaining 
viable human oocytes coupled to the low efficiency of the procedure has meant that 
SCNT is unlikely to see the light of day in the clinic. 
1.1.1.2.2. iPS by direct somatic cell nuclear reprogramming 
(SCNR) 
To overcome the problems associated with SCNT, another method of generating 
pluripotent cells using somatic cells was pioneered by Yamanaka and co-workers in 
2006 that generated mouse (Takahashi & Yamanaka, 2006) and human (Takahashi et 
al., 2007) iPS by retrovirus-mediated transfection of four key pluripotent 
transcription factor genes (Oct-3/4, Sox2, Klf4 and c-Myc) into fibroblasts to 
genetically re-programme the cells to a pluripotent state. The cells resembled ESC in 
morphology, surface antigen and gene expression, epigenetic status of pluripotent-
specific genes and telomerase activity. The mechanism by which the trans-acting 
factors induced pluripotency remains unknown but it is widely thought that Oct3/4 
and Sox2 synergistically upregulate ‗stemness‘ genes while suppressing 




differentiation associated genes while c-Myc and Klf4 are thought to modify 
chromatin structure to allow binding of Sox2 and Oct-3/4 to their targets (Ramalho-
Santos et al., 2002; Takahashi & Yamanaka, 2006). Although Oct4 seems to be 
important,  Sox2 and c-Myc were shown to be replaceable if specific cells such as 
neural stem cells that constitutively express high levels of Sox2 and c-Myc were used 
(Kim et al., 2008). 
The greatest disadvantage of this technology comes from its use of virus-mediated 
gene delivery. Risks such as random insertional mutagenesis, incomplete silencing, 
oncogene activation by Oct4 and activation of viral transgenes cannot be overlooked 
and may limit their clinical application despite the use of mechanisms such as de 
novo methylation that silence viral genes. iPS derived from some mice have been 
shown to have a high propensity to develop tumours. New strategies that are being 
employed in order to avert these risks include addition of the reprogramming 
proteins themselves (protein transduction); discovery of small molecules that are able 
to activate expression of reprogramming factors and so improve the efficiency of the 
reprogramming process and use of non-integrating vectors that express known 
reprogramming factors (Muller & Lengerke, 2009). 
1.1.1.2.3. Parthenogenesis 
Parthenogenesis is a form of asexual reproduction which refers to the growth and 
development of an embryo without fertilization. In the context of pluripotent stem 
cells, direct activation of oocytes is potentially more efficient compared to SCNT. 
This can be achieved by activation of oocytes with chemicals such as alcohol, 
ionomycin, 6-dimethylaminopurine and cycloheximide in addition to physical stimuli 
such as electrical shock and low temperature (Muller & Lengerke, 2009). This 
method was successfully used to generate ESC in various mammalian species 
including humans (Kim et al., 2007) and mice (Revazova et al., 2007). 
Parthenogenic ESC can differentiate into cells of all the three germ layers and are 
capable of forming teratomas in vitro and in vivo but demonstrate high levels of 
chimerism which suggests that additional selection pressures are imposed on the cells 
(Lengerke et al., 2007). Since these cells are genetically similar but not identical to 
the oocyte donor, they are a less attractive option for clinical application than other 




iPS. Another major drawback of these cells is that they are only available for women 
who are able to donate fresh oocytes (Muller & Lengerke, 2009). 
1.1.1.2.4. Cell fusion 
Another technique designed to be independent of oocyte or zygote donations uses the 
reprogramming capacity of embryonic carcinoma cells by fusing them with somatic 
cells to form hybrid cells capable of forming teratomas while expressing an 
embryonic identity such as transcriptional factors, surface antigens and enzymes. 
Such cells however are tetraploid, genetically unstable and immunologically 
incompatible with the donor (Muller & Lengerke, 2009). Without further 
modifications to reduce or silence the embryonic chromosomes (Matsumura et al., 
2006), it is unlikely that such technology will be clinically applicable.  
1.2. Adult stem cells (ASC) 
Adult stem cells (ASC) are defined as undifferentiated cells found among 
differentiated cells in tissues and organs that can self-renew and differentiate to yield 
some or all of the major specialized cell types of the tissue or organ. Their primary 
role is to maintain and repair the tissue from which they are derived (Pittenger et al., 
1999; Ringe et al., 2002). Usually, they are named according to the tissue 
source/niches. ASC that are resident in ectodermal tissues include neural, skin and 
ocular stem cells. Endodermal derived stem cells include pulmonary epithelial, 
pancreatic and urogenital stem cells. The most popular group of ASC are those 
derived from mesodermal tissues which include mesenchymal stem cells (MSC) and 
haematopoietic stem cells (HSC) (Körbling & Estrov, 2003; Mimeault & Batra, 
2006). Bone marrow-derived MSC are the focus of the work presented in this study 
and will be discussed in detail in Section 1.3. The bone marrow is known to harbour 
two distinct stem cell lineages namely HSC and MSC (Koide et al., 2007). 
1.2.1. Haematopoietic stem cells (HSC) 
HSC are multipotent stem cells which constitute up to 0.5 % of  bone marrow cells 
and are the precursor cells for all the myeloid (monocytes and macrophages, 
dendritic cells [DC], neutrophils, basophils, erythrocytes, eosinophils and platelets) 
and lymphoid (B-cells, T-cells and natural killer [NK] cells) blood cells (Gunsilius et 
al., 2001). They were the first type of stem cell to be discovered and are the best 




characterised of all stem cells. Though they are found primarily in the bone marrow 
of major bones such as femurs, sternum, ribs and hips, they also circulate in 
peripheral blood where they replenish missing or damaged components of the 
haematopoietic and immunologic systems (Trigg, 2004).   
Morphologically, HSC resemble lymphocytes, with a rounded nucleus and a low 
nucleus to cytoplasm ratio. They can be isolated by a variety of techniques including 
density centrifugation and surface antigen expression. To date, there are no specific 
characteristics that can uniquely identify them. HSC do not express most of the 
surface antigens expressed by their terminally differentiated progeny thus specific 
removal of such cells leaves a cell suspension of predominantly HSC (Bonnet, 2003). 
Expression of cluster of differentiation (CD) 34 has been widely used as a 
distinguishing marker for HSC since it is down-regulated during HSC differentiation 
although it has been later found in non-haematopoietic fibroblasts and vascular 
endothelial cells. The most commonly used markers aside from CD34 include CD45, 
CD38, CD90, CD105, CD117 and CD133. Negative selection for CD13 and CD133 




 distinguishes T-lymphocytes and B-
lymphocytes respectively and CD71 shows erythroid cells (Gunsilius et al., 2001; 
Bonnet, 2003). Clinical application of HSC includes treatment of leukaemia, aplastic 
anaemia, haematological cancers, thalassemias, severe combined immunodeficiency 
disease (SCID) and graft versus tumour treatment of cancer as well as graft versus 
host disease (GvHD) which can be achieved by allogeneic HSC transplantation 
(Gunsilius et al., 2001; Kondo et al., 2003).  
1.3. Mesenchymal stem cells (MSC)  
1.3.1. Historical background 
Before the phrase ‗stem cell‘ was used, scientists as early as  the early 19th century 
were familiar with the concept of tissue regeneration and self-repair as demonstrated 
by phenomena such as bone callus formation after fracture and formation of bone 
rudiments using autologous marrow at heterotopic sites in mice (Goujon, 1869), 
repair of blastema generated in amputated amphibians (Hay & Fischman, 1961) and 
mechanisms leading to wound healing (Marchand, 1901). Though in most cases the 
former experiments were carried out using bone-free fragments of marrow, the 




specific identities of the cells which acted as progenitors for mature bone and 
therefore non-haematopoietic cells, could not be precisely and accurately described. 
However, it had been suggested earlier in 1867 by Cohnheim that the bone marrow-
derived cells that played a role in facilitating wound repair were non-haematopoietic 
and had fibroblast-like morphology (Fehrer & Lepperdinger, 2005; Kode et al., 
2009). Thus, the hypothesis that ‗stem-like‘ cells took part in normal tissue repair 
was widely tested in the mid-20
th
 century and provided further insights about the role 
of bone marrow stromal cells.  
However, it was not until after a series of experiments by Friedenstein and co-
workers between 1966 and 1976 that the population of bone marrow-derived, clonal, 
plastic-adherent cells capable of undergoing differentiation into osteoblasts, 
adipocytes and chondrocytes was defined as ‗bone marrow stromal stem cells‘ 
(BMSSC) or osteogenic stem cells (Friedenstein et al., 1966; Friedenstein et al., 
1970a; Friedenstein & Kuralesova, 1971; Owen & Friedenstein, 1988; Friedenstein, 
1990). Because of their fibroblast-like appearance and strong affinity to adhere to 
tissue culture vessel plastic, these cells were easily distinguishable from the 
haematopoietic majority. Their clonal nature was determined when cell suspensions 
seeded at clonal density produced distinct single colonies which were called ‗colony-
forming units fibroblasts (CFU-F) (Friedenstein, 1970). 
When the stem cell niche hypothesis was postulated by Schofield in 1978 it brought 
to the fore the concept that stem cell self-renewal and differentiation were tightly 
controlled by their microenvironment and supporting cells (Schofield, 1978). At the 
time, much focus was on experimental haematology and the bone marrow was 
therefore widely regarded as a niche for HSC while other cells of the bone marrow 
determined their behaviour. This opened a new avenue which explored the functional 
relationships between HSC and the cellular components of the bone marrow and led 
to the suggestion that a ‗second type‘ of stem cell was present in the haematopoiesis-
supporting stroma of bone marrow. The earlier pioneering work by Friedenstein on 
BMSSC supported this concept albeit with the ‗second type‘ of stem cell being non-
haematopoietic. After the successful isolation of ESC from mouse embryos (Evans & 
Kaufman, 1981; Martin, 1981) and later from human embryos (Thomson et al., 
1998), the term ‗mesenchymal‘ replaced ‗stromal‘ or ‗osteogenic‘ to describe the 




non-haematopoietic stem cells from bone marrow and hence the current term 
‗mesenchymal stem cells (MSC) was born (Caplan, 1991; Pittenger et al., 1999).  
1.3.2. Other sources of multipotent stem cells 
Bone marrow-derived MSC belong to a wider group of ASC broadly defined as 
plastic-adherent, non-haematopoietic cells possessing self-renewal properties and the 
capacity to differentiate in vitro into adipocytes, chondrocytes and osteoblasts 
(Caplan & Bruder, 2001). Despite their demonstrated ability for differentiating into 
typical mesodermal cell lineages, trans-differentiation and differentiation into non-
mesenchymal phenotypes including neuron-like cells (Keilhoff et al., 2006; Choong 
et al., 2007), astrocytes (Kopen et al., 1999), myocardium (Pittenger & Martin, 
2004), endothelial cells (Oswald et al., 2004) and keratinocytes (Sasaki et al., 2008) 
has been reported as shown in Figure 1.1. However, controversy remains as to 
whether the observed phenotypic plasticity represented functional trans-
differentiation. 
Though initially isolated from mouse bone marrow (Friedenstein et al., 1976), which 
for some time was widely thought to be the most abundant source, MSC have since 
been shown to reside in virtually all adult mouse organs and tissues (da Silva 
Meirelles et al., 2006). This universal distribution of MSC is widely thought to be 
necessitated by the need for maintenance of integrity and repair of the tissues from 
which they are derived from. In humans, several MSC niches have been identified 
including peripheral and cord blood (Erices et al., 2000; Tondreau et al., 2005; 
Goldberg et al., 2007), amniotic fluid (Tsai et al., 2004), placenta (Fukuchi et al., 
2004), dental pulp (Gronthos et al., 2000), adipose tissue (Zuk et al., 2002), brain 
(Galli et al., 2003), hair follicles (Yu et al., 2006) and synovial fluid (Fan et al., 
2009). However, bone marrow-derived MSC remain to date the better understood 
and commonly used type of ASC. 





Figure 1.1. Multipotency of MSC. The self-renewal ability of MSC (red arrows) allows 
them to divide continuously and differentiate into various typical mesodermal cell lineages 
(solid arrows). In vitro trans-differentiation into ectodermal and endodermal cell lineages has 
been reported (dashed arrows). 
 
1.3.3. MSC characterisation 
1.3.3.1. Nomenclature 
To date, the defining characteristics of MSC are inconsistent among different 
laboratories. Variations in isolation methodologies, species, tissue sources, culture 
media, and culture conditions have resulted in subtle and in some cases obvious 
differences in the features of the resultant cells. This has made it difficult for direct 
comparisons on many biological properties to be made for MSC obtained from 
different research groups. Names such as mesenchymal progenitor cells (MPC) (Sun 




et al., 2003), multipotential adult progenitor cells (MAPC) (Jiang et al., 2002b), 
BMSSC (Bianco et al., 2001) have all been used to refer to MSC and this has led to 
some confusion regarding their definition. Objections about the inappropriateness of 
the word ‗mesenchymal‘ have been raised primarily because it was thought that other 
non-skeletal mesenchymal tissues such as myocardium, smooth muscle and tendon 
could be generated by MSC but there is no in vivo evidence to date to support this 
notion (Horwitz et al., 2005; Dominici et al., 2006). Furthermore, it is known that 
many tissue cells previously thought to be derived from MSC have since been shown 
to originate from different progenitors as evidenced by the presence of different 
tissue-specific stem cells. However, the name MSC has gained universal acceptance 
though not precisely accurate in its description of the cells. Other scientific bodies 
such as the International Society for Cellular Therapy (ISCT) have developed their 
own criteria and nomenclature for defining human MSC naming them as 
multipotential mesenchymal stromal cells (MMSC) rather than ‗stem cells‘ with the 
inclusion of the tissue source from which the cells were derived (Horwitz et al., 
2005). The minimum requirements set for human cells to be classified as MMSC by 
the ISCT  (Dominici et al., 2006) are; 
 Plastic adherence when maintained under standard culture conditions in tissue 
culture flasks. 
 Expression of specific cell surface antigens (≥ 95%) including CD73, CD90, 
and CD105 and negative for (≤ 2%) CD34, CD45, CD11b, CD19 and human 
leukocyte antigen DR (HLA DR) as measured by flow cytometry. 
 Demonstration of multipotential differentiation capacity into adipocytes, 
osteocytes and chondrocytes by in vitro staining of cultures. 
Though these criteria were set for human derived cells, other mammalian MSC 
including murine have met these definitions but are still commonly referred to as 
mesenchymal ‗stem cells‘ rather than ‗stromal cells‘. 
1.3.3.2. Abundance 
Current models suggest that postnatal bone marrow, in addition to a variety of other 
stromal cells, houses MSC and HSC (Koide et al., 2007). MSC have been reported to 
constitute a small fraction of bone marrow nucleated cells, approximately 1 in 10
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cells in mice (Sung et al., 2008) and between 0.001 and 0.01 % in humans (Pittenger 
et al., 1999). 
1.3.3.3. Isolation of MSC from bone marrow 
The most commonly used approach for obtaining MSC from animal donors such as 
mouse involves harvesting by flushing the bone marrow with culture medium to 
remove marrow plugs from compact bone followed by isolation which exploits their 
physical propensity to adhere to the plastic substrate of cell culture plates. This 
method is generally known as the plastic adherence method [PAM] (Friedenstein et 
al., 1970a; Phinney et al., 1999). The non-adherent cells are progressively removed 
from the cultures during successive medium changes until fibroblast-like cells 
become prominent in the culture. This is based on the premise that differentiated 
cells as well as HSC lack longevity in culture under these conditions and are 
progressively lost with time. This technique has been reported to generate poor yields 
of mouse MSC as well as being time consuming since cells have to be maintained in 
culture for a long time and this could potentially affect their biological properties. 
Studies in both mice and humans have shown that MSC are located in the endosteum 
or compact bone. This deep location makes it difficult to harvest them even after 
strong flushing. The heterogeneous cell suspensions obtained from mouse bone 
marrow have a higher frequency of haematopoietic cells which also are plastic-
adherent and therefore could hinder the adherence of MSC. These cells are also 
known to persist in culture after serial passages due to their ability to bind stromal 
cells via engagement with adhesion molecules, cytokine receptors and extra-cellular 
matrix (ECM) proteins even in the absence of exogenous growth factors or cytokines 
(Short et al., 2001; Baddoo et al., 2003). Most of the murine plastic-adherent stromal 
cells have been shown to exhibit differentiated phenotypes even in the absence of 
differentiation inducing culture conditions (Sun et al., 2003). Therefore, cultures 
resulting from mouse marrow aspirates remain morphologically heterogeneous with 
cells ranging from narrow spindle-shaped to large polygonal and tightly packed cells 
(Park et al., 2007c). Despite these disadvantages, the PAM has remained the most 
commonly used method because it does not involve treating the cells or processing 
them before plating which could potentially affect the subsequent behaviour of the 
cells.  




1.3.3.4. Phenotypic markers 
At present, there is no specific marker or combination of markers that uniquely 
defines MSC. However, ex vivo expanded human and murine MSC have been shown 
in many studies to commonly and consistently express antigens such as Sca-1, CD29, 
CD44, CD73, CD90, CD105, CD106 but are devoid of haematopoietic markers 
CD34 and CD45 or endothelial and macrophage markers CD11b, CD14 and CD31 
(Pittenger et al., 1999; Sung et al., 2008). Surface expression of major 
histocompatibility complex class I (MHC I) in mice or HLA A, B and C in humans 
has been best described as low, intermediate or partial but MHC II and HLA DP, DQ 
and DR are completely absent (Le Blanc et al., 2003b; Soleimani & Nadri, 2009). 
Importantly, both human and murine MSC do not express the immunological co-
stimulatory molecules CD80 (B7-1), CD86 (B7-2), CD40 or it ligand CD40L. The 
commonly used markers for the identification of MSC are listed in Table 1.1. 
It is noteworthy to mention that there are variations in terms of the actual percentages 
of cells expressing the same markers by different researchers largely due to 
differences in MSC tissue source, isolation and expansion methodologies, passage 
number and donor age and sex. It has been noted that CD45 and CD14 expression by 
human MSC more than quadrupled between paediatric and older donors though there 
is currently not enough evidence to support this (Rojewski et al., 2008). It remains 
unclear how different isolation techniques could affect expression of certain markers 
but it is well known that manipulation of MSC could result in the up or down-
regulation of specific markers. The age and passage number of MSC are important 
considerations in the characterisation of MSC. It had been shown that senescent 
MSC expressed normal levels of CD29, CD44, CD90, CD105 and CD166 despite 
having reduced differentiation capacity. In addition, prolonged culture could lead to 
down-regulation of certain markers as a result of age, plastic-adherence, cell to cell 
contact, exposure to xenogeneic growth factors such as foetal calf serum (FCS) used 
in culture medium and enzymatic manipulation resulting from use of proteolytic cell 
dissociation solutions (such as trypsin) commonly used during cell passage 






Table 1.1. Common surface markers used in the characterisation of mouse and human MSC 





 Sca-1 is a member of the Ly-6 antigen family and is the most common MSC 
marker in mice with both Ly-6 haplotypes. Sca-1 has also been discovered in 
several non-haematopoietic tissues and can be used to enrich progenitor cell 
populations other than MSC. It is thought to be involved in regulating both B-and 
T- cell activation 
Baddoo et al. (2003); da Silva Meirelles & 
Nardi (2003); Koide et al. (2007); Sung et al, 
(2008); Soleimani & Nadri (2009); Schurgers et 
al. (2010) 
MHC I +/- + MHC I molecules are constitutively expressed by all nucleated cells and their 
function is to bind intracellular peptides for display to cytotoxic CD8
+
 T-cells. 
They also function as inhibitory ligands for NK cells.  
Jiang et al. (2002b); Le Blanc et al. (2004a); 
Jones et al. (2007); Soleimani & Nadri (2009); 
Schurgers et al. (2010) 




Jiang et al. (2002b); Le Blanc et al. (2004a); 
Jones et al. (2007); Soleimani & Nadri (2009); 
Schurgers et al. (2010) 
CD29 + + Membrane receptor associated with cell adhesion and recognition in processes 
such as tissue repair, immune response and homeostasis. 
Baddoo et al. (2003); da Silva Meirelles & 
Nardi (2003); Sun et al. (2003); Le Blanc et al. 
(2004a); Chamberlain et al. (2007); Sung et al. 
(2008) 
CD44 +/- + A type of cell adhesion molecule used to identify several types of mesenchymal 
cells including MSC and HSC. Functions as a bone homing receptor for HSC and 
MSC migration to the bone marrow. Its expression in mouse MSC has been found 
to be variable among studies. 
Jiang et al. (2002b); Baddoo et al. (2003); da 
Silva Meirelles & Nardi (2003); Sun et al. 
(2003); Le Blanc et al. (2004a); Chamberlain et 




+ + It is an enzyme that hydrolyses extracellular nucleotides into membrane 
permeable nucleosides. It is normally used as a marker of lymphocyte 
differentiation 
Chamberlain et al. (2007); Jones et al. (2007); 
Schurgers et al. (2010) 
CD90 
(Thy-1) 
-/+ + It is a cell surface protein with a single V-like immunoglobulin domain, originally 
discovered as a thymocyte antigen. Generally used as a marker for a variety of 
stem cells including MSC and for the axonal processes of mature neurons. Its 
roles are thought to involve cell-cell and cell-matrix interactions, with implication 
in neurite outgrowth, nerve regeneration, apoptosis, metastasis, inflammation, and 
fibrosis. 
Baddoo et al. (2003); Chamberlain et al. (2007); 




+/- + It is a type I membrane glycoprotein located on the cell surface of endothelial 
cells, activated macrophages, fibroblasts and smooth muscle cells as part of the 
Sun et al. (2003); Le Blanc et al. (2004a); Jones 






TGF receptor complex. Its main functions include cytoskeletal organisation, 
affecting cell morphology, migration and vascular remodelling. 




+/- + Mainly serves as an adhesion molecule. Mostly found in haematopoietic cells 
particularly white blood cells where it facilitates binding to the vascular 
endothelium. 
Baddoo et al. (2003); Jones et al. (2006); 
Chamberlain et al. (2007); Jones et al. (2007); 
Soleimani & Nadri (2009) 
CD 13 - + It is a transmembrane glycoprotein commonly expressed on granulocytes, 
myeloid progenitors, endothelial cells, epithelial cells and subset of granular 
lymphoid cells. It is thought to be involved in the metabolism of many regulatory 
peptides and functions in antigen processing and the cleavage of chemokines. 
Jiang et al. (2002b); Jones et al. (2006) 
CD31 
(PECAM-1) 
- - Commonly found on haematopoietic and endothelial cells and participates in 
angiogenesis, leukocyte migration, integrin activation and removal of aged 
neutrophils from the body. 
Baddoo et al. (2003); Sun et al. (2003); 
Chamberlain et al. (2007); Soleimani & Nadri 
(2009); Schurgers et al. (2010) 
CD49e 
(ITGA5) 
+ + CD49e is an integral protein which binds with CD29 to form the receptor VLA5, 
which binds the ligands fibronectin and fibrinogen. Its expressed on multiple cell 
types including thymocytes, mast cells, activated T-cells and splenic B-cells. In 
addition to its role in adhesion, VLA5 contributes to T-cell co-stimulation. 
da Silva Meirelles & Nardi (2003); Koide et al. 
(2007) 
CD63 + + CD63 is a member of the transmembrane-4 superfamily and mediates signal 
transduction events that play a role in the regulation of cell development, 
activation, growth and motility and is also known to complex with integrins. 
Jones et al. (2006) 
CD166 
(ALCAM) 
+ + A transmembrane glycoprotein of the immunoglobulin family which is commonly 
expressed on activated T-cells, activated monocytes, epithelial cells, fibroblasts, 
neurons and melanoma cells. CD166 plays an important role in mediating 
adhesion interactions between thymic epithelial cells and CD6 cells during 
intrathymic T-cell development and is now regarded as a marker for cancer stem 
cells.  
Le Blanc et al. (2004a); Chamberlain et al. 
(2007); Jones et al. (2007) 
CD86 
(B7-2) 
- - This protein is a member of the immunoglobulin superfamily commonly 
expressed by APC. It acts as a co-stimulatory ligand for CD28 (auto-regulation 
and intracellular association) and CTLA-4 (attenuation of regulation and cellular 
disassociation) on T-cells. It works in tandem with CD80 to prime T-cells. 
Klyushnenkova et al. (2005); Jones et al. 
(2006); Chamberlain et al. (2007); Soleimani & 
Nadri (2009); Schurgers et al. (2010) 
CD40 - - CD40 is constitutively expressed by APC, including DC, B-cells and 
macrophages and in some cases endothelial cells, smooth muscle cells, fibroblasts 
and epithelial cells. It functions as a co-stimulatory signal required for their 
activation. The binding of CD154 (CD40L) on CD4
+
 T-cells to CD40 activates 
the APC and induces a variety of downstream effects. 
Klyushnenkova et al. (2005); Chamberlain et al. 
(2007); Soleimani & Nadri (2009) 






(B7-1) stimulatory signal necessary for T-cell activation and survival. It is the ligand for 
CD28 (auto-regulation and intercellular association) and CTLA-4 (for attenuation 
of regulation and cellular disassociation). CD80 works in tandem with CD86 to 
prime T-cells. The activated protein induces T-cell proliferation and cytokine 
production.  
(2006); Chamberlain et al. (2007); Jones et al. 
(2007); Soleimani & Nadri (2009); Schurgers et 
al. (2010) 
CD34 -/+ - It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may 
also mediate the attachment of stem cells to bone marrow ECM or directly to 
stromal cells. Generally regarded as a marker for distinguishing MSC from HSC. 
Baddoo et al. (2003); Sun et al. (2003); Le 
Blanc et al. (2004a); Chamberlain et al. (2007); 
Koide et al. (2007); Sung et al. (2008); 
Soleimani & Nadri (2009) 
CD45 - - A member of the protein tyrosine phosphatase (PTP) family which acts as a  
signalling molecule that regulate a variety of cellular processes including cell 
growth, differentiation, mitotic cycle, and oncogenic transformation. Also 
regarded as a marker for distinguishing MSC from HSC. 
Jiang et al. (2002b); Sun et al. (2003); Tropel et 
al. (2004); Le Blanc et al. (2004a); Chamberlain 




- - It is generally expressed on many leukocytes involved in the innate immune 
system including monocytes, granulocytes, macrophages, and NK cells. It 
mediates inflammation by regulating leukocyte adhesion and migration and has 
been implicated in several immune processes such as phagocytosis, cell-mediated 
cytotoxicity, chemotaxis, cellular and complement activation.  
Baddoo et al. (2003); Tropel et al. (2004); 
Chamberlain et al. (2007); Sung et al. (2008); 




- - It is a cytokine receptor expressed on the surface of haematopoietic stem cells as 
well as other cell types. CD117 is a receptor tyrosine kinase type III, which binds 
to stem cell factor (a substance that causes certain types of cells to grow), also 
known as "steel factor" or "c-kit ligand". Signalling through CD117 plays a role 
in cell survival, proliferation and differentiation. 
Jiang et al. (2002b); Baddoo et al. (2003); 
Koide et al. (2007); Park et al. (2007c); 
Soleimani & Nadri (2009) 
CD271  + Also known as low-affinity nerve growth factor receptor (LNGFR), it belongs to 
the low affinity neutrophin receptor and tumour necrosis factor receptor 
superfamily. Its precise function remains controversial but it is widely thought to 
be involved in the survival and differentiation of neuronal cells by acting as a sink 
for neutrophins. It has been found to potentially define a MSC subpopulation and 
for the enrichment of non-haematopoietic stem cells from human bone marrow 
and adipose tissue. 
Thomson et al. (1988); Quirici et al. (2002); 
Jones et al. (2002); Kuci et al. (2010) 
CD146  + Also known as melanoma cell adhesion molecule (MCAM), it is commonly used 
as an endothelial cell marker. Its exact function remains unknown but it is thought 
to form part of the endothelial junction associated with the actin cytoskeleton. Its 
expression on human MSC is thought to be associated with multipotency with 
higher expression linked to greater differentiation potential. 
Covas et al. (2008); Shrugar et al. (2009); 






STRO-1 + + It was originally identified as an antibody for identifying both human and mouse 
plastic-adherent bone marrow stromal cells but was also later used successfully to 
identify endothelial cells. 
Delorme et al. (2006); Lin et al. (2008); Yang et 
al. (2008); Ning et al. (2011) 
CD133 
(Prominin) 
- - It is a marker for HSC, endothelial cells and neural stem cells  Koide et al. (2007) 
[MHC; major histocompatibility complex. CD; cluster of differentiation. APC; antigen presenting cell. TGF transforming growth factor-beta. VLA5; very late activation 
antigen-5. CTLA-4; cytotoxic T-lymphocyte antigen-4.  ALCAM; activated leukocyte cell adhesion molecule. VCAM-1; vascular cell adhesion molecule-1. PECAM-1; 
platelet endothelial cell adhesion molecule-1. ITGA5; integrin alpha-5. NT5E; ecto-5‘-nucleotidase. NK; natural killer] 
 





Not enough attention has been put into how different culture media and growth 
factors used for the growth and expansion of MSC could affect their differentiation 
potential or expression of cell surface markers. To date, there is no specialised 
medium for the growth of MSC and different studies have used different types of 
medium and growth factors. The commonly used media are Dulbecco‘s modified 
Eagle‘s medium (DMEM), Eagle‘s minimum essential medium (-MEM) and Opti-
MEM, Iscove‘s modified Dulbecco‘s medium (IMDM) supplemented with either 
FCS, human serum, platelet lysate, low or high glucose, additional amino acids such 
as L-glutamine, deoxyribonucleotides, fibroblast growth factor (FGF) and many 
others. Current opinion suggests that expansion medium may only influence the 
proliferation potency, but it is probable that the effects may go beyond mere cell 
division. Therefore, the full repertoire of factors that potentially influence the 
behaviour of MSC in culture remains unresolved. MSC in culture are best described 
as heterogeneous mixtures of cells with varying proliferation and differentiation 
capacities. A hierarchical model has been proposed that suggests that MSC cultures 
lose their clonogenic capacity and multipotency with increasing passaging in culture. 
It is thought that the majority of the cells in vitro are transitional cells with specific 
lineage potential (Park et al., 2007c) 
1.3.3.6. Differentiation 
From the previous sections, it has been highlighted that there is no specific marker(s) 
or isolation method that purely separates MSC from other related cells. To date, the 
most practical and important presumptive method for defining MSC is the 
‗functional assay‘ or ‗tri-lineage differentiation assay‘ that tests the differentiation 
capacity of the MSC (Pittenger et al., 1999). The capacity of the cells to undergo in 
vitro differentiation to bone, fat, and cartilage under chemical, hormonal or 
mechanical stimulation is the single critical requirement for identifying putative 
MSC populations. Even clonal selection does not ensure that a cell population 
derived from a single colony will be homogeneous after several rounds of division as 
MSC have been shown to gradually lose their multipotency with time due to several 
factors which include inherent telomere shortening and experimental conditions 
(Park et al., 2007c). Efforts to find the major signalling pathways or ‗master‘ 
regulatory genes that control MSC differentiation are on-going. Though genetic and 




or epigenetic programs that govern cell differentiation have remained elusive, much 
has been learnt from ESC genetics which then led to the development of iPS by 
Yamanaka and co-workers through genetic reprogramming of mouse (Takahashi & 
Yamanaka, 2006) and human (Takahashi et al., 2007) fibroblasts discussed earlier in 
Section 1.1.12. 
The ability to modulate specific genetic programs in order to maintain a specific 
differentiation pathway while avoiding spurious differentiation is a pre-requisite for 
the application of MSC in tissue engineering and regenerative medicine. Some of the 
known mechanisms that are thought to control the tri-lineage differentiation process 
in mouse MSC are discussed. 
1.3.3.6.1. Adipogenesis 
Generally, adipogenic differentiation is induced in vitro by culturing confluent MSC 
in culture medium supplemented with several hormonal and chemicals cues such as: 
the hormone, insulin; the cyclooxygenase inhibitor, indomethacin, the corticosteroid 
dexamethasone and the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX). In vitro adipogenic differentiation follows a well characterised two-stage 
sequence summarised below; 
 Determination – involves the commitment of MSC to the adipocyte lineage 
by changing into preadipocytes which are morphologically indistinguishable 
from the precursor cells but would have lost their plasticity. 
 Terminal differentiation – preadipocytes develop into mature adipocytes by 
acquiring the ability to synthesize and transport lipids, sensitivity to insulin 
and secretion of adipocyte specific proteins. 
The process is initiated by the expression of the nuclear hormone receptor 
peroxisome proliferator-activated receptor gamma (PPAR), the master adipogenic 
regulator which promotes adipogenesis whilst suppressing osteogenesis (Nuttall & 
Gimble, 2004).  During the early stages of adipogenic differentiation, PPAR triggers 
expression of the CCAAT/enhancer binding proteins (C/EBP) family of 
transcriptional factors whereby C/EBP and C/EBP induction is followed by 
C/EBP expression which is required for insulin sensitivity in preadipocytes (Rosen 
et al., 2002; Rosen & MacDougald, 2006).  In vitro, the binding of PPAR to specific 




cellular ligands induces the transactivation and transrepression of PPAR thereby 
promoting adipogenesis whilst blocking osteogenesis. The process is enhanced by 
increasing intracellular cyclic adenosine monophosphate (cAMP) as a result of 
IBMX and further binding to specific upregulated nuclear receptors by other 
differentiation inducing factors in the medium. Insulin exerts its effects by binding 
with the insulin growth factor-receptor signalling. However the exact link between 
insulin signalling cascade and the intrinsic adipogenesis cascades remains unknown 
(Gimble et al., 2008). After 3-9 days the predominantly fibroblast-like MSC are 
converted to oval, neutral lipid containing cells whose lipid vesicles increase in size 
with time in culture or through the addition of fatty acids such as oleic, palmitic and 
linolenic acid to the culture medium (Diascro JR et al., 1998). The differentiated 
MSC have been reported to exhibit biochemical characteristics similar to those of 
mature adipocytes (Gimble et al., 1990) including expression of adipogenic genes 
such as fatty acid-binding protein-4 (FABP4) and lipoprotein lipase as well as 
secretion of the adipokine, adiponectin and the hormone, leptin (Gimble et al., 2008).  
1.3.3.6.2. Chondrogenesis 
Chondrogenic differentiation of MSC is induced in vitro by the addition of 
stimulatory compounds including dexamethasone, ascorbate phosphate, pyruvic acid, 
insulin, transferrin, selenium and transforming growth factor-beta (TGF). Unlike 
adipogenic and osteogenic differentiation which require cell cultures in monolayer, 
chondrogenic differentiation occurs effectively when MSC are cultured in 3-
dimensional conformation such as pellet or micromass cultures (Worster et al., 2001; 
Goessler et al., 2005; Longobardi et al., 2006; Bernardo et al., 2007). Differentiation 
can also be achieved through mechanical stimulation and reduced oxygen tension 
(Malladi et al., 2006; Terraciano et al., 2007) without use of chemical or hormonal 
factors. The specific signalling pathways that initiate chondrogenic differentiation 
are still unknown. However, it is thought that the differentiation process is initiated 
in part by culture medium constituents such as TGF, bone morphogenetic protein-2 
(BMP2) and growth and differentiation factor (GDF) signalling (Chen et al., 2004; 
Massagué & Gomis, 2006). Binding of these ligands to their specific receptors 
initiates signalling through specific intracellular Smad proteins and major mitogen-
activated protein kinase (MAPK) cascades which result in the activation of the 
transcription factors Sox-9 and scleraxis which cause the upregulation of the genes 




for ECM proteins and proteoglycans including collagen types II and IX, aggrecan, 
decorin, versican and cartilage oligomeric matrix protein (Tuan et al., 2003; Baksh et 
al., 2004). The early changes in the differentiation process are marked by a 
progressive increase in the levels of the glycosaminoglycans (GAGs) chondroitin-6-
sulphate relative to chondroitin-4-suphate in a similar pattern to that observed during 
the maturation of articular cartilage (Bayliss et al., 1999). Gradually, the MSC lose 
their fibroblast-like morphology as expression of ECM proteins and biosynthesis of 
GAGs increase leading to a dramatically altered morphology (Barry & Murphy, 
2004). 
1.3.3.6.3. Osteogenesis 
The in vitro osteogenic differentiation of MSC requires confluent monolayer cultures 
and the presence of stimulatory chemicals such a -glycerophosphate, 
dexamethasone, ascorbate-2-phosphate and in some case BMP2 in culture medium. 
Though the exact mechanisms controlling osteogenic differentiation are not fully 
elucidated, the differentiation process is considered to be a three-stage process 
involving proliferation, matrix formation and mineralisation punctuated by 
expression of osteoblastic phenotype markers (Olsen et al., 2000).  
The proliferation stage is highlighted by increased expression of cell cycle genes. 
One proposed model of osteogenesis suggests that BMP2 promotes osteogenic 
differentiation by inducing the p300-mediated acetylation of the master osteogenesis 
regulator Runt-related transcriptional factor-2 (Runx2), which enhances its 
transactivation capability while increased Wnts protein levels has also been shown to 
promote the transformation of MSC to osteocytes (Chen et al., 2004; Jeon et al., 
2006). Other transcriptional factors thought to regulate the differentiation process 
include tafazzin, osterix and activating transcriptional factor-4 (Deng et al., 2008). It 
is hypothesized that crosstalk between BMP2 and Wnts is responsible for the 
upregulation of Runx2 and together with other signalling pathways leads to the 
subsequent acquisition of an osteoblastic morphology with upregulation of the 
enzyme alkaline phosphatase activity which defines the matrix formation stage. 
Finally, the mineralisation phase is characterised by the deposition of calcium-rich 
mineralised ECM (Barry & Murphy, 2004; Friedman et al., 2006; Kolf et al., 2007). 
The differentiated phenotype is also characterised by a large nucleus, enlarged Golgi 




apparatus and extensive endoplasmic reticulum to cope with the increased secretion 
of bone matrix proteins. Expression of markers such as osteopontin and osteocalcin 
are indicative of differentiated osteoblasts (Deng et al., 2008). 
1.4. Clinical application and potential of MSC 
The ideal stem cells for clinical application are ESC primarily because of their 
pluripotency (Pera & Trounson, 2004) but ethical, moral and legal concerns have so 
far limited their consideration for therapeutic and clinical use (Weissman, 2002) as 
discussed in Section 1.1.1.1. This has led to the growing interest in ASC particularly 
MSC the use of which does not involve the ethical issues that surround ESC. The last 
decade has seen an unprecedented interest in the biology of human MSC and 
exploration of their therapeutic potential. Their self-renewal properties and 
multilineage differentiation potency have made them candidates for the repair, 
regeneration and replacement of diseased cells and tissues. MSC offer the options of 
either being used in their undifferentiated state in cell based therapies or after ex vivo 
differentiation on biomimetic scaffolds in tissue engineering.  
Importantly, there has been an accumulation of evidence that proposes that MSC are 
immunoprivileged in addition to possessing immunosuppressive properties (Le Blanc 
& Ringden, 2007). Studies carried out using human (Aggarwal & Pittenger, 2005; 
Klyushnenkova et al., 2005), rodent (Krampera et al., 2003) and primate 
(Bartholomew et al., 2002) models have shown that MSC failed to elicit a 
proliferative response from allogeneic lymphocytes in lymphocyte transformation 
assays (LTA) and suppressed mixed lymphocyte reactions (MLR). Though the 
mechanisms responsible for their immunomodulatory properties are yet to be 
resolved, their ability to escape detection by allogeneic lymphocytes 
(immunoprivilege) has been suggested to be MHC-independent (Le Blanc et al., 
2003c). Also, their reported capacity to skew both the innate and adaptive immune 
responses towards anti-inflammatory/tolerant phenotype (immunosuppression) is 
thought to be due to a combination of secreted factors and direct cell to cell contact 
(Kode et al., 2009). In animal models, intravenous administration of MSC has been 
reported to improve outcomes of renal (Tögel et al., 2005), neural (Zappia et al., 
2005) and lung (Ortiz et al., 2003) injury through paracrine effects and a shift from 
pro-inflammatory to anti-inflammatory cytokine production at the site of injury. 




These reported properties would enable the therapeutic application of allogeneic 
MSC without the risks of rejection normally associated with allogeneic cells and 
tissues. There is also the potential of the ‗universal donor‘ concept whereby MSC 
from a single donor might be infinitely expanded and used to commercially 
manufacture ―off-the-shelf‖ tissue engineered products or individually tailored for 
multiple patient therapies. Thus both the clinical and commercial potential of 
allogeneic MSC rest solely on their immunomodulatory properties. Specific 
applications of MSC can be categorised into three major approaches namely; 
 tissue engineering 
 local implantation of MSC into diseased tissues 
 systemic implantation 
1.4.1. Tissue engineering 
Tissue engineering is an inter-disciplinary field of regenerative medicine that applies 
the principles of engineering and biological sciences to understand tissue growth in 
order to apply this to produce functional tissue for clinical use (Dawson & Oreffo, 
2008). It allows for the isolation of a patient‘s own cells such as MSC, seeding them 
into biological scaffolds and allowing specific tissues to grow ex vivo before 
implantation back to the patient to repair damage due to disease or trauma. The 
traditional approach of tissue and organ donation to replace degenerate tissues and 
organs is increasingly threatened by challenges which include the shortage of donors, 
physical mismatch of dimensions and importantly, limitations attributable to 
immunological rejection of donor tissue by the recipient‘s immune system (Abdallah 
& Kassem, 2007). However, the reported ability of allogeneic MSC to avoid immune 
rejection has raised interest in their potential application in tissue engineering 
procedures. Since MSC can undergo specific guided differentiation, the 
immunological consequences of differentiated allogeneic MSC would require 
thorough investigations. Tissue engineering based approaches that utilise MSC 
would be more suitable for bone, cartilage and adipose tissue engineering since they 
can easily differentiate into these cell lineages. 
1.4.1.1. Bone tissue engineering 
Bone defects have been traditionally treated using artificial, autologous and in some 
cases allogeneic bone grafts. Artificial grafts are mainly limited by their mechanical 




properties and biodegradation which should mirror those of natural bone whereas 
autologous grafts are limited by donor-site morbidity. Immunological rejection poses 
the major risk for allogeneic grafts (Salgado et al., 2004; Hosseinkhani et al., 2006).  
The ability of MSC to undergo osteogenic differentiation under chemical and 
hormonal stimulation has been exploited with clinical success in the treatment of 
bone defects by using a tissue engineering protocol that involved seeding ex vivo 
expanded autologous MSC on macroporous hydroxyapatite scaffolds followed by 
implantation at defect sites. Post-surgery examination revealed callus formation 
along the implants and good integration at the interface with host bones (Quarto et 
al., 2001). The authors claimed that since these were ‗challenging cases‘ with 
multiple previous failed treatments, the success validated the effectiveness of this 
tissue engineering approach. This clinical trial was conducted following similar 
successes using autologous and syngeneic MSC in ovine (Kon et al., 2000), canine 
(Scott et al., 1998) and rodent (Kadiyala et al., 1997) models.   
Due to the success with autologous MSC, allogeneic MSC have been used in animal 
studies mimicking real clinical situations to repair bone defects. In independent 
studies using a canine model, both allogeneic and autologous MSC seeded on 
hydroxyapatite tricalcium phosphate scaffolds were used to fill critically-sized bone 
defects. On examination, the allogeneic MSC grafts enhanced repair of the defects by 
forming new bone comparable to autologous MSC grafts without need for 
immunosuppressive therapy or adverse immune response against the allogeneic MSC 
as measured by the absence of circulating antibodies in sera and infiltrating 
lymphocytes after histological analysis (Arinzeh et al., 2003; De Kok et al., 2003). 
This suggested that the in vivo osteogenic differentiation process did not alter the 
immunoprivilege of the allogeneic MSC and thus provided evidence for the potential 
clinical application of allogeneic MSC. However, in a xenogeneic model in which 
undifferentiated and osteogenic differentiated human MSC were implanted in 
immunocompetent mice, the undifferentiated MSC but not the osteogenic 
differentiated MSC survived the host immune response (Niemeyer et al., 2008). 
These findings cast a shadow of doubt on the reported immunoprivileged status of 
differentiated MSC. 




1.4.1.2. Cartilage tissue engineering 
Due to the poor healing potential of articular cartilage (Tuan et al., 2003), damage 
due to trauma or degenerative diseases such as osteoarthritis is debilitating to patients 
and provides a huge challenge to current cartilage tissue engineering procedures. 
Traditional treatment methods for the restoration of function range from autografting, 
allografting, periosteal and perichondrial grafting, stimulation of intrinsic 
regeneration by intentionally drilling full-thickness defects, pharmacological 
intervention and autologous cell transplantation such as in periosteal flap technique 
marketed by Genzyme Corporation (Brittberg et al., 1994). However, most of these 
techniques had higher failure rates in young patients or failed to provide repair to the 
fully functional state (O'Driscoll, 1998; Tuan et al., 2003). The chondrogenic 
differentiation capacity of MSC makes them a suitable cell source for cartilage tissue 
engineering and could be exploited to regenerate cartilage without donor site 
morbidity.  
In separate experiments using rabbit models, autologous MSC seeded on a type I 
collagen gel and a calcium phosphate and hyaluronan sponge have been used to 
successfully repair full-thickness cartilage defects in knees and the weight-bearing 
surface of femoral condyles (Wakitani et al., 1994; Gao et al., 2002). These findings 
were applied clinically in a study which used autologous MSC embedded in collagen 
gel to successfully treat patients suffering from osteoarthritis with hyaline cartilage-
like tissue forming 8 months post-surgery (Wakitani et al., 2002). Advances in 
materials science have led to the development of many scaffold materials  such as 
lactic and glycolic acid and their co-polymers, poly(ethylene glycol)-terephthalate  
and poly(butylene terephthalate) which are highly porous structures to allow for 
cellular ingrowth, has helped to improve outcomes (Tuan et al., 2003) and more 
recently attention has been focused on de-cellularisation of natural xenogeneic and 
allogeneic tissues such as the medial meniscus (Stapleton et al., 2008) for use as 
biological scaffolds.  
1.4.1.3. Adipose tissue engineering 
Millions of plastic and reconstructive surgery procedures are carried out every year 
to repair soft tissue defects that arise from a wide range of trauma and disease 
conditions such as from tumour resection in mastectomy and carcinoma removal, 




traumatic injury such as resulting from deep burns, hereditary and congenital defects 
such as Romberg‘s disease and Poland syndrome (Vashi et al., 2008). Current 
methods for treating adipose tissue defects include autografts, fat-free grafts and 
alloplastic materials (Girandon et al., 2011), however these techniques have 
shortcomings  such as donor site trauma and morbidity, suboptimal volume retention 
and poor biocompatibility. In addition, the poor healing of adipose tissue grafts is 
compounded by the shortage of or premature apoptosis of adipogenic cells (Stosich 
& Mao, 2007).  
The adipogenic potential of MSC can be exploited in tissue engineering approaches 
using a wide range of both natural and synthetic scaffolds such as injectable or 
implantable hydrogels, hyaluronic acid, collagen and modified alginate (Gomillion & 
Burg, 2006). In separate studies, 3D cultures using rat (Neubauer et al., 2005) and 
human (Hong et al., 2005) MSC loaded onto polylactide-co-glycolide and gelatin 
sponges respectively successfully generated mature adipose tissues. 
Autologous human and murine MSC delivered in a fibrin spray have been reported to 
accelerate cutaneous wound healing (Falanga et al., 2007). When human MSC were 
seeded on photopolymerized polyethylene glycol diacrylate scaffolds and implanted 
in subcutaneous pockets in SCID mice, expression of adipogenic genes and 
histological staining successfully demonstrated in vivo adipogenesis together with 
retention of shape and dimensions (Alhadlaq et al., 2005; Bauer-Kreisel et al., 2010). 
Further studies using rabbit MSC implanted into nude mice showed new fat tissue 
formation (Choi et al., 2005). However, by using immunocompromised mice, these 
xenogeneic implantation studies only tested the adipogenic potential of MSC but not 
their immunogenicity. Thus, despite the authors suggesting the potential utility of 
MSC in adipose tissue engineering, such applications may be restricted to autologous 
cells only. 
1.4.2. Implantation of MSC into diseased tissues  
Implantation of MSC at the local site of injury or trauma has been reported in several 
animal studies which have demonstrated the efficacy of exploiting their multilineage 
differentiation capacity and immunomodulatory properties. In early studies, 
autologous MSC were injected in patients with ischaemic limbs due to peripheral 
artery disease and the findings showed that MSC achieved therapeutic angiogenesis 




due their ability to provide endothelial progenitor cells and secretion of angiogenic 
factors (Tateishi-Yuyama et al., 2002). Badiavas and co-workers used autologous 
MSC in patients with chronic wounds which did not heal for over one year and in 
whom other therapies and autologous skin grafting had failed. Complete wound 
closure and evidence of dermal healing was observed and evidence of engraftment of 
applied cells and reduced scaring was obtained from biopsies of the healed wounds 
(Badiavas & Falanga, 2003). In the treatment of patients with fracture non-union, 
autologous MSC combined with calcium sulphate were applied to the non-healing 
sites and led to callus formation and bone union  (Bajada et al., 2007). 
Allogeneic MSC have been tested in small and large animal models particularly in 
cardiac therapeutics with interesting findings. In two independent studies using 
porcine models of myocardial infarction, labelled allogeneic MSC were injected into 
the infarct and peri-infarct areas post-coronary ligation without use of   
immunosuppressive therapy. The results showed successful intramyocardial 
engraftment of the allogeneic MSC and their differentiation into cardiomyocytes and 
endothelial cells without any evidence of allogeneic rejection. The treatment led to 
preservation of left ventricular function (Caparelli et al., 2001; Makkar et al., 2005). 
These findings were supported by other independent studies using rodent (Dai et al., 
2005) and porcine (Amado et al., 2005; Quevedo et al., 2009) models of myocardial 
infarction which reported long-term survival, differentiation and engraftment of 
allogeneic MSC which contributed to the functional improvement of the hosts 
myocardium without use of immunosuppressants. In light of this evidence and 
previous findings with autologous MSC (Pouzet et al., 2001), it was thought that the 
efficacy of allogeneic MSC intramyocardial transplantation could be dose-dependent, 
thus Poh and co-workers investigated the short and intermediate-term effects of a 
repeated MSC administration strategy to evaluate the safety of an ‗off-the-shelf‘ 
allogeneic MSC cell source in a porcine model. They concluded that repeated high 
dose administration of allogeneic MSC was safe and posed no immunological risk 
(Poh et al., 2007).  
However, Poncelet and co-workers reported that allogeneic MSC were rejected in 
vivo in an allogeneic porcine model despite having been shown to be non-
immunogenic in vitro. In that study, allogeneic MSC were injected into infarcted 
areas of the myocardium while allogeneic skin grafts and MSC injected sub-




cutaneously were used as controls without immunosuppression. In all cases, it was 
found the animals developed donor-specific cellular and humoral allogeneic 
responses with antibody-complement mediated cytotoxicity (Poncelet et al., 2007). 
The study highlighted the differences between the in vitro and in vivo characteristics 
of MSC suggesting that more research is required to fully understand the 
mechanisms that control MSC immunomodulatory properties before the prospect of 
clinical application of allogeneic MSC becomes possible. 
1.4.3. Systemic implantation of MSC 
The systemic administration of MSC is aimed at exerting the immunoregulatory 
properties of MSC throughout the body due to their homing and engraftment 
capabilities at disease or trauma sites where they can differentiate into specific cell 
lineages to facilitate tissue repair and regeneration (Devine et al., 2001).  
Bartholomew and co-workers used a MHC-mismatched primate model and reported 
that intravenously administered donor MSC prolonged the survival of donor and 3
rd
 
party skin grafts (Bartholomew et al., 2002). The same group went further to report 
that following intravenous infusion of green fluorescent protein (GFP)-tagged 
autologous or allogeneic MSC resulted in the distribution and engraftment of the 
cells in 16 different tissues. They concluded that engrafted MSC participated in on-
going cell replacement and turnover in the long term (Devine et al., 2003). 
However, the results in their first study showed that the rejection of donor and 3
rd
 
party grafts was only extended by 4 days after a single or double MSC dose. Thus 
despite claims by the authors that allogeneic MSC could improve graft survival, such 
an improvement (4 days) would be of no clinical utility. Even though the 
improvement in graft survival was attributed to MSC-mediated immunosuppression, 
the immunogenicity of the donor MSC was not investigated since intravenous 
administration of antigens is known to be tolerogenic. Interestingly, when animals 
received donor grafts injected with allogeneic MSC subcutaneously, the authors 
reported that these grafts failed 4 days post-transplantation as a result of technical 
reasons. However, it is conceivable that the presence of allogeneic MSC in close 
proximity to the danger signals produced during grafting could have initiated rapid 
rejection. 




An area that has generated a great deal of interest is the systemic administration of 
MSC in the treatment of GvHD particularly during allogeneic HSC transplantation 
for treating different types of leukaemia. In a phase II clinical study, Le Blanc and 
co-workers reported the treatment of 55 patients with acute GvHD by both haplo-
identical and mismatched MSC over a 6-year period. None of the patients suffered 
any side effects during or after MSC transplantation (Le Blanc et al., 2004c; Le 
Blanc et al., 2008). Due to myeloablative conditioning which renders the recipient‘s 
immune system inactive, infused donor MSC therefore suppressed donor T-cells 
from mounting immune attack on the recipient‘s tissues. These studies therefore 
demonstrated the immunosuppressive capacity of allogeneic MSC but not their lack 
of immunogenicity.  
In a study using a murine model of GvHD however, Sudres and co-workers reported 
that allogeneic MSC failed to prevent GvHD after intravenous administration in 
lethally irradiated mice despite showing significant immunosuppressive property in 
vitro (Sudres et al., 2006). These findings therefore contradicted the reports by Le 
Banc and co-workers mentioned earlier by suggesting that the immunosuppressive 
effects of the allogeneic MSC were inadequate in stopping donor T-cell alloreactivity 
despite using MSC doses that had previously demonstrated significant 
immunosuppression in vitro. Though factors such as administered dose or their 
passage/age could affect the immunosuppressive potency of MSC, it was found that 
only traces of the infused MSC engrafted in the target organs of GvHD.  
Eliopoulos and co-workers using a murine model reported that allogeneic MSC were 
rejected after subcutaneous implantation in immunocompetent hosts. The rejection 
was characterised by an increased presence of host-derived CD8 and NK cells 
infiltrating in the implantation site (Eliopoulos et al., 2005). This study demonstrated 
that allogeneic MSC were not immunoprivileged. The rejection could have been 
facilitated by immunological danger signals at the site of implantation which are 
absent when MSC are infused intravenously. 
Similar findings were also reported by Nauta and co-workers who used a murine 
model for bone marrow transplantation in which recipient mice were either infused 
with allogeneic or syngeneic MSC under non-myeloablative settings. Though 
syngeneic MSC significantly enhanced long-term engraftment associated with 




tolerance to host and donor antigens, allogeneic MSC were associated with 
significantly increased rejection. This was further clarified when infusion of 
allogeneic MSC in naïve mice was met with robust rejection due to a memory T-cell 
response suggesting that MSC may not be intrinsically immunoprivileged and under 
appropriate conditions are rejected (Nauta et al., 2006). Furthermore, in a xenogeneic 
model of myocardial infarction in which human MSC were infused in 
immunocompetent rats showed significant rejection of the engrafted MSC 
(Grinnemo et al., 2004).  
Collectively, the evidence from both human and animal models discussed thus far 
has demonstrated the immunosuppressive potency of autologous and allogeneic MSC 
in immunocompromised settings. However, allogeneic MSC were found to be 
immunogenic when immunocompetent hosts were used.  
 
1.5. Autologous MSC or allogeneic MSC, does it matter? 
From the evidence discussed in Section 1.4, it is clear that the genetic origin of 
MSC, autologous or allogeneic, was important in the design of the experiments and 
in some cases this was the difference between success and failure of the MSC 
therapies (Tse et al., 2003; Nauta et al., 2006; Sudres et al., 2006). Ideally, 
autologous MSC are the most suitable since they pose no immunological risk to the 
patient. However, in practice there are several challenges associated with this 
approach.  
Firstly, the fraction of MSC obtained from bone marrow aspirate is very small and 
may require ex vivo expansion to increase their numbers to therapeutic levels before 
they are used in the patient. This time lag between harvesting and application, though 
more suitable for chronic conditions, is unfavourable in acute conditions. In tissue 
engineering based applications whereby ex vivo expanded MSC have to undergo 
directed differentiation in culture before use in the patient, this further increases the 
time lag from cell harvesting to the delivery of treatment. Secondly, patient-derived 
MSC may be unsuitable due to the risk of them being diseased such as in diseases of 
the bone marrow or they may be too old such as in elderly patients. These factors 
make the use of autologous MSC clinically and commercially unattractive.  




Allogeneic MSC however overcome all the challenges associated with autologous 
cells since they can be harvested, expanded and packaged prior to use. There is also 
the choice of screening potential donors to obtain the best ‗quality‘ of disease-free 
cells. Tissue engineered products could be manufactured and made available ‗off-
the-shelf‘ on demand with huge commercial benefits for industry. The major 
drawback of allogeneic MSC however, is their inherent risk of being rejected by the 
recipient immune system which could lead to failure of treatment and potential life-
threatening consequences to the patient.  
The accumulation of evidence on the immunosuppressive properties and 
immunoprivileged status of MSC has however led to an increase in studies utilising 
MSC in allogeneic settings with the hope of potential clinical utility. In order to 
appreciate the controversy surrounding the immunological status of allogeneic MSC, 
it is necessary to understand the basis of allorecognition and the mechanisms by 
which allogeneic cells are rejected by the recipient immune system. 
 
1.6. The immune system – how does it work? 
1.6.1. The immune system 
All the mechanisms used by an organism to protect itself from foreign environmental 
agents such as pathogenic microorganisms and their products, chemicals and 
materials from other organisms in order to prevent corruption of ‗self‘, form the 
immune system. In vertebrates including humans and mice, the immune system is 
divided into two parts namely innate and adaptive/acquired immunity.  
1.6.1.1. Innate immunity 
This is the natural resistance with which an organism is born and includes physical 
barriers (skin and mucous membranes), chemical agents (cytokines associated with 
the inflammatory response and complement) and cellular responses (non-specific 
leukocytes). All these elements combine synergistically to eliminate foreign 
substances. Though this type of immunity has no memory and generally referred to 
as non-specific, this is not entirely true as cellular components such as macrophages 
and DC are able to recognise ‗self‘ from ‗non-self‘ by use of pattern recognition 
receptors (PRR), for example the well characterised toll-like receptors [TLR] (Akira 




et al., 2006). This is particularly important in the elimination of microorganisms that 
have penetrated or evaded detection by the physical and chemical barriers and also in 
the initiation of the adaptive immune response. 
1.6.1.2. Adaptive/ acquired immunity 
This is the specialised branch of the immune system and is characterised by two 
main features absent in innate immunity; specificity and long-term immunological 
memory (an increased and rapid response against a previously encountered antigen) 
against specific foreign antigens. Active adaptive immunity involves the acquisition 
of immunity through natural encounter with foreign antigens (such as during 
infection) or through deliberate administration of live or attenuated foreign antigens 
(such as during vaccination). 
The cellular components that participate in this type of immunity are T- and B-
lymphocytes as well as antigen presenting cells (APC) such as DC which are also 
involved in innate immunity. Both types of lymphocytes are formed in the bone 
marrow from their HSC progenitor cells during lymphoid haematopoiesis. Whereas 
T-cells migrate to the thymus for maturation, B-cells mature in the bone marrow and 
spleen. B- and T-lymphocytes mediate the two branches of adaptive immunity 
namely humoral and cell-mediated immunity. Despite using different mechanisms, 
these systems collaborate to achieve the goal of protecting the body from foreign 
antigens (Coico & Sunshine, 2009).  
1.6.1.2.1. Humoral immunity 
This arm of acquired immunity is mediated by antibodies (immunoglobulin [Ig] 
molecules) produced and secreted into the plasma by differentiated B-cells (plasma 
cells). Antibody production in response to specific antigens is initiated when the 
antigen binds to the specific antibody surface receptor expressed by B-cells which 
triggers clonal expansion and differentiation leading to the production of the 
antibodies specific for the stimulating antigen. This process is CD4
+ 
T-cell dependent 
in most cases. The antibody-antigen complexes are eliminated by phagocytes which 
may be facilitated by complement activation via the classical pathway (Janeway et 
al., 2001).  




1.6.1.2.2. Cell-mediated immunity 
This type of immunity is mediated by T-lymphocytes and does not involve 
antibodies. The T-cells recognise foreign antigens displayed via molecules of the 
MHC on APCs by means of surface bound T-cell receptors (TCR) which are specific 





 (cytotoxic) cells based on the type of co-receptor molecules 
associated with the TCR which play an important role in binding of T-cells with 
APC during antigen presentation, a process that leads to the distinction of ‗self‘ from 
‗non-self‘ antigens (Coico & Sunshine, 2009).  
In the context of the work carried out in this study, emphasis was focused on the cell-
mediated immune response (specifically T-lymphocytes) towards syngeneic (self) 
and allogeneic (non-self or foreign) cells. Therefore, an explanation of the basis of 
allorecognition is necessary. 
 
1.7. Basis of immunological response to allogeneic cells and tissues – 
allorecognition 
1.7.1. Antigen presentation 
When allogeneic or foreign cells are transplanted into an immunocompetent host, 
they are rejected by the host immune system. The first step in this process occurs 
when foreign antigens bound to the MHC molecules are presented at the cell surface 
by donor or recipient APC for recognition by the recipient‘s T-cells. This process is 
known as ‗antigen processing and presentation‘ and includes all the events involved 
in the generation of peptide epitopes from proteins inside APC and the subsequent 
binding of these epitopes to MHC molecules and display at the cell surface.  
The MHC in humans is a highly polymorphic cluster of genes which encodes protein 
products (HLA molecules) divided into class I and II. MHC I molecules (HLA A, B 
and C) are expressed on all nucleated cells while MHC II (HLA DP, DQ and DR) 
molecules are expressed on specialised APC including DC, macrophages and B-
cells. When a protein epitope is bound, they form an immunologically recognisable 
complex. The APC acquire foreign antigens by phago-, pino- and endocytosis and 




process them to yield smaller peptides (epitopes) which become bound to MHC II 
molecules before they are presented on the cell surface of the APC. Other cells such 
as dermal fibroblasts (DF) and endothelial cells however, can be induced by 




 cells recognise epitopes on APC bound to MHC II and are the predominant 
mediators of the immune response through secretion of cytokines that can modulate 
the immune response by exacerbating or suppressing it. CD8
+
 cells however, 
recognise epitopes bound to MHC I and are capable of killing the cells bearing the 
foreign epitopes. CD8
+
 cells are involved in the destruction of transplanted cells 
during allograft rejection. 
The difference in the nature of antigens presented by MHC I and MHC II molecules 
is that the former binds intracellular or endogenous antigens synthesized within the 
cell (generally of viral or parasitic origin present in the cytoplasm) while the latter 
only binds extracellular or exogenous antigens internalised in acid vesicles taken up 





 T-cells recognise foreign epitopes bound to surface MHC II or 
I molecules of APC via their T-cell receptors (TCR), the resulting interaction usually 
leads to T-cell activation which then triggers the immune response. The TCR is 
comprised of two disulphide bond-linked and  trans-membrane proteins which 
are capable of binding epitope but are incapable of transducing the signal 
downstream. TCR are constitutively linked to the CD3 molecule complex whose 
intracellular portions contain protein tyrosine kinase (PTK) recognition motif also 
known as immunoreceptor tyrosine-based activation motif (ITAM). These ITAMs 
are substrates of src family PTKs whose phosphorylation is the initial step in T-cell 
signalling (Qian et al., 1993; Iwashima et al., 1994). 
The binding of MHC-epitope complex by TCR, though being the first signal, is not 
necessarily sufficient for T-cell activation but requires the presence and participation 
of co-stimulatory and adhesion molecules which help to strengthen and stabilise the 
MHC-epitope-TCR complex as explained by the single encounter model (Friedl & 
Gunzer, 2001). The overall association between the T-cell and APC, known as the 




‗immunological synapse‘ (Irvine et al., 2002), brings larger areas of the cells into 
contact and increases the contact time between the cells. Immunological synapses 
have been observed to be stable for at least one hour after formation (Friedl & 
Gunzer, 2001). The CD4 and the CD8 proteins bind to the invariant regions of the 
MHC II and MHC I respectively to strengthen the binding of the MHC-epitope 
complex to the TCR. This ‗clustering‘ of the CD4 and CD8 molecules with the TCR 
complexes is an important process for triggering signal transduction that leads to T-
cell activation, cell division and effector functions (Konig & Zhou, 2004).  
The most important co-stimulatory interactions are between CD40 and B7 molecules 
(CD80 and CD86) on the APC with their corresponding ligands CD40L and CD28 or 
CTLA-4 (cytotoxic T-lymphocyte antigen 4) on the T-cells respectively. The co-
stimulatory molecules provide additional signals required for full T-cell activation 
especially the activation of unprimed T-cells but are thought to be less necessary for 
activation of primed T-cells or memory T-cells (Coico & Sunshine, 2009). It is 
thought they help to bring the intracellular molecules involved in T-cell activation 
into close proximity to the TCR-MHC-epitope complex while dispersing those not 
involved away from the contact area thereby enhancing and sustaining the signals 
transduced by the MHC-epitope to the TCR-CD3 complex (Figure 1.2).  
The adhesion molecules CD2 and LFA-1 (lymphocyte function-associated antigen 1) 
on the T-cells also bind to their corresponding ligands CD58 and CD54 on APC 
respectively and these interactions are thought to form an outer adhesive ring whose 
major function is to provide strong adhesive anchoring of the T-cell to the APC. 
These adhesive interactions prevent the T-cell and APC moving apart in order to 
allow the time for the TCR to ‗sample‘ the contents of the MHC-peptide complex. 
Thus, adhesive molecules stabilize what would otherwise be transient interaction 
between the cells.  
Once, activated, CD4
+
 cells undergo interleukin-2 (IL-2) dependent clonal expansion 
and further differentiation. The differentiated effector cells secrete various cytokines 
which affect the function of multiple cell types of both the innate and adaptive 
immunity. A population of the dividing CD4
+
 cells develop to become antigen-
specific CD4
+
 memory cells which are responsible for the swiftness and 
effectiveness of the secondary T-cell response. The CD4
+
 memory cells differ from 






 cells by expressing increased levels of CD44 and reduced levels of 
CD62l as well as changes of CD45RA to CD45RO. It is currently believed that the 
B7-CD28 co-stimulation is not a necessity for the stimulation of CD4
+
 memory cells 
(Coico & Sunshine, 2009). Once activated by recognition of MHC I-epitope, naïve 
CD8
+
 cells also undergo clonal expansion and differentiation into effector cells and 
memory cells. Clonal expansion is dependent upon IL-2 generated by CD4
+
 cells. 
Hence the priming of CD8
+





 cells also known as cytotoxic T-lymphocytes (CTL) kill the cells 
bearing the foreign epitopes by two main mechanisms both of which require efferent 
recognition of MHC I-epitope. One pathway involves the release of granules 
containing perforins and granzymes into target cells. The second pathway involves 
activation-induced cell death via the Fas-FasL caspase apoptotic mechanism (Coico 
& Sunshine, 2009). It is relevant to note at this point that the lack of MHC II and co-
stimulatory molecule expression by MSC could have implications for their ability to 
interact with various cellular components of the immune system. 
 
Figure 1.2. Antigen presentation by a professional APC to T-lymphocytes. Processed 





 T-lymphocytes respectively. Successful antigen presentation is enabled by binding 
of co-stimulatory molecules to form a strong and long-lasting immunological synapse which 
leads to activation of the lymphocytes accompanied by secretion of a milieu of 
immunoactive cytokines and growth factors. Adapted from Coico & Sunshine (2009). 





The transplantation of cells or tissues between genetically distinct individuals of the 
same species initiates a unique and complex immune response with the purpose of 
distinguishing ‗self‘ from ‗non-self‘ and the eventual rejection of the allograft. 
Allorecognition refers to the T-cell mediated recognition of genetically encoded 
polymorphisms between members of the same species which are present in the MHC 
molecules. In clinical transplantation, donor-derived polymorphic HLA molecules 
are recognised as foreign by recipient T-cells which initiate allograft rejection. 
Unless immunosuppression therapy is employed, the donor allografts are rejected. 
The rejection can be classified according to its swiftness as acute and chronic 
depending on the mechanism of the rejection process. Acute and chronic rejection 
are mediated by T-cells and detected within two weeks to months respectively. A 
third type of allograft rejection is theoretically possible, known as hyperacute 
rejection. This is mediated by pre-formed antibodies to donor antigens and occurs 
within minutes. In clinical transplantation, however, this is mitigated by cross-
matching of recipient serum with donor graft (Caballero et al., 2006).  
Although MHC incompatibility is responsible for allograft rejection, minor 
histocompatibility antigens (mH) have also been reported to be responsible for rapid 
allograft rejection (Game & Lechler, 2002). These antigens are derived from 
allelically polymorphic proteins which are usually presented in the groove of MHC I 
and II molecules. Approximately 40 mH antigenic differences are thought to exist 
between strains of inbred mice and several mH antigens have also been identified in 
humans. HLA matching can reduce the severity of alloimmune responses in clinical 
transplantation (25-30 % chance of finding an identical HLA haplotype among 
family members) but the chances of finding an HLA identical unrelated donor is 
virtually impossible given the enormous polymorphisms of the MHC system. 
Immunity against mH antigens is a clinically significant problem evidenced by the 
need for immunosuppressive treatment of recipients of HLA identical organ grafts 
and the incidence of GvHD following HLA identical HSC transplantation 
(Hernandez-Fuentes et al., 1999; Game & Lechler, 2002).  
Allorecognition was first demonstrated in vitro in MLR experiments in which 
peripheral blood mononuclear cells (PBMC) from two unrelated individuals were co-




cultured with resulting ‗blast-formation‘ or lymphocyte proliferation resulting from 
allorecognition (Bain et al., 1964; Bach & Voynow, 1966; Moorhead et al., 1967). 
MLR have been used as a model in the study of mechanisms involved in allograft 
rejection and the determination of histocompatibility in tissue matching as they are 
considered to be the in vitro correlate of in vivo acute allotransplant rejection. 
There are three major pathways of allorecognition namely the direct, indirect and 
semi-direct pathways. The development of knockout and transgenic mice has 
allowed the study of the different pathways in isolation. It was historically thought 
that the direct pathway alone was responsible for allorecognition since the T-cell 
repertoire was found to contain a high proportion of alloreactive cells (Gökmen et 
al., 2008). 
1.7.2.1. Direct pathway 
This pathway involves the recognition of intact donor MHC I and II plus epitope on 




 T-cells respectively 
(Figure 1.3). Paradoxically, the classic self-MHC restriction property of T-cells 
would suggest non-reactivity since the donor antigens are not presented in the 
context of ‗self‘ MHC (Gökmen et al., 2008).  
Several models for the direct pathway have been postulated but the widely accepted 
ones include the high determinant density (HDD) model and the multiple binary 
complex (MBC) model which differ in the importance given to the presence of 
peptide antigen in the MHC-epitope complex.  
The HDD model proposes that recipient T-cells recognise the exposed unique 
residues on allogeneic MHC molecules regardless of the nature of epitope in the 
MHC groove (Portoles et al., 1989). Since donor MHC molecules are present at high 
density on the cell surface of APC, thus each molecule serves as a ligand for a 
specific alloreactive T-cell and then there will be a high density of ligands for the T-
cells in comparison to the density of MHC-epitope complexes. This high ligand 
density therefore allows T-cells of lower affinities to respond to the donor MHC 
leading to a high frequency of alloreactivity. Evidence of this model was 
demonstrated in independent studies in mice in which blocking the TCR contact 
regions of allogeneic MHC using synthetic peptides inhibited specific alloresponses 




presumably by inhibition of MHC-TCR contact (Schneck et al., 1989; Lombardi et 
al., 1991). Stronger evidence for this model was demonstrated in mouse CD8
+
 
lymphocytes whereby stimulation occurred in the absence of  peptide antigens in the 
MHC groove (Smith et al., 1997). 
The MBC model however proposes that the presence of peptide antigen in the 
allogeneic MHC groove is a pre-requisite for allorecognition by recipient T-cells in a 
similar manner to conventional self-restricted responses. The hypothesis is that host 
T-cells recognise specific antigenic peptides in the donor MHC grooves and 
differences in allogeneic MHC groove causes different sets of peptides to be 
presented from homologous proteins. Thus a single MHC mismatch between donor 
and recipient would be adequate to stimulate an immune response (Game & Lechler, 
2002). Another version of the model proposes that any particular cell surface MHC 
protein is complexed with a naturally arising peptide from the intracellular 
proteolytic machinery forming a heterogeneous population of binary complexes 
which can be recognised by many different T-cell clones in the host (Bharat & 
Mohanakumar, 2007). Therefore, each allogeneic MHC-antigen complex is 
recognised by a different T-cell and a single MHC incompatibility potentially results 
in the stimulation of a wide diversity of alloreactive T-cells (Afzali et al., 2007). This 
hypothesis was supported by evidence that a mutant cell-line incapable of antigen-
processing and allostimulation regained the ability to stimulate alloresponse 
properties after transfection with MHC II-antigen complexes (Weber et al., 1995). In 
another study, CD8
+
 T-cells were shown to be specific to a self-peptide presented by 
foreign MHC I molecules with no evidence of peptide-independent components 
(Whitelegg et al., 2005).  
It is thought that both mechanisms can contribute to the direct pathway with the 
contribution of each being related to the site and magnitude of differences in MHC 
molecules between donor and recipient cells (Afzali et al., 2007). The direct 
recognition of allo-MHC-epitope without the need for antigen processing and 
presentation with ‗self‘ MHC is thought to be responsible for the rapid and vigorous 
nature of in vitro MLR and in vivo acute rejection.   





Figure 1.3. The direct pathway of allorecognition. Intact donor MHC-peptide complexes 
on donor APC are recognised by the recipient‘s T-cells, with CD8+ cells recognising MHC I 
molecules and CD4
+ 
cells recognising the MHC II molecules. Adapted from Gökmen et al., 
(2008). 
1.7.2.2. Indirect pathway 
This pathway involves the presentation of processed donor antigens by recipient 
APC to recipient T-cells. It differs from the direct pathway by its requirement for 
antigen processing and use of ‗self‘ MHC during antigen presentation. It is widely 
thought to be the mechanism involved during chronic allograft rejection (Gökmen et 
al., 2008). CD4
+
 T-cells dominate the indirect response as alloantigens shed from the 
graft are processed by recipient professional APC and presented in the context of 
‗self‘ MHC II (Figure 1.4). Though this response is chronic, it is amplified through 
the continuous processing of alloantigens so long the allograft is present.  
Prior to discovery of the indirect pathway, allograft rejection was thought to be 
elicited by the direct pathway alone due to the high frequency of direct pathway 
alloreactive T-cells in the T-cell repertoire. Analysis of mouse lymph node T-cells 
showed that over 90% of the allospecific T-cell repertoire was capable of direct 
allorecognition while only 1-5% accounted for the indirect alloantigen recognition 
(Benichou et al., 1999). Auchincloss and co-workers provided conclusive evidence 
of the existence of the indirect pathway by demonstrating that MHC I knock-out 
recipient mice rejected skin grafts from MHC II knock-out donor mice (Auchincloss 
et al., 1993). In this case, the recipient mice lacked CD8
+
 cells capable of 




recognising donor MHC I molecules by the direct pathway, thus the recipient CD4
+
 
cells could only be stimulated by donor MHC I indirectly presented in the context of 
recipient MHC II molecules. This demonstrated that the indirect pathway alone was 
sufficient to elicit allograft rejection. It has also been shown that recipient APC such 
as DC, are capable of acquiring and processing intact donor MHC molecules from 
donor cell debris and subsequently stimulating CD8
+
 cells by cross priming (Albert 




 cells are 
involved in the indirect pathway. In rodent models, animals immunised with 
allogeneic MHC II peptides prior to receiving allografts which by definition should 
stimulate the indirect but not direct pathway, swiftly and strongly rejected the 
allografts. However, intrathymic injection of the same peptides resulted in the down 
modulation of the indirect pathway sufficiently to allow prolonged survival of 
subsequent allografts of the same MHC thus demonstrating the importance of help 
from CD4
+
 T-helper cells stimulated by the indirect but not the direct response 
(Afzali et al., 2007). 
The concept of ‗passenger cells‘, in which an allograft brings with it 
immunostimulatory ‗passenger‘ APC was supported by several studies including the 
prolonged survival of in vitro cultured thyroid tissue in mice presumably due to loss 
of ‗passenger‘ APC (Lafferty et al., 1976) and permanent survival of rat renal 
allografts by ‗parking‘ the kidney in an intermediate recipient  thereby depleting the 
allograft of donor passenger cells. However, in later studies, it was shown that 
inhibition of acute rejection by depleting ‗passenger‘ APC significantly delayed but 
did not prevent the later development of chronic rejection (Bharat & Mohanakumar, 
2007). Despite the rapid decline of direct pathway alloreactive T-cells after 
transplantation, the indirect pathway continues to present donor antigens to the 
recipient immune system for as long as the allograft is present due to the continuous 
influx of donor-processed antigens by recipient APC and this has been shown in 
several clinical studies involving patients with chronic heart, kidney and lung 
transplant rejection (Liu et al., 1996; SivaSai et al., 1999).  
Since the indirect pathway is a slower mechanism than the direct pathway in eliciting 
allograft rejection, the current hypothesis is that the direct pathway dominates the 
early post-transplant period while the indirect pathway becomes prominent with 
time.  







Figure 1.4. The indirect pathway of allorecognition. Antigens from any donor cells, 
resulting from shed, donor MHC-antigen complexes, apoptotic or necrotic cells are 




 T-lymphocytes by 
recipient APC in the context of recipient‘s own MHC II and MHC I respectively. The result 
is presentation of foreign peptide complexed to self MHC to self T-cells. Adapted from 
Gökmen et al., (2008). 
 
1.7.2.3. Semi-direct pathway 
This pathway was proposed after the transfer of intact MHC molecules between cells 
was observed with DC acquiring MHC I and II-epitope complexes by either cell to 





T-cells (Théry et al., 2002; Jiang et al., 2004). This 
pathway combines both the direct and indirect pathways. 
Traditionally, ‗cross-talk‘ between the direct and indirect pathways (whereby CD4+ 
with indirect alloreactivity could stimulate or suppress direct pathway CD8
+ 
T-cell 
responses) was thought to be based on the 4-cell unlinked model in which CD8
+
 cells 
are stimulated via the direct pathway by donor cells whereas CD4
+
 T-helper or T-
regulatory cells were recruited by ‗self‘ professional APC via the indirect pathway 
(Afzali et al., 2007). 




 However, in the semi-direct pathway, intact donor MHC-epitope complexes are 
transferred to recipient professional APC thereby allowing the stimulation of CD8
+
 
T-cells by the direct pathway whilst alloantigens picked up by the same recipient 
professional APC are processed and presented in association with ‗self‘ MHC II to 
recruit CD4
+ 
T-cells by the indirect pathway (Caballero et al., 2006; Afzali et al., 
2007; Gökmen et al., 2008). In this way, both donor-MHC-epitope and self-MHC 
loaded with donor-MHC derived epitope can be presented on the surface of the same 
cells thus allowing CD8
+
 T-cells with direct allospecificity to receive linked help 
from helper CD4
+
 T-cells with indirect allospecificity in a 3-cell model (Figure 1.5) 
(Lee et al., 1994; Smyth et al., 2007). This model fills the gaps in which the 4-cell 
unlinked model is non-compliant (Afzali et al., 2007)  
 Recent work has confirmed that MHC transfer occurs in vivo (Riond et al., 2007) 
and that allo-MHC can stimulate T-cell responses when delivered in exosomes 
(Morelli et al., 2004). Importantly, work by Peche and co-workers showed 
immunological tolerance induction in rats that had received MHC mismatched 
cardiac allografts through the delivery of donor MHC-epitope complexes in 
exosomes (Pêche et al., 2006). However the transfer of intact donor MHC-epitope 
complexes may also provide a means by which CD8
+
 cells with direct allospecificity 
continue to be stimulated after donor APC have been depleted, potentially 
accounting for the longevity of the direct pathway following transplantation in some 
cases (Gökmen et al., 2008). However, there is no evidence yet to suggest the 
clinical relevance of this pathway in the context of allograft rejection. 





Figure 1.5. The semi-direct pathway of allorecognition. The process results from the 
transfer of intact donor-MHC-antigen complexes from donor APC to recipient APC by 
mechanisms involving cell to cell contact or exosomes. Once taken up, recipient APC either 
presents intact donor-MHC I or II-antigen complex directly to recipient‘s CD8+ (a) or CD4+ 
(b) T-cells respectively. Alternatively, recipient APC processes the donor antigen and 
presents it in the context of self MHC II to recipient‘s CD4+ T-cells. Once activated, the 
CD4
+
 T-cells can help CD8
+
 T-cells with allospecificity. Adapted from Gökmen et al., 
(2008). 
 
1.8. Immunology of MSC 
1.8.1. Immunogenicity of MSC 
At this point, it is important to reflect on the perceived immunoprivilege properties 
of MSC. As was discussed previously, any allogeneic cell that expresses MHC 
molecules and the appropriate co-stimulatory and adhesion molecules is capable of 
stimulating allogeneic T-cells via the direct, indirect or semi-direct by mechanisms 




described in Section 1.7.2. Regardless of the pathway, the cells will be rejected. 
Considering the MSC phenotype described previously in Section 1.3.3.4, their lack 
of MHC II suggests that they are only potentially capable of stimulating CD8
+
 T-
cells. Their lack of the co-stimulatory molecules CD40, CD80 and CD86  makes 
them incapable of forming strong and longer lasting immunological synapses with 
CD8
+
 cells which makes them hypoimmunogenic or poorly immunogenic and less 
likely to stimulate CD8
+
 cells via the direct pathway (Figure 1.6). However, in light 
of the indirect and semi-direct pathways, it is possible to speculate that in the 
presence of recipient APC which can scavenge any shed MSC debris or MHC I and 
process them for presentation with ―self‖ MHC II, allogeneic MSC could eventually 
stimulate CD4
+
 cells by the indirect pathway. Also, after interaction with recipient 
APC, direct transfer of intact MHC I or indirectly through exosomes, could lead to 




 T-lymphocytes via the semi-direct pathway. 
These possibilities cannot be discounted when investigating the immunogenicity of 
allogeneic MSC  
The evidence that allogeneic MSC are immunoprivileged came from in vitro LTA in 
which allogeneic MSC were co-cultured with PBMC. The assay is based on the 
rationale that when lymphocytes encounter foreign MHC-epitope complexes, they 
are activated and proliferate to produce effector cells which participate in the 
response against the epitope. The LTA will be discussed in detail in Chapter 4.  
Klyushnenkova and co-workers tested whether human allogeneic MSC elicited a 
proliferative response against purified T-lymphocytes by measuring the in vitro 
uptake of radioactive tritiated thymidine (
3
H-thymidine). Over a 10 day period, the 
mitotically inactivated allogeneic MSC failed to stimulate lymphocyte proliferation. 
This suggested that the allogeneic MSC were non-immunogenic. Treatment of 
allogeneic MSC with IFN to stimulate MHC I and II expression and retroviral 
transduction to stimulate expression of co-stimulatory molecules prior to co-culture 
with T-lymphocytes failed to stimulate lymphocyte proliferation. When mitotically 
inactivated allogeneic PBMC were used as stimulator cells in the control experiment, 
significant stimulation of the responder lymphocytes was detected (Klyushnenkova 
et al., 2005).This evidence suggested that allogeneic MSC were incapable of 
stimulating T-lymphocytes via the direct pathway of allorecognition. When 
responder PBMC were co-cultured with allogeneic MSC, lymphocyte proliferation 




was detected despite being 60 % less than control (PBMC as stimulator). The authors 
concluded that allogeneic MSC were immunologically inert despite them having 
stimulated PBMC albeit lesser than the controls. This partial stimulation could be 
relevant in vivo. In addition, the failure of allogeneic MSC to stimulate purified T-
lymphocytes alone may be inadequate to suggest immunoprivilege as the presence of 
DC and macrophages in unseparated PBMC could facilitate allorecognition via the 
indirect and semi-direct pathways.  
Treatment of human allogeneic MSC with IFN to stimulate MHC I and II 
expression as well as retroviral transduction to stimulate expression of co-stimulatory 
molecules or use of anti-CD28 antibodies prior to co-culture with T-lymphocytes 
failed to stimulate lymphocyte proliferation in two independent studies (Tse et al., 
2003; Klyushnenkova et al., 2005). This was also confirmed in an allogeneic porcine 
model (Poncelet et al., 2007). However, following intracardiac injection of 
allogeneic MSC in vivo, they were robustly rejected by the recipient animals which 
demonstrated that allogeneic MSC were immunogenic. This highlighted the 
disparities between in vitro and in vivo studies particularly the time period allowed 
for experiments. In these studies, the in vitro assays (days) were carried out in much 
less time in comparison to in vivo experiments (weeks).  
In a murine model, irradiated allogeneic MSC co-cultured with mononuclear cells at 
a 1:1 ratio failed to stimulate allogeneic T-lymphocyte responses whereas control 
irradiated allogeneic MNC induced T-lymphocyte proliferation (Sudres et al., 2006). 
The authors concluded that allogeneic MSC were non-immunogenic. The 
experiments were carried out in 4 days which is within the standard 3 to 5 day period 
commonly used in LTA. However, it can be argued that this time was insufficient to 
detect allorecognition via the indirect and semi-direct pathways as previously 
discussed in Sections 1.7.2.2 and 1.7.2.3.  
Le-Blanc and co-workers investigated the immunogenicity of allogeneic human 
undifferentiated and differentiated (adipocytes, chondrocytes and osteocytes) MSC at 
different cell densities. In some assays, the allogeneic MSC were treated with IFN 
to stimulate expression of MHC II. The results showed that both undifferentiated and 
differentiated allogeneic MSC failed to stimulate PBMC after 6 days of co-culture 
(Le Blanc et al., 2003b). This study was similar to that by Klyushnenkova and co-




workers discussed earlier in which allogeneic MSC stimulated PBMC at day 8 but 
not at day 6. This illustrates the effect of incubation time for the LTA. Allowing 
more incubation time could facilitate allorecognition via the indirect or semi-direct 
pathways whereas shorter incubation may only capture direct allorecognition. This 
was highlighted in another study which used a rabbit model in which allogeneic 
MSC failed to stimulate PBMC in vitro after 6 days incubation but were rejected in 
vivo after 12 days (Liu et al., 2006). Interestingly, in a separate  in vivo murine study, 
transplanted allogeneic MSC were not rejected after 28 days post-transplantation and 
were found to participate in wound healing (Chen et al., 2009).  
Overall, the evidence from in vitro studies suggests that allogeneic MSC are 
immunoprivileged but in vivo studies show that they are immunogenic. Thus, to date, 
the immunogenicity of allogeneic MSC remains controversial. 
 
 
Figure 1.6. MSC antigen presentation. Due to lack of MHC II and co-stimulatory 
molecules CD40, CD80 and CD86, donor allogeneic MSC are unable to form a stable 
immunological synapse with recipient CD8
+
 T-cells. The weak associations are thought to 
potentially lead to T-cell anergy, tolerance induction and eventual immunoprivilege. 
Adapted from Coico & Sunshine (2009). 
 




1.8.2. MSC immunosuppression 
In addition to being regarded as immunoprivileged, MSC are also generally 
described as a ‗universal‘ suppressor of the immune system (Chen et al., 2006).  
Evidence that MHC–mismatched MSC transplanted into a recipient induced 
tolerance to allogeneic or xenogeneic grafts was first obtained using allogeneic 
mouse and rat models (Ildstad & Sachs, 1984). Two decades later, these findings 
were reported for the first time using human bone marrow-derived MSC (Di Nicola 
et al., 2002). Since then, a great deal of studies using animal and human MSC have 
been carried out using adaptations of the MLR to test their immunomodulatory 
properties. The MLR is described in detail in Chapter 4. 
This assay involves the co-culture of two sets of allogeneic PBMC and results in 
proliferation of T-lymphocytes due to MHC disparity hence it is regarded as the in 
vitro correlate to allogeneic rejection. The incorporation of MSC in MLR has been 
widely reported to suppress T-cell proliferation. Although the mechanisms by which 
they achieve this are not fully understood, MSC are thought to actively interact with 
individual constituents of both the innate and adaptive immunity inducing a wide 
range of effects which culminate in immunosuppression, anergy and tolerance 
induction (Ryan et al., 2005). 
1.8.2.1. MSC and T-lymphocytes 





activation and proliferation induced by non-specific mitogens, polyclonal antibodies 
against CD3 and CD28 and 3
rd
 party alloantigens in many in vitro models 
(Bartholomew et al., 2002; Di Nicola et al., 2002; Krampera et al., 2003; Tse et al., 
2003; Le Blanc et al., 2003b; Xu et al., 2007). When treated with IFNto induce 
MHC II expression(Le Blanc et al., 2003b), both allogeneic and autologous MSC 
equally suppressed MLR. This suggested that the immunosuppression was 
independent of MHC (Le Blanc et al., 2003c). The degree of T-lymphocyte 
suppression was found to be dose-dependent; with marked suppression observed 
when a higher (1:10) MSC to T-lymphocyte ratio was used while lower ratios (1:100 
- 1:1000) produced a stimulatory effect (Di Nicola et al., 2002; Le Blanc et al., 
2003b). This is particularly interesting in clinical application as it suggests that 




inadequate doses of allogeneic MSC could be harmful whereas high doses could 
potentially render patients immunocompromised. 
One theory proposes that MSC may have ‗veto-like‘ activity, acting as ‗fraudulent‘ 
APC which specifically inhibit naïve T-lymphocyte clones that interact with them 
(Potian et al., 2003). Generally, CD8
+
 ‗veto‘ cells are known to facilitate graft 
acceptance by causing the deletion of responding T-lymphocytes in a pathway 
mediated by TGF1 which has been reported to play a role in MSC-induced 
suppression of CD8
+
 T-lymphocyte proliferation. Therefore, by acting directly or 
indirectly through other ‗veto‘ cells, MSC may inhibit T-lymphocytes (Chen et al., 
2006). 
Cell division arrest in T-lymphocytes exposed to both non-specific and alloantigen 
stimulation in the presence of either autologous or allogeneic MSC is thought to be at 
the G0/G1 phase of mitosis. Accumulation of T-lymphocytes at the G0 phase has been 
detected (Uccelli et al., 2006) which suggested T-lymphocyte quiescence as opposed 
to T-lymphocyte apoptosis. MSC have also been shown to support the survival of 
over-stimulated T-lymphocytes which would otherwise undergo Fas/FasL-dependent 
activation induced cell death (Benvenuto et al., 2007). Thus, the MSC-induced T-
lymphocyte anti-proliferative effect is associated with quiescence which can be 
reversed by IL-2 stimulation (Uccelli et al., 2006).  
MSC have been shown to down-regulate CTL-mediated cytotoxicity in MLR when 
added before the start but not during the cytotoxic phase (Rasmusson et al., 2003; 
Angoulvant, 2004). MSC pulsed with viral peptides were protected from CTL-
mediated lysis, even after IFN treatment to increase expression of MHC I (Morandi 
et al., 2008) suggesting that MSC may affect the afferent phase of alloreactivity and 
prevent CTL-mediated cytotoxicity. Once CTL are activated, MSC have no effect 
suggesting they do not affect  CTL (Uccelli et al., 2006) but there is little evidence to 
support this notion. 
Another school of thought suggested that MSC induced T-lymphocyte anergy after 
cell to cell contact. Some T-lymphocyte encounters with MHC-epitope complexes 
led to clonal anergy. In such cases, whether anergy ensued or clonal expansion was 
reinstated largely depended on the absence or presence of co-stimulatory signals 




respectively. Since MSC lacked the key co-stimulatory signals, it was thought that 
they achieved immunosuppression by inducing T-lymphocyte anergy. However, 
experiments using mouse models suggested that allogeneic MSC induced T-
lymphocyte tolerance, as opposed to anergy, since the lymphocytes failed to 
proliferate after the removal of the MSC (Glennie et al., 2005; Zappia et al., 2005). 
Earlier studies using mouse and human MSC however disagreed with this notion by 
suggesting that the perceived tolerance was transient and T-lymphocyte 
responsiveness could be restored (Di Nicola et al., 2002; Krampera et al., 2003).  
Another model postulated that MSC exerted immunomodulatory properties by 
stimulating the development of a subset of CD4
+
 T-lymphocytes known as T-
regulatory cells (T-regs). Naïve CD4
+
 cells expressing CD25 develop into T-regs 
whose role is to regulate or suppress other cells in the immune system and are 
important in cases such as prevention of autoimmune diseases. The two types of T-








) which are 





) which are antigen-specific and formed by differentiation of 
naïve T-lymphocytes outside the thymus; they include IL-10 secreting T-reg1 and 
TGF secreting TH-3 lymphocytes (Levings et al., 2001b; Sakaguchi, 2004).  
In MLR, MSC have been reported to induce IL-10 production which led to an 















 cells in IL-2 stimulated cultures. CTLA4 is a ligand for the 
co-stimulatory CD80 and CD86 and is thought to transmit a T-cell inhibitory signal. 




 (a marker for cell activation) 
lymphocytes decreased in the presence of MSC in mitogen-stimulated lymphocyte 
cultures (Le Blanc et al., 2004a; Aggarwal & Pittenger, 2005). However, this 
evidence is controversial as other studies found conflicting results (Aggarwal & 
Pittenger, 2005; Glennie et al., 2005; Maccario et al., 2005) and this was attributed to 
the differences in culture conditions (Chen et al., 2006). Also, there is no in vivo data 
to date to confirm this notion. An important consideration is that MSC-mediated 
induction of T-regs may pose a concern in the clinical application of MSC as 
excessive T-regs activity may leave the immune system unable to fight infections.   
                                                 
1
 FoxP3 – Forkhead box P3 
2
 CTLA4 – cytotoxic T lymphocyte antigen 4 




Finally, one of the major ways in which MSC are thought to modulate T-lymphocyte 
function is by secretion a milieu of soluble immunoactive factors. These factors were 
reported not to be constitutively expressed by MSC as supernatant from MSC 
cultures failed to suppress T-lymphocyte proliferation (Le Blanc & Ringden, 2007). 
This suggested that these factors were only secreted by MSC after ‗cross-talk‘ with 
other cells. Nitric oxide (NO), indoleamine-2,3-dioxygenase (IDO) and prostaglandin 
E2 (PGE2) are thought to be released by MSC after stimulation by IFN produced by 
T-lymphocytes (Ryan et al., 2007).  
IDO is an enzyme that converts tryptophan (essential for lymphocyte proliferation) to 
kynurenine. Its presence in culture causes tryptophan depletion which would inhibit 
T-cell proliferation. IFN has been reported to stimulate IDO activity in a dose-
dependent manner and high IDO activity has been detected in responder T-
lymphocytes stimulated by mitomycin C treated PBMC in the presence of MSC. 
Restoration of tryptophan restored T-lymphocyte proliferation suggesting that IDO 
activity acted as a T-cell inhibitory effector system (Meisel et al., 2004). On the 
contrary, when unseparated PBMC were used as responders, tryptophan depletion 
was not found to be responsible for immunosuppression as apoptotic cell death was 
not seen which would be expected to result from tryptophan depletion (Aggarwal & 
Pittenger, 2005).  
MSC secretion of PGE2 when cultured with T-lymphocytes has been reported to 
stimulate T-regs while suppressing T-lymphocyte response. However, this 
suppression was reversed in the presence of PGE2 inhibitors (Tse et al., 2003; 
Aggarwal & Pittenger, 2005). In mouse models, IFN alone or in combination with 
other pro-inflammatory cytokines such as TNF, IL-1, IL-1 activated the release of 
chemokines that attracted T-lymphocytes and produced NO which inhibited T-
lymphocyte activation. MSC from mice deficient of the IFN receptor IFNR1 did 
not exhibit immunosuppressive activity thus emphasizing the role of IFN in this 
model (Ren et al., 2008). Human MSC have been reported to produce HLA-G5 
which suppressed T-lymphocyte proliferation, T-lymphocyte cytotoxicity and NK) 
cell activity but promoted generation of T-regs. Cell to cell contact between MSC 
and activated T-lymphocytes stimulated IL-10 production which in turn stimulated 
MSC to express HLA-G5 (Le Blanc & Ringden, 2007). 




Other reported soluble factors such as TGF, hepatocyte growth factor (HGF), IL-
10, haem oxygenase-1, IL-6 and tumour necrosis factor- (TNF) though 
constitutively expressed by MSC,  may be overexpressed when MSC are stimulated 
by cytokines released by T-lymphocytes (Uccelli et al., 2006; Le Blanc & Ringden, 
2007; Uccelli et al., 2008). TNF and IFN have been shown to increase MSC 
production of PGE2 while IL-6 was shown to inhibit the maturation of DC (Djouad et 
al., 2007).  
However, in a one-way MLR, it was found that neither MSC production of IL-10, 
TGF PGE2 nor tryptophan depletion was responsible for T-lymphocyte suppression 
(Tse et al., 2003).The reasons for conflicting results could be due to different 
experimental conditions; Tse and co-workers used unseparated mononuclear cells as 
responder cells (Tse et al., 2003) while other studies used purified T-lymphocytes 
(Le Blanc & Ringden, 2007). Different culture conditions, reaction kinetics, 
lymphocyte populations, species-specific differences and MSC doses could 
significantly contribute to the differences in findings. Most studies tend to use high 
doses of MSC in vitro but such doses are far from physiological conditions where the 
proportion of MSC in bone marrow to mononuclear cells is less than 1:10 000 
(Friedenstein & Kuralesova, 1971).  
Importantly, it has been shown that inhibition of any one of the reported molecules 
does not lead to complete loss of immunosuppression. Thus the relative contribution 
of the mentioned different factors to the immunosuppressive effects of MSC varies 
from study to study (Uccelli et al., 2008). Therefore, it is clear that the mechanisms 
of in vitro immunosuppressive effects of MSC are yet to be completely understood as 
current evidence suggests that none of the soluble molecules discussed has been 
shown to indispensable. The current view is that MSC employ a combination of cell 
to cell contact mechanisms and secreted soluble factors to modulate T-cell activity 
(Figure1.7). 
1.8.2.2. MSC and B-cells 
MSC are thought to modulate B-lymphocyte responses through cell to cell contact 
and soluble factor mechanisms (Uccelli et al., 2006). In a mouse model, B-
lymphocytes stimulated by anti-CD40 antibodies and IL-4 were inhibited by both 
syngeneic and allogeneic MSC at a high MSC to B-cell ratio of 1:10 to a similar 




degree as observed for MSC-mediated T-cell suppression (Glennie et al., 2005). 
Augello and co-workers employed a similar allogeneic mouse model in series of 
proliferation and blocking experiments which showed that MSC inhibited both B- 
and T-lymphocyte proliferation through direct cell contact via the inhibitory 
molecule programmed death-1 (PD-1) and its ligands PD-L1and PD-L2. This 
resulted in altered B-lymphocyte secretion of signal transduction molecules and 
cytokine receptors. In transwell experiments which blocked cell to cell contact, 
soluble factors secreted by MSC inhibited the proliferation of B-lymphocytes 
stimulated by pokeweed mitogen (Augello et al., 2005). These findings highlighted 
the complexity of MSC immunomodulatory mechanisms. When human allogeneic 
MSC were used at an MSC to B-cell ratio of 1:1, B-lymphocyte proliferation was 
inhibited at the G0/G1 cell cycle phase without induction of apoptotic pathways. 
Production of the immunoglobulins (IgM, 1gG and IgA) was markedly reduced 
suggesting that B-lymphocyte differentiation was inhibited by MSC secreted soluble 
factors. Interestingly, this was only observed at the MSC to B-cell ratio of 1:1 but not 
at lower MSC ratios of 1:2, 1:5 and 1:10 (Corcione et al., 2006). This was supported 
by another study in which a ten-fold lower MSC to B-lymphocyte dose apparently 
increased IgG secretion (Rasmusson et al., 2007).  
Allogeneic MSC when cultured at 1:1 ratio with B-cells reduced B-cell expression of 
the chemokine receptors CXCR4, CXCR5, and CCR7B. Subsequent chemotaxis to 
their respective ligands CXCL12, CXCL13 and CCL19 respectively was reduced. 
This demonstrated that MSC inhibited B-lymphocyte chemotactic ability. However, 
these findings could not be replicated at an MSC to B-cell ratio of 1:10. Despite 
these effects, B-cell cytokine production and expression of co-stimulatory molecules 
was unaltered by the presence of MSC (Corcione et al., 2006).  
Overall, these studies demonstrated that MSC modulate B-lymphocyte function at 
multiple levels which include cell proliferation, differentiation to immunoglobulin-
producing cells, antibody production and chemotaxis (Figure 1.7). In most of the 
cases, MSC appeared to have a dual effect determined by cell dosage, with high 
MSC to B-lymphocyte ratio having a suppressive effect while lower ratios had a 
stimulatory effect. Though the individual studies have supported the potential clinical 
application of allogeneic MSC, collectively the data are inconclusive and 
contradictory.  




1.8.2.3. MSC and APC and innate immune cells 
Although the interactions of MSC and cells of the innate immune system have been 
less studied, much of the attention has been focused on DC particularly because of 
their important role as professional APC which link the innate and adaptive immune 
responses by directly presenting foreign antigens to T-lymphocytes. MSC have been 
reported to inhibit the differentiation, maturation and activation of DC. Altering DC 
functions may result in generation of tolerogenic APC (Figure 1.7). 
MSC have been shown to inhibit the initial differentiation of monocytes to type 1 DC 
by downregulation of CD1a, CD86, and MHC II and later DC maturation by 
suppressing CD83 expression (Di Nicola et al., 2002; Zhang et al., 2004; Li et al., 
2008). In other studies, CD34
+




 interstitial DC in the presence of MSC which, in the absence of MSC, would 




 cell type. In addition to these phenotypical 
changes, the ability of immature DC to stimulate allogeneic T-lymphocyte 
proliferation in the presence of MSC has been shown to be significantly hampered 
(Fibbe et al., 2007). The secretion of TGF1 by MSC is thought to inhibit the 
activation and maturation of human DC (Di Nicola et al., 2002). 
Mature DC have been reported to exhibit decreased cell surface expression of MHC 
II, CD11c, CD83, co-stimulatory molecules and IL-12 production when cultured in 
the presence of MSC thus severely impairing the antigen presenting function 
(Aggarwal & Pittenger, 2005; Uccelli et al., 2008). Even after maturation, MSC 
changed plasmacytoid DC phenotype towards the immature status by downregulating 
CD83 expression and increasing IL-10 secretion whose knock-on effects led to 
decreased IFN production, increased IL-4 production, downregulation of CD40, 





 T-regs while inhibiting secretion of TNF. Collectively, these effects led to a 
state of immunotolerance  (Aggarwal & Pittenger, 2005; Maccario et al., 2005). IL-
10 producing type II DC have been reported to show minimal or no stimulatory 
effect in primary MLR and were largely inhibitory towards T-lymphocytes and are 
by and large functionally and phenotypically classified as inhibitory or tolerogenic 
cells (Chen et al., 2006). 




The mechanism of MSC-mediated DC suppression, though largely unknown, is 
thought to be mediated by soluble factors such as PGE2 which is released upon cell 
to cell contact (Aggarwal & Pittenger, 2005). It has also been noted that DC cell 
cycle was arrested at the G0/G1 phase in the presence of MSC as reported with T-and 
B-lymphocytes. Thus suppression of lymphocyte proliferation by MSC may not be 
exclusively due to a direct inhibitory effect on T-lymphocytes but may be associated 
with the suppressive effect on DC maturation, activation and antigen presentation 
(Uccelli et al., 2006).  
1.8.2.4. MSC and natural killer (NK) cells 
NK cells are an integral part of innate immunity owing to their anti-viral and anti-
tumour properties. They can lyse target cells without the aid of prior immunisation. 
They secrete pro-inflammatory cytokines and possess cytolytic activity (Male et al., 
2006). Their function is tightly controlled by cell surface receptors that transduce 
either inhibitory or activating signals. NK-mediated cytolysis is dependent on the 
expression of specific ligands by the target cells together with aberrant, low-level or 
absent expression of MHC I which is detected by NK cell-MHC I specific inhibitory 
receptors (Male et al., 2006; Uccelli et al., 2008).  
MSC have been shown to suppress NK cell cytotoxicity by downregulating the 
expression of NKp30 and NKG2D receptors which are important in NK cell 
activation and target cell cytolysis (Spaggiari et al., 2006). NK cells proliferate and 
acquire strong cytolytic activity in the presence of IL-2 and IL-15 however when 
MSC are introduced, NK cell proliferation and IFN production has been shown to 
be diminished (Aggarwal & Pittenger, 2005; Spaggiari et al., 2006; Selmani et al., 
2008). Activated NK cells however have shown significantly high resistance to MSC 
effects (Spaggiari et al., 2006). IL-15 activated NK cells have been shown to kill 
both allogeneic and autologous MSC in vitro but this was not shown with resting NK 
cells (Rasmusson et al., 2003). Susceptibility of MSC to NK-mediated killing is 
largely believed to be due to their low expression of MHC I molecules and 
expression of several ligands that are recognized by activating NK receptors 
(Spaggiari et al., 2006). MSC incubation in the presence of IFN has been shown to 
have a protective effect from NK-mediated cytotoxicity through the upregulation of 
MHC I expression by MSC (Spaggiari et al., 2006; Uccelli et al., 2008). As was 




observed with T-lymphocytes, soluble factors such as TGF1 and PGE2 are thought 
to play a role in the MSC-mediated suppression of NK cell proliferation (Uccelli et 
al., 2006).  
MSC interaction with NK cells has been shown to be dependent on the 
microenvironment; the presence of excess IFN in vivo may favour NK suppression 
by MSC whereas if IFN is limiting, the balance shifts towards the destruction of 
MSC by activated NK cells (Figure 1.7), the latter outcome is significant if MSC are 
to be used in clinical application. Potential application of MSC to help downregulate 
the abnormal activation of uterine NK cells which are one of the major causes of 
recurrent pregnancy loss is a promising prospect after the successful in utero 
transplantation of human MSC during the first trimester of pregnancy in a sheep 
model (Liechty et al., 2000).  
 
 





Figure 1.7. Mechanisms of MSC-mediated immunomodulation of the innate and 




 T and B-lymphocyte 




 T-regs which further inhibit 
immune responses. They also suppress the activation of NK cells and neutrophils as well as 
inhibiting the growth and maturation of type I myeloid DC while activating IL-10 secretion 
by type II DC which results in the inhibition of immune responses. MSC achieve these 
effects by a combination of cell to cell contact and secretion of immunoactive molecules 
such as PGE2, IDO, IL-10 and HLA-G5. Adapted from Uccelli, (2006). 
 
1.9. Differentiated MSC and allorecognition 
The ability to differentiate into new cell lineages is an important quality of MSC 
which provides different options for their application. Undifferentiated MSC alone 
offer so much promise in the field of cell-based therapeutics but differentiated MSC 
offer a much wider platform for application particularly in tissue engineering and 
regenerative medicine as discussed earlier. Tissue, repair, regeneration and 
replacement rely on the ability of MSC to differentiate and form new cells that 
provide similar biological, physiological and structural functions to the cells/tissues 
they seek to replace. Therefore, the immunological properties of differentiated MSC 




also require thorough investigations. This prospect is more challenging considering 
that the immunogenicity of undifferentiated allogeneic MSC remains controversial.  
MSC can be routinely differentiated into adipocytes, chondrocytes and osteoblasts 
either by chemical, hormonal or mechanical stimulation as discussed in Section 
1.3.3.6. This process relies upon the differential expression of lineage specific genes 
but more importantly their subsequent translation into functional proteins which alter 
the phenotype and function of the cells. This could have immunological 
consequences if the change in phenotype brings with it the expression of new surface 
antigens such as MHC II or secretion of immunostimulatory molecules. Since MSC 
are considered to be immunoprivileged, the key question would be whether they 
retain that status even after undergoing terminal differentiation. The challenges posed 
by the use of differentiated MSC are demonstrated by the work carried out by Chen 
and co-workers on rat MSC. Following tri-lineage differentiation, chondrogenic, but 
not adipogenic or osteogenic-differentiated MSC expressed the co-stimulatory 
molecules CD80 and CD86. The chondrogenic cells subsequently activated human 
DC and stimulated lymphocyte proliferation in contradiction to their undifferentiated 
precursors (Chen et al., 2007). In sharp contrast, using a rabbit model, Liu and co-
workers showed that osteogenic-differentiated MSC inhibited lymphocyte 
proliferation significantly more than undifferentiated MSC and secreted more IL-10 
and TGF Surprisingly this was reversed following IFN treatment. Osteogenic-
differentiated MSC‘s lack of MHC II even after differentiation meant they failed to 
stimulate allogeneic lymphocytes in co-cultures (Liu et al., 2006). The effects of 
differentiated MSC on their immunomodulatory properties are discussed widely in 
Section 6.4 and Section 7.3. 
Finally, it is important to note that chemicals used in the differentiation medium can 
confound the findings in some studies. For instance, indomethacin, a common 
constituent in most adipogenic differentiation media, is a known inhibitor for 
cyclooxygenase I and II (COX-I and COX II) enzymes which are involved in the 
synthesis of PGE2 hence its increased presence in culture medium supernatants. It 
could be possible that the presence of indomethacin in culture could affect the 
production of PGE2, a key molecule in the immunosuppressive milieu secreted by 
MSC. This could affect the overall immunomodulatory properties of the 
differentiated MSC. However, no study to date has investigated the role of chemicals 




commonly used in differentiation cocktails. It is important to note at this point that 
the immunological properties of differentiated MSC are as controversial as their 
undifferentiated precursors.   
1.10. Are MSC immunomodulatory properties unique to stem cells? 
Enter dermal fibroblasts (DF) 
As we have seen so far, the immunomodulatory properties of MSC have been a key 
area of research over the past decade and studies are focused on bringing them from 
the ‗bench to the bedside‘. An important question to ask is whether the inherent 
hypoimmunogenicity and immunomodulatory properties displayed by MSC in a 
wide range of human and animal models discussed thus far are a unique property of 
stem cells or are shared by other related cells. If the latter is true, this would open up 
opportunities to exploit other cells for clinical use.  
Another important finding based on some studies suggested that osteoblasts, 
chondrocytes and adipocytes obtained after MSC differentiation retained their 
immunosuppressive and immunoprivileged status (Le Blanc et al., 2003b). This 
might imply that other differentiated cell types could potentially exhibit similar 
properties and thus potentially amenable to similar application.    
Fibroblasts have long been thought to be related to MSC. In fact, Friedenstein 
initially described MSC as ‗fibroblast-like‘ cells (Friedenstein et al., 1970a; 
Friedenstein et al., 1974). Over time, it has been shown that the resemblance goes 
beyond morphology. Fibroblasts were first thought of as primitive cells (Kindblom & 
Angervall, 1978) but have recently been shown to express most of the markers used 
commonly expressed by MSC (Haniffa et al., 2007). They have also been shown to 
undergo differentiation into the typical mesenchymal cell lineages such as 
adipocytes, chondrocytes and osteocytes (Wagner et al., 2005; Haniffa et al., 2007; 
Lorenz et al., 2008). In fact, soon after human MSC were defined at the turn of the 
century (Pittenger et al., 1999), Toma and co-workers, in a bid to find new MSC 
niches, isolated cells from the dermis of mouse skin which were capable of neural, 
adipogenic and myogenic differentiation and long-term self-renewal (Toma et al., 
2001) which they later described as skin precursors cells [SKP] (Toma et al., 2005).  




In terms of immunomodulatory properties and immunoprivileged status, prior to the 
MSC-era, fibroblasts from various tissues have been reported to inhibit mitogen or 
alloantigen-stimulated lymphocyte proliferation and IFN secretion (Korn, 1981; 
Shimabukuro et al., 1992; Donnelly et al., 1993), properties which are associated 
with MSC as discussed earlier. Importantly, DF have also been shown to secrete 
immunomodulatory molecules such as PGE2, IDO, HGF and TGF in the presence 
of stimulated lymphocytes with the suppressive effect enhanced by IFN and TNF 
(Donnelly et al., 1993; Krampera et al., 2006; Haniffa et al., 2007). MHC II 
expression by DF was similarly induced by treatment with IFN and TNF (Haniffa 
et al., 2009). In the presence of IL-6, DF have been shown to inhibit monocyte 
differentiation into mature DC in a similar manner reported for MSC (Chomarat et 
al., 2000). However, Saalbach and co-workers demonstrated that DF promoted DC 
maturation (Saalbach et al., 2007). Direct comparison of MSC and fibroblasts from 
different tissue sources showed similar in vitro immunosuppressive properties 
(Bocelli-Tyndall et al., 2006; Haniffa et al., 2007). It has also been shown that both 
cell types induced non-apoptotic T-lymphocyte arrest using a mechanism that 
arrested cell division at the G0/G1 phase (Filer et al., 2006; Jones et al., 2007).  
Collectively, the data available in the literature clearly shows that MSC are 
indistinguishable from fibroblasts and importantly share similar immunomodulatory 
properties. However, these studies have focused on the immunosuppressive 
properties of these cells but not their immunogenicity. The most recent attempt at 
distinguishing MSC from fibroblasts employed the detection of anti-inflamatory and 
angiogenic factors such as vascular endothelial growth factor (VEGF), HGF and 
several angiopoietins. The authors concluded that MSC displayed strong angiogenic 
activity in comparison to DF. Upon priming with TNF, MSC displayed anti-
inflammatory activity whereas DF were pro-inflammatory (Blasi et al., 2011). 
Despite these variations, the overall immunomodulatory behaviour of MSC and DF 
remained similar. It is possible to speculate that the immunomodulatory properties 
described for undifferentiated MSC could be shared by other stromal cells such as 
differentiated MSC and fibroblasts.  
 
 




1.11. Aim and objectives 
1.11.1. Background 
The major challenge hindering the clinical application of allogeneic MSC is the risk 
of rejection due to immunological incompatibility. As discussed throughout this 
chapter, there is overwhelming evidence regarding their immunomodulatory 
properties as tested in both human and animal models under different experimental 
conditions. These properties are broadly classified as immunosuppression and 
immunoprivilege.  
Immunosuppression is thought to be achieved through mechanisms that involve cell 
to cell contact and secretion of immunomodulatory molecules. This is thought to 
result in the inhibition of on-going non-specific and specific immune responses 
against immunostimulatory mitogens and antigens. This property could be useful in 
therapeutic interventions to prevent allogeneic transplant rejection.  
Immunoprivilege is thought to be due to the inherent hypo- or non-immunogenic 
nature of MSC as a result of their lack of co-stimulatory molecules (CD40, CD 80 
and CD 86) and MHC II as well as partial expression of MHC I. This is thought to 
make them incapable of stimulating T-cell responses in an allogeneic setting. Many 
authors believe that immunoprivilege would allow allogeneic MSC to be used as 
‗universal donor‘ cells in engineering ‗off-the-shelf‘ tissues and organs that are 
transplantable across histocompatibility barriers without the risk of rejection. 
The studies in support of these claims used in vitro human and animal models of 
allogeneic transplantation by way of MLR to investigate immunosuppression and 
LTA to investigate immunoprivilege. These tests are the ‗gold-standard‘ 
immunological methods used for determining alloreactivity of responder 
lymphocytes to stimulation by allogeneic stimulator cells in histocompatibility tests 
usually lasting between 3-5 days.  
1.11.2. Hypothesis 
The lack of co-stimulatory molecules CD40, CD80, CD86 and MHC II expression 
by MSC implies that they are incapable of stimulating allogeneic lymphocytes by the 
direct pathway of allorecognition in LTA. However, the hypothesis of this study was 
that despite their apparent lack of MHC II and co-stimulatory molecules, MSC could 




stimulate allogeneic lymphocytes via the indirect and semi-direct pathways (chronic 
rejection). This is testable in vitro by extending the culture period beyond the 
traditional 3-5 days to 15 days. An allogeneic mouse model system was employed to 
test this hypothesis. 
1.11.3. Why mouse model? 
A mouse model system was preferred to human cells for the following reasons; 
 There is minimal variation in terms of lymphocyte ‗identity‘ in a mouse 
model since the same strains were used throughout the study. It may not be 
possible to obtain lymphocytes from the same human donors over a 3 year 
period and hence use of different lymphocyte donors can confound the results 
due to the differences in cell quality and immunological state of the donors at 
any given time.  
 Mouse models allowed better ‗quality‘ MSC to be used in tests unlike human 
MSC which are generally obtained from elderly patients undergoing hip 
replacement procedures. MSC can be obtained from healthy and younger 
sources which are known to demonstrate better stem cell properties than 
‗mature‘ MSC.  
 Use of genetically mismatched strains allowed the testing of MSC in bona 
fide MLR where the allogeneic MSC are genetically matched to the 
stimulator lymphocytes. With human cells, it is difficult to obtain both MSC 
and lymphocytes from the same donor. Thus, most MLR experiments with 
human MSC use 3
rd
 party MSC which are allogeneic to both the responder 
and stimulator lymphocytes and though referred to as MLR in most studies, 
such a system does not represent a true MLR.  
 In a mouse model, syngeneic controls (equivalent of autologous) can be set 
up to allow for more accurate comparison with allogeneic experiments which 
may not be possible when using human cells.  
1.11.4. Aim 
This study sought to systematically investigate the immunological properties of 
allogeneic MSC namely immunosuppression and immunogenicity using a mouse 
model system which used two genetically distinct strains; Balb/c (H2-d) and C3H 
(H2-k) which were used as responder (recipient) and stimulator (donor) respectively. 




DF were tested alongside MSC as a control for mesenchymal non-stem cells in order 
to determine if the immunomodulatory properties were unique to stem cells or were 
shared by other mesenchymal cells. 
1.11.5. Objectives 
The objectives of the study were divided into four broad sections namely; 
1. To isolate, expand and characterise MSC from bone marrow (femoral) and 
DF from abdominal skin of Balb/c and C3H mice  
2. To define the most suitable conditions for performing MLR and LTA using 
splenic and lymphoid (inguinal and axillary) mononuclear cells from Balb/c 
and C3H mice. 
3. To investigate the immunosuppressive properties and immunogenicity of 
allogeneic (C3H) and syngeneic (Balb/c) MSC and DF using adaptations of 
the MLR (one-way and 2-way) and LTA respectively. 
4. To investigate the immunosuppressive properties and immunogenicity of 
chondrogenic-differentiated allogeneic and syngeneic MSC and DF using 
adaptations of the MLR (one-way and 2-way) and LTA respectively. 
Objective 1 is covered in detail in Chapter 3, objective 2 in Chapter 4, objectives 3 














2. CHAPTER TWO: GENERAL MATERIALS AND 
METHODS 
2.1. Materials 
All the equipment, plastic ware, general consumables, chemicals and reagents used 
in this study are listed in the Appendix. Specific reagents and chemicals used in 
specific experiments including their preparation and storage are listed at the 
beginning of each chapter.  
2.1.1. Animals 
Female Balb/c (H2-d) and C3H (H2-k) mice (4-8 weeks) were obtained from Harlan 
Laboratories, UK and kept under standard animal housing settings in the University 
of Leeds Central Biomedical Services with food and water administered ad libitum. 
2.1.2. Glassware 
All laboratory glassware used in this study was sourced from Thermo Fisher 
Scientific, Loughborough, UK unless stated otherwise.  
2.1.3. Dissection kits 
Dissection kit comprising standard forceps, rat tooth forceps, surgical scissors and 
scalpel handle (No 4) were supplied by Thackray Instruments, Leeds, UK. 
2.2. Methods 
2.2.1. Disinfection and sterilisation 
2.2.1.1. Washing and disinfection 
2.2.1.1.1. Dissection instruments 
Dissection kits, cell sieves and glass pestles used for dissection and cell harvesting 
were washed with running hot water, disinfected with 1 % (v/v) Virkon disinfectant 
for 20 minutes and washed in running tap water for 5 minutes followed by air drying 
and dry heat sterilisation. 
 




2.2.1.1.2. Tissue culture cabinets 
Class II safety cabinets used for carrying out aseptic techniques for cell harvesting 
and culture were thoroughly cleaned with 1 % (v/v) Virkon followed by 70 % (v/v) 
ethanol before and after use. All items entering the safety cabinets including medium 
bottles, test-tube racks and gloved hands were first sprayed with 70 % (v/v) ethanol 
as a disinfection step.  
2.2.1.2. Dry heat sterilisation  
All items and objects were placed in a hot air oven and held at a temperature of 190 
ºC for 4 hours. 
2.2.1.3. Moist heat sterilisation 
Items and solutions unsuitable for dry heat sterilisation were sterilised by autoclaving 
at 121 ºC for 20 minutes and 15 psi
3
 pressure. 
2.2.1.4. Filter sterilisation 
Solutions unsuitable for autoclaving were filtered through single-use Ministat™ 0.2 
μm syringe filters (Sartorius Ltd, UK) using disposable syringes in a class II safety 
cabinet. 
2.2.2. Culture media and reagents 
All radioactive 
3
H-thymidine stocks were purchased, handled, used and disposed of 
in accordance to the University health and safety regulations for radioactive 
substances. All assays involving use of radioactive chemicals were carried out in 
specially designated workspaces. 
2.2.2.1. Minimum essential medium (-MEM) 
-MEM medium was supplemented with 10% (v/v) foetal calf serum (FCS), 2 mM 
L-glutamine and 100 g.ml-1 penicillin/streptomycin. 
2.2.2.2. Dulbecco’s modified Eagle’s medium High glucose 
(DMEM-HG) culture medium 
DMEM-HG was supplemented with 10% (v/v) FCS, 2 mM L-glutamine and 100 
g.ml-1 penicillin/streptomycin. 
                                                 
3
 psi; pounds per square inch 




2.2.2.3. Dulbecco’s modified Eagle’s medium Low glucose 
(DMEM-LG) culture medium 
DMEM-LG was supplemented with 10% (v/v) FCS, 2 mM L-glutamine and 100 
g.ml-1 penicillin/streptomycin. 
2.2.2.4. Cryopreservation medium (cryo-medium) 
Cryo-medium was made by supplementing DMEM-LG (for MSC) or DMEM-HG 
(for DF) with 20% (v/v) FCS, 100 g.ml-1 penicillin/streptomycin and 10% (v/v) 
dimethyl sulphoxide (DMSO). 
2.2.2.5. MesenCult™ culture medium 
MesenCult™ mesenchymal stem cell basal medium was supplemented with 20 % 
(v/v) MesenCult™ mesenchymal stem cell stimulatory supplements and 100 g.ml-1 
penicillin/streptomycin. 
2.2.2.6. StemXVivo™ culture medium 
StemXVivo™ mouse mesenchymal stem cell medium was supplemented with 100 
g.ml-1 penicillin/streptomycin. 
2.2.2.7. Lymphocyte culture medium 
Lymphocyte culture medium was made by supplementing Rosslyn Park Memorial 
Institute 1640 (RPMI-1640) medium with 10 % (v/v) FCS, 20 mM 
4
HEPES buffer, 2 
mM L-glutamine and 50 M -mercaptoethanol. 
2.2.2.8. Lymphocyte transport medium 
Transport medium was made by supplementing RPMI-1640 medium with 20 mM 
HEPES buffer and 100 g.ml-1 penicillin/streptomycin. 
2.2.2.9. Mitomycin C stock solution 
Mitomycin C from Streptomyces caespitosus supplied in powder form and classified 
as a highly toxic substance was opened and weighed in a specially designated 
‗Poisons room‘ (Level 4, Garstang South). Stock solutions of 1 mg.ml-1 were made 
by dissolving mitomycin C into sterile PBS without calcium (Ca
2+
) or magnesium 
(Mg
2+
). The 1 mg.ml
-1
 stock solution was aliquoted into clean sterile Bijous which 
                                                 
4
 HEPES; [N-(2-hydroxyethyl) piperazine N;-(2-ethansulphonic acid)]  buffer 




were individually wrapped in aluminium foil and stored at -20 ºC until use. On day 
of use, frozen mitomycin C was first thawed in a water bath at 37 ºC before being 
added into lymphocyte culture medium at the appropriate concentration. 
2.2.2.10. Concanavalin-A (Con-A) stock solution 
Concanavalin A (Con-A) lyophilised powder was opened and weighed in a specially 
designated Poisons room. Stock solution was made by dissolving in phosphate 
buffered saline (PBS) to make a 1 mg.ml

 solution which was divided into 200 l 
aliquots and kept at -20 ºC until use. 
2.2.2.11. Phytohemagglutinin (PHA) stock solution 
PHA lyophilised powder was opened and weighed in a specially designated Poisons 
room. Stock solution made by dissolving in PBS to make a 1 mg.ml

 solution which 
was divided into 200 l aliquots and kept at -20 ºC until use. 
2.2.2.12. Camptothecin stock solution 
Camptothecin was opened and weighed in a specially designated Poisons room. A 1 
mg.ml

 stock solution was made by dissolving in Hank‘s balanced salt solution 
(HBSS). 
2.2.2.13. 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester 
(CFSE) stock solution 
A 5 mM stock solution was made by dissolving CFSE in DMSO. The solution was 
divided into 100 l aliquots which were individually wrapped with aluminium foil 
and kept at -20 ºC. 
2.2.2.14. Low activity 3H thymidine 
Low activity 
3
H-thymidine (specific activity – 6.7 Ci.mmol-1; concentration – 1 
mCi.ml
-1
) was diluted with RPMI-1640 medium (1:40 dilution ratio) to give a 
working solution with a final radioactivity concentration of 25 Ci.ml-1. The solution 
was aliquoted into 2 ml vials and stored at 4 ºC until use. 




2.2.2.15. Saline solution (0.85 % w/v) 
Saline solution (0.85 % w/v) for use during cell harvesting (Section 2.2.13) was 
made by dissolving 0.85 g sodium chloride in 1 litre of distilled water. The solution 
was kept at room temperature until use. 
2.2.2.16. Substrate solution (ATPLite™) 
ATPLite™ lyophilized substrate (77 mg) was reconstituted in 5 ml of ATPLite™ 
substrate buffer at room temperature in a light proof  container and used fresh or kept 
frozen at -20 °C in tubes wrapped with light proof foil. 
2.2.2.17. Trichloroacetic acid (10 % w/v) solution (TCA) 
TCA (10 % w/v) working solution for use during cell harvesting (Section 2.2.13) 
was made by dissolving 100 g TCA in 1 litre of distilled water. The solution was 
kept at room temperature in Duran bottle until use. 
2.2.3. pH measurement 
The pH of solutions was measured using a Jenway 3020 pH meter calibrated using 
standards of pH 4, 7 and 10. Solutions to be measured were gently stirred and stable 
readings were taken. To adjust the pH of solutions, 1-6 M hydrochloric acid or 1-6 M 
sodium hydroxide solutions were added drop wise whilst stirring. 
2.2.4. Mouse sacrifice and dissection 
Mice were humanely sacrificed under Schedule 1 guidelines by controlled CO2 
asphyxiation and death confirmed by cervical dislocation. The mice were then 
transferred to the laboratory where dissection was immediately carried out under 
sterile conditions using sterilised dissection instruments. Mice were first sprayed 
with 70 % (v/v) ethanol to disinfect the fur and pinned on a dissection board ventral 
side up.  
For MSC isolation, femurs were dissected and all attached epiphyses carefully 
removed to minimize contamination by other cells before femoral aspiration 
(described in Section 3.2.1). For isolation of DF, mouse abdominal skin was first 
shaven clean with a sterile scalpel to remove fur and then small pieces of skin 
(approximately 2 cm x 2 cm) carefully cut out, soaked in 70 % (v/v) ethanol for 5 
minutes to further disinfect them before dispase II digestion as described in Section 




3.2.3. For isolation of mononuclear cells, an incision down the mid ventral line of the 
skin was made and the skin pinned backwards to reveal the areas inside the skin 
below the four limbs. From each mouse, peripheral lymph nodes (two inguinal and 
two auxiliary) and the whole spleen were carefully removed and placed in sterile 
petri dishes containing transport medium before cell harvesting as described in 
Section 2.2.11. 
2.2.5. Maintenance and culture of mouse primary cells 
All cell culture procedures were carried out under aseptic conditions in a Heraeus 
Hera Safe Class II bio-safety cabinet (Thermo Electron Corporation, USA. Primary 
cells cultures (MSC and DF) extracted from Balb/c and C3H mice were cultured in 
Nunclon™  surface 75 cm2 (10 ml culture medium) and 125 cm2 (20 ml culture 
medium) cell culture flasks with culture medium (DMEM-LG for MSC and DMEM-
HG for DF) which was changed every 2-3 days. The cultures were incubated at 37 ºC 
in an atmosphere of 5% (v/v) CO2 in air in a SANYO MCO-20AIC (SANYO 
Biomedical BV, Holland) humidified incubator. 
2.2.6. Cell passaging 
Upon reaching 80-90 % confluence, culture medium from the flasks was aspirated 





 (10 ml for 75 cm
2
 and 20 ml for 125 cm
2
) to ensure removal of culture 
medium constituents especially FCS which inhibits cell dissociation agents. Hy-Q-
Tase™ cell dissociation solution (for MSC) or 0.5 % (v/v) trypsin-EDTA solution 
(for DF) were added to dislodge and disaggregate the monolayer of cells from the 
bottom of the flask into suspension (2 ml for 75 cm
2
 and 3 ml for 125 cm
2
). For MSC 
cultures, flasks were kept at room temperature in the class II cabinet for 3-5 minutes 
while for DF, flasks were kept at 37 ºC in 5% (v/v) CO2 in air in a humidified 
incubator for 5-8 minutes. Complete cell detachment was checked under an Olympus 
CK40-SLP light microscope. The resultant cell suspensions were transferred into 50 
ml centrifuge tubes to which equal volumes of culture medium were added to 
inactivate the cell dissociation agents. The cell suspensions were then centrifuged for 
10 minutes at 180 g and the supernatant discarded while the resulting cell pellet was 
re-suspended in fresh culture medium and split into a 1:3 ratio. The cells, now 
assigned the next consecutive passage number, were plated in 75 cm
2
 or 125 cm
2
 




flasks with fresh culture medium added and incubated at 37 ºC in an atmosphere of 
5% (v/v) CO2 in air.  
2.2.7. Microscopy 
Mouse MSC and DF were analysed for morphology before and during differentiation 
using an Olympus IX71 inverted microscope set up for phase contrast and images 
captured using an attached Evolution MP digital camera controlled though Image-
Pro
®
 Plus imaging software 4.5 (Media Cybernetics) or an Olympus digital camera 
controlled through Cell^B image acquisition software (Olympus). 
2.2.8. Cell counting by the Trypan blue dye exclusion method 
Trypan blue is a dye which when mixed with a cell suspension allows viable cells to 
be distinguished from non-viable/dead cells by virtue of cell membrane integrity. 
The dye permeates into non-viable cells due to loss of cell membrane integrity 
whereas viable cells with intact cell membranes, actively excludes the dye. Thus 
non-viable cells are coloured blue (and therefore excluded from the count) while 
viable cells appear colourless when visualised under a light microscope. To perform 
a cell count, 20 l of thoroughly resuspended cell suspension was mixed with an 
equal volume of 0.4 % (v/v) Trypan blue dye in a Bijou vial and 20 l of the mixture 
loaded carefully into each chamber of an improved Neubauer counting chamber. 
Viable cells were counted under an Olympus CK 40-SLP light microscope (x100 
magnification) and enumeration aided by a cell counter. The whole chamber had a 
depth of 0.1 mm and was divided into 9 large squares each with an area of 1 mm
2 
and 




 ml) volume of cell suspension. The centre 
square was further divided into 25 small squares each containing 0.004 mm
3




For counting MSC and DF, viable cells were counted from n of the 9 large squares (n 
= number of large squares in which the viable cells count was between 100 and 300) 
and the mean count contained in 0.1 mm
3
 obtained by dividing by n. For counting 
mononuclear cells, viable cells were counted from 5 of the 25 small squares in the 
large centre square (4 corner squares plus central square). The total count was then 
divided by 5 to obtain the mean count per square. This value was then multiplied by 
25 to obtain the number of cells in 0.1 mm
3
. This was then multiplied by 10
4
 and the 




dilution factor to obtain the number of viable cells per millilitre as shown by the 
formula below; 
 
Where d.f. = dilution factor due to dilution of cell suspension with Trypan blue (in 
this case d.f. is 2). 
2.2.9. Cryopreservation of MSC and DF 
Mouse MSC and DF cell cultures for future use were harvested from culture flasks 
(80-90 % confluence) as described in Section 2.2.6, resuspended in cold cryo-
medium (Section 2.2.2.4), quickly counted  by the Trypan blue method (Section 




. The cells were then aliquoted into pre-chilled 
cryovials (1 ml per vial) which were immediately placed in a Nalgene freezing 
container filled with isopropanol and placed into a -80 ºC freezer for a minimum of 4 
hours to provide a cooling rate of -1 °C.min
-1
. The vials were then transferred to 
liquid nitrogen (-196 °C) for long term preservation. 
2.2.10. Resurrection of frozen mouse primary cells 
Cryovials containing frozen cells (MSC or DF) were removed from liquid nitrogen 
storage and defrosted in a 37 °C water bath. The cells were transferred into 25 ml 
centrifuge tubes and pre-warmed culture medium was added to make up 15 ml before 
centrifugation at 180 g for 10 minutes to remove the DMSO which is toxic to cells 
on prolonged exposure. This washing step was repeated, each time discarding the 
supernatant and the cells were finally resuspended in fresh culture medium and 
plated in 75 cm
2
 tissue culture flasks in a volume of 10 ml. The flasks were then 
incubated at 37 °C in 5 % (v/v) CO2 in air and maintained as described in Section 
2.2.5.  
2.2.11. Isolation of mononuclear cells from mouse peripheral lymph 
nodes and spleens 
Lymph nodes and spleens were isolated from either Balb/c or C3H mice and placed 
in petri-dishes containing transport medium as described in Section 2.2.4. In a class 
II bio-safety cabinet, the lymph nodes and spleens were placed in a 100 m fine 
mesh steel sieve using sterile forceps. They were chopped into smaller pieces using a 




scissors and gently teased and pressed through the mesh using a sterile glass pestle 
and washed with transport medium to release single cells from the tissue matrix 
which were collected in a clean petri-dish. The resulting cell suspension was 
transferred into sterile plastic test tubes and left to stand for 15 minutes to allow the 
debris to settle at the bottom under gravity while the mononuclear cells remained in 
suspension. The cell suspension was then carefully transferred into fresh test tubes 
using sterile glass Pasteur pipettes and centrifuged at 450 g for 10 minutes with the 
resulting supernatant carefully decanted leaving behind approximately 0.5 ml fluid 
and cell pellets at the base of each tube. The cell pellets were then resuspended into 
the remaining fluid by gently bashing the tubes against each other after which 6.5 ml 
of lymphocyte culture medium was added to each tube and the contents gently mixed 
by inversion. 
The cell suspensions were then gently layered into test tubes containing 3 ml of 
Lymphoprep™ gradient solution (10 ml total volume) while ensuring that the cell 
suspension formed a layer above the Lymphoprep™ and the tubes were centrifuged 
at 800 g for 30 minutes. The Lymphoprep™ gradient separates mononuclear cells 
which remain in suspension and form a white band at the Lymphoprep™ / transport 
medium interface from erythrocytes and granulocytes which settle at the bottom of 
the tube as illustrated in Figure 2.1. Mononuclear cells have a lower buoyant density 
less than 1.077 g.ml
-1
 compared to other blood cells. Using glass Pasteur pipettes, the 
mononuclear cell bands were carefully removed and transferred to clean test tubes to 
which fresh lymphocyte culture medium was added to make up the volume in each 
tube to 10 ml. The cells were then centrifuged at 450 g for 10 minutes to wash off 
any Lymphoprep™. The supernatant was decanted leaving behind whitish cell 
pellets of mononuclear cells which were resuspended in 5 ml of lymphocyte culture 
medium and counted by the Trypan blue method (Section 2.2.8) prior to use in 
assays. 





Figure 2.1. Schematic showing separation of mouse mononuclear cells from lymphoid and 
splenic cell suspensions using Lymphoprep™ density gradient method. After centrifugation, 
mononuclear cells settle at the Lymphoprep™/medium interface as a whitish band. 
 
2.2.12. Dosing mononuclear cell cultures with 3H-thymidine   
Assays involving use of 
3
H-thymidine were carried out in specially designated 
workspaces. Cell cultures assayed for 
3
H-thymidine uptake were spiked with 10 l 
per well of low activity 
3
H-thymidine (25 Ci.ml-1) to give a final concentration of 
0.25 Ci per well. Spiking was carried out 16 hours before the end of the specific 
assay period. After dosing, cell cultures were returned for incubation in a humidified 
incubator at 37 °C in an atmosphere of 5% (v/v) CO2 in air. At the end of the culture 
period, cell cultures were harvested (Section 2.2.13) to facilitate the detection of 
3
H-
thymidine incorporated in the DNA.  
2.2.13. Cell harvesting using the FilterMate™ cell harvester and 
scintillation counting using the TopCount™ scintillation and 
luminescence counter 
A FilterMate™ cell harvester was used to process cell cultures to facilitate the 
detection of 
3
H-thymidine incorporated into cellular DNA. Cells cultured in U or V 
bottom 96-wellplates were harvested by vertical vacuum suction onto 96-well 
UniFilter-96 GF/B plates (Perkin Elmer) pre-wetted with distilled water. These 
polystyrene plates have wells made of mesh bottoms with glass fibre filters of 1 m 
pore size and PEI coating to reduce non-specific binding and Barex plastic coating 
for compatibility with liquid scintillation counting. The aspirated cells were bound to 
the glass fibre filters while the medium was sucked through to waste containers. The 




cells were then washed with 0.85 % (w/v) saline solution (150 ml per plate) in order 
to remove medium constituents. A 10% (w/v) TCA solution (100 ml per plate) was 
aspirated through the bound cells for the purpose of  lysing the cells and precipitating 
the DNA (and other nucleic acids) of the cells. The precipitated DNA remained 
bound to the glass fibre filters. A final wash with 100 % methanol (150 ml per plate) 
further precipitated the DNA while washing the TCA and assisted in drying the 
filters. Plates were removed and left to further dry in the dark at room temperature 
for at least 45 minutes. Afterwards, 35 l of MicroScint™-20 liquid scintillation 
counter (LSC) cocktail (Perkin Elmer) per well was added and the plates sealed with 
TopSeal™ clear adhesive (Perkin Elmer) followed by radioactivity reading by a 
TopCount™ NXT scintillation and luminescence counter (Perkin Elmer). 
Incorporation of 
3
H-thymidine into cellular DNA was detected as the number of 
radioactive disintegrations of 
3
H-thymidine per minute, recorded as counts per 
minute (CPM) after an initial 10 minute count delay to allow for dark adjustment. 
2.2.14. Determination of cell viability using the ATPLite™ assay 
The ATPLite™ assay measures the amount of luminescence (light) emitted when 
cellular adenosine triphosphate (ATP) reacts with D-luciferin in the presence of 
luciferase to produce luminescence in a reaction summarised in the equation below; 
ATP  +  D-luciferin  +  O2    Oxyluciferin  +  
5
AMP  + 
6
 PPi  +  
7
CO2  + Light 
The amount of emitted light is proportional to the concentration of ATP released 
from the cells. In turn, the amount of ATP is related to the metabolic state of cells 
with viable cells producing more ATP than dead or necrotic cells and since ATP is 
unstable and is readily degraded outside the cell, it is unlikely dead and necrotic cells 
will produce ATP. The reaction ensures that ATP released from the cells after cell 
lysis is not readily hydrolysed by intracellular ATPases or reaction reagents by 
increasing the pH to 11 thus increasing the stability of ATP. Addition of substrate 
solution lowers the pH to 7.6 which is favourable for ATP to react with D-luciferase. 
On the day of assay, the substrate solution (Section 2.2.2.16) was prepared fresh or 
defrosted at room temperature in a dark cupboard. Meanwhile, cell cultures in 96-
                                                 
5
 AMP - adenosine monophosphate 
6
 PPi - inorganic pyrophosphate 
7
 CO2 - carbon dioxide 




well plates were thoroughly mixed and 100 l of the cell suspension transferred into 
corresponding wells of a white OptiPlate™ 96-well plate (Perkin Elmer). 
Mammalian cell lysis solution (50 l) was added into each well and the plates sealed 
with TopSeal™ adhesive before they were placed on an orbital shaker at 700 8rpm 
for 5 minutes. Afterwards, 50 l of substrate solution was added into each well and 
the plates sealed and covered in aluminium foil to avoid light before being mixed on 
an orbital shaker at 700 rpm for 5 minutes. The plates were then placed in a 
TopCount NXT scintillation and luminescence plate reader which was programmed 
to dark adapt the plates for 10 minutes before measuring the luminescence in each 
well for 5 seconds and results expressed as counts per second  (CPS). 
2.2.15. Mitotic inactivation of stimulator cells using mitomycin C 
Cells (Balb/c or C3H MSC, DF or mononuclear cells) were suspended in appropriate 
culture medium supplemented with 10 g.ml-1 of mitomycin C in sterile test tubes. 
The cells were incubated in a humidified incubator at 37 °C in an atmosphere of 5 % 
(v/v) CO2 in air for 30 minutes. After incubation, the cells were removed from the 
incubator and washed five times by centrifugation at 180 g (MSC and DF) or 450 g 
(mononuclear cells) for 10 minutes with fresh culture medium changes each time to 
remove the mitomycin C. Cells were resuspended in appropriate culture medium for 
subsequent assays. 
2.2.16. Statistical analysis 
All numerical data obtained from replicate samples was analysed using Microsoft
®
 
Excel 2010 and GraphPad Prism
®
 version 5.00 software (GraphPad Software Inc, 
California, USA). Raw data from 
3
H-thymidine (CPM) and ATP counts (CPS) was 
first transformed to Log10 and analysed by one-way or two-way analysis of variance 
(ANOVA) for comparing one or two variables respectively. Log10 transformation 
was carried out in order to satisfy the normality assumption required for ANOVA. 
Statistical significant differences between groups were calculated using the minimum 
significant difference (MSD) at 95 % confidence level (CL) according to the T-
method for equal samples sizes and the T‘-method for unequal sample sizes 
according to Sokal & Rohlf (1981). The MSD is given by the formula; 
                                                 
8
 rpm – rotations per minute 





Where; k – Number of treatment groups 
 v – Degrees of freedom of MSwithin groups (from Excel ANOVA table) 
SE (standard error) was calculated as follows; 
 
Where; n   =  number of replicates 
 MSwithin  =  Mean square (within) (from Excel ANOVA table) 
The mean values and 95 % CL obtained from Log10 transformed data were  then 
back-transformed by taking antilogarithms (10
n
; where n is the log10 value) and data 
was plotted as mean values ± 95 % CL, whereby the upper limit (UL) and lower limit 
(LL) for each mean value were calculated as follows;  
 
 












3. CHAPTER THREE: ISOLATION, EXPANSION AND 
CHARACTERISATION OF MURINE MSC AND DF 
3.1. Introduction 
The term ‗mesenchymal stem cell‘ has been and is still used to define groups of non-
haematopoietic cells of mesenchymal origin which possess the ability to differentiate 
into multiple cell lineages of typical mesodermal tissues such as adipose, bone and 
cartilage. Friedenstein and co-workers were the first group to report on this type of 
‗fibroblastic-like‘ cell capable of ‗spontaneous bone formation‘ isolated from 
Guinea-pig bone marrow (Friedenstein et al., 1970). Later, they discovered that, in 
addition to clones of these cells forming bone rudiments in vitro, they were also able 
to form cartilage thus making them candidates for osteo-chondrogenic ―stem‖ cells 
(Friedenstein et al., 1987). Since then, bone marrow stromal cells have been isolated 
from various mammalian species including postnatal mice (Jiang et al., 2002) and 
manipulated in vitro to yield cells of the adipogenic, chondrogenic and osteogenic 
lineages with relative ease (Prockop, 1997).   
There is little consensus regarding the terminology of MSC partly because of lack of 
standard procedures for their identification, isolation and characterisation and also 
because stem cell biology is a relatively new field as discussed broadly in Section 
1.3.3. Differences amongst research groups in terms of choice of species, 
methodologies for isolation and conditions for culture led to various names such as 
BMSSC (Bianco et al., 2001), MPC (Sun et al., 2003), BMSC (Horwitz et al., 2002), 
MAPC (Jiang et al., 2002) being used to describe them. The most common approach 
for isolating murine MSC from compact bone is by the PAM described in Section 
1.3.3.3 which involves the flushing of bone marrow with culture medium followed 
by isolation which exploits the physical tendency of MSC to adhere to the plastic 
substrate of cell culture flasks (Friedenstein et al., 1970b). This technique was used 
in this study.  
The bone marrow stroma houses two types of stem cells; MSC and HSC in addition 
to stromal cells which form the majority of the cells (Koide et al., 2007). Due to the 
presence of multiple cell types in the marrow microenvironment, the isolation and 





subsequent characterisation of MSC is rather a complex process due to the following 
contributing factors; 
 MSC constitute a very small proportion of marrow nucleated cells estimated 
to be 1 in 10
6
 cells in mice (Sung et al., 2008).  
 Mouse MSC are located in the endosteum whereas HSC tend to exist around 
the centre of the marrow while other stromal cells are present near the surface 
of the bone (Short et al., 2001). These deep locations of MSC present 
difficulties to their harvesting from bone marrow. 
 Flushing murine marrow inadvertently yields a heterogeneous cell suspension 
which possess a higher frequency of haematopoietic cells that also adhere to 
tissue culture plastic and persist in culture even after serial passages (Baddoo 
et al., 2003).  
 Most murine plastic-adherent stromal cells have been shown to exhibit 
differentiated phenotypes even in the absence of cell-specific differentiation-
inducing factors (Sun et al., 2003).  
Therefore, cell cultures resulting from bone marrow aspirates remain 
morphologically heterogeneous. Efforts to develop new methods that specifically 
isolate MSC from bone marrow aspirates have been investigated in the last two 
decades and these include chemical selection (Modderman et al., 1994), negative 
selection by immunodepletion of contaminating cells (Baddoo et al., 2003) and 
positive selection utilising cell surface antigens (Nadri & Soleimani, 2007a). The 
latter two methods are dependent on flow cytometry selection and have made it 
possible for the phenotype of MSC to be defined based on the expression of and lack 
of specific markers. 
The lack of definitive markers for MSC has led to confusion with regard to the 
nomenclature for defining them. To date MSC are defined by three main criteria; 
 Self-renewal in culture and maintenance of spindle-morphology. 
 Expression of and lack of specific surface markers. 
 Tri-lineage differentiation into fat, cartilage and bone cells. 





The self-renewal capacity is the only phenotypic trait that is considered to be 
exclusive to all stem cells. The clonogenic potential of MSC can be demonstrated 
easily by seeding the cells at low density. They divide continuously until confluence 
thus regular passaging allows the generation of large quantities of cells which is 
useful for clinical applications. It is important to note that continuous passaging leads 
to reduced differentiation potential and loss of ‗stem‘ properties. The mechanisms 
responsible for loss of the intrinsic clonogenic capacity are unknown though 
telomere shortening is thought to play a part (Park et al., 2007c).  
Mouse MSC have been shown to express MHC I, Sca-1, CD29, CD44, CD54, CD73 
CD90, CD105 and CD106 while being negative for MHC II, the co-stimulatory 
molecules CD80 and CD86, the macrophage marker CD11b, the B-cell marker 
CD19, haematopoietic markers CD34, CD45 and  CD133 (Tropel et al., 2004; Sung 
et al., 2008; Soleimani & Nadri, 2009). However, this criterion does not distinguish 
MSC from other cells such as DF (Haniffa et al., 2009) and therefore cannot be used 
in isolation. Even the expression of MHC I has been described as partial (Soleimani 
& Nadri, 2009) while a few studies have reported the presence of CD80 (Schurgers 
et al., 2010) on mouse MSC in culture.   
The tri-lineage differentiation test is currently the only functional test used to 
distinguish MSC and has been demonstrated in all studies. When cultured under 
defined conditions involving chemical and hormonal cues, mouse MSC differentiate 
into adipocytes, chondrocytes and osteoblasts. The mechanisms that control MSC 
differentiation are discussed in detail in Section 1.3.3.6. Adipogenic differentiation 
can be achieved by the addition of dexamethasone, indomethacin, IBMX and insulin 
in culture medium. Intracellular lipid vesicles become visible under light microscopy 
and accumulate into larger vesicles which can be positively stained with oil red-O 
after 14-21 days (Tropel et al., 2004). To induce chondrogenic differentiation, high-
density cell-pellets or micromass cultures (Denker et al., 1995) are cultured in 
medium containing ascorbic-2-phosphate, dexamethasone, insulin, transferrin, 
selenous acid, pyruvic acid and TGF. Alcian blue staining shows the presence of 
glycosaminoglycans which is indicative of cartilage (Tropel et al., 2004). 
Osteogenesis is achieved by culturing monolayer confluent cells in medium 
supplemented with ascorbic-2-phosphate, -glycerophosphate and dexamethasone. 





To observe calcium deposition and matrix mineralization, cells stain positive with 
alizarin red S (Phinney et al., 1999). 
It is important to emphasize that despite the tri-lineage test being the cardinal test for 
MSC multipotency, only a fraction of cells within any MSC population actually 
undergo differentiation even in cultures obtained from a single clone (Park et al., 
2007c). It is not known why some cells fail to undergo differentiation but there is a 
school of thought that suggests that the differentiation potency diminishes with cell 
‗ageing‘.  
DF unlike MSC, can easily be isolated from mouse skin by a combination of dispase 
and collagenase digestion with the former separating the dermis from the epidermis 
and the latter loosening the ECM to release individual cells which can be propagated 
in culture for relatively long periods of time  (Kitano & Okada, 1983). DF closely 
resemble MSC in both morphology and phenotype expressing and lacking the same 
cell surface markers commonly used for identifying MSC (Haniffa et al., 2009). 
Interestingly, human DF have been reported to undergo differentiation into 
adipocytes, chondrocytes and osteoblasts but in most of these studies, tri-lineage 
differentiation has not been demonstrated in individual experiments (Lysy et al., 
2007; Lorenz et al., 2008). The tri-lineage capacity of murine DF however is yet to 
be demonstrated in a single experiment. 
3.1.1. Aims and Objectives 
The aim of this part of the study was to isolate and characterise MSC from the bone 
marrow of Balb/c and C3H mice in order to provide MSC for subsequent 
immunological studies.  
DF were isolated from both Balb/c and C3H mice skin and characterised in the same 
manner as MSC. 
The specific objectives were; 
1. To isolate Balb/c and C3H MSC from femoral bone marrow. 
2. To expand the bone marrow MSC using different culture media to find 
the most appropriate followed by morphological characterisation. 
3. To determine the phenotype of the MSC using flow cytometry. 





4. To determine the potency of the MSC using tri-lineage differentiation into 
fat, cartilage and bone. 
5. To isolate Balb/c and C3H DF from abdominal skin. 































3.2. Materials and Methods 
3.2.1. Reagents 
The following reagents were used and were prepared as described in Section 2.2.2 
unless stated otherwise; 
 3-Isobutyl-1-methylxanthine (IBMX); 100 mg was dissolved in 225 l of 
DMSO to make a 2 M stock which was filtered through a 0.2 m pore size 
filter. Solution was kept frozen at -20 °C. 
 Alcian blue stain solution 1% (w/v) in acetic acid 
 Alizarin red S dye; 500 mg of powder was dissolved in 50 ml of distilled 
water to make a 1 % (w/v) stock solution. The solution was stirred for 2 hours 
in a flask and filtered through a 0.2 m pore size filter. The stock solution 
was covered with aluminium foil and kept in a dark cupboard at room 
temperature to prevent damage by light.  
 Ammonium hydroxide solution; A 10 % (v/v) ammonium hydroxide solution 
was made by diluting 30 ml of the stock (28 %) with 60 ml distilled water. 
 Antibody diluent; PBS supplemented by 0.1% (v/v) sodium azide. 
 Ascorbate-2-phosphate; 2.57 g was dissolved in 50 ml of distilled water to 
make a 200 mM stock solution. Aliquots were stored at -20 ºC. 
 Collagenase 1A; 5 mg collagenase 1A dissolved in 10 ml DMEM-HG 
medium (without antibiotics and FCS) to make a 0.5 mg.ml
-1
 solution. 1 mg 





 Dexamethasone; 25 mg was dissolved in 1274 l sterile methanol to make a 
stock of 50 mM which was filtered through a 0.2 m pore size filter. Stock 
was stored frozen at -20 °C. 
 Dispase II; 5 mg of dispase II dissolved in 10 ml of DMEM-HG medium 
(without antibiotics and serum) to make a 0.5 mg.ml
-1




 DMEM-HG culture medium 
 DMEM-LG culture medium 
 Ethanol; 100 % 
                                                 
9
 CDU – collagen digestion units 





 FACS blocking buffer (2x); PBS supplemented with 2.5 mM EDTA and 4 % 
(v/v) FCS. 
 Formalin in PBS (10 % v/v): 27 ml of formalin stock (37 %) was diluted with 
63 ml of distilled water and 10 ml of 10 PBS. 
 Hy-Q-Tase™ cell dissociation solution  
 Indomethacin; 100 mg was dissolved in 559 l DMSO to make a stock of 
0.5M which was filtered through a 0.2 m pore size filter. Stock was stored at 
-20 °C. 
 Insulin; 10 mg.ml-1 stock  
 Insulin-transferrin-selenium-X (ITS) 100x; stored at 4 ºC. 
 Isopropanol; 60% (v/v). 6 ml of 100 % isopropanol was diluted with 4 ml 
distilled water. 
 MesenCult™ culture medium 
 Oil red-O solution. 35 mg of Oil red-O powder was dissolved in 10 ml of 100 
% isopropanol to make a stock solution of 0.35 % (w/v) oil red-O which was 
filtered through a 0.2 m pore size filter and stored in a lightproof container. 
 PBS 
 Sodium pyruvate 100 mM stock solution; stored at 4 ºC. 
 StemXVivo™ culture medium  
 Trypsin-EDTA solution; 0.5 % (v/v) 
 -MEM culture medium  
 -glycerophosphate; 10 g was dissolved in 23 ml of distilled water to make a 
2 M stock solution which was stored at -20 ºC. 
 -mercaptoethanol 
 
3.2.2. Harvesting and culture of plastic-adherent cells from Balb/c 
and C3H mice bone marrow 
Balb/c and C3H female mice 4-8 weeks old were killed using a schedule (1) method. 
Femurs were carefully dissected using sterile scissors and forceps and all attached 
epiphyses were carefully removed to minimize contamination by other cells. Whole 
marrow plugs were aseptically flushed out using a syringe filled with DMEM-LG 





culture medium (18G x 1‖ hypodermic needle attached to a 2 cm3 syringe) and 
collected into sterile petri-dishes. The marrow plugs were carefully dispersed by 
pipetting up and down and the resulting cell suspensions were plated into T75 tissue 
culture flasks (10 ml per flask) and incubated for 24 hours in a humidified incubator 
at 37 °C in an atmosphere of 5 % (v/v) CO2 in air to allow adherent cells to attach 
onto the plastic surface. Non-adherent cells and free-floating marrow debris were 
removed and discarded from the culture by changing the medium. Few randomly 
scattered plastic-adherent cells remained in the flasks and were designated passage 
zero (p0) and maintained in culture with medium changes carried out every 48 hours. 
Whenever the cells reached 90 % confluence, they were passaged using Hy-Q-
Tase™ cell detachment solution to consecutive passage numbers as described in 
Section 2.2.6 while some were cryo-preserved as described in Section 2.2.9. 
3.2.3. Isolation and expansion of Balb/c and C3H mouse DF 
Balb/c and C3H 4-8 weeks old female mice were sacrificed using a schedule (1) 
method. They were thoroughly sprayed with 70 % (v/v) ethanol to disinfect the skin. 
Using a sterile scalpel blade, abdominal skin was shaved clean of fur with care taken 
not to cut the skin to prevent contamination. Small pieces of skin approximately 2 cm 
x 2 cm were aseptically dissected and soaked in 70 % (v/v) ethanol for 5 minutes 
followed by 3 washes with sterile PBS. The pieces were then carefully placed into 
petri-dishes with the epidermis side facing upwards. A solution of 0.5 mg.ml
-1 
dispase II enzyme solution in DMEM-HG was carefully added to fully submerge the 
tissues which were then left overnight for at least 15 hours at 4 ºC. Afterwards, the 
tissues were carefully placed in fresh petri-dishes and washed 3 times with PBS. 
Using sterile forceps, the epidermis was gently separated from the dermis. The 
dermis were placed in sterile 40 ml pots containing 10 ml of 0.5 mg.ml
-1
 collagenase 
1A in DMEM-HG medium and incubated on a shaking platform at 37 ºC for 4 hours 
to allow the dermis to be disaggregated to release single cells. After the dermis had 
completely digested (no visibly large pieces), the cell suspensions were gently 
pipetted up and down for a minute followed by the addition of an equal volume of 
DMEM-HG culture medium to inactivate the collagenase 1A. The cells were washed 
3 times by centrifuging at 400 g for 10 minutes and then counted by the Trypan blue 
method descried in Section 2.2.8. The cells were then seeded in T75 flasks at 1 x 10
5
 
cells per flask in DMEM-HG culture medium and incubated at 37 ºC in an 





atmosphere of 5 % (v/v) CO2 in air. The first medium change was carried out after 24 
hours to wash off any debris from the p0 cells. Subsequently, medium was changed 
every 3 days. Upon reaching 90 % confluence, the cells were passaged to the next 
consecutive number using 0.5 % (v/v) trypsin-EDTA solution for cell detachment as 
described in Section 2.2.6 or cryo-preserved as described in Section 2.2.9 for later 
use.  
3.2.4. Evaluation of different types of culture media for expansion 
of mouse MSC 
In order to determine the most favourable medium which supported MSC expansion, 
five types of commercially available medium were evaluated for their ability to 
support cell expansion by means of cell doubling times (CDT). DMEM-LG, DMEM-
HG, -MEM, StemXVivo™, and MesenCult™ culture media were used in the 
culture of p3 Balb/c and C3H marrow plastic-adherent cells. P2 cells were passaged 
as described in Section 2.2.6, counted by the Trypan blue method (Section 2.2.8) 
and seeded at 1 x 10
5
 cells per T75 flask. Into each flask, 10 ml of any of the five 
media was added and the flasks were cultured at 37 °C in an atmosphere of 5 % (v/v) 
CO2 in air. 
Medium was changed every 2 to 3 days until the flasks were nearly 100 % confluent 
at which point the cells were detached as described in Section 2.2.6 and counted by 
the Trypan blue method as described in Section 2.2.8. CDTs were calculated 
according to the formula; 
 
Where; T1 - time at start (hours) 
T2 - time at confluence (hours) 
N2 - final cell count of monolayer 
N1 - initial number of seeded cells 
 





3.2.5. Characterisation of Balb/c and C3H mouse MSC and DF 
3.2.5.1. Flow cytometry 
Balb/c and C3H bone marrow plastic-adherent cells (p3 and p10) and DF (p6) were 
analysed for the expression of and lack of a panel of markers commonly used to 
characterize MSC by flow cytometry. 
Upon reaching 95% confluence in culture, the cells were washed twice with PBS and 
detached using Hy-Q-Tase™ (for plastic-adherent cells) or 0.5 % (v/v) trypsin-
EDTA (for DF) as described in Section 2.2.6, counted using the Trypan blue method 





Aliquots of 100 l of the cell suspension were placed into sterile 1.5 ml Eppendorf 
tubes and an equal volume of 2x FACS blocking buffer was added to the cells 
followed by incubation for 20 minutes on ice. Specific conjugated antibody solutions 
were prepared with appropriate dilutions in antibody diluent according to Table 3.1 
and kept on ice in the dark. Labelled antibody solutions (100 l) were added to the 
cell suspensions, gently mixed and incubated on ice for 1 hour in the dark with 
occasional flicking to ensure mixing. The cells were then washed 3 times with 300 l 
of ice-cold PBS by centrifugation at 3000 g for 5 minutes at 4 °C. Two further 
washes with 500 l of ice-cold PBS were carried out after which the cell pellets were 
resuspended in 200 l of ice-cold PBS. A FACSCalibur (Becton Dickinson) flow 
cytometer was used to measure the fluorescence intensities of all samples. Data was 
collected (10 000 events per sample) using CellQuest™ v.3.1 flow cytometry data 
acquisition software (Becton Dickinson) and analysed using FlowJo
™
 v.7.6.5 flow 











Table 3.1. Conjugated antibodies used for the phenotypic characterisation of 
Balb/c and C3H bone marrow MSC and DF. 
Antibody Isotype Clone Label Host Diluti
on 
Supplier 
Sca-1 IgG2,  D7 FITC Rat 1:50 eBioscience 
CD29 IgG eBioHMb1-1 PE Hamster 1:10 eBioscience 
CD90.2 IgG2 5a-8 FITC Rat 1:50 Invitrogen 
CD80 IgG 16-10A1 FITC Hamster  1:400 eBioscience 
CD86 IgG2,  PO3.1 PE Rat 1:100 eBioscience 
CD86 IgG2,  PO3.1 FITC Rat 1:100 BioLegend 
CD11b IgG2,  M1/70 FITC Rat 1:100 eBioscience 
MHC I IgG2,  34-1-2S FITC Mouse 1:100 eBioscience 
MHC II IgG2,  M5/114.15.2 FITC Rat 1:400 eBioscience 
CD44 IgG2,  IM7 FITC Rat 1:200 eBioscience 
CD45 IgG2,  30-F11 FITC Rat 1:20 BioLegend 
CD45 IgG2,  30-F11 PE Rat 1:20 Invitrogen 
Isotype control Clone Label Host Diluti
on 
Supplier 
IgG2,  6H3 FITC Mouse 1:50 MBL 
IgG2,  RMG2a-62 FITC Rat 1:50 BioLegend 
IgG2,  3D12 FITC Mouse 1:50 MBL  
IgG2,  RMG2b-1 FITC Rat 1:50 BioLegend 
IgG2,  3D12 PE Mouse 1:20 Invitrogen 
IgG RMG1-1 FITC Rat 1:50 BioLegend 
IgG 2E12 FITC Mouse 1:50 eBioscience 
IgG 2E12 PE Mouse 1:100 eBioscience 
[FITC; fluorescein isothyocyanate absorption/ emission max 494-250 nm. PE; phycoerythrin 
absorption/emission max 496-578 nm. CD; cluster of differentiation; Ig; immunoglobulin; 
MHC; major histocompatibility complex] 
 
3.2.5.2. Tri-lineage differentiation of Balb/c and C3H MSC and DF 
3.2.5.2.1. Adipogenic differentiation 
Adipogenic differentiation medium (ADM) was made by supplementing DMEM-LG 
culture medium (MSC) or DMEM-HG culture medium (DF) with
 
insulin, IBMX, 
indomethacin and dexamethasone stock solutions prepared as described in Section 
3.2.1 to give final concentrations of 10 g.ml-1 insulin, 100 M indomethacin, 1 M 
dexamethasone and 0.5 M IBMX. Adipogenic maintenance medium (AMM) was 
made by supplementing DMEM-LG or DMEM-HG culture medium with insulin 
stock solution (Section 3.2.1) to give a final concentration of 10 g.ml-1 insulin.  





Balb/c and C3H MSC (p10) and DF (p6) cultures were maintained in culture until 
they reached 90% confluence in T75 flasks. The cells were washed twice with 10 ml 




 and detached from the surface using Hy-Q-
Tase™ (MSC) and 0.5 % (v/v) trypsin-EDTA (DF) solution for MSC and DF for 5 
minutes at room temperature and 37 °C respectively as described in Section 2.2.6. 
The resulting cell suspensions were washed with DMEM-LG and DMEM-HG 
culture medium by centrifugation at 180 g for 10 minutes. The cell pellets were 
resuspended in 5 ml of their respective culture medium followed by counting using 
the Trypan blue dye method (Section 2.2.8). Cells were plated in 6-well tissue 




 growth area (1 x 10
5
 cells per well)  in 
3 ml of DMEM-LG and DMEM-HG culture medium. The plates were incubated at 
37 °C in an atmosphere of 5% (v/v) CO2 in air and maintained in culture until they 
reached 95 % confluence. Culture medium was replaced with ADM while in control 
cultures, cells were maintained in DMEM-LG or DMEM-HG culture medium and 
this was marked as the 1
st
 day of differentiation. In the differentiation cultures, ADM 
was replaced with AMM after each 48 hour period and this medium interchange was 
maintained throughout the culture period. Cultures were regularly checked for the 
presence of lipid vesicles under a light microscope during the differentiation period.  
3.2.5.2.1.1. Oil red O (ORO) staining for adipogenesis 
At day 14 of adipogenic differentiation, the cells (MSC and DF) were washed twice 
with PBS and fixed with 10% (v/v) formalin (Section 3.2.1) for 10 minutes at room 
temperature (2 ml per well). Meanwhile, Oil red O (ORO) working solution was 
prepared by mixing 6 ml of ORO stock solution (Section 3.2.1) with 4 ml of distilled 
water followed by filtering through a 0.2 m filter. Formalin was removed from the 
wells and the cells were washed twice with distilled water and twice with 60% (v/v) 
isopropanol (Section 3.2.1) for 5 minutes followed by air-drying at room 
temperature. Filtered ORO working solution (2 ml per well) was added to the wells 
and kept for 10 minutes at room temperature in the dark. Afterwards, the ORO 
solution was removed and the stained cells were immediately washed twice with 
distilled water. Finally, distilled water enough to cover the cells was added into each 
well and the cells were viewed under an Olympus BX 71 inverted microscope and 
images were captured using Cell^B image acquisition software (Olympus). 





3.2.5.2.2. Chondrogenic differentiation 
Chondrogenic differentiation medium (CDM) was made by supplementing DMEM-
LG (MSC) and DMEM-HG (DF) culture medium with 150 M ascorbate-2-
phosphate, 1 mM sodium pyruvate, 0.1 M dexamethasone, 6.25 ng.ml-1 selenous 
acid, 6.25 g.ml-1 transferrin and 6.25 g.ml-1 insulin The supplements were 
prepared as described in Section 3.2.1.. 
Balb/c and C3H MSC (p10) and DF (p6) were cultured in T75 flasks until they 





(10 ml per flask) and then detached using Hy-Q-Tase™ (MSC) and 0.5 % (v/v) 
trypsin-EDTA (DF) for 5 minutes at room temperature and 37 °C respectively as 
described in Section 2.2.6. The resulting cell suspensions were washed with DMEM-
LG or DMEM-HG culture medium by centrifugation at 180 g for 10 minutes and 
then counted using the Trypan blue method (Section 2.2.8) and finally resuspended 





. In order to create micromass chondrogenic nodules in 24-well plates, 10 l of the 
cell suspension was carefully placed at the centre of each well using a 20 l pipette. 
The plates were incubated at 37 °C in an atmosphere of 5% (v/v) CO2 in air for 3 
hours to allow the cells to attach. Afterwards, the wells were gently flooded with 1 
ml of CDM. Control cultures were cultured in DMEM-LG and DMEM-HG culture 
medium for MSC and DF respectively. The seeded plates were incubated at 37 °C in 
an atmosphere of 5% (v/v) CO2 in air for 21 days with medium changed each 3 days. 
3.2.5.2.2.1. Alcian blue staining for glycosaminoglycans 
At day 21 of chondrogenic differentiation, the cells were washed twice with distilled 
water and fixed with 10% (v/v) formalin for 10 minutes at room temperature (2 ml 
per well). After fixation, the formalin was removed from the wells and the cells were 
washed twice with distilled water and then left air dry. The cells were stained with 
500 l of 1 % (w/v) alcian blue staining solution (Section 3.2.1) at a pH of 2.5 for 30 
minutes. The stain was removed and the cells washed with running tap water for 2 
minutes to remove excess stain. To view the cells, 1 ml per well of distilled water 
was added and the staining viewed with an Olympus BX 71 inverted microscope and 
images were captured using Cell^B image acquisition software (Olympus). 





3.2.5.3. Osteogenic differentiation 
Osteogenic differentiation medium (ODM) was made by supplementing DMEM-LG 
(MSC) and DMEM-HG (DF) culture medium with 0.1 mM of ascorbate-2-
phosphate, 10 mM of -glycerophosphate and 0.0001 mM of dexamethasone. The 
supplements were prepared as described in Section 3.2.1. Balb/c and C3H MSC 
(p10) and DF (p6) cells were cultured in DMEM-LG and DMEM-HG culture media 
respectively until they reached 90% confluence. The cells were washed twice with 




to remove culture medium and they were detached 
using Hy-Q-Tase™ and 0.5 % (v/v) trypsin-EDTA for 5 minutes at room 
temperature and 37 °C respectively for MSC and DF. The resulting cell suspensions 
were washed with DMEM-LG or DMEM-HG culture medium by centrifugation at 
180 g for 10 minutes. The cell pellets were resuspended in their respective culture 
medium, counted by Trypan blue method (Section 2.2.8) and plated in 6-well tissue 




 growth area (1 x 10
5
 cells per well) in 
3 ml of appropriate culture medium. The plates were incubated at 37 °C in an 
atmosphere of 5% (v/v) CO2 in air accompanied by medium changes every 3 days 
until they reached 95 % confluence at which point culture medium was replaced with 
ODM in the test wells while control wells were maintained in DMEM-LG or 
DMEM-HG culture medium for MSC and DF respectively. Medium was changed 
after each 3 day period for a total culture period of 14 days.  
3.2.5.3.1.1. Alizarin red S staining for calcium deposition 
Alizarin red S working solution (0.1% w/v) was made by making a 1:10 dilution of 
the 1% (w/v) stock with distilled water and adjusting the pH to 4.1 with 10 % (v/v) 
ammonium hydroxide solution. At day 14 of osteogenic differentiation, the cell 
cultures were washed twice with distilled water and fixed with 10% (v/v) formalin 
for 10 minutes at room temperature (2 ml per well). After fixation, the formalin was 
removed from the wells and the cells were washed twice with distilled water and 
then left to air dry. The cells were stained with 0.1 % (w/v) alizarin red S staining 
solution (pH 4.1) for 20 minutes (1 ml per well). The cells were washed four times 
with distilled water to remove excess dye and 1 ml of distilled water was added into 
each well before viewing the cells with an Olympus BX 71 inverted microscope 
followed by capturing images using Cell^B image acquisition software (Olympus). 






3.3.1. Harvesting and initial culture of Balb/c and C3H mouse bone 
marrow stromal cells  
Balb/c and C3H 4-8 weeks old female mice were sacrificed and aseptically dissected 
to separate the femurs. Bone marrow stroma was harvested by femoral aspiration 
using DMEM-LG culture medium and plated in tissue culture flasks to allow 
attachment to the plastic surface overnight as described in Section 3.2.2. 
Three hours post seeding, the cells appeared densely populated (Figure 3.1A-B)  but 
after the first medium change 24 hours later, most of the non-adherent cells were lost 
leaving behind sparse cells (Figure 3.1C-D). These cells appeared to exhibit 
different morphologies including individual spindle-shaped bipolar fibroblastic-like 
cells, dendritic-like cells and macrophage-like cells (Figure 3.2A-B). Most of these 
heterogeneous cells in the early cultures appeared to become smaller and rounded 
and were gradually lost during subsequent medium changes (Figure 3.2C-D). Some 
few spindle-shaped fibroblastic-like cells remained attached and were quiescent for 
some time before gradually dividing and populating the flasks; Balb/c and C3H cells 
took approximately 3 and 5 weeks respectively to achieve 90 % confluence before 
the 1
st
 passage. Though these fibroblastic-like cells became more prominent during 
the initial stages, other morphologies became less apparent. 
For the 2
nd




 (1 x 10
2
 
cells per T75 flask) in order to test their clonogenic capacity. The cells initially 
appeared as sparse colonies of colony forming units-fibroblasts (CFU-F) which 
gradually grew into small cell clusters (Figure 3.3A-B) which assumed a radial 
growth pattern eventually forming larger populations (Figure 3.3C-D).  
By late 2
nd
 passage, homogeneous cultures of the fibroblastic-like cells which 
resembled MSC dominated the cultures and achieved 90 % confluence (Figure 3.3E-
F) at which point they were passaged and achieved 95 % confluence much faster 
(within 5 days) compared to the earlier heterogeneous culture. 
 






Figure 3.1. Appearance of freshly harvested mouse bone marrow cells before and after 
the first medium change. Balb/c (A) and C3H (B) bone marrow cells were extracted by 
femoral aspiration and plated in tissue culture flasks in DMEM-LG culture medium. After 24 
hours, the medium was changed with the concomitant loss of non-adherent cells leaving 
behind few and sparse Balb/c (C) and C3H (D) plastic-adherent cells. Images were captured 
at x100 magnification using Image-Pro
® 
Plus imaging software (MediaCybernetics). 
 
 
Figure 3.2. Morphological heterogeneity of early cultures of mouse bone marrow-
derived plastic-adherent cells. 1
st
 passage Balb/c (A) and C3H (B) cells grown in DMEM-
LG culture medium exhibited distinct morphologies. After several days in culture some of 
the Balb/c (C) and C3H (D) plastic-adherent cells appeared thin and rounded and were 
eventually lost during subsequent medium changes. Images were captured at x100 
magnification using Image-Pro
® 
Plus imaging software (MediaCybernetics). 
 






Figure 3.3. Growth and early expansion of mouse bone marrow-derived plastic-
adherent fibroblastic-like cells. Persistence of fibroblastic-like cells in Balb/c (left) and 
C3H (right) cell cultures gave rise to colony forming units (A and B) which gave rise to 
larger colonies that grew in a radial pattern (C and D). On reaching 90 % confluence, the 
cells were split to the 2
nd
 passage at low density and after a few days the cells yielded 
homogeneous cultures of bipolar spindle-shaped fibroblastic-like cells (E and F). Images 
were captured at x100 (C, D, E and F) and x200 (A and B) magnification using Image-Pro
® 
Plus imaging software (MediaCybernetics). 
 
3.3.2. Appropriate medium for expansion of p3 C3H and Balb/c 
plastic-adherent bone marrow cells 
The type and composition of medium is important for the growth and expansion of 
MSC. For mouse MSC, different media have been used in different studies hence it 
was necessary to determine the appropriate culture medium for C3H and Balb/c 
MSC. Five types of commercially available general purpose (DMEM-HG, DMEM-
LG and -MEM) and MSC-specific (StemXVivo™ and MesenCult®) culture media 
were tested for their capacity to support growth and expansion of 3
rd
 passage Balb/c 





and C3H bone marrow plastic-adherent cells in terms of maintenance of cell 
morphology and CDT or growth rate.  
Cells, except those cultured in -MEM appeared healthy, maintained their fibroblast-
like morphology and were relatively easy to dislodge from the plastic surface during 
passage using Hy-Q-Tase
™
 but not 0.5 % (v/v) trypsin-EDTA cell dissociation 
solution. DMEM-LG and StemXVivo
™
 cultured cells produced the lowest CDT of 8 
hours per doubling which was the fastest rate of cell expansion compared to 
MesenCult
®
, DMEM-HG and -MEM which had CDTs of 24, 30 and 42 hours per 
doubling respectively (Figure 3.4). Cells cultured in -MEM in addition to having 
the slowest CDT, appeared thin with an elongated morphology and arranged in a 
linear pattern in stark contrast to those cultured in DMEM-LG (Figure 3.5). These 
cells were resistant to dissociation by both 0.5 % (v/v) trypsin-EDTA and Hy-Q-
Tase
™
 treatment during passage and could only be dislodged with the aid of a cell 
scraper. Based on the CDTs and morphological examination, DMEM-LG and 
StemXVivo
™
 provided the fastest growth conditions for expansion of both C3H and 
Balb/c plastic-adherent cells. DMEM-LG was preferred to StemXVivo
™ 
due to cost. 
 
Figure 3.4. Measurement of cell doubling times (CDTs) to determine the appropriate 
culture medium for the expansion of mouse bone marrow-derived plastic-adherent 
cells. Balb/c and C3H p3 plastic-adherent cells were cultured in DMEM-LG, DMEM-HG, 
StemXVivo
™
, -MEM and MesenCult® culture media at an initial density of 1 x 105.ml-1 and 
medium changed every 3 days in T75 tissue culture flasks. Cells were counted after reaching 
95-100 % confluence and CDT computed. The fastest expansion rate was obtained with 
DMEM-LG and StemXVivo with -MEM giving the slowest growth rate. Data presented 
was for C3H cells and is plotted as mean ± 95 % CL of triplicate samples. Results are 
representative for Balb/c cells.   





































Figure 3.5. Effects of medium type on the growth and expansion of mouse bone 
marrow-derived plastic-adherent cells. C3H cells (p3) were cultured in -MEM (left) and 
DMEM-LG (right) culture media. Initially, the cells exhibited similar morphology (A and B) 
but after the 1
st
 week, the cells cultured in-MEM appeared elongated and arranged in a 
linear pattern (C) whereas those cultured in DMEM-LG (D) retained their bipolar spindle-
shaped morphology and were evenly spread across the flask. Prolonged culture in -MEM 
resulted in the cells becoming thin and elongated (E) as opposed to those in DMEM-LG cells 
which appeared healthy (F). Images were captured at x100 (A, B, C and D) and x200 (E and 
F) magnification using Image-Pro
® 
Plus imaging software (MediaCybernetics). 
 
3.3.3. Expansion of C3H and Balb/c mouse plastic-adherent cells 
Having established the most suitable culture medium for cell expansion, both C3H 
and Balb/c plastic-adherent cells (p3) were expanded in DMEM-LG culture medium. 
The cells maintained morphological homogeneity consistently over time and were 
cryo-preserved at every passage until the 14
th
 passage (Figure 3.6). 
 






Figure 3.6. Morphological homogeneity of mouse bone marrow-derived plastic-
adherent cells after long term culture. Balb/c (A) and C3H (B) p14 cells showing typical 
bipolar spindle shaped morphology. Images were captured at x100 magnification using 
Image-Pro
® 
Plus imaging software (MediaCybernetics). 
 
3.3.4. Growth and expansion of Balb/c and C3H mouse DF 
DF were isolated from abdominal skin by a double enzymatic digestion process 
using dispase II and collagenase 1A, washed and cultured in DMEM-HG culture 
medium. The adherent cells showed typical fibroblastic morphology; bipolar spindle-
shaped cells, which reached 95 % confluence after two to three days of seeding and 
passage. The cells retained their morphology and growth rate in subsequent passages 
(Figure 3.7). 
 






Figure 3.7. Isolation and expansion of mouse DF. Balb/c (left) and C3H (right) mouse 
abdominal skin were treated with dispase II to separate the epidermis and the dermis 
followed by collagenase 1A digestion of the dermis to liberate individual cells which thrived 
in culture giving homogeneous cells (A and B). These cells proliferated in culture for several 
passages and maintained morphological homogeneity throughout (C and D). Images were 
captured using Cell^B imaging software (Olympus). 
 
3.3.5. Characterisation of mouse MSC and DF 
3.3.5.1. Phenotypic characterisation of Balb/c and C3H bone 
marrow-derived plastic-adherent cells and DF by flow cytometry 
The expression of, or lack of, specific cell surface antigens is commonly used in the 
characterisation of MSC. Balb/c and C3H bone marrow-derived plastic-adherent 
cells were analysed by flow cytometry to determine whether they possessed a 
phenotype consistent with that known for MSC listed in Table 3.1. Lower passage 
(p3) and higher passage (p12) cells were analysed in order to investigate if prolonged 
culture had an effect on the phenotype of the cells. The same markers were also 
analysed on Balb/c and C3H (p6) DF in order to assess whether the panel of markers 
used could be used to distinguish between MSC and DF. 





For the bone marrow-derived plastic-adherent cells, the cells were prepared as 
described in Section 3.2.5.1. Unstained cells were used to define the population of 
cells of interest from debris and dead cells while isotype control-stained cells were 
used to set limits for positive and negative cells. All the antibodies used for these 
analyses were labelled with fluorescein isothyocyanate (FITC) whose fluorescence 
intensity was detected in the FL-1 channel. Cells exhibiting fluorescence intensity 
above 10
2
 were considered positive for the specific marker whereas those below this 
threshold were considered negative or not different from the isotype control.  
Early passage cells (p3) from Balb/c (Figure 3.8) and C3H (Figure 3.9) were 
positive for Sca-1, MHC I, CD29, CD44, CD90.2 and CD105. The cells were 
negative for MHC II, CD80, CD86, CD11b, CD34 and CD45 (less than 5 %). Late 
passage (p12) Balb/c (Figure 3.10) and C3H (Figure 3.11) cells showed a phenotype 
profile similar to that observed with early passage (p3) cells despite regular passage 
and extended culture for over 6 months. This showed that the cells maintained their 
phenotype for prolonged periods. 
Expression of CD105 and MHC I was partial in both Balb/c (59 % and 77 %) and 
C3H (54 % and 75 %) early passage (p3) cells respectively but CD105 was highly 
expressed (99 %) in p12 cells whilst MHC I expression did not change. CD90.2 
expression in p3 Balb/c cells was 67 % and increased to 99 % in p12 cells but it was 
the same (above 95 %) for both early and late passage C3H cells. CD29 expression 
in C3H cells however decreased from 100 % in p3 cells to 67 % in p12 cells whilst in 
Balb/c cells in increased from 88 % to 100 % in p3 and p12 cells respectively.  
Despite these variations, the overall phenotype of both early and late passage Balb/c 
and C3H bone marrow-derived plastic-adherent cells was consistent with the 
phenotype for MSC reported in many studies. The different specific marker 
expression profiles between early and late passage cells is also consistent with the 
heterogeneity of bone marrow cell cultures as was observed throughout the literature. 
Though the phenotype resembled that of MSC, the cells were further tested to prove 







Figure 3.8. Phenotype of Balb/c mouse p3 bone marrow-derived plastic-adherent cells using flow cytometry. Data shown is representative of 10
4
 events 
acquired and analysed using CellQuest Pro software. Histograms were gated with fluorophore staining above 10
2
 considered positive expression of specific marker. 
Shaded (grey) histograms represented isotype controls, while the red bold lines represented specific marker expression profile. The fraction of positively stained 
cells is shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29, CD44 and CD105 but negative for MHC II, 
haematopoietic markers CD34 and CD45, co-stimulatory molecules CD80 and CD86 and the macrophage marker CD11b. This profile was consistent with the 








Figure 3.9. Phenotype of C3H mouse p3 bone marrow-derived plastic-adherent cells using flow cytometry. Data shown is representative of 10
4
 events acquired 
and analysed using CellQuest Pro software. Histograms were gated with fluorophore staining above 10
2
 considered positive expression of specific marker. Shaded 
(grey) histograms represented isotype controls, while the blue bold lines represented specific marker expression profile. The fraction of positively stained cells is 
shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29, CD44 and CD105 but negative for MHC II, 
haematopoietic markers CD34 and CD45, co-stimulatory molecules CD80 and CD86 and the macrophage marker CD11b. This profile was consistent with the 








Figure 3.10. Phenotype of Balb/c mouse p12 bone marrow-derived plastic-adherent cells using flow cytometry. Data shown is representative of 10
4
 events 
acquired and analysed using CellQuest Pro software. Histograms were gated with fluorophore staining above 10
2
 considered positive expression of specific marker. 
Shaded (green) histograms represented isotype controls, while the red bold lines represented specific marker expression profile. The fraction of positively stained 
cells is shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29, CD44 and CD105 but negative for MHC II, 
haematopoietic markers CD34 and CD45, co-stimulatory molecules CD80 and CD86 and the macrophage marker CD11b. This profile was consistent with the 








Figure 3.11. Phenotype of C3H mouse p12 bone marrow-derived plastic-adherent cells using flow cytometry. Data shown is representative of 10
4
 events 
acquired and analysed using CellQuest Pro software. Histograms were gated with fluorophore staining above 10
2
 considered positive expression of specific marker. 
Shaded (pink) histograms represented isotype controls, while the blue bold lines represented specific marker expression profile. The fraction of positively stained 
cells is shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29, CD44 and CD105 but negative for MHC II, 
haematopoietic markers CD34 and CD45, co-stimulatory molecules CD80 and CD86 and the macrophage marker CD11b.This profile was consistent with the known 
MSC phenotype. [CD; cluster of differentiation. MHC; major histocompatibility complex] 





DF were also analysed for the same markers (Table 3.1) as the bone marrow-derived 
plastic-adherent cells (except CD34) in order to determine whether they shared the 
same phenotype. Due to their fast growth rate, intermediate passage (p6) Balb/c and 
C3H DF were analysed by flow cytometry. 
Unstained cells were used to distinguish the population of cells of interest from dead 
cells and debris while isotype control-stained cells were used to set limits for positive 
and negative cells. All the marker-specific antibodies were FITC-labelled except for 
CD29 and CD105 which were labelled with phycoerythrin (PE) whose fluorescence 
was detected in the FL2 channel. Cells which exhibited fluorescence intensity above 
10
2
 for FITC-labelled or 10
1
 for PE-labelled were considered positive for the specific 
marker whereas those below this threshold were considered negative. 
 Both Balb/c (Figure 3.12) and C3H (Figure 3.13) DF were positive for Sca-1, MHC 
I and CD29 but were negative for MHC II, CD11b, CD44, CD45, CD80, CD86 and 
CD105 expression. For the positive markers, only Sca-1 had above 95 % expression 
in both Balb/c and C3H DF. CD90.2, MHC I and CD29 expression was 54 %, 91 % 
and 90 % respectively in Balb/c DF while for C3H cells it was 78 %, 82 % and 80 % 
respectively. All the negative markers, except for CD44, had expression less than 5 
% in both Balb/c and C3H DF. In the case of CD44, expression was 43 % and 53 % 
respectively in Balb/c and C3H DF respectively. 
The phenotype displayed by DF, though largely resembling that exhibited by bone 
marrow-derived plastic-adherent cells, showed differences in CD105 and CD44 
which were negative in the former but positive in the later.  
 
 








Figure 3.12. Phenotype of Balb/c mouse p6 DF using flow cytometry. Data shown is representative of 10
4
 events acquired and analysed using CellQuest Pro 




 considered positive expression of specific markers bound to FITC and PE-labelled 
antibodies respectively. Shaded (grey) histograms represented isotype controls while the bold green lines represented specific marker expression profile. The 
fraction of positively stained cells is shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29 and MHC I but 








Figure 3.13. Phenotype of C3H mouse p6 DF using flow cytometry. Data shown is representative of 10
4
 events acquired and analysed using CellQuest Pro 




 considered positive expression of specific markers bound to FITC and PE-labelled 
antibodies respectively. Shaded (grey) histograms represented isotype controls, while the bold blue lines represented specific marker expression profile. The 
fraction of positively stained cells is shown above the gate as a percentage of total cells. Cells were positive for the markers Sca-1, CD90.2, CD29 and MHC I but 
negative for CD44, CD105, MHC II, CD45, CD80, CD86 and CD11b. [CD; cluster of differentiation. MHC; major histocompatibility complex]





3.3.6. Tri-lineage differentiation of Balb/c and C3H bone marrow 
plastic-adherent cells and DF 
In order to define the bone marrow-derived plastic-adherent cells as MSC, the cells 
should be able to demonstrate multipotential differentiation capacity by changing 
from their bipolar fibroblastic morphology to fat, cartilage and bone cells. The tri-
lineage differentiation test involved treatment of the bone marrow-derived plastic-
adherent cells (p10) with specific lineage differentiating media as described in 
Section 3.2.5.2 accompanied by morphological examination during the 
differentiation period followed by histological staining. DF (p6) were also treated in 
the same way in order to test whether they possessed multipotential differentiation 
capacity. 
3.3.6.1. Adipogenic differentiation 
When cultured in ADM, the bone marrow-derived plastic-adherent cells changed 
from their bipolar spindle-shaped morphology and assumed a rounded morphology 
while the control cells cultured in non-differentiating conditions (DMEM-LG culture 
medium only) retained their spindle-shaped morphology. By the 3
rd
 day of culture, 
small lipid vesicles became visible under light microscopy in both Balb/c (Figure 
3.14) and C3H (Figure 3.15) cells cultured in ADM. With time, these vesicles 
gradually became larger in size and appeared like ‗bunches of grapes‘ which 
coalesced to form larger lipid bodies by the 14
th
 day. The adipogenic differentiated 
cells stained positive with Oil red O (ORO) stain while those cultured in non-
differentiating conditions were negative. However, some cells cultured in ADM 
remained morphologically unchanged throughout the differentiation period and thus 
were unable to take up the ORO stain.  
Similarly, both Balb/c (Figure 3.16) and C3H (Figure 3.17) DF cultured in ADM 
accumulated lipid vesicles by the 3
rd
 day and after 14 days, substantial lipid deposits 
stained positive with oil ORO. Control cells cultured in DMEM-HG culture medium 
did not develop lipid vesicles and were negative with ORO stain. Thus both the bone 
marrow-derived plastic-adherent cells and DF demonstrated comparable adipogenic 
differentiation capacity.  






Figure 3.14. Adipogenic differentiation potential of p10 Balb/c mouse bone marrow-
derived plastic-adherent cells. The cells were seeded in 6-well plates until confluent and 
cultured in either ADM and AMM or DMEM-LG culture medium for 14 days. Lipid vesicles 
accumulated in adipogenic-induced cells (A) while control cells retained their fibroblastic 
morphology (B). The lipid vesicles stained positive with ORO staining (C) while control 
cultures were negative (D). Images were captured at x200 magnification (A and B) and x100 
(C and D). [ADM; adipogenic differentiation medium. AMM; adipogenic maintenance 
medium. ORO; oil red O] 
 
 
Figure 3.15. Adipogenic differentiation potential of p10 C3H mouse bone marrow-
derived plastic-adherent cells. The cells were seeded in 6-well plates until confluent and 
cultured in either ADM and AMM or DMEM-LG culture medium for 14 days. Lipid vesicles 
accumulated in adipogenic-induced cells (A) while control cells retained their fibroblastic 
morphology (B). The lipid vesicles stained positive with oil ORO staining (C) while control 
cultures were negative (D). Images were captured at x100 magnification. [ADM; adipogenic 
differentiation medium. AMM; adipogenic maintenance medium. ORO; oil red O] 






Figure 3.16. Adipogenic differentiation potential of p6 Balb/c mouse DF. The cells were 
seeded in 6-well plates until confluent and cultured in either ADM and AMM or DMEM-HG 
culture medium for 14 days. Lipid vesicles accumulated in adipogenic-induced cells (A) 
while control cells retained their spindle-shaped morphology (B). The lipid vesicles stained 
positive with ORO staining (C) while control cultures were negative (D). Images were 
captured at x100 magnification. [ADM; adipogenic differentiation medium. AMM; 
adipogenic maintenance medium. ORO; oil red O]  
 
 
Figure 3.17. Adipogenic differentiation potential of p6 C3H mouse DF. The cells were 
seeded in 6-well plates until confluent and cultured in either adipogenic induction medium 
and AMM or DMEM-HG culture medium for 14 days. Lipid vesicles accumulated in adipo-
induced cells (A) while control cells retained their spindle-shaped morphology (B). The lipid 
vesicles stained positive with oil red O staining (C) while control cultures were negative (D). 
Images were captured at x100 magnification. [ADM; adipogenic differentiation medium. 
AMM; adipogenic maintenance medium. ORO; oil red O] 





3.3.6.2. Chondrogenic differentiation 
To achieve chondrogenic differentiation, Balb/c and C3H bone marrow-derived 
plastic-adherent cells (p10) and DF (p6) were cultured as micro-pellets in CDM for 
21 days. Control cells were also cultured as micro-pellets in non-differentiating 
conditions. 
Light microscopy examination of the chondrogenic-induced Balb/c (Figure 3.18) 
and C3H (Figure 3.19) bone marrow-derived plastic-adherent cells showed an 
elongated morphology in comparison to control cells. After 21 days, micro-pellets in 
chondrogenic medium stained positive with alcian blue dye which stained 
glycosaminoglycans (GAGs) while control cells cultured in DMEM-LG culture 
medium were negative for the stain. Interestingly, both Balb/c (Figure 3.20) and 
C3H (Figure 3.21) DF cultured in chondrogenic differentiation medium stained 
positive with alcian blue while cells cultured in DMEM-HG culture medium were 
negative. 
These findings showed that both Balb/c and C3H bone marrow-derived plastic-















Figure 3.18. Chondrogenic differentiation potential of p10 Balb/c mouse bone marrow-
derived plastic-adherent cells. The cells were seeded as micro-pellets in 24-well plates and 
cultured in CDM or DMEM-LG culture medium for 21 days. Chondrogenic-induced cells 
were closely packed and assumed an elongated morphology (A) in comparison to control 
cells (B). Chondrogenesis was detected by alcian blue staining with chondrogenic-induced 
cells showing substantial GAGs accumulation (C) while control cells were negative (D). 
Images were captured at x100 magnification. [CDM; chondrogenic differentiation medium. 
GAGs; glycosaminoglycans]  
 
 
Figure 3.19.  Chondrogenic differentiation potential of p10 C3H mouse bone marrow-
derived plastic-adherent cells. The cells were seeded as micro-pellets in 24-well plates and 
cultured in CDM or DMEM-LG culture medium for 21 days. Chondrogenic-induced cells 
were closely packed and assumed an elongated morphology (A) in comparison to control 
cells (B). Chondrogenesis was detected by alcian blue staining with chondrogenic-induced 
cells showing substantial GAG accumulation (C) while control cells were negative (D). 
Images were captured at x100 magnification. [CDM; chondrogenic differentiation medium. 
GAG; glycosaminoglycans]  






Figure 3.20. Chondrogenic differentiation potential of p6 Balb/c DF. The cells were 
seeded as micro-pellets in 24-well plates and cultured in CDM or DMEM-HG culture 
medium for 21 days. Chondrogenic-induced cells were closely packed and assumed an 
elongated morphology (A) in comparison to control cells (B). Chondrogenesis was detected 
by alcian blue staining with chondrogenic-induced cells showing substantial GAG 
accumulation (C) while control cells were negative (D). Images were captured at x100 
magnification. [CDM; chondrogenic differentiation medium. GAG; glycosaminoglycans]  
 
 
Figure 3.21. Chondrogenic differentiation potential of p6 C3H DF. The cells were seeded 
as micro-pellets in 24-well plates and cultured in CDM or DMEM-HG culture medium for 
21 days. Chondrogenic-induced cells were closely packed and assumed an elongated 
morphology (A) in comparison to control cells (B). Chondrogenesis was detected by alcian 
blue staining with chondrogenic-induced cells showing substantial GAG accumulation (C) 
while control cells were negative (D). Images were captured at x100 magnification. [CDM; 
chondrogenic differentiation medium. GAG; glycosaminoglycans] 





3.3.6.3. Osteogenic differentiation 
Osteogenic differentiation was induced by culturing confluent Balb/c and C3H p10 
bone marrow-derived plastic-adherent cells and p6 DF in osteogenic ODM for 14 
days. Control cells were cultured in DMEM-LG or DMEM-HG culture medium for 
bone marrow-derived plastic-adherent cells and DF respectively. 
Light microscopy examination on the 5
th
 day of both Balb/c (Figure 3.22) and C3H 
(Figure 3.23) bone marrow-derived plastic-adherent cells cultured in osteogenic 
medium showed the cells became smaller and appeared to change morphology by 
developing dendrite-like projections By the 6
th
 day, mineralisation was visible under 
the microscope, appearing as whitish plaques between cells while in control cultures, 
the cells retained their spindle-shaped morphology. After staining with alizarin red S, 
cells cultured in ODM stained bright orange and this confirmed the presence of 
calcium deposition while control cells cultured in DMEM-LG culture medium were 
negative. 
Similarly, Balb/c (Figure 3.24) and C3H (Figure 3.25) DF cultured in ODM also 
developed dendrite-like projections and stained positive with alizarin red S while 
control cells cultured in DMEM-HG culture medium were negative after 14 days of 
culture.  
Both the bone marrow-derived plastic-adherent cells and DF from the two mouse 
strains demonstrated their ability to successfully differentiate into bone cells. Also, 
the differentiated cells were resistant to dislodging with either 0.5% (v/v) trypsin-
EDTA or Hy-Q-Tase™ cell dissociation solutions after 14 days even after incubation 
for 15 minutes; this is a common phenomenon for bone cells which is a result of 











Figure 3.22. Osteogenic differentiation potential of p10 Balb/c mouse bone marrow-
derived plastic-adherent cells. The cells were seeded in 6-well plates and cultured to 
confluence in ODM or DMEM-LG culture medium for 14 days. Osteogenic-induced cells 
had elaborate whitish boundaries indicative of calcium deposits (A) while control cells 
showed no morphological changes (B) These calcium deposits stained bright orange with 
alizarin red S showing extensive mineralisation (C) relative to control cells (D). Images were 
captured at x100 magnification.[ODM; osteogenic differentiation medium]  
 
 
Figure 3.23. Osteogenic differentiation potential of p10 C3H mouse bone marrow-
derived plastic-adherent cells. The cells were seeded in 6-well plates and cultured to 
confluence in ODM or DMEM-LG culture medium for 14 days. Osteogenic-induced cells 
had elaborate whitish boundaries indicative of calcium deposits (A) while control cells 
showed no morphological changes (B) These calcium deposits stained bright orange with 
alizarin red S showing extensive mineralisation (C) relative to control cells (D). Images were 
captured at x100 magnification. [ODM; osteogenic differentiation medium] 






Figure 3.24. Osteogenic differentiation potential of p6 Balb/c mouse DF. The cells were 
seeded in 6-well plates and cultured to confluence in ODM or DMEM-HG culture medium 
for 14 days. Osteogenic-induced cells had elaborate whitish boundaries indicative of calcium 
deposits (A) while control cells showed no morphological changes (B) These calcium 
deposits stained bright orange with alizarin red S showing extensive mineralisation (C) 




Figure 3.25. Osteogenic differentiation potential of p6 C3H mouse DF. The cells were 
seeded in 6-well plates and cultured to confluence in ODM or DMEM-HG culture medium 
for 14 days. Osteogenic-induced cells had elaborate whitish boundaries indicative of calcium 
deposits (A) while control cells showed no morphological changes (B) These calcium 
deposits stained bright orange with alizarin red S showing extensive mineralisation (C) 
relative to control cells (D). Images were captured at x100 magnification. [ODM; osteogenic 
differentiation medium] 





Collectively, the results obtained from the tri-lineage differentiation assay showed 
that both Balb/c and C3H bone marrow-derived plastic-adherent cells were capable 
of differentiating into adipocytes, chondrocytes and osteoblasts when stimulated with 
specific chemicals and hormones added to culture medium. Thus, taken together with 
the phenotypic analysis, these cells demonstrated the characteristics of cells 
commonly defined as MSC and were therefore referred to as MSC from this point 
onwards. Interestingly, DF also demonstrated multipotential properties though their 




























The aim of this chapter was to define the isolation, expansion and characterisation of 
bone marrow derived MSC from Balb/c and C3H mouse strains which were tested 
for their immunomodulatory properties in subsequent assays described in Chapter 5. 
Female 4-8 week old Balb/c and C3H mice were used as the source of cells. DF, 
which were used for comparison, were also isolated from abdominal skin of the two 
mouse strains and characterised in the same manner as MSC.  
Whole bone marrow extracts were obtained by femoral aspiration using DMEM-LG 
culture medium. The bone marrow-derived cells were cultured overnight to allow the 
plastic-adherent cells to attach while non-adherent cells were washed off during 
ensuing medium changes. Few scattered cells with different morphologies including 
spindle-shaped fibroblastic-like cells, dendritic-like cells and macrophage-like cells 
remained in the flasks after the initial medium changes. These cultures were marked 
by a 3-5 week period of minimal growth and expansion particularly during p0 and 
p1. Several studies have also identified a diverse range of cell types from mouse 
bone marrow cultures including macrophages, endothelial cells, fibroblasts (Wang et 
al., 1990), dendritic cells (Inaba et al., 1992), B-cell progenitors, granulocytic and 
monocytic precursors which were reported to persist in cultures for several weeks 
(Phinney et al., 1999). Therefore, to overcome the inevitable contamination of MSC 
with other bone marrow-derived cells, a strategy of prolonged culture of the plastic-
adherent cells at low density with regular medium changes was employed based on 
the postulate that stem cells would continue to proliferate in culture whereas other 
terminally differentiated cells would be lost over time.  
Gradually, some of the morphologically diverse cells appeared smaller, rounded and 
were eventually lost in ensuing medium changes leaving behind sparsely scattered 
bipolar spindle-shaped fibroblast-like cells. These cells, known as colony forming 
unit-fibroblasts (CFU-F), gradually expanded forming colonies which appeared in a 
distinct radial pattern. Their expansion became rapid by the 2
nd
 passage and cultures 
appeared homogeneously fibroblast-like. Generally, it was observed that C3H 
cultures produced more CFU-F than Balb/c cultures though the former took longer to 
establish than the latter. By the 3
rd
 passage, both Balb/c and C3H cultures appeared 
homogeneous though this was not interpreted to mean the cells were phenotypically 





and functionally identical since previous studies have suggested that other cells, 
including haematopoietic cells and fibroblasts may persist even after several serial 
passages (Baddoo et al., 2003) despite cultures appearing morphologically 
homogeneous. This means that most MSC cultures obtained from bone marrow 
aspirates are inherently heterogeneous. This notion has been shown to be true in this 
study particularly following characterisation by flow cytometry as will be discussed 
later. 
At this stage, different types of culture medium were tested to find the most suitable 
for the expansion of the bone marrow-derived plastic-adherent cells. This was 
necessitated by the fact that in all mouse MSC studies, different isolation techniques, 
growth conditions and culture medium have been used. The most common types 
used include DMEM-HG (Meirelles & Nardi, 2003), DMEM-LG (Jiang et al., 2002), 
-MEM (Baddoo et al., 2003) and more recently specialist MSC media such as 
StemXVivo
™
 (Sung et al., 2008). These media were tested for their ability to support 
rapid expansion of the 3
rd
 passage cells by computing the CDT which is the time 
taken by the cells to divide in vitro. The fastest growth rates of 8 hours per doubling 
were obtained with cells cultured in DMEM-LG and StemXVivo
™
 followed by those 
cultured in MesenCult
®
 (24 hours), DMEM-HG (30 hours) and -MEM (40 hours) 
respectively. DMEM-LG, instead of StemXVivo
™
, was chosen as the expansion 
medium for all cultures on the basis of cost. The unusual linear conformation and 
subsequent senescence exhibited by cells cultured in -MEM illustrated the 
importance of culture medium for successful MSC culture. In addition, the cells 
cultured in -MEM were resistant to dislodging using 0.5% (v/v) trypsin-EDTA or 
Hy-Q-Tase
™
 cell dissociation solutions and could only be dislodged using a cell 
scraper. This suggested that either these cells formed stronger adhesions or had 
mineralised. It is thought that culture medium nutrient composition has a direct effect 
on cell signalling and consequently impacts cell growth, behaviour (including 
production of adhesion molecules) and fate (Park et al., 2007c). All the plastic-
adherent cells were subsequently expanded in DMEM-LG culture medium over a 6-
month period with cells cryo-preserved at different stages until the 15
th
 passage. 
Though the cells preserved morphological homogeneity from p3 to p15, they were 
not regarded as MSC. 





DF were isolated by digesting small pieces of Balb/c and C3H abdominal skin with 
dispase II to separate the dermis from the epidermis thus minimising contamination 
of cells from the dermis with the epidermal keratinocytes. The dermis was subjected 
to collagenase 1A digestion to release individual fibroblasts which were washed and 
cultured in DMEM-HG culture medium. Cell expansion was rapid from the onset 
and cultures were populated by cells showing typical fibroblast morphology and the 
cells were easy to dislodge with 0.5 % (v/v) trypsin-EDTA solution. Despite the bone 
marrow-derived plastic-adherent fibroblastic-like cells sharing morphological 
similarity with DF, the former were however resistant to dislodging using trypsin-
EDTA solution during passage and were dislodged using Hy-Q-Tase
™
 solution. This 
feature could be potentially used to remove fibroblast contamination from MSC 
cultures. Despite this characteristic, DF and the bone marrow-derived plastic-
adherent cells were morphologically indistinguishable. 
The next step was to characterise these bone marrow-derived plastic-adherent cells to 
determine whether they met the criteria commonly used in the literature to define 
cells as MSC. Phenotypic examination by flow cytometry using a panel of common 
cell surface markers showed that both Balb/c and C3H early (p3) and late (p12) 
passage cells were phenotypically similar, expressing Sca-1, MHC I, CD29, CD44, 
CD90.2 and CD105 while being negative for MHC II, CD34, CD45, CD80, CD86 
and CD11b. This was consistent with other reports (Sun et al., 2003), (Nadri & 
Soleimani, 2007a) and (Sung et al., 2008). The lack of CD34 and CD45 expression 
indicated the absence of haematopoietic cells in the cultures and lack of CD11b, a 
macrophage marker further suggested that the cell cultures were less contaminated 
with other cells noticed earlier in heterogeneous cultures during the 1
st
 passage. Lack 
of MHC II and the co-stimulatory molecules CD80 and CD86 is regarded as the an 
important feature of MSC and a major reason for their widely reported 
immunomodulatory properties (Le Blanc et al., 2003b). Interestingly, CD105 and 
CD90.2 expression increased from intermediate levels in p3 cells to over 95 % in p12 
cells while CD29 expression was variable between the two mouse species. Such 
variations have been reported in previous mouse MSC studies but it remains 
unknown whether these differences have a profound effect on the function of MSC. 
However, these variations could underline the heterogeneity of MSC cultures as 
previously alluded. 





In comparison, both p6 Balb/c and C3H DF were positive for Sca-1, MHC I and 
CD29 while negative for CD105, CD44, MHC II, CD34, CD45, CD80, CD86 and 
CD11b. Despite showing a similar phenotype to the bone marrow-derived MSC, 
there were differences in CD44 and CD105 expression which was positive in MSC 
but negative in DF. Blasi and co-workers however, reported that both MSC and DF, 
were positive for CD44 and CD105 (Blasi et al., 2011).  
To date, there is no consensus regarding the definitive phenotype of both MSC and 
DF since most of the markers used to define MSC are not unique to them but have 
been shown to be expressed by many different cells of mesenchymal origin. CD105 
expression has been reported to be reduced in DF in other studies (Wagner et al., 
2005; Lysy et al., 2007) but Haniffa et al. (2007) and Lorenz et al. (2008) reported 
similar expression levels to MSC (Haniffa et al., 2007; Lorenz et al., 2008). 
Interestingly, Jin et al. (2007) suggested that down-regulation of CD105 expression 
in MSC is associated with cell differentiation and recommended that it can be used 
as a marker for stem cell differentiation status (Jin et al., 2009). In this study 
however, lack of CD105 expression on DF could not be associated with terminal 
differentiation as they successfully underwent tri-lineage differentiation; this was 
also supported by Lysy et al. (2007). Though CD105 expression could be a potential 
marker for distinguishing between MSC and DF, results from this study suggested 
that CD105 expression in combination with CD44 and CD90.2 expression could be 
used to distinguish between these two cell types.  
For a long time, fibroblasts were thought of as primitive cells in adult tissues 
(Takahashi & Yamanaka, 2006) but there is increasing uncertainty not only because 
fibroblasts are now thought to be phenotypically and functionally equivalent to MSC 
(Haniffa et al., 2007), but also due to the identification of skin-derived precursors 
(SKP) which were differentiated into cells of mesodermal and neural lineages and 
retained self-renewal and differentiation potency for over a year (Toma et al., 2001). 
There have been many reports documenting the existence of sub-populations of stem 
cell-like cells in mammalian skin (Fernandes et al., 2004; Shih et al., 2005; Toma et 
al., 2005; Crigler et al., 2007) and  hair follicles (Yu et al., 2006). These findings 
could therefore imply that the stem cell properties displayed by skin-derived DF are 





due to the presence of SKP. Thus the lack of specific markers that can distinguish 
MSC from other mesenchymal cells remains a major challenge in MSC studies.  
Tri-lineage differentiation studies of both Balb/c and C3H p10 MSC demonstrated 
their ability to differentiate into adipocytes, chondrocytes and osteocytes as 
confirmed by ORO, alcian blue and alizarin red S staining respectively. For 
adipogenic differentiation, it was observed that lipid vesicle accumulation did not 
occur in all the cells. This could be interpreted as further demonstration that MSC 
cultures are heterogeneous with regard to their differentiation capacity. This could be 
as a result of age-differences within cultures since it is thought that the differentiation 
capacity of murine MSC declines with mouse age and passage (Kretlow et al., 2008) 
rather than it being due to heterogeneity resulting from having different cell types. 
Micromass cultures in chondrogenic medium stained positive with alcian blue while 
the control cells cultured in DMEM-LG culture medium were negative. Osteogenic 
differentiation was more prominent as most cells stained orange with alizarin red S 
due to extensive mineralisation. These cells were resistant to dissociation by Hy-Q-
Tase
™
 or 0.5 % (v/v) trypsin-EDTA solutions even after extended incubation for 15 
minutes; a phenomenon attributed to extensive calcification (Yoon et al., 2004).  
Cells were grown to confluence before they underwent differentiation as cell to cell 
contact appeared to be a pre-requisite for the in vitro differentiation of the MSC. 
Close cell to cell contact was thought to play an important role in facilitating 
adipogenic differentiation as lipid vesicle formation was concentrated in highly 
confluent areas and osteogenic differentiated cultures were deeply stained in areas of 
high cell density. This was also illustrated in chondrogenic differentiation where 
micromass cultures comprising densely populated cells, facilitated GAGs 
accumulation while in control cultures, cell expansion resulted in dispersal of the 
cells in the wells.  
Curiously, both p6 Balb/c and C3H DF differentiated into adipocytes, chondrocytes 
and osteoblasts. The tri-lineage differentiation potential was thought to be similar to 
that shown by MSC. Though there have been few reports of DF differentiation into 
adipocytes and osteoblasts (Lorenz et al., 2008) and hepatocytes (Lysy et al., 2007), 
other studies have found them incapable of adipogenic or osteogenic differentiation 





(Wagner et al., 2005). Only one study to date (Haniffa et al., 2007) has demonstrated 
human DF differentiation in the standard tri-lineage test used for defining MSC.  
Interestingly, osteogenic and chondrogenic differentiation were achieved in the 
absence of BMP2 and TGF3 respectively in culture media despite them being used 
in most studies. This raises the question of whether these factors are absolute 
requirements for achieving differentiation or that their presence may facilitate faster 
differentiation or indeed triggers a larger fraction of the cells to undergo 
differentiation. Since differentiation was not quantified in this study, it would have 
been important to assess the extent of differentiation at various stages in the presence 
and absence of these factors. The fact that most human MSC studies use cells 
obtained from older donors and also that in this case mouse MSC obtained from 
young donors were used may be important in determining the specific chemical and 
hormonal cues for facilitating differentiation. Although it is known that donor age 
significantly affects the quality of MSC, there are no studies to date that describe 
how age related differences could influence the choice and amounts in vitro 
differentiation factors.  
To summarize, both early and late passage Balb/c and C3H bone marrow-derived 
plastic-adherent cells were demonstrated to possess self-renewal properties by 
undergoing numerous rounds of passaging without observable morphological 
changes, expressed Sca-1, MHC I, CD29, CD44, CD90.2 and CD105 but did not 
express MHC II, CD80, CD86, CD34, CD45 and CD11b. Functionally, they showed 
multipotential capacity by differentiating into adipocytes, chondrocytes and 
osteocytes. Thus, these cells fulfilled the criteria used in defining MSC and were 
therefore used in subsequent immunological assays. DF displayed similar properties 
to MSC such as morphological homogeneity, tri-lineage differentiation capacity but 
slight phenotypic variations were detected by flow cytometry included absence of 
CD105, CD44 and CD90.2. The tri-lineage differentiation capacity of mouse DF had 
not been reported in the available literature to date. 
 




4. CHAPTER FOUR: DEVELOPMENT OF 
CONDITIONS FOR LYMPHOCYTE 
TRANSFORMATION ASSAYS (LTA) AND MIXED 
LYMPHOCYTE REACTIONS (MLR) 
4.1. Introduction 
Historically, the need to overcome the effects of allograft rejection led to an 
increased interest in immunology in an effort to improve understanding of the 
mechanisms underlying immunological competence and histocompatibility 
(Billingham & Silvers, 1959a). Early studies in the 1960s had reported the 
appearance and subsequent proliferation of blasts of ―immature-appearing‖ cells in 
cultures containing human leukocytes and the plant extract phytohemagglutinin 
(PHA) which was used in the isolation procedure of leukocytes because of its ability 
to clump red blood cells (Nowell, 1960). Importantly, blastogenesis was detected in 
co-cultures of allogeneic but not syngeneic murine and rabbit mononuclear cells 
(Bain et al., 1964; Chapman & Dutton, 1965; Schwarz, 1968). These observations 
demonstrated that histocompatibility disparities but not matching, triggered 
leukocyte proliferation.  
This provided the basis for the development of the MLR which could be used as a 
clinical tool for monitoring the immunological competence of the lymphocytes in 
patients suffering from immunological disorders, or patients undergoing 
immunosuppressive therapy and organ transplantation (Oppenheim et al., 1968; 
Janossy & Greaves, 1971). Since then, the MLR has been used as an in vitro 
correlate for immunological tolerance (Schwarz, 1968), allograft survival (Bradley et 
al., 1972) and in testing diseases such as rheumatoid arthritis (Stastny, 1976), 
Crohn‘s disease (Richens et al., 1974) and human immunodeficiency virus [HIV] 
(Lederman et al., 1998). By definition, MLR refers to a mixture of lymphoid cells 
from syngeneic, allogeneic or xenogeneic sources.  
The commonly used and most informative form of the MLR is the ―one-way‖ MLR 
(Bach & Voynow, 1966) whereby one set of lymphocytes, known as ‗responder‘ 
cells are allowed to respond to another set of mitotically inactivated lymphocytes 




known as ‗stimulator‘ cells. The lymphocyte proliferative response in the one-way 
MLR is thus directly attributed to the responder lymphocytes only (Harrison & Paul, 
1973). Mitotic inactivation can be achieved by treatment of the stimulator cells with 
non-lethal doses of mitomycin C or x-irradiation. Both these methods have been 
shown to be similarly effective (Bach & Bach, 1972). In the ‗two-way‘ MLR, mitotic 
inactivation is not required as both sets of lymphocytes act as responders and 
stimulators to each other and contribute to the overall lymphocyte proliferative 
response. Adaptations of the both the one-way and two-way MLR in which 
mitotically inactivated non-lymphoid cells are incorporated at the beginning or 
during on-going cultures have been used extensively in studying the 
immunomodulatory properties of different cell types. In this study, the 
immunomodulatory properties of allogeneic MSC and DF were tested and are 
discussed in detail in Chapter 5. 
In instances where responder lymphocytes are co-cultured with stimulator cells of 
non-lymphoid origin or when the stimulating agents are non-cellular such as the non-
specific mitogens PHA or Con-A, the capacity of the stimulating cells or agents to 
induce a proliferative response can be determined. This approach is called the LTA 
and has been widely used in testing the immunogenicity of different chemicals and 
cell types (Mills, 1966; Nyfeler & Pichler, 1997). In this study, the LTA was used in 
investigating the immunogenicity of allogeneic MSC and DF and is discussed in 
detail in Chapter 5. 
The proliferative response of the responder lymphocytes in MLR or LTA can be 
detected and quantified by the incorporation of radioactive tritiated thymidine [
3
H-
thymidine] in vitro (Huemer et al., 1968). 
3
H-thymidine is a radioactive nucleoside 
and precursor of thymidine found in DNA
10
 which becomes incorporated in the DNA 
strands of daughter cells during mitosis. The uptake or utilisation of 
3
H-thymidine 
can be measured to determine the extent of the proliferative response of the 
responder lymphocytes. This radioactivity is proportional to the number of 
proliferating cells which in turn is a function of the number of responder 
lymphocytes that were stimulated to enter the proliferative response (Caron et al., 
1965; Börjeson et al., 1966). The amount of 
3
H-thymidine incorporated into the 
                                                 
10
 DNA – deoxyribonucleic acid 




DNA of daughter cells is recorded as the number of radioactive disintegrations or 
counts per minute (CPM).  
Due to the inconsistencies that arise when data is presented as CPM as a result of 
varying initial cell densities, specific activity of the 
3
H-thymidine, incubation periods 
and instrumentation settings, data is often presented as stimulation indices (SI) which 
are expressed as;  
 
Measurement of DNA biosynthesis is the most commonly used method amongst 
immunologists as recommended by the International Union of Immunological 
Societies (IUIS) in 1976. Generally, SI between 2 and 3 are regarded as strongly 
suggesting a positive response and values above 3 are taken as statistical biological 
positive [SBP] (Frome et al., 2003; Klein et al., 2004). In practice however, a 
positive SI may not be clinically significant but may merely reflect responsiveness of 
the responder lymphocytes towards the stimulating agent. It has been argued that 
CPM data show more consistency and better discriminate between immune and non-
immune responses than data expressed as SI (Hicks et al., 1986).  
As a result of the variety in specific biological mechanisms other than DNA 
biosynthesis that occur in transforming cells, a variety of physical and chemical 
techniques which can detect cell transformations such as protein biosynthesis and  
other metabolic processes have been developed. Spectrophotometric and fluorimetric 
based assays such as the reduction of Amalar blue dye (Ansar Ahmed et al., 1994), 
esterase-mediated hydrolysis of fluorescein diacetate by proliferating lymphocytes 
(Dotsika & Sanderson, 1987) and the determination of ATP bioluminescence using 
the luciferin-luciferase reaction (Crouch et al., 1993) have been widely used. More 
recently, flow cytometry has provided a powerful platform which utilises 
intracellular fluorescence measurement to determine cell proliferation. The most  
common approach uses the tracking dye carboxyfluorescein diacetate succinimidyl 
ester (CFSE) to quantify overall responder lymphocyte proliferation as well as 
providing further insight into the history of the dividing lymphocytes (Lyons & 
Parish, 1994). Using this approach, parameters such as absolute cell numbers (Al-




Rubeai et al., 1997), number of cell divisions undergone by different cell types 
(Hawkins et al., 2007), distinction between various classes of lymphocytes and cell 
viability (Jones & Senft, 1985; Quah et al., 2007), which cannot be obtained by the 
3
H-thymidine method, can be obtained to provide more information with regard to 
the processes involved during lymphocyte stimulation.  
Despite the numerous options available for measuring LTA and MLR, the 
3
H-
thymidine uptake method remains the gold standard and reference for all the other 
techniques due to its sensitivity and reliability over a long period of time. It is 
directly related to the DNA of proliferating cells rather than secreted enzymes or 
fluorescent dyes whose activity is influenced by many in vitro factors other than cell 
division. 
Though the LTA and MLR have a long history of clinical application as tests for 
immunological tolerance and hypersensitivity (Schwarz, 1968; Milovanova, 2007), 
the reliability and sensitivity of these assays heavily depend on the optimisation of 
the key methodology variables. The main assumption is that the in vitro responses 
mirror wholly or in part the in vivo primary or secondary immunological response 
(Moorhead et al., 1967). Therefore, it is crucial for both the micro and macro 
environmental conditions for experiments to parallel those of living organisms. Thus, 
it is important to define and assess the key variables for MLR and LTA to ensure 
sensitivity and reproducibility. The work in this chapter was therefore dedicated to 
defining and assessing the appropriate conditions for carrying out MLR and LTA for 
determining the immunomodulatory properties and immunogenicity of allogeneic 











4.1.1. Aim and Objectives 
The aim of this part of the study was to develop appropriate methodology and 
conditions for performing LTA and MLR which were used in subsequent assays to 
investigate the immunological status of allogeneic MSC and DF. 
In this model, Balb/c (H2-d) mononuclear cells were used as responder cells in LTA 
assays. They were stimulated with non-specific mitogens (positive control) which 
tested the effects of various parameters on their capacity to mount proliferative 
responses. Mitotically inactivated C3H (H2-k) and Balb/c mononuclear cells were 
used as stimulator cells against Balb/c mononuclear cells in one-way MLR as a 
positive control for the allogeneic and syngeneic response respectively.  
The specific objectives were; 
1. To determine the type and effective concentration of mitogen (PHA or Con-
A) to use as a positive control for Balb/c mononuclear cell stimulation over a 
7 day culture period. 
2. To determine the effects of replenishing culture medium in on-going cultures 
up to 21 days. 
3. To determine the effective concentration of mitomycin C required for 
inducing mitotic inactivation in C3H mononuclear cells (stimulator cells). 
4. To determine the appropriate type (mouse or FCS) and concentration of 
serum for culture medium enrichment. 
5. To determine the appropriate total cell numbers and ratio of responder 
(Balb/c) to stimulator (C3H) cells for performing one-way MLR. 
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4.2. Materials and Methods  
4.2.1. Reagents 
The following reagents were used and were prepared as described in Section 2.2.2 
unless stated otherwise. 
 ATPLite™ kit 
 Camptothecin stock solution (1 mg.ml-1) 
 CFSE stock solution (5 mM) 
 Con-A stock solution (1 mg.ml-1) 
 CountBright™ fluorescent counting beads 
 FCS 
 Low activity 3H-thymidine working solution (25 Ci.ml-1)  
 Lymphocyte culture medium 
 Lymphocyte transport medium 
 Methanol; 100 % (Merck) 
 Microscint-20 scintillation fluid  
 Mitomycin C stock solution (1 mg.ml-1) 
 Mouse serum (Autogen Bioclear) 
 PBS (without Ca2+ and Mg2+) 
 PHA stock solution (1 mg.ml-1) 
 Saline solution (0.85 % w/v)  
 TCA (10 % w/v)  
 Viaprobe™ 7-AAD cell viability probe solution 
4.2.2. Comparison of PHA and Con-A for the determination of the 
suitable mitogen and concentration for stimulation of Balb/c mouse 
mononuclear cells 
Mononuclear cells were isolated from Balb/c mouse spleens and lymph nodes, 
counted and resuspended in lymphocyte culture medium as described in Section 
2.2.11. The mononuclear cells were seeded in uncoated 96-well U-bottom plates at a 
density of 1 x 10
5
 cells per well in 100 l volumes. Frozen PHA and Con-A stocks 
were defrosted and serially diluted in lymphocyte culture medium to create solutions 




of 100, 80, 70, 60, 50, 40, 30, 20 and 10 g.ml-1. PHA or Con-A solutions (100 l) 
were added to 100 l of Balb/c mononuclear cells per well to give cultures 
containing final concentrations of 50, 40, 35, 30, 25, 20, 15, 10 and 5 g.ml-1 of  
PHA or Con-A as shown in the experimental setup (Figure 4.1). Each mitogen 
concentration was tested in triplicate wells. Cells without either mitogen were set up 
as controls for unstimulated and non-dividing cells. The outermost wells of the plates 
were filled with 200 l of PBS to minimise evaporation from the test wells during 
incubation. The plates were cultured in a humidified incubator at 37°C in an 
atmosphere of 5% (v/v) CO2 in air for 3, 5 and 7 days.  
For the 
3
H-thymidine uptake assay, sixteen hours prior to completion of each time 
point, individual wells were spiked with 10 l of 25 Ci.ml-1 low activity 3H-
thymidine to give a concentration of 0.25 Ci per well as described in Section 
2.2.12. Post spiking, plates were returned for incubation to complete the required 
culture period. Upon reaching their specific time points, the plates were removed 
from incubation and the cells were harvested onto glass fibre filter UniFilter-96 
GF/B plates and radioactivity counts were read as CPM using a TopCount NXT 
scintillation plate reader as described in Section 2.2.13. 
For the ATPLite
™
 assay, on completion of the incubation period, cultures were 
briefly mixed on an orbital shaker for one minute to resuspend the cells before they 
were transferred to white OptiPlate™ 96-well plates. Cell viability was then analysed 
as described in Section 2.2.14. The ATP content was measured in a TopCount NXT 
luminescence plate reader and data was obtained and recorded as luminescence 
counts per second (CPS). 
 





Figure 4.1. Diagram showing the 96-well experimental set up for the comparison of 
PHA and Con-A in stimulating Balb/c mononuclear cells. Triplicate wells were prepared 
for each mitogen concentration. The cultures were analysed after 3, 5 and 7 days without 
medium changes. Unstimulated cells were used as controls for non-dividing cells. Cultures 
were analysed by the 
3
H-thymidine uptake assay to determine the most appropriate mitogen 
and concentration that give highest counts. The ATPLite assay was used to determine cell 
viability by measuring cellular ATP content. Outer wells (grey) were filled with PBS to 
minimise evaporation. 
 
4.2.3. Effect of medium changes and extended culture time on the 
stimulation of Balb/c mononuclear cells with Con-A  
Mononuclear cells were isolated from Balb/c mouse spleens and lymph nodes, 
counted and resuspended in lymphocyte culture medium as described in Section 
2.2.11. The cells were seeded in uncoated 96-well U-bottom plates at a density of 1 x 
10
5
 cells per well in 100 l volumes. Con-A stock was defrosted and serially diluted 
in lymphocyte culture medium to create solutions of 50, 40, 30, 20 and 10 g.ml-1. 
Each well volume was made up to 200 l by addition of 100 l of Con-A medium to 
give final concentrations 25, 20, 15, 10 and 5 g.ml-1 in replicates of six. The 
outermost wells of the plates were filled with PBS to minimise evaporation from the 
test wells and the plates were cultured in a humidified incubator at 37°C in an 
atmosphere of 5% (v/v) CO2 in air for 3, 5, 10, 15 and 20 days.  
For cultures accompanied with medium changes, 100 l of medium was aseptically 









1        2         3        4         5         6        7         8         9       10      11      12
Mitogen concentration (g.ml-1)
0       5      10     15     20     25     30     35    40     50 
PHA
Con A




while ensuring minimal disturbance to the cell pellet at the bottom of the well) and 
replaced with 100 l of fresh culture medium containing the appropriate 
concentration of Con-A every three days and the plates were returned for incubation. 
Replicate cultures (without medium changes) were prepared and incubated for 
similar periods. For each time point, cultures with and without medium changes were 
tested at the same time. Sixteen hours prior to completion of each time point, 
individual wells were spiked with 10 l of 25 Ci.ml-1 low activity 3H-thymidine as 
described in Section 2.2.12. Post spiking, plates were returned for incubation to 
complete the required culture period after which the plates were removed from 
incubation and the cells harvested and radioactivity counts read as CPM using a 
TopCount NXT scintillation plate reader as described in Section 2.2.13. 
4.2.4. Determination of the appropriate mitomycin C concentration 
for achieving stimulator cell mitotic arrest using C3H mononuclear 
cells 
4.2.4.1. ATPLite™ assay 
Lymphoid and splenic mononuclear cells were isolated from C3H mice as described 
in Section 2.2.11. The cells were counted by the Trypan blue method (Section 2.2.8). 
Mitomycin C stock (1 mg.ml
-1
) was thawed and serially diluted in lymphocyte 
culture medium to make 10 ml aliquots in sterile test tubes of the following 
concentrations; 5, 10, 20, 30, 40, 50, 60 and 100 g.ml-1. Cells (1.8 x 106) were 
added to the medium containing mitomycin C corresponding to the eight different 
concentrations. Untreated (positive control) cells (1.8 x 10
6
) were suspended in 10 ml 
culture medium without mitomycin C. The tubes were closed and placed in a 
humidified incubator at 37 °C in an atmosphere of 5 % (v/v) CO2 in air for 30 
minutes. The cells were removed from the incubator and centrifuged at 450 g for 10 
minutes. This was followed by five more washes with fresh culture medium, each 
time discarding the supernatant in order to wash off the mitomycin C. The cells were 
then plated in uncoated 96-well U-bottom plates at a density of 1 x 10
5
 cells in 100 
l of culture medium per well. The volume in each well was made up to 200 l by 
addition of either 100 l of culture medium (unstimulated group) or 100 l of culture 
medium containing 20 g.ml-1 of Con-A to give a final concentration of 10 g.ml-1 
per well (Con-A stimulated group). As a positive control for cell death, cells (1.8 x 






) were incubated in 10 ml of culture medium containing 10 g.ml-1 camptothecin 
for 30 minutes followed by five washes by centrifuging in culture medium at 450 g. 
The cells were also plated at a density of 1 x 10
5
 cells per well as unstimulated or 
Con-A stimulated. The experiment was set up as shown in Figure 4.2. The plates 
were kept in a humidified incubator at 37 °C in an atmosphere of 5 % (v/v) CO2 in 
air for 3, 5 and 7 days. Upon reaching the desired time point, the plates were 
removed from the incubator and 100 l of cell suspension from each well was 
transferred to its corresponding well (pipette tips changed for each well) of a white 
OptiPlate™ 96-well plate and cell viability determined using the ATPLite™ assay as 
described in Section 2.2.14. 
 
Figure 4.2. Experimental set up showing the 96-well plate plan for investigation of the 
effects of mitomycin C concentration on ATP content of Con-A stimulated and 
unstimulated C3H mononuclear cells to determine mitotic inactivation. Each well 
contained 1 x 10
5
 cells in a volume of 200 l. Camptothecin treated cells (Campt) were used 
as a positive control for dead cells. Cells in medium only without mitomycin C (0) were used 
as control for viable non-proliferating cells. Con-A stimulated cells without mitomycin C 
were positive controls for stimulated proliferating cells. Wells in grey were filled with PBS 
to minimise evaporation. 
 
4.2.4.2. 3H-thymidine uptake method 
Lymphoid and splenic mononuclear cells were isolated from C3H mice as described 
in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.8). The cells 
were divided into four groups each comprising 1.8 x 10
6 
cells. Each cell group was 
transferred into test tubes containing 10 ml of lymphocyte culture medium with 0, 5, 




10 and 20 g.ml-1 of mitomycin C. The tubes were closed and incubated at 37 °C in 
an atmosphere of 5 % (v/v) CO2 in air for 30 minutes. Afterwards, the cells were 
washed five times by centrifuging at 450 g for 5 minutes with culture medium 
changed each time. A positive control for dead cells was prepared by incubating cells 
1.8 x 10
6 
cells in 10 ml of lymphocyte culture medium containing 10 g.ml-1 
camptothecin at 37 °C in an atmosphere of 5 % (v/v) CO2 in air for 30 minutes 
followed by five washes at 450 g for 5 minutes each time discarding the medium. 
Cells (1 x 10
5
 cells in 100 l of culture medium) were then plated in uncoated 96-
well U-bottom plates in triplicate wells as either unstimulated cells or stimulated 
cells (10 g.ml-1 Con-A) as shown in the experimental set up in Figure 4.3.  
The plates were incubated in a humidified incubator at 37 °C in an atmosphere of 5 
% (v/v) C02 in air for 3, 5 and 7 days. Sixteen hours prior to reaching each specific 
time point, each well was spiked with 10 l of low activity 3H-thymidine as 
described in Section 2.2.12. Afterwards, the cells were harvested and 
3
H-thymidine 
incorporation was measured using a TopCount NXT plate reader as described in 










Figure 4.3. Diagram showing the 96-well plate plan for assessing the effects of 
mitomycin C treatment on C3H mononuclear cells as measured by the 
3
H-thymidine 
uptake assay for the determination of mitotic inactivation. The numbers at the bottom of 
the plate represent the different cell treatments. Treatment 1 (no mitomycin C and no Con-A) 
was a control for non-proliferating viable cells. Treatment 2 (Con-A stimulated) was a 
control for stimulated and mitotically active cells. Treatment 3 were the test wells which 
contained unstimulated cells treated with graded doses of mitomycin C. Treatment 4 were 
test wells which contained Con-A stimulated cells treated with graded doses of mitomycin C. 
Treatment 5 were camptothecin treated cells (no mitomycin C, no Con-A) which were used 
as  controls for non-viable/dead cells. 
 
4.2.4.3. CFSE dilution method 
4.2.4.3.1. CFSE labelling of C3H mouse mononuclear cells 
Lymphoid and splenic mononuclear cells from C3H mice were isolated as described 
in Section 2.2.11. The cells were split into two groups; CFSE labelled (9.9 x 10
6
) and 
unlabelled cells (1.8 x 10
6
). The CFSE labelled group was suspended in 9 ml of PBS. 
Meanwhile under dim light, CFSE stock (5 mM) was thawed and 10 l was 
withdrawn and added to 990 l of PBS to make 1 ml of 50 M CFSE working 
solution which was then mixed with the cell suspension in a light proof paper-
wrapped test-tube to give a final CFSE concentration of 5 M in 10 ml. The cells 
were mixed by vortexing for two seconds followed by incubation for 5 minutes at 
room temperature to allow CFSE uptake by the cells. After the incubation, the CFSE-
labelled cell suspension was diluted with 10 volumes of PBS containing 5 % (v/v) 
FCS followed by centrifugation at 450 g for 5 minutes at 20 ºC to wash off excess 




unabsorbed CFSE. The washing steps were repeated thrice to ensure a thorough 
wash. 
4.2.4.3.2. Mitomycin C treatment of CFSE labelled C3H 
mononuclear cells 
In separate light-proof paper wrapped test tubes, CFSE labelled mononuclear cells 
(1.8 x 10
6
) were transferred into 5 ml volumes of culture medium which were 
supplemented with mitomycin C to give final concentrations of 5, 10, 20 and 50 
g.ml-1. The tubes were incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 30 minutes. Afterwards, the cells were 
washed five times by centrifuging at 450 g for 5 minutes. The cells were finally 
resuspended in 1.8 ml of lymphocyte culture medium. 
4.2.4.3.3. Treatment of CFSE labelled and unlabelled C3H 
mononuclear cells with camptothecin as a positive control for cell 
death 
In separate tubes, unlabelled and CFSE labelled cells (9 x 10
5
) that were used as 
controls for dead cells were resuspended at 9 x 10
5 
cells in 4.5 ml of culture medium. 
Into each test tube, 50 l of 1 mg.ml-1 camptothecin was added to give a final 
concentration of 10 g.ml-1. The tubes were incubated at 37 °C in an atmosphere of 5 
% (v/v) CO2 in air for 30 minutes. After incubation, the cells were washed five times 
by centrifugation at 450 g for 5 minutes with fresh culture medium changed each 
time. The cells were finally resuspended in 900 l of lymphocyte culture medium. 
4.2.4.3.4. Cell plating 
The cells were plated in triplicate wells at a density of 1 x 10
5
 cells in 100 l of 
culture medium per well in uncoated 96-well U-bottom plates according to the plan 
in Figure 4.4. For unstimulated cells, a further 100 l of lymphocyte culture medium 
was added into each well to give a total culture volume of 200 l. For stimulated 
cells, a further 100 l of lymphocyte culture medium containing 20 g.ml-1 of Con-A 
was added into each well to give a final concentration of 10 g.ml-1. The plates were 
incubated in a humidified incubator at 37 ºC in an atmosphere of 5 % (v/v) CO2 for 
3, 5 and 7 days prior to analysis by flow cytometry. The camptothecin treated cells 
were used as controls for CFSE labelled or unlabelled dead cells. Cells which had no 




mitomycin C, camptothecin or Con-A were controls for viable non-proliferating 
cells. Controls for proliferating cells (Con-A stimulated) were cultured without 
mitomycin C.  
 
Figure 4.4. Schematic representation of the 96-well plate plan of the CFSE dilution 
assay for the determination of mitotic inactivation of C3H mononuclear cells by 
mitomycin C treatment using flow cytometry. The numbers below the plate indicate the 
different types of cell treatments. Treatment 1 (no mitomycin C, no Con-A) was a control for 
unlabelled non-proliferating viable cells. Treatment 2 (no mitomycin C, no Con-A) was a 
control for CFSE labelled non-proliferating cells. Treatment 3 (Con-A stimulated with no 
mitomycin C) was a control for CFSE labelled mitotically active proliferating cells. 
Treatments 4 (no Con-A) and 5 ( Con-A) were test samples for CFSE labelled unstimulated 
and stimulated cells respectively treated with similar concentrations of mitomycin C. 
Treatment 6 and 7 (camptothecin treated; no mitomycin C) were controls for unlabelled and 
CFSE labelled non-viable cells respectively.  
 
4.2.4.3.5. Flow cytometry analysis of CFSE dilution of C3H 
mononuclear cells for the determination of mitotic inactivation and 
cell viability  
On completion of the incubation period, CFSE labelled cell cultures were prepared 
for analysis by flow cytometry using a BD FACSCalibur cytometer. Prior to the 
analysis, 5 l of Via-probe™ 7-AAD (7-aminoactinomycin D) probe was added into 
each well, gently mixed and left for 10 minutes. The 7-AAD solution stained dead 
cells only thus allowing for the exclusion of non-viable cells from viable cells during 
analysis. After 7-AAD staining, 50 l of CountBright™ counting beads were added 




into each well and thoroughly mixed. By comparing the ratio of bead to cell events, 
absolute numbers of cells in the sample could be calculated. The cytometer was set to 
collect 1000 beads per sample with the side scatter parameter set to logarithmic scale 
in order to assess bead and cell numbers simultaneously. Data was acquired using 
CellQuest™ v.3.1 flow cytometry data acquisition software (BD Bioscience) as 
shown in the schematic (Figure 4.5) and analysed using FlowJo
™
 v.7.6.5 flow 
cytometry analysis software (Tree Star Inc).  
 
Figure 4.5. Schematic diagram showing the flow cytometer data collection template for 
the determination of mitotic inactivation of C3H mononuclear cells using mitomycin C. 
Cells were collected in four quadrants in which viable proliferating or non-proliferating cells 
collected in LL and LR quadrants according to their CFSE fluorescence intensity. Non-
viable/dead unlabelled or CFSE labelled cells stained with 7-AAD collected in the UL or UR 
quadrants depending on their CFSE fluorescence. [CFSE; 5(6)-Carboxyfluorescein diacetate 
N-succinimidyl ester. 7-AAD; 7-aminoactinomycin D. UL; upper left. UR; upper right. LL; 
lower left. LR; lower right] 
 
4.2.5. Comparison of the effects of FCS and mouse serum on Balb/c 
mononuclear cell stimulation 
The rationale for this experiment was to determine the suitable type of serum (FCS 
or mouse serum) and effective concentration for supplementing lymphocyte culture 
medium. Mononuclear cells were isolated from Balb/c mouse spleens and lymph 
nodes as described in Section 2.2.11 and counted by the Trypan blue method as 
described in Section 2.2.9. The cells (1.8 x 10
6
 cells per group) were suspended in 
1.8 ml of lymphocyte culture medium containing either mouse serum or FCS at 2, 5, 




10 and 20 % (v/v) concentrations. Cells cultured in lymphocyte culture medium 
without serum were used as controls for the need for serum supplementation. Cells 
cultured in lymphocyte transport medium were also used as controls to show the 
importance of culture medium for cell growth and proliferation.  
The cells were seeded in uncoated 96-well U-bottom plates at a density of 1 x 10
5
 
cells in 100 l per well. For unstimulated cells, a further 100 l of the appropriate 
culture medium was added to give a final volume of 200 l per well. For stimulated 
cells, a further l00 l of corresponding medium containing 20 g.ml-1 of Con-A was 
added to give a final concentration of 10 g.ml-1. Triplicate wells were plated for 
each type and concentration of serum as illustrated in Figure 4.6. The plates were 
incubated in a humidified incubator at 37°C in an atmosphere of 5% (v/v) CO2 in air 
for 3, 5 and 7 days without medium changes. Sixteen hours prior to completion of 
each time point, cells were spiked with 10 l of 25 Ci.ml-1 low activity 3H-
thymidine as described in Section 2.2.12, harvested onto glass fibre filter plates and 
followed measurement of the radioactivity counts using a TopCount™ NXT 
scintillation counter as described in Section 2.2.13. 
 
Figure 4.6. Schematic diagram showing the 96-well plate plan for the assessment of the 
effects of graded amounts of FCS and mouse serum in culture medium on the 
stimulation of Balb/c mononuclear cells. Unstimulated or Con-A stimulated cells (1 x 10
5
 
per well) were cultured in lymphocyte culture medium supplemented with graded amounts 
of FCS or mouse serum. Cells cultured in serum-free medium (0) were used as a control for 
serum. Cells cultured in transport medium [TM] were a control for culture medium. [FCS; 
foetal calf serum] 




4.2.6. Determination of appropriate cell numbers and ratio of 
responder and stimulator cells for one-way MLR using 10 % (v/v) 
FCS and 2 % (v/v) mouse serum as culture medium supplements 
Mononuclear cells were isolated from spleens and lymph nodes from Balb/c 
(responder) and C3H (stimulator) mice as described in Section 2.2.11 and counted 
by the Trypan blue method described in Section 2.2.9. Balb/c mononuclear cells 
(1.95 x 10
7
) were suspended in 10.4 ml of lymphocyte culture medium supplemented 
with 10 % (v/v) FCS or 2 % (v/v) mouse serum.  
C3H mononuclear cells (1.23 x 10
7
) were mitotically inactivated by treatment with 
10 g.ml-1 mitomycin C as described in Section 2.2.15. Half of the cells (6.15 x 106) 
were suspended in 25.7 ml of lymphocyte culture medium supplemented with 10 % 
(v/v) FCS and the other half was suspended in lymphocyte culture medium 
supplemented with 2 % (v/v) mouse serum. 
Balb/c (responder) and mitotically inactivated C3H mononuclear cells (stimulator) 
were seeded in uncoated 96-well U-bottom plates at responder to stimulator cell 
ratios of 1:1, 1:10 and 1:100 in quadruplicates with total cell numbers per well set at 
1 x 10
4
, 5 x 10
4
 and 1 x 10
5
 as shown in (Figure 4.7). The total volume per well was 
200 l and seeding volumes were computed from a cell density of 5 x 104 cells in 




Balb/c mononuclear cells, seeded at 1 x 10
4
, 5 x 10
4
 and 1 x 10
5
 cells per well 
(triplicates) in lymphocyte culture medium containing either 10 % (v/v) FCS or 2 % 
(v/v) mouse serum with or without 10 g.ml-1 Con-A were used as controls for 
stimulated proliferating cells and unstimulated non-proliferating cells respectively as 
shown in Figure 4.8. 
The plates were incubated in a humidified incubator at 37°C in an atmosphere of 5% 
(v/v) CO2 in air for 3, 6, 9 and 12 days accompanied with medium changes every 
three days as described in Section 4.2.3. Sixteen hours prior to completion of each 
time point, each well was spiked with 10 l of 25 Ci.ml-1 low activity 3H-thymidine 
(Section 2.2.12), harvested onto glass fibre filter plates and radioactivity counts read 
on a TopCount™ NXT scintillation counter (Section 2.2.13). 





Figure 4.7. Schematic representation of 96-well plate for the one-way MLR for the 
determination of appropriate responder to stimulator cells ratios and total cell 
numbers. Balb/c (responder) mononuclear cells and mitomycin C treated C3H (stimulator) 
mononuclear cells were co-cultured at different cell ratios and different total cell numbers in 
culture medium supplemented with 10 % (v/v) FCS or 2 % (v/v) mouse serum. Grey wells 
were filled with transport medium only to minimise evaporation. 
 
Figure 4.8. Schematic diagram showing the 96-well plate plan for positive (Con-A 
stimulated) and negative (unstimulated) controls of Balb/c (responder) cells for the one-
way MLR. Cells were cultured in medium containing either 10 % (v/v) FCS or 2 % (v/v) 
mouse serum. Grey wells were filled with transport medium only to minimise evaporation. 





4.3.1. Determination of the suitable type and concentration of 
mitogen for use as positive control for Balb/c mouse lymphocyte 
transformation 
The magnitude of mitogen induced lymphocyte stimulatory responses depend on the 
type and concentration of the mitogen. Non-specific mitogens such as PHA or Con-A 
are the most commonly used mitogens in immunology and are potent lymphocyte 
stimulatory agents. In this study, PHA and Con-A were compared for their ability to 
stimulate a fixed number (1 x 10
5
) of Balb/c mouse mononuclear cells over an 
increasing concentration range for 3, 5 and 7 days. The type and concentration of 
mitogen that gave the highest 
3
H-thymidine counts and SI was to be used as the 
positive control for future LTA assays. The time point at which the highest counts 
were obtained was regarded as the time point at which lymphocyte proliferation 
peaked. Cell viability and proliferation (as measured by the intracellular ATP content 
of mitogen stimulated cell cultures) at all mitogen concentrations and time points 
were also assessed by the ATPLite assay. The mitogen concentration at which 
highest counts (CPS) were obtained represented metabolically active viable and 
proliferating cells. 
At day 3, PHA stimulated Balb/c mononuclear cells exhibited a dose-dependent 
increase in 
3
H-thymidine uptake with increasing mitogen concentration peaking at 25 
g.ml-1. For Con-A stimulated cells, 3H-thymidine uptake peaked at 10 g.ml-1 and 
counts were higher than those for PHA at this concentration. Significant differences 
between PHA and Con-A stimulation were observed at 5, 10, 35 g.ml-1 and above. 
The SI showed that increasing the Con-A concentration above 10 g.ml-1 resulted in 
reduced
 
stimulation. SI less than 3 was recorded at 50 g.ml-1 of Con-A (Figure 4.9).  
At day 5, the 
3
H-thymidine uptake trend was similar to that observed at day 3 for 
both PHA and Con-A. Peak responses were observed with 25 and 10 g.ml-1 of PHA 
and Con-A respectively. There were significant differences in counts between PHA 
and Con-A stimulated cells at all mitogen concentrations except between 25 and 35 
g.ml-1. The SI for cells stimulated with 35 g.ml-1 and above of Con-A were below 
3.  




At day 7, the counts for Con-A stimulated cells were significantly higher than those 
for PHA stimulated cells at the 5 and 25 g.ml-1 mitogen concentration range. At 
mitogen concentrations of 30 g.ml-1 and higher, the SI for both Con-A and PHA 
stimulated cells were below 3.  
At days 3 and 5, the SI for Con-A stimulated cells were higher than those for PHA 
stimulated cells at mitogen concentrations between 5 and 20 g.ml-1. From 25 g.ml-
1
 onwards, PHA stimulated cells produced higher SI compared to those stimulated 
with Con-A. At day 7, SI above 3 were recorded for both PHA and Con-A stimulated 
cells at mitogen concentrations between 5 and 25 g.ml-1. Overall, 3H-thymidine 
counts and SI were highest at day 3 followed by day 5 and day 7 respectively for 
each given mitogen concentration. 
Results from the ATP assay showed that Balb/c mononuclear cells stimulated with 
PHA at all the mitogen concentrations and Con-A between 5 and 25 g.ml-1 
produced more ATP compared to unstimulated controls at all the time points (Figure 
4.10). At day 3, there was a dose-dependent increase in counts at mitogen 
concentrations between 5 and 25 g.ml-1 followed by a dose-dependent decline from 
25 g.ml-1 to 50 g.ml-1. The highest ATP counts at day 3 were obtained at 25 g.ml-
1 
PHA and Con-A. At day 5 and day 7 however, the counts produced at Con-A 
concentrations of 25 g.ml-1 and above fell sharply and from 35 g.ml-1 and 
onwards, the counts dropped below those for the unstimulated controls. This dose 
dependent decrease in ATP was not observed with PHA at all concentrations. Also, 
at these time points, ATP counts were higher for cells stimulated with Con-A than 
PHA at mitogen concentrations between 5 and 25 g.ml-1 but above 30 g.ml-1 PHA 
counts were higher than Con-A counts. Therefore, these results showed that higher 
doses of Con-A drastically reduced cell viability. 
Taken together, these data showed that Con-A, at 10 g.ml-1, gave the highest 3H-
thymidine counts and SI compared to PHA throughout the incubation period. At this 
concentration, ATP counts were also high showing that cells viability was not 
affected. Therefore, 10 g.ml-1 Con-A was used as a positive control for lymphocyte 
stimulation in future assays. 
 





Figure 4.9. Comparison of the effect of PHA and Con-A stimulation of Balb/c 
mononuclear cells to determine the most suitable mitogen concentration as measured 
by the incorporation of low activity 
3
H-thymidine. Balb/c mononuclear cells (1 x 10
5
 per 
well) were stimulated with increasing mitogen concentration (5-50 g.ml-1) for 3, 5 and 7 
days. Unstimulated cells (0) were used as controls for non-proliferating cells. CPM and SI 
data is shown respectively for day 3 (A and D), day 5 (B and E) and day 7 (C and F). CPM 
data was Log10 transformed and analysed by 2-way ANOVA followed by calculation of the 
MSD (p<0.05) by the T method to determine individual differences between PHA and Con-
A at each concentration. Data (n=3) was then back-transformed for presentation and plotted 
as mean CPM ± 95 % CL (Left). 
*
 indicates significant difference between PHA and Con-A 
for a given concentration. Stimulation is presented as SI for each mitogen (Right). The red 
line at SI=3 denotes statistical biological positive, SI above 3 are considered significant 
responses for cells stimulated with PHA or Con-A while those below 3 are not. [CPM; 
counts per minute. 





Figure 4.10. Comparison of the effect of PHA and Con-A on Balb/c mononuclear cell 
viability and proliferation as measured by cellular ATP content. Balb//c mononuclear 
cells (1 x 10
5
 per well) were treated with increasing mitogen concentrations between 5 and 
50 g.ml-1 for 3 days (A), 5 days (B) and 7 (C) days. Unstimulated cells (0) were used as 
negative controls. Data was Log10 transformed and analysed by 2-way ANOVA followed by 
calculation of the MSD (p<0.05) by the T method to determine individual differences 
between PHA and Con-A at each concentration. Data (n=3) was then back-transformed for 
presentation and plotted as mean CPS ± 95 % CL. 
* 
indicates significant difference between 
PHA and Con-A for a given concentration. 
 
4.3.2. Effects of medium replacement and extended culture period 
on Con-A stimulated Balb/c mouse mononuclear cells 
The rationale behind this experiment was born out of the observation that most LTA 
and MLR studies in the literature have been carried out between 3 and 7 days. This 
could limit the detection of responses to the direct pathway but not capture the semi-




direct or indirect pathways of allorecognition which may take longer than 7 days. 
Over extended culture periods, the availability of nutrients and build-up of toxic 
metabolic by-products may become limiting. Therefore, this experiment was 
designed to investigate the effects of culture medium change during an extended 
assay period.  
Balb/c mononuclear cells were stimulated with increasing doses of Con-A (5-25 
g.ml-1) and cultured with and without medium change. For cultures with medium 
change, half the culture medium (100 l per well) was replaced with fresh culture 
medium every 3 days. 
3
H-thymidine uptake was measured at days 3, 5, 10, 15 and 
20. 
The results showed that cultures with medium changes produced higher counts 
compared to cultures without medium change at all the time points and Con-A 
concentrations with the exception of day 3 and day 20. Peak counts were obtained at 
day 5 with 10 g.ml-1 of Con-stimulation for cultures with medium changes whereas 
for cultures without medium changes peak counts were obtained at day 3 with the 
same concentration of Con-A (Figure 4.11). Counts for days 5, 10 and 15 cultures 
with medium changes were approximately double those without medium changes at 
all Con-A concentrations. There was a dose–dependent decrease in counts at Con-A 
concentrations above 10 g.ml-1 in both cultures with and without medium changes. 
With regard to the stimulation, SI for cultures with medium changes were higher 
than those for cultures without medium changes at all Con-A concentrations at days 
5, 10 and 15. At day 20, all the SI were below 3 except at 10 g.ml-1 Con-A in 
cultures with medium changes. For cultures without medium changes however, SI of 
3 and below were obtained at day 10 onwards.  
Taken together, these results showed that medium changes after 3 days considerably 
increased 
3
H-thymidine uptake in Con-A stimulated cells but not in unstimulated 
cells. This enabled significant lymphocyte proliferation to be detected up to 20 days 
at 10 g.ml-1 of Con-A. However, without changing the medium, significant 
lymphocyte proliferation was not detected beyond 10 days. Therefore, future MLR 
and LTA experiments were carried out with medium changes every 3 days for up to 




15 days with the intention to capture the indirect and semi-direct pathways of 
allorecognition. 
 
Figure 4.11. Effects of changing culture medium on Con-A stimulated Balb/c 
mononuclear cells over time as measured by 
3
H-thymidine uptake. Cells (1 x 10
5
 per 
well) were stimulated with Con-A (5-25 g.ml-1) and cultured for 3, 5, 10, 15 and 20 days 
with and without medium changes. The medium changes were carried out every 3 days by 
replacing 100 l of medium per well. Unstimulated cells (no Con-A) were used as controls 
for non-proliferating cells. CPM data (n=6) was Log10 transformed to compute upper and 
lower 95% CL. Data was then back-transformed for presentation and plotted as mean CPM ± 
95 % CL for cultures with medium changes (A) and without medium changes (B). 
Lymphocyte stimulation was presented as SI for cultures with (C) and without (D) medium 
changes. The red line at SI = 3 denotes statistical biological positive; Only SI above 3 were 
considered significant responses against Con-A. 
 
4.3.3. Determination of the appropriate mitomycin C concentration 
for achieving mitotic arrest in stimulator cells 
Mitomycin C treatment was the chosen method for arresting cell division in 
stimulator cells for use in one-way MLR and LTA. In these assays, mitotically 
inactive but viable stimulator cells provide allogeneic stimulation to responder 
lymphocytes whose proliferative response can then be measured. Mitomycin C is 
toxic to cells hence its use must be evaluated to determine the most appropriate 
working concentration which ensures that stimulator cells are rendered incapable of 




mitosis but remain viable. Concentrations between 10 and 50 g.ml-1 mitomycin C 
have been used in many previous studies but without evidence on the viability of the 
cells after treatment.  
In these experiments, C3H mononuclear cells were treated with increasing 
concentrations of mitomycin C (5 - 100 g.ml-1) for 30 minutes and then either 
stimulated with Con-A (10 g.ml-1) or left unstimulated. The cells were cultured for 
3, 5 and 7 days without medium changes. Lymphocyte proliferation was determined 
using 
3
H-thymidine uptake whilst cell viability was tested using the ATPLite
™
 assay. 
The CFSE dilution assay was also used to test for cell proliferation and viability. 
After analysis, the appropriate mitomycin C concentration for inducing mitotic arrest 
was determined on the premise that when mitotically inactivated, viable C3H 
mononuclear cells, should be unable to proliferate when stimulated with Con-A.  
4.3.3.1. Determination of mitotic inactivation using the ATPLite 
assay  
C3H mononuclear cells were treated with increasing mitomycin C concentrations (5-
100 g.ml-1). Cells treated with 5 g.ml-1 camptothecin were used as positive control 
for cell death. The results for both unstimulated and Con-A stimulated cells showed 
that counts decreased with increasing mitomycin C concentration in a dose-
dependent fashion at all the time points (Figure 4.12). The differences between 
unstimulated and Con-A stimulated cells at all mitomycin C concentrations were 
significant, except at 100 g.ml-1 mitomycin C. This showed that Con-A stimulated 
cells produced more ATP than unstimulated cells.  
Since there were significant differences between unstimulated and Con-A stimulated 
cells between 5 and 60 g.ml-1 of mitomycin C, it was not possible to determine 
whether or not there was mitotic inactivation. The ideal result would have been no 
significant differences between counts obtained from stimulated and unstimulated 
cells at any given concentration of mitomycin C. Although at 100 g.ml-1 of 
mitomycin C no significant difference was found between stimulated and 
unstimulated cells, the ATP content of these cells was not significantly different from 
that of camptothecin treated cells. This indicated that 100 g.ml-1 of mitomycin C 
was toxic to the cells.  





Figure 4.12. Effects of mitomycin C treatment on cellular ATP content of Con-A 
stimulated and unstimulated C3H mononuclear cells. Cells (1 x 10
5
 per well) were 
treated with increasing doses of mitomycin C (5 – 100 g.ml-1) for 30 minutes, washed 
thoroughly and cultured either as unstimulated cells or stimulated (10 g.ml-1 Con-A) for 3, 
5 and 7 days. Cellular ATP content was measured as an indicator of cell proliferation and 
viability. Untreated and unstimulated cells (0) were used as controls for viable non-
proliferating cells while untreated and Con-A stimulated cells (0) were used as controls for 
viable proliferative cells. Camptothecin-treated cells were used as control for dead cells. CPS 
data (n=3) was Log10 transformed and analysed by 2-way ANOVA followed by calculation 
of the MSD (p<0.05) by the T method to determine differences between unstimulated and 
stimulated cells for a given mitomycin C concentration. Data was then back-transformed for 
presentation and plotted as mean CPS ± 95 % CL for day 3 (A), day 5 (B) and day 7 (C).
*
 
indicates significant difference between unstimulated and Con-A stimulated cells for a given 
mitomycin C concentration. [Campt; camptothecin] 
 
4.3.3.2. Determination of mitotic inactivation by the 3H-thymidine 
uptake assay 
Results from the ATP assay described in Section 4.3.3.1 were inconclusive as 
mitomycin C concentrations between 5 and 60 g.ml-1 gave significant differences 
between unstimulated and Con-A stimulated cells. Therefore the 
3
H-thymidine 
uptake assay was used.  
In this experiment, C3H mononuclear cells were treated with mitomycin C (5, 10, 20 
and 50 g.ml-1) and either left unstimulated or stimulated using Con-A (10 g.ml-1).  




The cells were cultured for 3, 5 and 7 days without medium changes. Untreated cells 
(no mitomycin C), either unstimulated or stimulated were used as controls for viable 
non-proliferating cells and viable proliferating cell respectively. Camptothecin (10 
g.ml-1) treated cells were used as controls for dead cells. 
The results showed that increasing mitomycin C concentration significantly inhibited 
3
H-thymidine uptake in Con-A stimulated cells at all the time points (Figure 4.14). 
At days 3, 5 and 7 respectively, significant differences in counts between 
unstimulated and Con-A stimulated cells were obtained for untreated cells and cells 
treated with 5 g.ml-1, but not for cells treated with 10, 20 and 50 g.ml-1 of 
mitomycin C. Only cells treated with 5 g.ml-1 mitomycin C had SI above 3. The SI 
for cells treated with between 10 and 50 g.ml-1 mitomycin C had SI equal to and 
less than 3 at all the time points. This showed that mitotic inactivation could have 
been achieved at any of these mitomycin C concentrations.  
However, the assay was not informative with regard to cell viability at any given 
concentration of mitomycin C. Therefore, a further approach to determine the 
viability of the cells at these mitomycin C concentrations was necessary in order to 
ensure that future MLR and LTA used viable cells.  





Figure 4.13. Effects of mitomycin C treatment on the proliferation of unstimulated and 
Con-A stimulated C3H mononuclear cells as measured by 
3
H-thymidine uptake. C3H 
mononuclear cells (1 x 10
5
 per well) were treated with increasing concentrations of 
mitomycin C (5 – 50 g.ml-1) for 30 minutes, washed thoroughly and cultured either as 
unstimulated cells or Con-A (10 g.ml-1) stimulated for 3, 5 and 7 days. Untreated and 
unstimulated cells (0) were used as controls for viable non-proliferating cells while untreated 
and Con-A stimulated cells (0) were used as controls for viable proliferating cells. 
Camptothecin-treated cells were used as control for dead cells. CPM data (n=3) was Log10 
transformed and analysed by 2-way ANOVA followed by calculation of the MSD (p<0.05) 
by the T method to determine differences between unstimulated and stimulated cells for a 
given mitomycin C concentration. Data was then back-transformed for presentation and 
plotted as mean CPM ± 95 % CL for day 3 (A), day 5 (B) and day7 (C).
*
 indicates 
significant difference between unstimulated and stimulated cells for a given mitomycin C 
concentration. Stimulation is presented as SI (D) for each mitomycin C concentration and 
time point. The red line at SI=3 denotes statistical biological positive. Only SI above 3 were 
considered significant responses of C3H mononuclear cells against Con-A stimulation. 
[Campt; camptothecin] 
 
4.3.3.3. Determination of mitotic inactivation using the CFSE 
dilution assay 
Having determined a broad concentration range (10–50 g.ml-1) at which mitomycin 
C had a significant effect on cell division by the 
3
H-thymidine assay, the CFSE 
dilution assay was used to determine the most suitable concentration of mitomycin C 
by determining the cell viability and proliferation capacity of unstimulated and Con-
A stimulated cells at these concentrations. Cell division was determined by tracking 




intracellular CFSE fluorescence intensity and cell viability was analysed using the 
viability stain 7-AAD. Absolute cell numbers of unstimulated and Con-A stimulated 
cells were estimated using fluorescent counting beads. Positive controls for dead 
cells were set up by treating CFSE labelled and unlabelled cells with camptothecin 
(10 g.ml-1). Representative data (n=3) is shown in Figure 4.14. 
 
Figure 4.14. Determination of cell viability using CFSE tracking of mitomycin C 
treated cells by flow cytometry. Unlabelled (A) and CFSE labelled (B) C3H mononuclear 





 dead cells respectively. Unlabelled (C) and CFSE labelled (D) viable cells 








 viable cells respectively. 
Absolute cell numbers in each quadrant were estimated by collecting 1000 CountBright™ 
fluorescent counting beads and then using the bead to cell ratio to obtain the cell numbers. 
This set up was used to analyse the viability of mitomycin C treated CFSE labelled cells 
which were either unstimulated or stimulated with Con-A (10 g.ml-1). Data was acquired 
using CellQuest™ flow cytometry data acquisition and analysis software v 3.1. The results 
are representative for three experiments.  
 
For unstimulated cells treated with 5 and 10 g.ml-1 mitomycin C, cell viability was 
above 90 % but at 20 and 50 g.ml-1 mitomycin C, viability decreased from 80 % to 
40 % and 60 % to 30 % at day 3 and day 5 respectively (Figure 4.15). At day 7, cell 
viability dropped from 80 % at 5 g.ml-1 mitomycin C to 20 % at 50 g.ml-1. These 
results showed that mitomycin C concentrations above 10 g.ml-1 reduced cell 
viability. 




For Con-A stimulated cells treated with 5 and 10 g.ml-1 mitomycin C, cell viability 
was above 90 % at day 3 but dropped to 60 % at day 5 and 20 % at day 7. At 20 
g.ml-1 mitomycin C, cell viability was 58 % at days 3 and 5 and 20 % at day 7. At 
50 g.ml-1 mitomycin C, cell viability dropped to 36 % at days 3 and 5 and 18 % at 
day 7. For Con-A stimulated control cells (no mitomycin C) however, cell viability 
was reduced from 100 % at day 3, 76 % at day 5 and 30 % at day 7. The results from 
the Con-A stimulated controls demonstrated that cell viability dropped considerably 
over the 7 day period compared to unstimulated control cells (no mitomycin C) in 
which viability was above 90 % at days 3 and 5 and 80 % at day 7.  
These results showed two phenomena; firstly, that stimulation by Con-A reduced the 
viability of the C3H mononuclear cells and secondly, that treatment of either 
unstimulated or Con-A stimulated cells with mitomycin C concentrations above 10 
g.ml-1 further reduced the cell viability. At 5 and 10 g.ml-1 mitomycin C, cell 
viability was comparable to that for control cells. In practice, mitotic inactivation is 
required for unstimulated cells. Therefore, 5 and 10 g.ml-1 mitomycin C appeared to 
be the most appropriate doses for inducing mitotic arrest. 
 
Figure 4.15. Effects of mitomycin C treatment on cell viability of Con-A stimulated and 
unstimulated C3H mononuclear cells as measured by CFSE and 7-AAD staining assay. 
Cells were treated with different concentrations (5, 10, 20 and 50 g.ml-1) of mitomycin C 
for 30 minutes, washed and labelled with CFSE. The cells were cultured either as 
unstimulated cells (A) or Con-A stimulated (B) for 3, 5 and 7 days. Cultures were spiked 
with 5 l per well of Via-probe™ 7-AAD probe and mixed with 50 l of counting beads 
before data was captured by collecting 1000 bead events and computing the fractions of cells 
in each quadrant. 7-AAD stained cells were regarded as dead while unstained cells were 
considered as viable. Data was captured and analysed by CellQuest™ software (BD 
Bioscience) v3.1 
 




Further insights into the status of the cells were obtained by analysing CFSE 
fluorescence intensities of the cell fractions to determine whether or not the viable 
cells were mitotically inactivated (dividing cells exhibit CFSE dilution). Data 
collected using CellQuest™ software was further analysed using FlowJo™ data 
analysis software.  
The results showed that mitotic inactivation was achieved when mitomycin C treated 
cells (10 g.ml-1) failed to respond to stimulation by Con-A as there was no apparent 
fluorescence shift to the left on histograms. Shifting of fluorescence intensity to the 
left indicated CFSE dilution which meant that the cells were capable of dividing. At 
5 g.ml-1 mitomycin C, a shift to the left was noted in Con-A stimulated cells. This 
showed that at this concentration of mitomycin C, the cells were not completely 
mitotically inactivated (Figure 4.16). 
Further analysis of the CFSE dilution profiles for all the samples using the cell 
proliferation platform of FlowJo™ software showed that between 3 and 14 % of the 
unstimulated cells treated with different mitomycin C concentrations and control 
cells underwent mitosis at all the time points (Figure 4.17A).  
Following stimulation by Con-A however, 80 % of control cells underwent mitosis at 
day 3, 60 % at day 5 and 42 % at day 7 (Figure 4.17B). For stimulated cells treated 
with 5 g.ml-1 mitomycin C, 60 %, 30 % and 20 % of the cells underwent mitosis at 
days 3, 5 and 7 respectively compared to 18 %, 10 % and 3 % for cells treated with 
10 g.ml-1 mitomycin C at the same time points. Less than 2 % of the cells treated 
with 20 and 50 g.ml-1 of mitomycin C however, underwent cell division. Based on 
these results, mitotic inactivation would have been achieved between 20 and 50 
g.ml-1 mitomycin C but considering the cell viability results, these observations 
showed that the lack of stimulation was largely due to mitomycin C toxicity. 
Further evaluation of the mitotic cell fractions of unstimulated cells revealed that all 
the cells treated with different mitomycin C concentrations and control cells 
underwent a single cycle of cell division (Figure 4.17C). Analysis of the cells treated 
with 5 and 10 g.ml-1 mitomycin C that had undergone mitosis showed that the 
dividing cells treated with 10 g.ml-1 mitomycin C had gone through one mitotic  
cycle at all the time points whereas those treated with 5 g.ml-1 mitomycin C, cell 










 division cycles at days 3, 5 and 7 
respectively (Figure 4.17D).  
Taken together, these data showed that treatment of cells with 10 g.ml-1 mitomycin 
C achieved mitotic arrest and maintained cell viability above 90 % for up to 5 days 
and 70 % for 7 days. A small fraction of these cells (less than 20 %) was found to be 
capable of only a single round of mitosis following Con-A stimulation for 7 days. 
Higher concentrations (20 and 50 g.ml-1), though inhibiting cell division even after 
Con-A stimulation, considerably reduced cell viability (below 50 %) whereas lower 
concentrations (5 g.ml-1) left the cells viable but also a sizeable proportion of the 
cells (up to 60 %) capable of undergoing several (4 to 9) mitotic cycles after 7 days 
of culture. Hence 10 g.ml-1 of mitomycin C was chosen as the appropriate 
concentration for achieving mitotic arrest and was used in subsequent experiments. 
 





Figure 4.16. CFSE dilution assay for mitomycin C treated C3H mononuclear cells to 
detect mitosis using FlowJo
™
 software cell proliferation platform. Representative 
histograms plotted to show CFSE fluorescence intensities of unstimulated cells (A) and Con-
A stimulated cells (B) treated with 5 and 10 g.ml-1 mitomycin C. Positive (Con-A 
stimulated) and negative (unstimulated) control cells were not treated with mitomycin C. A 
shift to the left of peak fluorescence intensities denoted CFSE dilution which in turn 
represented separate cell fractions of daughter cells. The peaks of the Con-A stimulated cells 
were further resolved using the cell proliferation platform on FlowJo™ to expose groups of 
cells with the different CFSE fluorescence intensities which corresponded to specific 
generations of cell division (C). Data is representative of three experiments. 
 





Figure 4.17. Analysis of the effects of mitomycin C treatment on cell division of 
unstimulated and Con-A stimulated C3H mononuclear cells as determined by CFSE 
dilution analysis using flow cytometry. Representative data was analysed using the cell 
proliferation platform in FlowJo™ software v.7.6.5 which resolved the proportion of all cells 
with CFSE fluorescence intensity lower than control (unstimulated CFSE labelled) cells 
(mitotic cells). The fractions of divided cells at each mitomycin C concentration are shown 
for unstimulated (A) and Con-A stimulated cells (B). The number of cell division cycles 
entered by the dividing cells is shown for unstimulated (C) and Con-A stimulated cells (D) at 
each mitomycin C concentration. The method used the reduction of cellular CFSE 
fluorescence intensity relative to the control cells. Halving of the fluorescence intensity was 
regarded as representative of a single mitotic cycle. 
 
4.3.4. Investigation of mouse serum as an alternative to FCS for 
supplementing culture medium 
Throughout the literature, mouse LTA and MLR have been carried out in culture 
medium supplemented with 10 % (v/v) FCS. Considering that FCS contains many 
complex bovine proteins, it is conceivable that in proliferation assays involving 
mouse lymphocytes that FCS proteins may provide xenogeneic antigens that could 
initiate responses and give false positive results. For this study, it was important to 
ensure that any potential stimulatory components of the culture medium were 
evaluated in order to accurately detect specific allogeneic responses of Balb/c 
lymphocytes in response to C3H cells. Therefore, commercially sourced heat-
inactivated mouse serum at 2, 5, 10 and 20 % (v/v) was used to supplement 
lymphocyte culture medium in LTA using Balb/c mononuclear cells stimulated with 




Con-A (10 g.ml-1). For comparison, the same assays were carried out in medium 
supplemented with FCS at the same concentrations. To check whether serum 
supplementation was necessary at all, cells were cultured in medium without serum 
(0 %) as a control for serum supplementation. Similarly, identical cultures were set 
up in lymphocyte transport medium which is used during the isolation of 
mononuclear cells. 
3
H-thymidine uptake was measured at 3, 5 and 7 days without 
medium changes. Cellular ATP content analysis using the ATPLite
™
 assay was also 
carried out to assess cell viability at day 3. 
Analysis of day 3 data showed that unstimulated Balb/c mononuclear cells cultured 
in medium containing graded amounts of FCS produced significantly higher counts 
compared to those cultured in mouse serum (Figure 4.18). For Con-A stimulated 
cells however, 
3
H-thymidine uptake increased proportionally with increasing FCS 
concentration peaking at 20 % (v/v) at day 3 and 10 % (v/v) at days 5 and 7. 
Conversely, 
3
H-thymidine uptake decreased inversely with increasing mouse serum 
concentration with the highest counts obtained at 2 % (v/v). Similar trends were 
observed at day 5 and day 7. Significant differences in counts were noted at each 
concentration of FCS and mouse serum. Stimulation indices showed that 10 % (v/v) 
FCS and 2 % (v/v) mouse serum were optimum for Balb/c mononuclear cells 
response to stimulation by Con-A. Stimulated cells cultured in 2 % (v/v) mouse 
serum produced higher counts than cells cultured in 10 % (v/v) FCS at days 3 and 5 
but the reverse was true at day 7. Control cells cultured in medium without serum or 
in lymphocyte transport medium showed no significant differences between 
unstimulated and Con-A stimulated cells at all the time points. This showed that 
serum supplementation is an important requirement for lymphocyte transformation.  
Analysis of the cellular ATP content of day 3 unstimulated cultures showed that cells 
cultured in FCS produced significantly more ATP compared to cells cultured in 
mouse serum at each concentration (Figure 4.19). The ATP content was consistently 
similar at all FCS concentrations. For unstimulated cells cultured in mouse serum 
however, the ATP levels declined with increasing serum concentration. For Con-A 
stimulated cells, the ATP levels increased sharply with increasing FCS serum 
concentration with peak counts at 10 % (v/v) FCS. For Con-A stimulated cells 
cultured in mouse serum however, ATP levels declined inversely with increasing 
serum concentration with peak counts obtained at 2 % (v/v). Stimulation with Con-A 




had no effect on ATP levels of cells cultured in either lymphocyte transport medium 
or culture medium without serum.  
Taken together, these data showed that increasing FCS concentration increased both 
3
H-thymidine uptake and ATP content of Con-A stimulated cells with peak counts 
obtained at 10 % (v/v). The opposite was true for cells cultured in mouse serum in 
which increasing the serum concentration above 2 % (v/v) was accompanied with a 
dose dependent decrease in 
3
H-thymidine uptake and cellular ATP content. 
Therefore, both 10 % (v/v) FCS and 2 % (v/v) mouse serum were deemed 














Figure 4.18. Evaluation of mouse serum and FCS concentration on the transformation 
of Balb/c mononuclear cells. Cells (1 x 10
5
 per well) were cultured in medium 
supplemented with 2, 5, 10 and 20 % (v/v) of either FCS or mouse serum. Cells cultured in 
serum free medium (0%) and transport medium (Tmed) were used as controls. Cultures were 
either left unstimulated or stimulated with 10 g.ml-1Con-A followed by incubation for 3, 5 
and 7 days without medium changes. Data (n=3) was Log10 transformed and analysed by 2-
way ANOVA followed by calculation of the MSD (p<0.05) by the T method to determine 
differences between mouse serum and FCS at the same concentration. Data was then back-
transformed for presentation and plotted as mean CPM ± 95 % CL for unstimulated and 
Con-A stimulated cells at day 3 (A and B), day 5 (C and D) and day 7 (E and F) respectively. 
*
 indicates significant differences between FCS and mouse serum at the each concentration. 
SI were computed and are shown for cells cultured in FCS (G) and mouse serum (H) 
respectively. The red line at SI=3 denotes statistical biological positive; only SI higher than 3 
were considered significant responses of Balb/c mononuclear cells to Con-A. [MS; mouse 
serum] 





Figure 4.19. Effects of FCS and mouse serum on cellular ATP content of unstimulated 
and Con-A stimulated Balb/c mononuclear cells. Cells (1 x 10
5
 per well) were cultured in 
medium supplemented with 2, 5, 10 and 20 % (v/v) of either FCS or mouse serum for 3 days. 
Cellular ATP content was measured as an indicator of cell proliferation and viability. Cells 
cultured in serum-free medium (0 %) and transport medium (T-med) were used as controls. 
Data (n=3) was Log10 transformed and analysed by 2-way ANOVA followed by calculation 
of the MSD (p<0.05) by the T method to determine differences between cells at in FCS and 
mouse serum at the same concentration. Data was then back-transformed for presentation 
and plotted as mean CPS ± 95 % CL for unstimulated cells (A) and Con-A stimulated cells 
(B).
*
 indicates a significant difference in intracellular ATP content between cells cultured in 
FCS and mouse serum at the same concentration. [MS; mouse serum]  
 
4.3.5. Determination of appropriate responder to stimulator cell 
ratios for performing one-way MLR using 2 % (v/v) mouse serum 
and 10 % (v/v) FCS in culture medium 
The purpose of this experiment was to determine the appropriate responder to 
stimulator cell ratio and suitable total cell numbers for performing one-way MLR. In 
Section 4.3.4, it was found that lymphocyte culture medium containing either 10 % 
(v/v) FCS or 2 % (v/v) mouse serum was suitable for Balb/c lymphocyte 
transformation. Therefore, Balb/c mononuclear cells (responder) were co-cultured 
with mitotically inactivated (10 g.ml-1 mitomycin C) C3H mononuclear cells 




(stimulator) using culture medium containing either 10 % (v/v) FCS or 2 % (v/v) 
mouse serum. Responder to stimulator cell ratios were set at 1:1, 1:10 and 1:100 and 
cultures contained total cell numbers (responder + stimulator) of 1 x 10
4





 cells. The cells were cultured with medium changes every 3 days for 3, 6, 9 
and 12 days. The response of Balb/c mononuclear cells to allogeneic C3H cells was 
tested using the 
3
H-thymidine uptake assay. SI for the one-way MLR reactions were 
calculated as follows; 
𝑆𝐼 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑃𝑀 𝑅𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑟 + 𝑆𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑜𝑟 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑃𝑀 (𝑅𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑟 𝑜𝑛𝑙𝑦)
 
 
The results showed that control cultures of Con-A stimulated Balb/c cells cultured in 
either 10 % (v/v) FCS or 2 % (v/v) mouse serum were equally stimulated and gave 
high counts which peaked at day 6 and gradually reduced during the time course. 
Highest counts were recorded with the highest total cell numbers, in the order 1 x 10
5
 
> 5 x 10
4
 > 1 x 10
4
 respectively (Figure 4.20).  
 
 





Figure 4.20. Stimulation of different cell numbers of Balb/c mononuclear cells cultured 
in medium containing 10 % (v/v) FCS and 2 % (v/v) mouse serum as controls for the 
one-way MLR. Balb/c mononuclear cells were plated at 1 x 10
4
, 5 x 10
4
 and 1 x 10
5
 in 
medium supplemented with 10 % (v/v) FCS or 2 % (v/v) mouse serum as either unstimulated 
cells or Con-A (10 g.ml-1) stimulated cells. The cells were cultured for 3, 6, 9 and 12 days 
respectively accompanied by medium changes (100 l replaced with equal volume) at each 3 
day period. Lymphocyte proliferation was measured by the incorporation of 
3
H-thymidine 
into newly formed DNA of dividing cells. Data (n=3) was Log10 transformed and analysed 
by 2-way ANOVA followed by calculation of the MSD (p<0.05) by the T method to 
determine differences between CPM at each time point. Data was then back-transformed for 
presentation and plotted as mean CPM ± 95 % CL for unstimulated cells (A) and Con-A 
stimulated cells (B) in 10 % (v/v) FCS and unstimulated cells (C) and Con-A stimulated cells 
(D) in 2 % (v/v) mouse serum.
*
 indicates significant differences between 1 x 10
5




 indicates significant differences between 1 x 10
5 




 indicates significant 
differences between 5 x 10
4
 and 1 x 10
4
 for a given time point. 
 
For the one-way MLR carried out in culture medium supplemented with 10 % (v/v) 
FCS, the responder to stimulator cell ratio that gave the highest counts was the 1:1 
followed by 1:10 and 1:100 respectively in the order 1:1 > 1:10 > 1:100 at each time 
point (Figure 4.21). In terms of total cell numbers, the highest counts were obtained 
in cultures containing 1 x 10
5
 followed by 5 x 10
4
 and 1 x 10
4
 respectively in the 
order 1 x 10
5 
> 5 x 10
4
 > 1 x 10
4
. Peak counts were obtained at day 6 of culture. For 
one-way MLR carried out in culture medium supplemented with 2% (v/v) mouse 




serum however, significantly low counts were obtained for all the responder to 
stimulator cell ratios in comparison to reactions in 10 % (v/v) FCS at all the points.  
In order to determine the extent of the allogeneic response, SI were computed for 
each different responder to stimulator cell ratio and total cell number at all the time 
points. The results showed that for MLR in 10 % (v/v) FCS medium, the SI peaked 
at day 6 and declined thereafter at day 9 and day 12 respectively (Figure 4.22). 
Highest SI were obtained at the 1:1 ratio of responder to stimulator cells followed by 
1:10 and 1:100 respectively. At any given time point and cell ratio, the magnitude of 
the SI was in the order 1 x 10
5 
> 5 x 10
4
 > 1 x 10
4
. 
For cells cultured in 2 % (v/v) mouse serum however, the SI for all the different cell 
ratios and cell numbers at any given time point were equal to or below 3. This 
showed that the Balb/c lymphocytes failed to respond to allogeneic C3H 
mononuclear cell in culture medium containing 2 % (v/v) mouse serum. This was 
despite prior positive lymphocyte transformation observed when Balb/C 
mononuclear cells were stimulated with Con-A in 2 % (v/v) mouse serum as 
described earlier in Section 4.3.4. 
Taken together, these data showed that the most appropriate conditions for the one-
way MLR were achieved at a 1:1 responder to stimulator cell ratio and 1 x 10
5
 total 
cells in medium containing 10 % (v/v) FCS but not 2 % (v/v) mouse serum. These 
conditions were used in subsequent assays.  
 





Figure 4.21. One-way MLR in 10 % (v/v) FCS and 2 % (v/v) mouse serum containing 
medium for the determination of appropriate responder to stimulator cell ratio and 
total cell numbers. Balb/c (responder) and mitotically inactivated C3H (stimulator) 
mononuclear cells were co-cultured at ratios of 1:1, 1:10 and 1:100 respectively in cultures 
containing total cell numbers of 1 x 10
5
 (A), 5 x 10
4 
(B) and 1 x 10
4 
(C) in medium 
supplemented with either 10 % (v/v) FCS or 2 % (v/v) mouse serum for 3, 6, 9 and 12 days 
respectively. Medium changes (100 l replaced with equal volume of fresh medium) were 
carried out after every 3 days. The allogeneic response of the responder lymphocytes against 
the stimulators was measured by the incorporation of 
3
H-thymidine. Data (n=3) was Log10 
transformed and analysed by 2-way ANOVA followed by calculation of the MSD (p<0.05) 
by the T method to determine differences between CPM of cells cultured in FCS and mouse 
serum at each time point. Data was then back-transformed for presentation and plotted as 
mean CPM ± 95 % CL.
*
 indicates significant differences in 
3
H-thymidine uptake between 
cells in 10 % (v/v) FCS and 2 % (v/v) mouse serum at a given time point.  
 





Figure 4.22. Effects of total cell number and different responder to stimulator cell 
ratios for one-way MLR in 10 % (v/v) FCS and 2 % (v/v) mouse serum culture 
medium. Balb/c (responder) and C3H (stimulator) mononuclear cells were co-cultured at 
ratios of 1:1, 1:10 and 1:100 respectively in cultures containing total cell numbers of 1 x 10
5
 
(A), 5 x 10
4 
(B) and 1 x 10
4 
(C) in medium supplemented with 10 % (v/v) FCS or 2 % (v/v) 
mouse serum. The cells were cultured for 3, 6, 9 and 12 days respectively accompanied by 
medium changes (100 l replaced with equal volume of fresh medium) every 3 days. The 
allogeneic response of the Balb/c lymphocytes to C3H stimulators was measured by the 
incorporation of 
3
H-thymidine. Results are displayed as SI (ratio between mean CPM of 
MLR and responder cells only) for each cell ratio at a given time point. The red line at SI=3 
denotes statistical biological positive; SI above 3 are considered significant allogeneic 














The work carried out in this chapter aimed to test several experimental parameters in 
order to establish the most suitable conditions for carrying out LTA and one-way 
MLR which are the key assays employed in the study of the immunogenicity and 
immunomodulatory properties of allogeneic MSC and DF respectively. As with most 
immunological assays, the sensitivity and responsiveness of lymphocytes largely 
depends on in vitro micro and macro environmental factors. Therefore, it was 
important to investigate some of the important variables in order to minimise 
confounding of the results by these factors. Among the factors investigated were the 
type and concentration of mitogen to be used as a positive control for lymphocyte 
proliferation, culture period and medium replacement for longer incubations, 
effective concentration of mitomycin C for inducing mitotic arrest for stimulator 
cells, the type and concentration of serum for supplementing culture medium, the 
ratio of responder to stimulator cells and total cell numbers suitable for sensitivity of 
the LTA and one-way MLR.  
Mouse mononuclear cells were isolated from spleens and lymph nodes of female 
mice by iso-osmotic density gradient separation at 1.077g.ml
-1 
using Lymphoprep™. 
This method removed erythrocytes, polymorphonuclear leukocytes and other stromal 
cells leaving behind a white band of mononuclear cells (Kruisbeek, 2001). The 
mononuclear cells, which contain lymphocytes, were used in all the experiments 
instead of separated lymphocytes in order to allow the participation of other 
accessory cells such as DC in the reactions. 
Mitogen stimulated mononuclear cells were used as positive controls in most 
experiments throughout this study. In order to test the responsiveness of the 
mononuclear cells, Balb/c mononuclear cells which were used as responder cells, 
were stimulated with increasing doses of PHA and Con-A to determine the most 
effective mitogen and appropriate dose. 
3
H-thymidine uptake and intracellular ATP 
content were measured after 3, 5 and 7 days to establish the peak time and mitogen 
concentration at which DNA synthesis and cell proliferation was highest. Peak 
counts were obtained at day 3 with 10 g.ml-1 of Con-A and 25 g.ml-1 of PHA. It 
was found that Con-A was effective at low concentrations whereas PHA was 
effective at higher concentrations. Stimulation using Con-A at 30 g.ml-1 or greater 




appeared to have an inhibitory effect on 
3
H-thymidine uptake. This was further 
highlighted by the ATPLite
™
 assay which showed that at these Con-A 
concentrations, cellular ATP levels dropped significantly below those for control 
unstimulated cells but this was not the case with PHA stimulated cells. This 
suggested that these high concentrations of Con-A are toxic to the Balb/c 
mononuclear cells. This also suggested that despite both mitogens being non-
specific, their potency or tolerability by cells was different. It has been suggested that 
Con-A stimulates a larger proportion of cells that would be otherwise unresponsive 
to PHA. Early studies on lymphocyte proliferation suggested that unlike PHA, Con-
A is capable of stimulating immature T-lymphocytes (Jacobsson & Blomgren, 1974), 
although this remains unresolved to date.  
The results also showed that highest counts and SI were obtained at day 3 followed 
by day 5 and day 7 respectively. This concurred with other studies which showed 
that peak DNA synthesis occurred between 3-5 days of lymphocyte stimulation by 
mitogens (Janossy et al., 1973; De Fries & Mitsuhashi, 1995). Thus, most LTA and 
MLR from the literature have been carried out between 3 and 5 days. Although this 
period is suitable when mitogens and other potent stimulators are used, it may be 
inadequate when less potent stimulators are used. As discussed in Chapter 1, MSC 
have been reported to be poorly immunogenic and failed to stimulate allogeneic 
lymphocyte in vitro. However, the hypothesis of this study suggested that if given 
adequate time under suitable conditions, MSC could potentially stimulate allogeneic 
lymphocytes in vitro by the indirect or semi-direct pathways. 
 It has been suggested that capturing the indirect or semi-direct pathways could 
require up to 10 days or more in culture (Chitilian et al., 1998) or 2-4 weeks in vivo 
(Costa et al., 2004). Therefore, in order to extend the culture period from 3-5 days, 
the accumulation of toxic metabolic by-products and nutrient depletion may become 
limiting. It has been shown that lymphocyte stimulation by mitogens and antigens is 
a highly energy demanding process accompanied by amplified glucose uptake and 
diminished oxygen intake which results in anaerobic respiration leading to raised 
lactate levels which inadvertently impact on cell division and viability (Loos & Roos, 
1973; Roos & Loos, 1973; Hume et al., 1978). Therefore, a strategy of changing 
medium during culture was employed in order to extend the culture period to 20 




days. This involved the removal of half (100 l per well) of the culture medium and 
replacing it with fresh culture medium every 3 day period. 
 To test this strategy, Balb/c mononuclear cells were stimulated with Con-A at 
different concentrations (5 to 25 g.ml-1) for 20 days with and without medium 
changes. It was found that medium changing significantly increased 
3
H-thymidine 
uptake and shifted peak stimulation from day 3 as observed in cultures without 
medium changes to day 6. In addition, SI higher than 3 were obtained in cultures 
with medium changes up to day 15 at all but 10 g.ml-1 of Con-A in which SI above 
3 were obtained at day 20. In cultures without medium changes, SI higher than 3, 
were only obtained at day 3 and day 5 but not beyond. This in part could explain why 
most LTA and MLR in the literature have not been tested beyond a 5 day culture 
period. The medium change experiments suggested that LTA cultures could be 
maintained for longer than the standard 5 day period. This strategy was therefore 
employed in future assays and also in MLR. 
It was constantly observed that in Con-A stimulated cultures without medium 
changes, the phenol red indicator in the culture medium changed from bright red to 
yellow at day 5 and day 7. When the pH was measured, it was found to be between 
5.6 and 6.2. This was not observed in cultures with medium changes. Previous 
reports have shown that pH drops below 6.6 significantly impacted on lymphocyte 
proliferation (Frauwirth & Thompson, 2004). The drop in pH could be attributed to 
the accumulation of lactic acid and other metabolic by-products. For instance, acidic 
pH could alter protein structure and function of key protein molecules such as 
enzymes which are involved in vital cellular activities. 
The next step in establishing appropriate conditions for LTA and one-way MLR was 
to determine the concentration of mitomycin C required to induce mitotic arrest 
while maintaining cell viability in C3H mononuclear cells which were the stimulator 
cells subsequent one-way MLR. It has been noted in many studies in the literature 
that a broad range of concentrations of mitomycin C (5 – 120 g.ml-1) have been 
used for achieving mitotic inactivation during MLR. However, most of such studies 
did not report on the effects of the mitomycin C on cell viability. This is very 
important since it has been demonstrated that mitomycin C affects cellular 
mitochondrial DNA which leads to cytotoxicity even at low concentrations (Kulkarni 




et al., 2009). It is conceivable that since mitomycin C induces mitotic arrest by cross-
linking genomic DNA, mitochondrial DNA, which contains genes that control 
important metabolic functions including oxidative phosphorylation and synthesis of 
transfer ribonucleic acid (tRNA) and messenger RNA (mRNA) will also be 
susceptible to irreversible damage. Arrest of oxidative phosphorylation which 
provides cellular ATP, starves the cells of vital energy and the inhibition of tRNA 
and mRNA disables the cells ability to synthesize proteins including key enzymes, 
hormones, cytokines and other essential molecules. Therefore, it was very important 
to determine the most suitable concentration of mitomycin C which achieved mitotic 
inactivation while maintaining cell viability.  
C3H mononuclear cells were treated with increasing doses of mitomycin C and 
cultured for 3, 5 and 7 day without medium changes as unstimulated or Con-A (10 
g.ml-1) stimulated cells. Using cellular ATP content as a measure of cell viability 
and mitotic inactivation, it was found that mitomycin C significantly reduced cellular 
ATP levels in Con-A stimulated cells. However, the data was not informative enough 
as the ATP levels were not significantly different for cells treated with different 
doses (5-100 g.ml-1) of mitomycin C. Previous studies using Balb/c cells had 
showed that mitomycin C reduced cellular ATP levels after 48 hours exposure 
(Pritsos & Briggs, 1996). For this study however, exposure was for 30 minutes yet 
the ATP content of unstimulated cells was comparable to that of dead (camptothecin-
treated) cells. This demonstrated the potency of mitomycin C as an inhibitor of 
metabolism and respiration. Therefore, this method could not be reliably used to 
determine the appropriate non-lethal dose of mitomycin C. An explanation for this 
could be due to the previously mentioned effects of mitomycin on mitochondrial 
DNA which directly affects the ability of the cells to produce ATP. It is conceivable 
that once intracellular ATP levels are diminished, cells treated with mitomycin C fail 
to synthesize ATP thus making ATP measurements a poor indicator of cell viability 
under such conditions.  
It is also possible to hypothesize that once ATP synthesis via aerobic respiration is 
blocked, a switch to the anaerobic pathway could result in the production of more 
lactic acid. Accumulation of the lactic acid could lead to a drop in pH and as 
previously explained. Therefore, it would seem that in static cultures involving 




mitomycin C treated cells such as in LTA and one-way MLR, changing the culture 
medium helps to reduce the accumulation of lactic acid thus allowing cells to survive 
longer in culture.  
Another important factor is the time in which the cells are exposed to mitomycin C. 
As mentioned previously, Pritsos & Briggs used a 48-hour exposure  (Pritsos & 
Briggs, 1996) while this study used a 30 minute exposure. Although the results have 
not been presented in this study, analysis of cellular ATP was carried out at 10 
minute intervals for 60 minutes using C3H mononuclear cells during preliminary 
studies. The results showed that cellular ATP levels were similar between untreated 
cells and cells treated for 10 minutes with between 5 and 120 g.ml-1 mitomycin C. 
However, after 20 minutes, the ATP levels had dropped six-fold and remained 
constant up to 60 minutes at all the concentrations. This not only demonstrated that 
mitomycin C inhibits cellular ATP synthesis at all the concentrations tested, but 
importantly showed that mitomycin C exerts its inhibitory effects after the first 10 
minutes of exposure. Thus, a 30 minute exposure was chosen since the ATP content 
did not change after 20 to 60 minute exposure. 
3
H-thymidine uptake was then used to determine the effective mitomycin C 
concentration. Results showed that mitomycin C significantly reduced 
3
H-thymidine 
uptake by unstimulated and Con-A stimulated cells at all concentrations used. At 
mitomycin C concentrations between 10 and 50 g.ml-1 there were no significant 
differences in counts between stimulated and unstimulated cells which suggested 
mitotic inactivation. This was confirmed by SI values which were less than 3 at these 
concentrations. However, the range was deemed too broad considering that 
mitomycin C is cytotoxic. Therefore, despite the results suggesting mitotic 
inactivation, it had not been established whether the cells were viable or not. Thus, 
3
H-thymidine uptake alone was not informative in terms of cell viability since 
similarly low counts were obtained with camptothecin treated cells. 
 In most previous studies, 
3
H-thymidine uptake has been widely used for 
demonstrating mitotic arrest by mitomycin C and x-irradiation as both these methods 
have been described as similarly effective (Bach & Bach, 1972). However, judging 
from the results obtained in this study, this method, although suggesting mitotic 
arrest due to low counts in stimulated cells, did not shed light as to whether this was 




due to mitotic inactivation or cytotoxicity. It is possible to hypothesize that both sub-
lethal and lethal doses of mitomycin C are likely to inhibit the uptake of 
3
H-thyidine 
in different ways. A sub-lethal dose could inhibit both DNA and protein synthesis 
making the cells incapable of producing daughter cells. However, dead cells also are 
unable to utilise 
3
H-thymidine. Thus the results of the 
3
H-thymidine uptake alone 
could not be used to determine mitotic arrest without evidence of cell viability. 
The problem was solved by using the CFSE dilution assay alongside 7-AAD 
staining. Flow cytometry analysis of CFSE labelled and 7-AAD stained cells allowed 
the mitomycin C treated cells (unstimulated and Con-A stimulated) to be analysed 
for cell viability (only dead cells stained positive with 7-AAD) and cell proliferation 
(CFSE dilution). Incomplete mitotic inactivation was demonstrated by CFSE dilution 
in Con-A stimulated cells. 
 It was shown that mitotic inactivation while maintaining cell viability above 90 % 
for up to 5 days and 70 % for 7 days was achieved at 10 g.ml-1 of mitomycin C. 
Higher mitomycin C concentrations (20 and 50 g.ml-1) drastically reduced cell 
viability while lower concentrations (5 g.ml-1) were insufficient in stopping the 
cells from undergoing mitosis upon stimulation with Con-A. In addition, less than 16 
% of cells treated with 10 g.ml-1 mitomycin C, underwent one cycle of mitosis after 
Con-A stimulation compared to between 20 % and 60 % of cells treated with 5 
g.ml-1 of mitomycin C, which went up to 9 mitotic cycles over the 7 day period. 
Approximately 3 to 15 % of negative controls (untreated and unstimulated) also 
underwent a single mitotic round. This could be attributed to the natural loss of 
CFSE fluorescence or to a fraction of the cells reacting to some xenogeneic factors in 
FCS. 
CFSE is a fluorescent dye which can label intracellular molecules and is halved with 
each cell division cycle. This results in a sequential halving of its fluorescence 
intensity allowing the tracking of up to 10 cell division cycles in vivo and in vitro. 
The dye itself is not fluorescent but acquires its fluorescence after fluxing across cell 
membranes and reacting with intracellular esterases to produce a highly fluorescent 
but stable dye which forms lasting conjugates with intracellular proteins at neutral 
pH. 7-AAD is a dye that intercalates permanently with double stranded cellular DNA 




of dead cells since it cannot pass across intact membranes of viable cells thus 
allowing all non-viable cells to be detected and quantified. 
These findings showed that previous high concentrations of mitomycin C used in the 
literature may have been toxic to the cells since none of the studies has reported cell 
viability analysis following mitomycin C treatment. Using non-viable cells in one-
way MLR potentially gives false results as dead cells can indirectly stimulate viable 
lymphocytes in vitro via the indirect and semi-direct pathways. In addition, these 
findings have also demonstrated the limitations of the ATPLite
™
 assay which is often 
used for the determination of cell viability. 
Another important parameter considered was the type and concentration of serum for 
culture medium supplementation. Previous studies have used 10 % (v/v) FCS as the 
standard supplement but since this study used a mouse model system, it was thought 
that mouse serum would be more appropriate. Therefore, commercially sourced heat-
inactivated mouse serum was compared with FCS at different concentrations in LTA 
involving Con-A stimulated Balb/c mononuclear cells. The highest counts and SI 
were obtained at 2% (v/v) mouse serum and 10 % (v/v) FCS. Interestingly, higher 
mouse serum concentrations had an inhibitory effect on 
3
H-thymidine uptake 
whereas conversely, higher FCS concentrations were stimulatory.  
Consequentially, both 2 % (v/v) mouse serum and 10 % (v/v) FCS were used in 
subsequent experiments for the determination of appropriate ratio of responder to 
stimulator cells for carrying out one-way MLR. Balb/c mononuclear cells were used 
as responders and mitomycin C (10 g.ml-1) treated C3H mononuclear cells were 
used as stimulators at 1:1, 1:10 and 1:100 ratios. The high stimulator ratios provided 
different doses of allogeneic antigens thus testing the responsiveness of the responder 
cells under different allogeneic settings which could arise in applications where high 
doses of allogeneic cells could be used (such as MSC cell based cell therapies). The 
1:1 ratio gave the highest counts and SI followed by 1:10 and 1:100 respectively in 
10 % (v/v) FCS medium.  
In 2 % (v/v) mouse serum cultures, both the counts and SI were significantly lower 
with the latter below the significant threshold of 3. This was despite Con-A 
stimulated positive controls showing significant stimulation in previous experiments. 
The failure of the one-way MLR in 2% (v/v) mouse serum could be attributed to 




inhibitory factor(s) which could be present in the serum. Previous results on serum 
titration had shown that Con-A stimulation was significantly inhibited at 5 % (v/v) 
and above of mouse serum. These factors could be inhibitory by blocking antigen 
presentation to responder cells. Since Con-A controls were positive; this could be 
because mitogens use different stimulatory pathways to protein antigens. There are 
currently no studies in the literature over the past two decades that have evaluated the 
mechanism(s) behind mouse serum based immunosuppression. Only a few early 
studies in the 1970s and 1980s have reported similar problems with mouse serum in 
MLR (Veit & Michael, 1973). Several unknown factors thought to be 
immunoglobulin molecules such as the 7S antibodies (Chalon et al., 1979), 
gangliosides and all lipoproteins including low and intermediate and high density 
lipoproteins have been implicated as possible inhibitors (Hsu et al., 1981; Hsu et al., 
1982; Marcus, 1984). The mechanism of lipoprotein-mediated immunosuppression 
has been thought to be as a result of the lipoprotein binding to lipoprotein receptors 
on T-lymphocytes. It has been shown that more than 70 % of the lipoproteins in 
mouse serum are high density lipoproteins (Hsu et al., 1982) whereas in other species 
such as bovine and human the lipoprotein content is different. This could potentially 
explain why mouse serum suppressed lymphocyte proliferation whereas FCS did not. 
It remains unknown however, by which mechanism these factors suppress 
lymphocyte proliferation in vitro. Based on the evidence obtained in this study, it is 
possible to speculate that these factors are more potent against antigenic than non-
specific mitogenic stimulation. Therefore, 10 % (v/v) FCS medium supplementation 
was used in subsequent assays. 
In summary, the following conditions were deemed most appropriate for carrying out 
LTA and one-way MLR using the 
3
H-thymidine uptake assay; 10 g.ml-1 Con-A as a 
positive control for lymphocyte stimulation, 10 g.ml-1 of mitomycin C for achieving 
mitotic inactivation in stimulator cells, medium changes every 3 days for long term 
MLR and LTA cultures up to 15 days, and responder to stimulator cell ratio of 1:1 
with a total cells number of 1 x 10
5
 cells in culture These conditions were used in 
subsequent LTA and one-way MLR involving MSC and DF which are discussed in 
Chapter 5 and chondrogenic differentiated MSC and DF in Chapter 6. 




5. CHAPTER FIVE: INVESTIGATION OF THE 
IMMUNOMODULATORY ACTIVITY AND 
IMMUNOGENICITY OF UNDIFFERENTIATED AND 
CHONDROGENIC DIFFERENTIATED ALLOGENEIC 
MOUSE MSC AND DF 
5.1. Introduction 
The last decade has seen a surge in studies investigating the immunological status of 
allogeneic MSC in light of their potential application in tissue engineering and 
regenerative medicine. MSC, in addition to possessing immunosuppressive 
properties, have also been reported to be immunoprivileged and capable of evading 
detection by the host immune system when transplanted into an allogeneic host 
(Bartholomew et al., 2002; Di Nicola et al., 2002; Tse et al., 2003; Le Blanc et al., 
2003c).  
The ability to differentiate into new distinct cell types makes MSC and their 
differentiated products attractive for clinical use in the repair, regeneration and 
replacement of diseased or damaged tissues. Practically, allogeneic MSC would be 
more useful since cells from a single donor could be infinitely expanded, used to 
make ―off-the-shelf‖ tissue engineered products or individually tailored as therapies 
for multiple patients. This ―universal donor‖ concept though attractive is limited by 
immunological mismatches between donor MSC and the recipient‘s immune system. 
Studies using different animal models including mice have found that allogeneic 
MSC were rejected by hosts and therefore could not be described as intrinsically 
immunoprivileged (Nauta et al., 2006; Sudres et al., 2006; Poncelet et al., 2007). 
Thus to date, the immunological status of MSC remains largely unresolved.  
As discussed extensively in Chapter 1, donor allogeneic cells expressing surface 
MHC class I and class II molecules and co-stimulatory molecules can present foreign 
antigens directly to recipient‘s T-lymphocytes via the direct pathway or indirectly by 
cross presentation of foreign antigens by the host professional APC via the indirect 
or semi-direct pathways of allorecognition to elicit a lymphocyte proliferative 
response. The reported immunosuppressive and immunoprivilege properties of MSC 




are widely thought to be in part a result of their phenotype, which is characterised by 
low expression of MHC I and absence of cell surface MHC II and the co-stimulatory 
molecules CD40, CD80 and CD86. This phenotype has been thought to be 
responsible for the inability of MSC to elicit a proliferative response when co-
cultured with allogeneic lymphocytes (Di Nicola et al., 2002; Tse et al., 2003; 
Eliopoulos et al., 2005). Thus on account of this phenotype, it is conceivable that 
allogeneic MSC failed to stimulate responder T-lymphocytes in vitro via the direct 
pathway but theoretically, it is probable that they will have the capacity to stimulate 
proliferative responses via the indirect or semi-direct pathways in cultures involving 
unseparated mononuclear cells containing APC.  
A review of the literature showed that various adaptations of the MLR and LTA have 
been routinely used in assessing the immunological properties of allogeneic MSC 
using both human cells and animal models. The MLR can be setup as either one-way 
or two-way, the former involving co-culture of genetically distinct responder 
lymphocytes and mitotically inactivated stimulator lymphocytes and the latter 
involving the co-culture of untreated (mitotically active) allogeneic lymphocytes. In 
the one-way MLR, the ability of the responder lymphocytes to respond to the 
allogeneic stimulator lymphocytes is measured by the proliferative response of the 
responder lymphocytes. In the two-way MLR however, the mismatched lymphocytes 
are both capable of initiating a proliferative response against each other. Mitotically 
inactivated MSC can be added at the beginning or at different stages of ongoing 
MLR cultures in order to assess their immunomodulatory properties based on how 
they affect the course of a MLR.  
The LTA involves the co-culture of responder lymphocytes with mitotically 
inactivated cells (not lymphocytes) which act as stimulator cells, or other stimulatory 
agents such as antigens or mitogens. In the case of MSC studies, mitotically 
inactivated allogeneic MSC are used as stimulator cells. Taken together, these 
adaptations of the MLR and LTA provide a simple approach to determine whether 
allogeneic MSC are capable of suppressing responder cell proliferative response 
(immunomodulation) or inducing a proliferative response (or not) in the responding 
lymphocytes (immunogenicity). These assays and their adaptations have provided 
much of the current understanding of the immunological status of MSC as previously 
discussed. 




The majority of studies that have suggested that allogeneic MSC are 
immunoprivileged and immunosuppressive tested mouse MSC in LTA and MLR for 
3 to 5 days in vitro (Glennie et al., 2005; Sudres et al., 2006; Han et al., 2010). When 
tested in vivo after longer periods however, allogeneic MSC were found to be 
immunogenic (Nauta et al., 2006; Han et al., 2010). It was hypothesized that the 5 
day period generally used for LTA may not have been sufficient to capture the semi-
direct and indirect pathways. Thus, extending the incubation period of the MLR and 
LTA could give further insights into the long term immunomodulatory properties of 
allogeneic MSC.  
The claim by some studies in the literature that allogeneic MSC are 
immunoprivileged makes them a particularly suitable cell source for tissue 
engineering applications. In these applications, MSC may be used in their 
differentiated state. Given that the immunogenicity of undifferentiated MSC is 
currently controversial, it is also important to investigate whether differentiated MSC 
are immunogenic. Equally, it is also essential to investigate whether MSC lose or 
retain their immunosuppressive properties following differentiation into a specific 
lineage. Therefore, part of the work in this chapter was aimed at investigating the 
immunosuppressive properties and immunogenicity of allogeneic MSC differentiated 
into chondrocytes. This is particularly important in cartilage tissue engineering 
applications using allogeneic MSC. 
Tissue engineering aims to provide viable and functional biological products that can 
replace native tissues lost due to disease or injury. Such products should be able to 
provide structural and morphological homogeneity with native tissue but importantly 
should be able to restore the function of the tissue to be replaced. This requirement 
has contributed significantly to the potential role MSC could play in tissue 
engineering. The capacity of MSC to differentiate along the chondrogenic lineage 
offers the potential for living tissues to be engineered ex vivo using allogeneic MSC 
which can then be implanted into patients (Le Blanc, 2006; Nesic et al., 2006).  
The increase in life expectancy in developed countries has been accompanied with an 
increase in musculoskeletal diseases mainly those involving articular cartilage 
degeneration such as osteoarthritis (Kuo et al., 2006). Various approaches have been 
developed for cartilage repair as a measure to delay or prevent the need for total joint 




replacement. Methods such as autologous chondrocyte implantation/transplantation 
and matrix-supported autologous chondrocyte implantation use expanded articular 
chondrocytes (Peterson et al., 2000; Minas, 2001). These methods, though partially 
successful in small defects, are limited in complicated cases involving larger defects 
due to the poor proliferation capacity of chondrocytes and existing patho-
physiological conditions in patients. Poor vascularisation, nerve and lymph supply 
and the inherently limited differentiation capacity of articular chondrocytes limits the 
capacity of damaged cartilage to self-heal (Yuan et al., 2010).  
Methods that utilise autologous MSC to provide a source of chondrocytes for 
cartilage repair may be limited by the patients‘ own conditions which may not favour 
use of autologous cells. Moreover, patients would have to go through two 
procedures; firstly to harvest autologous MSC and secondly to implant the tissue 
engineered product. These limitations have opened new avenues for use of allogeneic 
MSC which would allow tissue engineered products to be manufactured to provide 
ready-made cartilage tissues for repair and replacement and limiting the number of 
operations patients would have to go through to a one step procedure. 
Allogeneic MSC have emerged as potential cells of choice in cartilage tissue 
engineering because of their multi-differentiation capacity and ease by which they 
can undergo chondrogenic differentiation in vitro as was demonstrated in Chapter 3. 
Chondrogenic differentiation of MSC can be carried out in vitro by using cocktails of 
growth factors and chemicals which are known to induce differentiation along the 
chondrogenic lineage such as BMP-2 and TGF1, insulin and selenium (Worster et 
al., 2001; Goessler et al., 2005; Longobardi et al., 2006; Bernardo et al., 2007). 
Mechanical stimulation such as dynamic compression of MSC seeded on biological 
or synthetic three dimensional scaffolds with or without growth factor cocktails has 
also been shown to induce chondrogenic differentiation in bioreactors (Campbell et 
al., 2006; Farrell et al., 2006; Terraciano et al., 2007; McMahon et al., 2008). These 
approaches have demonstrated that tissue resembling cartilage can be produced using 
allogeneic MSC which may be of utility for repair and replacement of large defects. 
However, immune reactivity to allogeneic cells remains the major obstacle for the 
clinical utility of such products. 




The immunological properties of differentiated MSC are largely unknown to date. In 
a study using a rabbit model, MSC differentiated into osteoblasts were reported to 
retain their immunoprivileged and immunosuppressive status in vitro though the 
latter was lost after transplantation (Liu et al., 2006). However, in a rat model using 
MSC differentiated to myocytes for cardiac repair, allogeneic but not syngeneic cells 
were reported to be immunogenic despite the undifferentiated MSC having been 
shown to be non-immunogenic in vitro prior to differentiation. Increased expression 
of MHC II was thought to be one of the possible reasons which could have 
contributed to the loss of their immunoprivilege status (Huang et al., 2010).  
It has been reported that differentiated MSC fail to express MHC II after treatment 
with IFN (Le Blanc et al., 2003b). In another study, chondrogenic but not 
adipogenic or osteogenic differentiated rat allogeneic MSC expressed CD80 and 
CD86 co-stimulatory molecules and activated DC resulting in an eight-fold increase 
in lymphocyte proliferation compared to undifferentiated MSC (Chen et al., 2007). 
This evidence suggested that the differentiation of MSC resulted in loss of their 
immunoprivilege and immunomodulatory properties. It is also widely accepted that 
most MSC cultures are heterogeneous due to loss of differentiation potency as a 
result of ageing (Crisostomo et al., 2006; Izadpanah et al., 2008; Kretlow et al., 
2008; Roobrouck et al., 2008; Liu et al., 2012). This often results in some fraction of 
MSC failing to undergo differentiation in vitro as was discussed in Section 3.4. 
Therefore, factors such as the efficiency of the differentiation protocols used by 
different researchers could lead to differentiated MSC exhibiting different 
immunological properties. This was demonstrated using a mouse model in a study in 
which differentiated MSC were found to secrete different types and reduced amounts 
of immunomodulatory molecules such as TGF and IL-10 as well as increased MHC 
I expression post differentiation (Liu et al., 2012). These changes could potentially 
alter the immunological properties of differentiated MSC particularly increased 
MHC I expression. 
Taken together, the evidence from the literature indicates that the immunological 
properties of differentiated MSC are as equally controversial as those of 
undifferentiated MSC. Given that it is well understood that the process of 
differentiation brings about physiological, morphological and functional changes, it 




was hypothesized that the immunomodulatory properties of undifferentiated MSC 
would be lost following chondrogenic differentiation. DF, which had previously been 
shown to undergo chondrogenic differentiation, were also tested alongside MSC.  
In Chapter 4, the appropriate conditions for performing MLR and LTA were defined 
as follows; 
 10 g.ml-1 Con-A; positive control for lymphocyte proliferation. 
 10 g.ml-1 mitomycin C; mitotic arrest of stimulator cells. 
 10 % (v/v) FCS; serum supplement for culture medium. 
 Medium replacement every 72 hours of culture (100 l replaced by fresh 100 
l in a total culture volume of 200 l per well). 
 Responder to stimulator cells ratio of 1:1 in MLR and LTA with a 1 x 105 
total cells. 
Both Balb/c and C3H MSC (p5-6) were incorporated in one-way and two-way MLR 
and LTA and cultured for 3, 6, 9, 12 and 15 days. Cell proliferation was measured by 
incorporation of low activity 
3
H-thymidine. DF from both Balb/c and C3H mice were 
used as controls for cells of mesenchymal origin. Chondrogenic differentiated MSC 
and DF were also tested using one-way MLR and LTA in order to determine their 
immunomodulatory properties and immunogenicity. 
5.1.1. Aims and Objectives 
The aim of this part of the experimental study was to investigate the immunological 
properties namely;  
i. immunomodulation 
ii. immunogenicity  
of undifferentiated and chondrogenic differentiated MSC using an allogeneic mouse 
model with two genetically distinct mouse strains Balb/c (H2-d) and C3H (H2-k) as 
responder and stimulator respectively. Immunomodulation was assessed using 
adaptations of the one-way and two-way MLR in which MSC were added at the 
beginning of the culture. Immunogenicity was assessed using LTA with mitotically 
inactivated allogeneic (C3H) and syngeneic (Balb/c) MSC used as stimulators 
against Balb/c mononuclear cells. Both MLR and LTA were assessed over a 15 day 




period. DF were also analysed in the same way as a control. This would determine 
whether the immunomodulatory properties of MSC were a unique feature of stem 
cells or a common property shared by other stromal cells of mesenchymal origin. 
Specific objectives were; 
1. To investigate the effects of mitotically inactivated C3H (allogeneic) and 
Balb/c (syngeneic) undifferentiated and chondrogenic differentiated MSC and 
DF in one-way and two-way MLR. 
2. To investigate the capacity of mitotically inactivated C3H (allogeneic) and 
Balb/c (syngeneic) undifferentiated and chondrogenic differentiated MSC and 
DF to stimulate Balb/c mononuclear cells in LTA. 
3. To determine the effects of increasing stimulator cell ratio (MSC or DF) on 
one-way MLR and LTA. 
4. To compare the suitability of using U or V well plates for LTA using MSC as 
stimulator cells. 



















5.2. Material and Methods 
5.2.1. Reagents 
The following reagents were used and were prepared as described in Section 2.2.2 
unless stated otherwise. 
 Alcian blue stain solution 1% (w/v) in acetic acid 
 Balb/c serum 
 Chondrogenic differentiation medium for DF (described in Section 3.2.5.2.2) 
 Chondrogenic differentiation medium for MSC (described in Section 
3.2.5.2.2) 
 Collagenase; 0.01 % (v/v) 
 Con-A stock solution (1 mg.ml-1) 
 DMEM-HG culture medium 
 DMEM-LG culture medium 
 Hy-Q-Tase™ cell dissociation solution 
 Low activity 3H-thymidine working solution (25 Ci.ml-1)   
 Lymphocyte culture medium 
 Lymphocyte transport medium 
 Methanol; 100 %  
 Microscint-20 scintillation fluid  
 Mitomycin C stock solution (1 mg.ml-1) 
 PBS  
 Saline solution (0.85 % w/v)  
 TCA; 10 % (w/v)  
 Trypsin-EDTA solution; 0.5 % (v/v) 
5.2.2. Effects of allogeneic and syngeneic MSC on one-way and two-
way MLR and LTA 
5.2.2.1. Preparation of responder Balb/c mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes from Balb/c mice as 
described in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). 
The cells (1.65 x 10
7
) were suspended in 16.5 ml of lymphocyte culture medium.  




5.2.2.2. Preparation of stimulator C3H mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes of C3H mice as 
described in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). 
The cells (1.2 x 10
7
) were suspended in 12 ml of lymphocyte culture medium and 
divided into two groups. One group of 6 x 10
6
 cells in 6 ml of lymphocyte culture 
medium was left untreated whilst the remainder of the cells were mitotically 
inactivated by treatment with 10 g.ml-1 mitomycin C as described in Section 2.2.15. 
The cells were then counted by the Trypan blue method described in Section 2.2.9 
and resuspended at 6 x 10
6
 cells in 6 ml of fresh lymphocyte culture medium. 
5.2.2.3. Preparation of Balb/c and C3H MSC 
Balb/c and C3H MSC (p5) were resurrected as described in Section 2.2.10 and 
maintained in DMEM-LG culture medium in 125 cm
2
 tissue culture flasks until they 
reached 80-90 % confluence as described in Section 2.2.5. The cells were then 
detached using Hy-Q-Tase™ cell dissociation solution as described in Section 2.2.6 
and counted by the Trypan blue method described in Section 2.2.8. The cells were 
then suspended at 9 x 10
6
 cells in 9 ml of lymphocyte culture medium. In separate 
test-tubes, both Balb//c and C3H MSC were divided into two groups of untreated and 
treated cells. For the untreated cells, 3 x 10
6
 cells were resuspended in 3 ml of 
lymphocyte culture medium. The remaining cells (treated group) were centrifuged at 
180 g for 10 minutes and the resulting cell pellets were resuspended in 10 ml of 
lymphocyte culture medium containing 10 g.ml-1 of mitomycin C for mitotic 
inactivation as described in Section 2.2.15. After washing, the cells were then 
counted by the Trypan blue method described in Section 2.2.9 and resuspended at 6 
x 10
6
 cells in 6 ml of fresh lymphocyte culture medium. 
5.2.2.4. Cell plating  
The experiments (one-way MLR, two-way MLR and LTA) were set up in uncoated 
U-bottom 96-well plates at the same time in replicates of six as shown in Figure 5.1. 
The controls were set up in triplicates on separate plates as shown in Figure 5.2.  
5.2.2.4.1. One-way MLR 
For the one-way MLR, responder Balb/c and mitomycin C treated stimulator C3H 
mononuclear cells were co-cultured by seeding 50 l containing 5 x 104 cells of each 




cell type per well. The wells were made up to a total of 200 l by adding 100 l of 
lymphocyte culture medium. To investigate the effects of allogeneic MSC on the 
one-way MLR, mitomycin C treated C3H MSC were added to one-way MLR at 1 x 
10
5
 cells in 50 l of lymphocyte culture medium per well. Similarly, to investigate 
the effects of syngeneic MSC on the one-way MLR, mitomycin C treated Balb/c 
MSC were added to one-way MLR at 5 x 10
4
 cells in 50 l of lymphocyte culture 
medium per well. The final responder to stimulator to MSC ratio was 1:1:1 and the 
total volume in each well made up to 200 l by adding 50 l of fresh lymphocyte 
culture medium. 
5.2.2.4.2. Two-way MLR 
For the two-way MLR, untreated Balb/c and C3H mononuclear cells were co-
cultured by mixing 50 l containing 5 x 104 cells of each per well. The wells were 
made up to a total of 200 l by adding 100 l of lymphocyte culture medium. To 
investigate the effects of MSC on two-way MLR, mitomycin C treated Balb/c or 
C3H MSC were co-cultured with two-way MLR by adding 50 l containing 5 x 104 
cells per well. The final responder to stimulator to MSC ratio was 1:1:1 and the total 
volume in each well made up to 200 l by adding 50 l of fresh lymphocyte culture 
medium. 
5.2.2.4.3. LTA 
To investigate the immunogenicity of MSC, responder Balb/c mononuclear cells (5 x 
10
4
 cells in 50 l per well) were co-cultured with mitomycin C treated or untreated 
Balb/c (syngeneic) or C3H (allogeneic) MSC (5 x 10
4
 cells in 50 l per well) at a 1:1 
cell ratio. Lymphocyte culture medium (100 l) was added into each well to give a 









Figure 5.1. Schematic diagram showing the 96-well plate plan for the investigation of 
the effects of allogeneic and syngeneic MSC on one-way MLR, two-way MLR and LTA 
as measured by 
3
H-thymidine uptake. The numbers above the plate correspond to the cell 
composition shown in the key. The cells in red were treated with 10 g.ml-1 of mitomycin C 
for mitotic inactivation. All cells were seeded at 5 x 10
4
 per well at 1:1:1 (MLR) and 1:1 
(LTA) ratios in replicates of 6. Samples 6, 7 (allogeneic), 8 (syngeneic) represented the one-
way MLR; samples 1, 9 and 10 represented the two-way MLR; samples 2, 3 (allogeneic) and 




All the controls were set up by seeding 50 l containing 5 x 104 cells of each cell 
type per well in triplicates. A further 150 l of lymphocyte culture medium was 
added in each well to give a total culture volume of 200 l. Cells were either left 
unstimulated or stimulated by 10 g.ml-1 of Con-A. Unstimulated cells were negative 
controls for cell proliferation whereas Con-A stimulated cells tested for the 
proliferative capacity of the cells in the presence of stimulation. Balb/c mononuclear 
cells tested the proliferative response of the responder cells for both the one-way and 
two-way MLR and the LTA. Untreated C3H mononuclear cells tested the 
proliferative capacity of the cells and were controls for the two-way MLR. 
Mitomycin C treated C3H mononuclear cells tested mitotic inactivation of the 
stimulator cells in one-way MLR. Mitomycin C treated Balb/c and C3H MSC tested 
mitotic inactivation of MSC and were controls for the one-way and two-way MLR 
and the LTA. Untreated and Con-A stimulated Balb/c and C3H MSC tested the 
proliferative potential of MSC and were controls for the LTA. 





Figure 5.2. Diagram showing the 96-well plate plan for positive (Con-A stimulated) and 
negative (unstimulated) controls for the one-way MLR, two-way MLR and LTA. The 
numbers above the plate correspond to the cell composition shown in the key. The cells in 
red were treated with 10 g.ml-1 of mitomycin C for mitotic inactivation. All cells were 
seeded at 5 x 10
4
 per well in triplicates. Shaded wells represented Con-A stimulated cells 
while clear wells represented unstimulated cells. Outer wells (grey) were filled with PBS to 
minimise evaporation. 
 
5.2.2.5. Incubation, harvesting and analysis 
The seeded plates were incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 3, 6, 9, 12 and 15 days with medium replaced 
every 3 days (100 l replaced with fresh culture medium) as described in Section 
4.2.3. Sixteen hours before completion of each time point, each well was spiked with 
10 l of 25 Ci.ml-1 of low activity 3H-thymidine as described in Section 2.2.12, 
harvested onto glass fibre filter plates and radioactivity counts read using a 
TopCount NXT scintillation counter as described in Section 2.2.13. 
 
5.2.3. Effects of allogeneic and syngeneic DF on one-way and two-
way MLR and LTA 
This experiment was carried out as described in Section 5.2.2 with Balb/c and C3H 
(p5) DF replacing MSC in one-way MLR, two-way MLR and LTA.  




5.2.3.1. Preparation of responder Balb/c mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes as described in 
Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). The 
mononuclear cells (1.65 x 10
7
) were suspended in 16.5 ml of lymphocyte culture 
medium.  
5.2.3.2. Preparation of stimulator C3H mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes as described in 
Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). The cells 
(1.2 x 10
7
) were suspended in 12 ml of lymphocyte culture medium and divided into 
two groups. One group of 6 x 10
6
 cells in 6 ml of lymphocyte culture medium was 
left untreated whilst the remainder of the cells were treated with mitomycin C as 
described in Section 2.2.15 and then counted by the Trypan blue method described in 
Section 2.2.9 and resuspended at 6 x 10
6
 cells in 6 ml of fresh lymphocyte culture 
medium. 
5.2.3.3. Preparation of Balb/c and C3H DF 
Balb/c and C3H DF (p5) were resurrected as described in Section 2.2.10 and 
maintained in DMEM-HG culture medium in 125 cm
2
 tissue culture flasks until they 
reached 80-90 % confluence as described in Section 2.2.5. The cells were then 
detached using 0.5 % (v/v) trypsin-EDTA solution as described in Section 2.2.6, 
counted by the Trypan blue method described in Section 2.2.8 and then resuspended 
at 9 x 10
6
 cells in 9 ml of lymphocyte culture medium respectively. In separate test-
tubes, the cells were divided into untreated and mitomycin C treated groups. For the 
untreated groups, 3 x 10
6
 cells were resuspended in 3 ml of lymphocyte culture 
medium. Cells from the treated group were treated with mitomycin C as described in 
Section 2.2.15. The cells were counted by the Trypan blue method described in 
Section 2.2.9 and resuspended at 6 x 10
6
 cells in 6 ml of fresh lymphocyte culture 
medium. 
5.2.3.4. Cell plating  
The experiments were set up in uncoated U-bottom 96-well plates as described in 
Section 5.2.2.4. The experiments (one-way MLR, two-way MLR and LTA) were set 
up at the same time in replicates of six as shown in Figure 5.3. The controls were set 




up in triplicates on separate plates shown in Figure 5.4. Cell numbers and seeding 
volumes used for plating in Section 5.2.2.4 were used in this experiment. 
5.2.3.4.1. One-way MLR 
To investigate the effects of DF on one-way MLR, mitomycin C treated Balb/c and 
C3H DF were co-cultured with one-way MLR as described in Section 5.2.2.4.1. 
5.2.3.4.2. Two-way MLR 
To investigate the effects of DF on two-way MLR, mitomycin C treated Balb/c and 
C3H DF were co-cultured with two-way MLR as described in Section 5.2.2.4.2. 
5.2.3.4.3. LTA 
To investigate the immunogenicity of DF, responder Balb/c mononuclear cells (5 x 
10
4
 cells in 50 l per well) were co-cultured with mitomycin C treated or untreated 
Balb/c (syngeneic) and C3H (allogeneic) DF (stimulators) as described in Section 
5.2.2.4.3.  
 
Figure 5.3. Diagram showing the 96-well plate plan for the investigation of the effects of 
allogeneic and syngeneic DF on one-way MLR, two-way-MLR and LTA as measured 
by 
3
H-thymidine uptake. The numbers above the plate correspond to the cell composition 
shown in the key. The cells in red were treated with 10 g.ml-1 of mitomycin C for mitotic 
inactivation. All cells were seeded at 5 x 10
4
 per well at 1:1:1 (MLR) and 1:1 (LTA) ratios in 
replicates of 6. Samples 6, 7 (allogeneic), 8 (syngeneic) represented the one-way MLR, 
samples 1, 9, 10 represented the two-way MLR and samples 2, 3 (allogeneic), 4, 5 
(syngeneic) represented the LTA. Outer wells (grey) were filled with PBS to minimise 
evaporation. 
 





All the controls were set up by seeding 5 x 10
4
 cells in 50 l per well as described in 
Section 5.2.2.4.4. A further 150 l of lymphocyte culture medium was added in each 
well to give a total culture volume of 200 l. Cells were either left unstimulated or  
stimulated by 10 g.ml-1 Con-A in triplicates.  
 
Figure 5.4. Diagram showing the 96-well plate plan for positive (Con-A stimulated) and 
negative (unstimulated) controls for the one-way MLR, two-way MLR and LTA. The 
numbers above the plate correspond to the cell composition shown in the key. The cells in 
red were treated with 10 g.ml-1 of mitomycin C for mitotic inactivation. All cells were 
seeded at 5 x 10
4
 per well in triplicates. Shaded wells represented Con-A stimulated cells 
while clear wells represented unstimulated cells. Outer wells (grey) were filled with PBS to 
minimise evaporation. 
5.2.3.5. Incubation, harvesting and analysis 
The cells were incubated, harvested and analysed as described in Section 5.2.2.5. 
 
5.2.4. Effect of increasing stimulator cell numbers on the 
immunogenicity of allogeneic MSC and DF 
This experiment was carried out to investigate the effects of increasing stimulator 
cell numbers (allogeneic and syngeneic MSC and DF) in LTA with Balb/c 
mononuclear cells as responders.  




5.2.4.1. Preparation of Balb/c responder mononuclear cells 
Balb/c mononuclear cells were isolated from spleens and lymph nodes as described 
in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). The 
mononuclear cells (2.55 x 10
7
) were suspended in 25.5 ml of lymphocyte culture 
medium.  
5.2.4.2. Preparation of C3H stimulator mononuclear cells 
C3H mononuclear cells were used in the one-way MLR which was a control for 
alloantigen stimulation. Mononuclear cells were isolated and treated with 10 g.ml-1 
of mitomycin C to mitotically arrest them as described in Section 2.2.15. After 
washing, the cells were counted and 1.2 x 10
7
 cells were resuspended in 7.2 ml of 
lymphocyte culture medium. 
5.2.4.3. Preparation of stimulator Balb/c and C3H MSC and DF 
Balb/c and C3H MSC and DF (p5) were separately detached from tissue culture 
flasks and treated with 10 g.ml-1 of mitomycin C as described in Section 2.2.15 and 
Section 5.2.3.3 respectively The cells were counted by the Trypan blue method 
described in Section 2.2.8 and then resuspended at 1.2 x 10
7
 cells in 7.2 ml of 
lymphocyte culture medium in separate tubes. 
5.2.4.4. Cell plating 
The experiment was set up in uncoated U-bottom 96-well plates. Two plates were 
used for each time point. One plate was for the LTA at responder to stimulator ratio 
of 1:1 in replicates of six and the other plate was for LTA involving responder to 
stimulator cell ratios of 1:2, 1:3, 1:4 and 1:5 in triplicates. 
5.2.4.4.1. Control plate 
Responder Balb/c mononuclear cells seeded at 5 x 10
4
 cells in 50 l per well were 
co-cultured with 5 x 10
4
 cells in 30 l of either Balb/c MSC, Balb/c DF, C3H 
mononuclear cells, C3H MSC or C3H DF giving a responder to stimulator ratio of 
1:1 as shown in Figure 5.5. Each well was made up to 200 l by adding 120 l of 
lymphocyte culture medium. Con-A stimulated (10 g.ml-1) Balb/c mononuclear 
cells and the one-way MLR were controls for mitogenic and alloantigen stimulation 
respectively. 





Figure 5.5. Diagram showing the 96-well plate plan for LTA for Balb/c mononuclear 
cells stimulated by allogeneic and syngeneic MSC and DF. Balb/c mononuclear cells 
(responders) were seeded at 5 x 10
4
 cells per well were co-cultured with an equal number of 
mitotically inactivated C3H (allogeneic) MSC or DF and Balb/c (syngeneic) MSC or DF in 
replicates of six. The numbers above the plate correspond to the cell composition shown in 
the key. Balb/c cells only (1) were a control for unstimulated cells while Con-A stimulated 
Balb/c cells (2) were a control for proliferating cells. The cells in red were treated with 10 
g.ml-1 of mitomycin C for mitotic inactivation. The cells were cultured for 3, 6, 9, 12 and 
15 days and cell proliferation was determined by the 
3
H-thymidine uptake assay. Outer wells 
(grey) were filled with PBS to minimise evaporation. 
 
5.2.4.4.2. LTA with increasing stimulator cell ratio 
Balb/c mononuclear cells were seeded at 5 x 10
4
 cells in 50 l per well and co-
cultured with increasing numbers of stimulator cells as shown in Figure 5.6. 
Stimulator cells were seeded at 1 x 10
5
 cells in 60 l, 1.5 x 105 cells in 90 l, 2 x 105 
cells in 120 l and 2.5 x 105 cells in 150 l to give final responder to stimulator cell 
ratios of 1:2, 1:3, 1:4 and 1:5 respectively. The wells were made up to a final volume 
of 200 l by adding lymphocyte culture medium. 





Figure 5.6. Diagram showing the 96-well plate plan for LTA for Balb/c mononuclear 
cells stimulated by increasing numbers of allogeneic and syngeneic MSC and DF 
stimulator cells. Balb/c mononuclear cells (responder) were seeded at 5 x 10
4
 cells per well 
were co-cultured with increasing numbers of mitotically inactivated C3H (allogeneic) MSC 
or DF and Balb/c (syngeneic) MSC or DF to give responder to stimulator cell ratios of 1:2, 
1:3, 1:4 and 1:5 in triplicate wells. The numbers above the plate correspond to the cell 
composition shown in the key. Samples 1 and 2 were one-way MLR which were controls for 
allogeneic stimulation of responder cells. The cells in red were treated with 10 g.ml-1 of 
mitomycin C for mitotic inactivation. The cells were cultured for 3, 6, 9, 12 and 15 days and 
cell proliferation was determined by the 
3
H-thymidine uptake assay. Outer wells (grey) were 
filled with PBS to minimise evaporation. 
5.2.4.5. Incubation, harvesting and analysis 
The seeded plates were incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 3, 6, 9, 12 and 15 days with medium 
replacement, harvested and analysed as described in Section 5.2.2.5.  
 
5.2.5. Comparison between U-bottom and V-bottom plates on one-
way MLR and LTA using allogeneic and syngeneic MSC and DF 
This experiment was carried out to compare between U-bottom and V-bottom plates 
in order to determine whether well shape influenced the extent of one-way MLR and 
LTA involving syngeneic and allogeneic MSC and DF. 




5.2.5.1. Preparation of Balb/c responder mononuclear cells 
Balb/c mononuclear cells were isolated from spleens and lymph nodes as described 
in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). The 
mononuclear cells (3.3 x 10
7
) were suspended in 33 ml of lymphocyte culture 
medium.  
5.2.5.2. Preparation of stimulator cells 
Balb/c and C3H MSC and DF and C3H mononuclear cells were treated with 10 
g.ml-1 of mitomycin C to mitotically arrest them as described in Section 2.2.15. 
After washing, the cells were counted and resuspended in lymphocyte culture 
medium at 1.5 x 10
7
 cells in 15 ml respectively. 
5.2.5.3. Cell plating 
The experiment was set up in uncoated U-bottom and V-bottom 96-well plates. Two 
plates were used for each time point. Responder and stimulator cells were seeded at 
1:1 ratio for LTA and 1:1:1 for one-way MLR in replicates of six. The LTA and one-
way MLR were set up on the same plate as shown in Figure 5.7. 
5.2.5.3.1. One-way MLR 
One-way MLR involving mitomycin C treated syngeneic and allogeneic MSC or DF 
were set up by co-culturing 5 x 10
4
 cells in 50 l each of Balb/c and mitomycin C 
treated C3H mononuclear cells with both allogeneic and syngeneic MSC or DF. The 
total culture volume in each well was made up to 200 l as described in Section 
5.2.2.4.1. The one-way MLR without MSC or DF was set up as a control for 
allogeneic stimulation of responder cells. 
5.2.5.3.2. LTA 
Balb/c responder mononuclear cells were co-cultured with mitomycin C treated 
syngeneic and allogeneic stimulator MSC or DF by mixing 50 l of each containing 
5 x 10
4
 cells per well as described in Section 5.2.2.4.3. 
5.2.5.3.3. Controls 
Balb/c mononuclear cells (5 x 10
4
 cells per well) cultured alone or stimulated with 10 
g.ml-1 Con-A were used as controls for non-proliferating and proliferating 




responder cells respectively as described in Section 5.2.2.4.4. The one-way MLR 
was used as a control for antigenic stimulation for responder cells.  
 
Figure 5.7. Diagram showing the 96-well plate plan for the investigation of the effects of 
allogeneic and syngeneic MSC and DF on one-way MLR and LTA cultured in U-
bottom and V-bottom uncoated plates. Balb/c mononuclear cells (responders) were seeded 
at 5 x 10
4
 cells per well and co-cultured with equal cell numbers of mitotically inactivated 
allogeneic C3H mononuclear cells, MSC or DF and syngeneic Balb/c MSC or DF to give 
responder to stimulator cell ratios of 1:1:1 (one-way MLR) and 1:1 (LTA) in replicates of 
six. The numbers above the plate correspond to the cell composition shown in the key. The 
cells in red were mitotically inactivated. Balb/c mononuclear cells only (1) were a control for 
unstimulated responder cells while allogeneic mononuclear cells (10) and mitogen (11) 
stimulated cells acted as controls for proliferating responder cells. Grey wells were filled 
with PBS to minimise evaporation. 
5.2.5.4. Incubation, harvesting and analysis 
The seeded plates were incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 3, 6, 9, 12 and 15 days. The cells were then 
harvested and analysed as described in Section 5.2.2.5. 
 
5.2.6. Effect of Balb/c serum on one-way MLR and LTA involving 
syngeneic and allogeneic MSC and DF 
This experiment was carried out to investigate the effects of Balb/c (syngeneic) 
serum on one-way MLR and LTA using Balb/c mononuclear cells as responders to 
syngeneic and allogeneic MSC and DF. 




5.2.6.1. Preparation of Balb/c serum 
Balb/c blood was obtained by cardiac puncture of mice sacrificed according to 
Schedule 1 procedures described in Section 2.2.4 (procedure carried out by Professor 
Eileen Ingham). The blood was collected in sterile tubes (without anticoagulant) and 
left to stand for one hour to allow clot formation. The clot was carefully removed and 
the uncoagulated fraction was centrifuged at 1500 g at 20 ºC for 10 minutes. The 
serum was collected as the supernatant and immediately heat treated to inactivate 
complement by holding the serum in a water-bath at 56 ºC for one hour with gentle 
swirling every 5 minutes to ensure the serum was evenly heated. The serum was used 
to supplement lymphocyte culture medium at a concentration of 2 % (v/v).  
5.2.6.2. Preparation of Balb/c responder mononuclear cells 
Balb/c mononuclear cells were isolated from spleens and lymph nodes as described 
in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). The 
mononuclear cells (1.65 x 10
7
) were suspended in 16.5 ml of lymphocyte culture 
medium supplemented with 2 % (v/v) Balb/c serum. 
5.2.6.3. Preparation of stimulator cells 
Balb/c and C3H MSC and DF and C3H mononuclear cells were treated with 10 
g.ml-1 of mitomycin C to mitotically inactivate them as described in Section 2.2.15. 
After washing, the Balb/c and C3H MSC and DF were counted and resuspended in 
lymphocyte culture medium supplemented with 2 % (v/v) Balb/c serum at 3 x 10
6
 
cells in 3 ml respectively. C3H mononuclear cells were resuspended at 7.5 x 10
6
 cells 
in 7.5 ml of culture medium. 
5.2.6.4. Cell plating 
The experiment was set up in uncoated U-bottom 96-well plates. Responder and 
stimulator cells were seeded at 1:1 ratio in LTA and 1:1:1 in one-way MLR in 
replicates of six as shown in Figure 5.8.  
5.2.6.4.1. One-way MLR 
One-way MLR involving mitomycin C treated syngeneic or allogeneic MSC or DF 
were set up according to the plan described in Section 5.2.5.3.1. 





Balb/c responder mononuclear cells were co-cultured with mitomycin C treated 
syngeneic or allogeneic stimulator MSC and DF by mixing 50 l of each containing 
5 x 10
4
 cells per well as described in Section 5.2.2.4.3.  
5.2.6.4.3. Controls 
Balb/c mononuclear cells (5 x 10
4
 cells per well) cultured alone or stimulated with 10 
g.ml-1 Con-A were used as controls for non-proliferating and proliferating 
responder cells respectively as described in Section 5.2.2.4.4.  
 
Figure 5.8. Diagram showing the 96-well plate plan for the investigation of the effects of 
allogeneic and syngeneic MSC and DF on one-way MLR and LTA cultured in medium 
supplemented with 2 % (v/v) Balb/c serum. Balb/c mononuclear cells (responders) were 
seeded at 5 x 10
4
 cells per well and co-cultured with equal cell numbers of mitotically 
inactivated C3H mononuclear cells, MSC or DF and Balb/c MSC or DF to give responder to 
stimulator cell ratios of 1:1:1 (one-way MLR) and 1:1 (LTA) in replicates of six. The 
numbers above the plate correspond to the cell composition shown in the key. Balb/c 
mononuclear cells only (1) were a control for unstimulated responder cells while antigen 
(10) and mitogen (11) stimulated cells acted as controls for mitogen and alloantigen 
stimulated proliferating responder cells. Grey wells were filled with PBS to minimise 
evaporation. 
5.2.6.5. Incubation, harvesting and analysis 
The seeded plates were incubated harvested and analysed as described in Section 
5.2.2.5. 




5.2.7. Chondrogenic differentiation of Balb/c and C3H MSC and 
DF 
Balb/c and C3H MSC (p5) and DF (p5) were resurrected as described in Section 
2.2.10 and maintained in DMEM-LG and DMEM-HG culture medium respectively 
in 125 cm
2
 tissue culture flasks until they reached 80-90 % confluence as described 
in Section 2.2.5. The MSC and DF were then detached using Hy-Q-Tase™ cell 
dissociation solution and 0.5 % (v/v) trypsin-EDTA solution respectively as 
described in Section 2.2.6 after which the cells were washed by centrifuging at 180  
g for 10 minutes. The resulting pellets for each cell type were resuspended in 10 ml 
of the appropriate chondrogenic differentiation medium, counted by the Trypan blue 
method described in Section 2.2.8 and adjusted to 1 x 10
7
 cells in 10 ml of 
chondrogenic differentiation medium in 50 ml conical tubes. The cells were then 
centrifuged at 200 g for 10 minutes to pellet and the supernatant carefully removed 
without disturbing the cell pellets. Fresh chondrogenic medium (10 ml per conical 
tube) was carefully added without disturbing the cell pellets. The tubes were closed 
loosely to allow aeration and incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air. After each 3 day period, the culture medium was 
replaced by carefully replacing with fresh chondrogenic differentiation medium for 
up to 21 days. 
5.2.7.1. Preparation of chondrogenic differentiated Balb/c and 
C3H MSC and DF for the one-way MLR and LTA 
After completion of the chondrogenic differentiation time course, culture medium 
was carefully removed from the tubes and the differentiated MSC and DF cell pellets 
were washed with PBS to remove remaining medium. In order to dissociate the 
pellets into individual cells, the pellets were treated with 0.01% (v/v) collagenase (2 
ml per pellet) for 15 minutes at 37 °C with regular bashing of tubes against each 
other until there were no visible clumps of cells. The resulting cell suspensions were 
mixed with lymphocyte culture medium (10 ml per tube) and centrifuged thrice at 
180 g for 5 minutes to remove the collagenase. The cells were then mitotically 
inactivated by suspending them in medium containing 10 g.ml-1 of mitomycin C for 
30 minutes at 37 °C in an atmosphere of 5 % (v/v) CO2 in air as described in Section 
2.2.15. The washed cells were counted by the Trypan blue method described in 




Section 2.2.8 and resuspended at 4.5 x 10
6
 cells in 4.5 ml of lymphocyte culture 
medium for each cell type for the one-way MLR and LTA assays. For the Alcian 
blue staining (Section 6.2.4), 3 x 10
5
 cells were resuspended in 30 l of 
chondrogenic differentiation culture medium. 
5.2.7.1.1. Alcian blue staining 
To test whether the MSC and DF had differentiated to chondrocytes, 10 l 
containing 1 x 10
5
 cells was carefully placed at the centre of each well (3 wells for 
each cell type) of a 24-well cell culture plate to create micromass nodules as 
described in Section 3.2.5.2.2. The seeded plates were then incubated at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 3 hours to allow the cells to attach. Each well 
was then flooded with 1 ml of chondrogenic differentiation medium and incubated 
overnight. Afterwards, the medium was removed and the cells were washed twice 
with PBS and fixed with 10% (v/v) formalin and stained with 1 % (w/v) alcian blue 
stain as described in Section 3.2.5.2.2.1. The cells were viewed using an Olympus 
BX 71 inverted microscope and images were captured using Cell^B image 
acquisition software (Olympus). 
5.2.7.2. Preparation of responder Balb/c mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes of Balb/c mice as 
described in Section 2.2.11 and counted by the Trypan blue method (Section 2.2.9). 
The cells (1.65 x 10
7
) were suspended in 16.5 ml of lymphocyte culture medium.  
5.2.7.3. Preparation of stimulator C3H mononuclear cells 
Mononuclear cells were isolated from spleens and lymph nodes of C3H mice as 
described in Section 2.2.11. The cells were centrifuged at 450 g for 10 minutes and 
the resulting cell pellet was resuspended in medium containing 10 g.ml-1 of 
mitomycin C in order to mitotically inactivate them as described in Section 2.2.15. 
The cells were counted by the Trypan blue method described in Section 2.2.8 and 
resuspended at 9 x 10
6
 cells in 9 ml of fresh lymphocyte culture medium. 
5.2.7.4. Cell plating 
The one-way MLR and LTA experiments for each time point were set up in the same 
uncoated V-bottom 96-well plate in replicates of 6 for both chondrogenic 
differentiated MSC and DF as shown in Figure 5.9. Controls were set up in 




triplicates as either unstimulated or Con-A stimulated cells except for stimulated 
Balb/c mononuclear cells which were set up in replicates of 6 as shown in Figure 
5.10.  
5.2.7.4.1. One-way MLR 
For this assay, both Balb/c and C3H chondrocyte differentiated MSC and DF were 
seeded at 5 x 10
4
 cells in 50 l of lymphocyte culture medium per well and incubated 
overnight for 16 hours at 37 °C in an atmosphere of 5 % (v/v) CO2 in air to allow the 
cells to form micro-pellets at the bottom of the wells. Afterwards, 5 x 10
4
 cells in 50 
l of each of responder Balb/c mononuclear cells and mitotically inactivated 
stimulator C3H mononuclear cells were added to the pre-seeded wells. The final 
responder to stimulator to MSC/DF ratio was 1:1:1 and the total volume in each well 
made up to 200 l by adding 50 l of fresh lymphocyte culture medium. 
5.2.7.4.2. LTA 
For this assay, the mitotically inactivated chondrogenic differentiated MSC and DF 
were pre-seeded as described in Section 5.2.7.1 and incubated overnight. Responder 
Balb/c mononuclear cells (5 x 10
4
 cells in 50 l per well) were then added to the pre-
seeded wells to give a 1:1 responder to stimulator cells ratio. The co-cultures were 
made up to a final volume of 200 l by adding a further 100 l of lymphocyte culture 
medium.  
5.2.7.4.3. Controls 
All the controls were set up by seeding 50 l containing 5 x 104 cells of each type per 
well. Triplicate wells for each cell type (except Balb/c mononuclear cells) were 
either left unstimulated or stimulated by treatment with 10 g.ml-1 of Con-A. The 
total culture volume was made up to 200 l by addition of fresh lymphocyte culture 
medium. Unstimulated and Con-A stimulated cells served to test whether mitotically 
inactivated cells were capable of undergoing mitogenic stimulation as a control for 
the mitotic inactivation procedure. Balb/c mononuclear cells stimulated with Con-A 
in replicates of 6 were used as a control for lymphocyte proliferation. 





Figure 5.9. Diagram showing the 96-well plate plan for investigating the effects of 
allogeneic and syngeneic chondrogenic differentiated MSC and DF on one-way MLR 
and LTA as measured by 
3
H-thymidine uptake. The numbers above the plate correspond 
to the cell composition shown in the key. Cells in red were mitotically inactivated using 
mitomycin C treatment (10 g.ml-1). All cells were seeded at 5 x 104 per well at 1:1:1 and 
1:1 ratio for the one-way MLR and LTA respectively in replicates of 6. Samples 2, 7, 8, 9 
and 10 represented the one-way MLR with MSC or DF while samples 3, 4, 5 and 6 
represented the LTA. The outer grey wells were filled with PBS to minimise evaporation. 
 
Figure 5.10. Diagram showing the 96-well plate plan for positive (Con-A stimulated) 
and negative (unstimulated) controls for the one-way MLR and LTA. The numbers 
above the plate correspond to the cell composition shown in the key. Cells in red were 
mitotically inactivated using mitomycin C treatment (10 g.ml-1). Cells were seeded at 5 x 
10
4
 per well in triplicates (except for Balb/c mononuclear cells which were in replicates of 
6). Shaded wells represented Con-A stimulated cells while clear wells were for unstimulated 










1        2         3        4         5         6        7         8         9       10      11      12
1        2        3         4         5         6        7         8        9       10   
KEY
1. Balb/c MNC 
2. Balb/c MNC + C3H MNC  (one-way MLR)
3. Balb/c MNC + Balb/c MSC-Chon
4. Balb/c MNC + C3H MSC-Chon
5. Balb/c MNC + Balb/c Fib-Chon
6. Balb/c MNC + C3H Fib-Chon
7. Balb/c MNC + C3H MNC + Balb/c MSC-Chon
8. Balb/c MNC + C3H MNC + C3H MSC-Chon
9. Balb/c MNC +  C3H MNC + Balb/c Fib-Chon









1        2         3        4         5         6        7         8         9       10      11      12
1        2        3         4         5         6  
KEY
1. Balb/c MNC + Con-A
2. C3H MNC 
C3H MNC + Con-A
3. Balb/c MSC-Chon
Balb/c MSC-Chon + Con-A
4. C3H MSC-Chon
C3H MSC-Chon + Con-A
5. Balb/c Fib-Chon
Balb/c Fib-Chon + Con-A
6. C3H Fib-Chon
C3H Fib-Chon + Con-A




5.2.7.5. Incubation, harvesting and analysis 
The seeded plates were incubated in a humidified incubator at 37 °C in an 
atmosphere of 5 % (v/v) CO2 in air for 3, 6, 9, 12 and 15 days with medium 





























5.3.1. Effects of allogeneic and syngeneic undifferentiated MSC on 
one-way and two-way MLR and LTA 
The immunomodulatory properties of both Balb/c (syngeneic) and C3H (allogeneic) 
undifferentiated MSC were investigated using adaptations of the MLR (one and two-
way) and LTA. Mitotically inactivated MSC were added to co-cultures of Balb/c 
(responder) and mitotically inactivated C3H (stimulator) mononuclear cells in one-
way MLR to determine whether syngeneic (Balb/c) and allogeneic (C3H) MSC had 
any effect on the proliferative response of the responder lymphocytes. In the two-
way MLR, mitotically inactivated MSC were added to co-cultures of Balb/c and C3H 
mononuclear cells to determine whether they had any effect on the proliferative 
response of mixed lymphocytes. LTA were carried out by co-culturing Balb/c 
mononuclear cells with mitotically inactivated Balb/c or C3H MSC to test their 
capacity to stimulate responding lymphocytes (immunogenicity).  
With regard to the control cultures for these experiments, monocultures of 
mitomycin C treated C3H mononuclear cells failed to take up 
3
H-thymidine with or 
without stimulation using Con-A during the 15 day culture period. This non-
proliferation after stimulation indicated mitotic inactivation of the stimulator cells. 
Untreated Balb/c and C3H mononuclear cells were significantly stimulated by Con-
A with peak counts and SI at day 6 (Figure 5.11A-B).  
For the one-way MLR, the results for the control experiment showed that responder 
Balb/c mononuclear cells were notably stimulated by C3H stimulator mononuclear 
cells. 
3
H-thymidine uptake peaked at day 6 with a SI of 40. In one-way MLR co-
cultured with either Balb/c (syngeneic) or C3H (allogeneic) MSC, 
3
H-thymidine 
uptake and SI were significantly (p<0.05) suppressed at day 6 onwards (Figure 
5.11C-D). Suppression of the Balb/c lymphocyte response at day 6 was 
approximately 90 % for both syngeneic and allogeneic MSC. With regard to the two-
way MLR, both Balb/c and C3H MSC significantly suppressed lymphocyte 
proliferation in a similar trend to that observed for the one-way MLR (Figure 5.11E-
F). Day 6 SI showed that lymphocyte proliferation in the two-way MLR was reduced 
by 89 % and 75 % by Balb/c and C3H MSC respectively suggesting that Balb/c MSC 
exhibited marginally higher immunosuppressive potency compared to C3H MSC.  




In LTA, Balb/c and C3H MSC which had and had not been mitotically inactivated 
were used as stimulators in co-cultures with Balb/c mononuclear cells. The results 
showed that C3H MSC (allogeneic), but not Balb/c MSC (syngeneic) stimulated 
Balb/c mononuclear cells (Figure 5.11G-H). Stimulation of the Balb/c mononuclear 
cells with allogeneic MSC (mitotically inactivated and not) was detected at all the 
time points (SI > 3) except at day 15 (SI < 3). 
3
H-thymidine uptake by the Balb/c 
responder cells peaked at day 6 and gradually decreased at subsequent time points. In 
contrast, co-cultures of Balb/c mononuclear MSC with syngeneic MSC produced 
counts comparable to those of Balb/c mononuclear cells cultured alone.  
When taken together, these results showed that both C3H (allogeneic) and Balb/c 
(syngeneic) MSC suppressed one-way MLR. Similar suppression was also shown in 
two-way MLR and demonstrated that mouse MSC, regardless of MHC differences, 
suppressed lymphocyte proliferative responses. In LTA, C3H MSC, but not Balb/c 
MSC, stimulated Balb/c mononuclear cells. Thus, allogeneic, and not syngeneic 









Figure 5.11. Immunomodulation and immunogenicity of C3H (allogeneic) and Balb/c 
(syngeneic) MSC in one-way and two-way MLR and LTA. Mitotically inactivated Balb/c 
and C3H MSC (5 x 10
4
 cells per well) were co-cultured in one-way MLR at a 1:1:1 ratio. For 
the two-way MLR, Balb/c and C3H mononuclear cells were cultured with mitotically 
inactivated Balb/c or C3H MSC at a 1:1:1 ratio. For the LTA, Balb/c mononuclear cells were 
co-cultured with syngeneic or allogeneic MSC which had and had not been mitotically 
inactivated at a 1:1 ratio. Balb/c mononuclear cells cultured alone or stimulated with Con-A 
were controls for non-proliferating and proliferating cells respectively. Culture medium was 
changed every 3 days by replacing 100 l with an equal volume of fresh medium and the 
cells were cultured for 3, 6, 9, 12 and 15 days and lymphocyte proliferation measured by the 
incorporation of 
3
H-thymidine. Data (n=6) was Log10 transformed and analysed by 2-way 
ANOVA followed by calculation of the MSD (p < 0.05) by the T method to determine 
individual differences between group means at each time point. Data was then back-
transformed for presentation and plotted as mean CPM ± 95 % CL and SI for the controls (A 
and B), one-way MLR (C and D), two-way MLR (E and F) and LTA (G and H) respectively. 
Mitotically inactivated cells are highlighted in red. The red line at SI=3 denotes SBP; SI > 3 
were considered significant. 
*
 indicates significant differences in 
3
H-thymidine uptake; (C) 
one-way MLR > one-way MLR + C3H / Balb/c MSC; (E) two-way MLR > two-way MLR + 
C3H / Balb/c MSC; (G) Balb/c MNC + C3H MSC > Balb/c MNC + Balb/c MSC at each 
time point. [MNC; mononuclear cells] 




5.3.2. Effects of allogeneic and syngeneic undifferentiated DF on 
one and two-way MLR and LTA 
Allogeneic (C3H) and syngeneic (Balb/c) DF were also tested for their capacity to 
modulate one-way and two-way MLR and for their capacity to stimulate lymphocyte 
proliferation in LTA. The experiments were set up as previously described in Section 
5.3.1 with DF replacing MSC. As previously mentioned, DF were chosen for 
comparison with MSC because of their mesenchymal origins and provided a test to 
determine whether the immunomodulatory properties demonstrated by MSC in the 
previous section were a unique property of MSC or a feature of other cells of the 
mesenchymal lineage.  
With regard to the controls for cell proliferation, monocultures of Balb/c and C3H 
mononuclear cells stimulated with Con-A showed significant 
3
H-thymidine uptake in 
contrast to unstimulated Balb/c and C3H mononuclear cells, which were controls for 
non-proliferating cells. Highest counts and SI were obtained at day 6 (Figure 5.12A-
B). Unstimulated and Con-A stimulated mitomycin C treated C3H mononuclear cells 
produced low counts comparable to those of the unstimulated cells which showed 
that they were incapable of proliferation.  
In the one-way MLR control, Balb/c mononuclear cells were stimulated by 
mitotically inactivated C3H mononuclear cells with 
3
H-thymidine uptake and SI 
peaking at day 6. When Balb/c (syngeneic) or C3H (allogeneic) DF were co-cultured 
with the one-way MLR, 
3
H-thymidine uptake was suppressed significantly (p<0.05) 
at days 3, 6 and 9 (Figure 5.12C-D). Day 6 control SI was reduced from 28 in the 
control culture to 7 in the co-cultures with either Balb/c or C3H DF, which 
represented a 75 % suppression of the Balb/c lymphocyte allogeneic response. A 
similar trend was observed in the two-way MLR in which approximately 80 % of the 
control response was suppressed by both Balb/c and C3H (Figure 5.12E-F).  
In the LTA in which Balb/c responder mononuclear cells were co-cultured with 
mitomycin C treated or untreated Balb/c and C3H DF, 
3
H-thymidine uptake was low 
and not significantly different to that for Balb/c negative control (unstimulated) 
mononuclear cells. This indicated that both Balb/c and C3H DF failed to stimulate 
Balb/c mononuclear cells with SI below 3 at all the time points (Figure 12G-H). 





Figure 5.12. Immunomodulation and immunogenicity of C3H (allogeneic) and Balb/c 
(syngeneic) DF in one-way and two-way MLR and LTA. Mitotically inactivated Balb/c 
and C3H DF (5 x 10
4
 cells per well) were co-cultured in one-way MLR at a 1:1:1 ratio. For 
the two-way MLR, Balb/c and C3H mononuclear cells were cultured with mitotically 
inactivated Balb/c or C3H DF at a 1:1:1 ratio. For the LTA, Balb/c mononuclear cells were 
co-cultured with syngeneic or allogeneic DF which had and had not been mitotically 
inactivated at a 1:1 ratio. Balb/c mononuclear cells cultured alone or stimulated with Con-A 
were controls for non-proliferating and proliferating cells respectively. Culture medium was 
changed every 3 days by replacing 100 l with an equal volume of fresh medium and the 
cells were cultured for 3, 6, 9, 12 and 15 days and lymphocyte proliferation measured by the 
incorporation of 
3
H-thymidine. Data (n=6) was Log10 transformed and analysed by 2-way 
ANOVA followed by calculation of the MSD (p < 0.05) by the T method to determine 
individual differences between group means at each time point. Data was then back-
transformed for presentation and plotted as mean CPM ± 95 % CL and SI for the controls (A 
and B), one-way MLR (C and D), two-way MLR (E and F) and LTA (G and H) respectively. 
Mitotically inactivated cells are highlighted in red. The red line at SI=3 denotes SBP; SI > 3 
were considered significant allogeneic responses. 
*
 indicates significant differences in 
3
H-
thymidine uptake; (C) one-way MLR > one-way MLR + C3H / Balb/c DF; (E) two-way 
MLR > two-way MLR + C3H / Balb/c DF at each time point. [MNC; mononuclear cells] 




5.3.3. Effects of increasing stimulator cell ratio on the 
immunogenicity of allogeneic undifferentiated MSC and DF 
The capacity of both allogeneic and syngeneic MSC and DF to suppress one-way and 
two-way MLR was demonstrated in Section 5.3.1 and Section 5.3.2 respectively. 
However, allogeneic MSC but not DF stimulated Balb/c mononuclear cells. The 
reactions used equal numbers of responders and stimulators (5 x 10
4
 cells at 1:1 
ratio). It was thought that increasing the density of stimulator cells in the LTA could 
potentially increase the stimulatory capacity of the stimulator cells by having more 
alloantigens available for interaction with responder cells. This was important to 
investigate further the lymphocyte stimulatory effect observed with allogeneic MSC. 
LTA co-cultures comprising Balb/c responder mononuclear cells and mitotically 
inactivated allogeneic or syngeneic MSC and DF were set up with responder to 
stimulator cell ratios of 1:1, 1:2, 1:3, 1:4 and 1:5. One-way MLR of Balb/c responder 
mononuclear cells co-cultured with mitotically inactivated C3H stimulator 
mononuclear cells were used as controls for stimulated cells. Balb/c mononuclear 
cells cultured alone were used as controls for unstimulated non-proliferating cells. 
With regard to the one-way MLR control, lymphocyte proliferation peaked at day 6 
as was seen in previous experiments. Highest counts and SI were obtained with the 
1:1 ratio followed by 1:2 in the order of increasing stimulator cell ratio with the 1:5 
ratio giving the lowest counts at any given time point (Figure 5.13A-B). The 
differences in counts among the different cell ratios at a given time point were 
however not significant. SI less than 3 were obtained with the 1:5 ratio at day 12 and 
at all the ratios (except the 1:1 and 1:2) at day 15. The data showed that the 1:1 ratio 
was the most appropriate for the one-way MLR and increasing the stimulator cell 
ratio reduced 
3
H-thymidine uptake and consequently the SI.  
In the LTA, co-cultures of responder Balb/c mononuclear cells with stimulator 
syngeneic MSC produced counts that were not significantly different from those of 
the control Balb/c mononuclear cell monocultures at all the time points. Also, the SI 
at all the time points were less than 3 (Figure 5.13C-D). This trend was also 
observed in LTA involving Balb/c mononuclear cells with syngeneic DF (Figure 
513G-H) and allogeneic DF (Figure 5.13I-J). Co-cultures of Balb/c mononuclear 
cells with stimulator C3H MSC (allogeneic) however, produced counts that were 




significantly different from control Balb/c mononuclear cells cultured alone at day 6 
(all ratios), day 9 (all ratios except 1:5) and day 12 (all ratios with the exception of  
1:4 and 1:5). The SI at these ratios and time points were above 3 (Figure 5.13E-F). 
The overall trend was that increasing the C3H MSC stimulator cell ratio above the 
1:1 ratio was accompanied by a reduction in 
3
H-thymidine uptake by the responder 
Balb/c mononuclear cells. 
Taken together, the results so far have showed that syngeneic undifferentiated Balb/c 
MSC and DF and allogeneic C3H DF failed to stimulate Balb/c mononuclear cells at 
any of the ratios used for the 15 day culture period. Only C3H MSC stimulated 
Balb/c mononuclear cells. Increasing the C3H MSC cell ratio relative to the 









Figure 5.13. Effects of increasing stimulator cell ratios on responder Balb/c lymphocyte 
transformation by syngeneic and allogeneic MSC and DF. Balb/c mononuclear cells [5 x 
10
4
 cells per well] were co-cultured with increasing numbers of mitotically inactivated 
Balb/c and C3H MSC or DF stimulator cells to give responder to stimulator cell ratios of 1:1, 
1:2, 1:3, 1:4 and 1:5. Co-cultures of Balb/c and mitotically inactivated C3H MNC (one-way 
MLR) and Balb/c MNC alone were used as controls for proliferating and non-proliferating 
cells respectively. Data (n=3) was Log10 transformed and analysed by 2-way ANOVA 
followed by calculation of the MSD (p < 0.05) by the T method to determine individual 
differences between means of different cell ratios. Data was then back-transformed for 
presentation and plotted as mean CPM ± 95 % CL and SI for the one-way MLR control (A 
and B) and co-cultures of Balb/c MNC with Balb/c MSC (C and D), C3H MSC (E and F), 
Balb/c DF (G and H) and C3H DF (I and J) respectively. 
*
 indicates significant differences in 
3
H-thymidine uptake between LTA involving Balb/c MNC and C3H MSC and control 
monocultures of Balb/c MNC at a given time point. The red line at SI=3 denotes SBP; SI > 3 
were considered significant allogeneic responses. [MNC; mononuclear cells] 




5.3.4. Comparison between U-bottom and V-bottom plates on the 
one-way MLR and LTA using undifferentiated allogeneic and 
syngeneic MSC and DF 
The type and surface coating of cell culture plates used in previous studies in the 
literature varied from flat bottom, U-bottom and V-bottom coated and uncoated 
plates. Surface coated (Nunc
™
 ) U-bottom plates were used initially in this study 
but were discontinued due to cells sticking to the bottom which affected cell 
harvesting. To address this problem, uncoated U-bottom plates were used for all the 
MLR and LTA reported thus far. V-bottom plates are thought to provide a narrow 
and closely packed environment which provides close cell to cell contact which 
could favour lymphocyte responses. In this experiment, uncoated V-bottom plates 
were compared to uncoated U-bottom plates in one-way MLR and LTA using C3H 
(allogeneic) and Balb/c (syngeneic) MSC and DF.   
Balb/c and C3H MSC and DF were incorporated in one-way MLR and LTA with 
Balb/c mononuclear cells as responders at a 1:1 ratio. Con-A stimulated Balb/c 
mononuclear cells were used as controls for mitogen stimulated cells whereas Balb/c 
mononuclear cells monocultures were used as controls for unstimulated non-
proliferating cells. With regard to the controls for these experiments, 
3
H-thymidine 
uptake for Con-A stimulated Balb/c mononuclear cells cultured in U-bottom and V-
bottom plates was comparable, with the highest counts obtained at day 6. A similar 
trend was also observed in the one-way MLR controls. Counts for control 
unstimulated Balb/c mononuclear cells in both U-bottom and V-bottom plates were 
not significantly different (Figure 5.14A).  
In the one-way MLR with Balb/c and C3H MSC or DF, the extent of 
3
H-thymidine 
uptake suppression observed with syngeneic or allogeneic MSC (Figure 5.14B) and 
DF (Figure 5.14D) was similar in both U-bottom and V-bottom plates. With regard 
to the LTA co-cultures of responder Balb/c mononuclear cells with Balb/c and C3H 
MSC (Figure 2.14C) and DF (Figure 5.14E) as stimulators, the counts obtained 
using U-bottom and V-bottom plates were not significantly different. Only C3H 
MSC significantly stimulated Balb/c mononuclear cells at day 6 and day 9 as was 
previously observed in earlier experiments. Since similar results were obtained with 




both U-bottom and V-bottom plates, these results indicated that either may be used in 
MLR and LTA experiments. 
 
 
Figure 5.14. Comparison of the effects of syngeneic and allogeneic MSC and DF on one-
way MLR and LTA cultured in uncoated U-bottom and V-bottom plates. One-way 
MLR co-cultures comprising 5 x 10
4
 cells per well of each of responder Balb/c mononuclear 
and mitotically inactivated C3H mononuclear cells were set up in separate uncoated U-
bottom and V-bottom plates. Mitotically inactivated Balb/c and C3H MSC or DF were then 
added to the one-way MLR cultures to give final ratios of 1:1:1. LTA co-cultures of 
responder Balb/c MNC with syngeneic and allogeneic MSC and DF were also set up at 1:1 
ratio. One-way MLR alone and monocultures of Balb/c MNC with or without Con-A were 
used as controls. The cultures were incubated for 3, 6, 9, 12 and 15 days with medium 
changed each 3 days (100 l replaced with fresh medium). Lymphocyte proliferation 
measured by 
3
H-thymidine uptake. Data (n=6) was Log10 transformed and analysed by 1-
way ANOVA followed by calculation of the MSD (p < 0.05) by the T method to determine 
individual differences between means of cells in U and V-bottom plates at a given time 
point. Data was then back-transformed for presentation and plotted as mean CPM ± 95 % CL 
for unstimulated and Con-A stimulated Balb/c MNC and one-way MLR controls (A), one-
way MLR with Balb/c and C3H MSC (B), LTA with Balb/c and C3H MSC (C), one-way 
MLR with Balb/c and C3H DF (D) and LTA with Balb/c and C3H DF (D). 
*
 indicates 
significant differences in 
3
H-thymidine uptake between Balb/c MNC + C3H MSC and 
Balb/c MNC only. Cells labelled in red were mitotically inactivated. [MNC; mononuclear 
cells] 




5.3.5. Effect of Balb/c serum on one-way MLR and LTA involving 
undifferentiated syngeneic and allogeneic MSC and DF 
All the MLR and LTA experiments described thus far in this chapter used 
lymphocyte culture medium supplemented with 10 % (v/v) FCS. Ideally, Balb/c 
mouse serum would be more suited for these experiments as it is syngeneic to the 
responder cells. As described in previous experiments in Section 4.3.5, commercial 
heat-inactivated 2 % (v/v) mouse serum inhibited 
3
H-thymidine uptake in one-way 
MLR involving responder Balb/c mononuclear cells and mitotically inactivated 
stimulator C3H mononuclear cells. When the same mouse serum was used in Balb/c 
mononuclear cells stimulated with Con-A however, significant stimulation 
comparable to that obtained with 10 % (v/v) FCS was obtained. It was thought that 
using Balb/c serum would be appropriate and specific for Balb/c lymphocyte 
responses in comparison to the commercial mouse serum which was obtained from 
mice from different strains. 
In this experiment, 2% (v/v) syngeneic Balb/c serum was used to supplement 
lymphocyte culture medium which was used in one-way MLR and LTA involving 
co-cultures of responder Balb/c mononuclear cells and mitotically inactivated Balb/c 
and C3H MSC or DF at 1:1:1 and 1:1 responder to stimulator cells ratios 
respectively. Balb/c mononuclear cells cultured alone were used as controls for 
unstimulated non-proliferating cells while Con-A stimulated Balb/c mononuclear 
cells were used as control for stimulated proliferating cells.  
With regard to the one-way MLR control, C3H mononuclear cells failed to stimulate 
responder Balb/c mononuclear cells with very low counts recorded at all the time 
points (Figure 5.15). This was similar to the results obtained previously in Section 
4.3.5 in which 2 % (v/v) commercial mouse serum was used to supplement culture 
medium. Similarly, all LTA and one-way MLR cultures with Balb/c and C3H MSC 
or DF produced low counts. Only the Con-A stimulated Balb/c mononuclear cell 
control produced high counts. These results showed that Balb/c serum supplemented 
culture medium did not support allogeneic stimulation of Balb/c lymphocytes with 
C3H antigens.   
 





Figure 5.15. Effects of 2 % (v/v) Balb/c mouse serum supplemented culture medium on 
one-way MLR and LTA involving syngeneic and allogeneic MSC and DF. Balb/c 
mononuclear cells seeded at 5 x 10
4
 cells per well were co-cultured with mitotically 
inactivated syngeneic Balb/c and allogeneic C3H MSC or DF at a 1:1 ratio in LTA in culture 
medium supplemented with heat-inactivated 2% (v/v) Balb/c mouse serum. Balb/c 
mononuclear cells cultured alone or stimulated with Con-A were used as controls for non-
dividing and proliferating cells respectively. One-way MLR comprising responder Balb/c 
mononuclear cells and mitotically inactivated stimulator C3H mononuclear cells were co-
cultured with mitotically inactivated Balb/c and C3H MSC and DF in a 1:1:1 ratio. One-way 
MLR without MSC and DF was used as a control for alloantigen stimulated cells. The 
cultures were incubated for 3, 6, 9, 12 and 15 days with medium changed each 3 days (100 
l replaced with fresh medium). Lymphocyte proliferation was measured by 3H-thymidine 
uptake. Data was Log10 transformed to calculate 95 % CL. Data was then back-transformed 










5.3.6. Effects of allogeneic and syngeneic chondrogenic 
differentiated MSC on one-way and LTA 
MSC and DF were differentiated along the chondrogenic lineage and assessed for 
their immunomodulatory properties using adaptations of the one-way MLR and 
LTA. For the one-way MLR, Balb/c (syngeneic) and C3H (allogeneic) chondrogenic 
differentiated MSC and DF micromass nodules were co-cultured with responder 
Balb/c and stimulator C3H mononuclear cells. This was carried out in order to 
determine whether differentiated cells possessed similar immunomodulatory 
properties to their undifferentiated progenitors. In the LTA, the capacity of the 
differentiated Balb/c and C3H MSC and DF to stimulate Balb/c lymphocyte 
proliferation was tested. 
After 21 days in chondrogenic medium, Balb/c and C3H MSC and DF stained 
positive (blue) when stained with alcian blue dye. Positive alcian blue stain is used to 
identify GAGs which indicated successful differentiation of the MSC and DF to 
chondrocytes. Control C3H cultures which were cultured in DMEM-LG and 
DMEM-HG culture medium were negative for the stain (Figure 5.16).  
 
Figure 5.16. Chondrogenic differentiation of mouse MSC and DF. MSC (p5) and DF 
(p5) were cultured in chondrogenic differentiation medium for 21 days and stained with 
Alcian blue. C3H MSC (A) and DF (D), which were used as controls were also cultured for 
21 days in DMEM-LG and DMEM-HG culture medium respectively and stained negative 
with Alcian blue. Balb/c and C3H MSC (B and C respectively) and DF (E and F 
respectively) cultured in chondrogenic differentiation medium stained positive for GAGs 











The differentiated cells and stimulator C3H mononuclear cells were mitotically 
inactivated by treatment with mitomycin C before they were used in one-way MLR 
and LTA.  
With regard to the control cultures of mitomycin C treated cells, comparisons in 
3
H-
thymidine uptake between Con-A stimulated (Figure 5.17A) and unstimulated 
(Figure 5.17B) cells showed no significant differences which demonstrated that the 
cells were mitotically inactivated. Only responder Balb/c mononuclear cells which 
were not mitotically inactivated showed significant 
3
H-thymidine uptake with the 
highest counts obtained at day 6. 
For the one-way MLR, control co-cultures of responder Balb/c mononuclear cells 
and mitotically inactivated C3H mononuclear cells showed significant 
3
H-thymidne 
uptake which demonstrated that Balb/c lymphocyte proliferation in response to C3H 
mononuclear cells as has been shown in previous experiments. When Balb/c 
(syngeneic) and C3H (allogeneic) chondrogenic differentiated MSC were cultured in 
the one-way MLR, significant suppression of 
3
H-thymidine uptake was observed at 
days 3, 6 and 9 in comparison to the one-way MLR control with approximately 50 % 
suppression achieved at day 6 (Figure 5.17C). A similar trend was also achieved 
when Balb/c or C3H chondrogenic differentiated DF were co-cultured in the one-
way MLR. Despite the suppression of Balb/c lymphocyte proliferation, SI above 3 
were obtained at all the time points except at day 15 (Figure 5.17E). 
With regard to the LTA in which Balb/c mononuclear cells were co-cultured with 
allogeneic or syngeneic chondrogenic differentiated MSC and DF, no significant 
increase in 
3
H-thymidine uptake relative to monocultures of responder cells, was 
obtained with either Balb/c (syngeneic) chondrogenic differentiated MSC or DF 
(Figure 5.17D). When C3H (allogeneic) chondrogenic differentiated MSC or DF 
were co-cultured with responder Balb/c mononuclear cells, significant 
3
H-thymidine 
uptake relative to monocultures of Balb/c mononuclear cells, was obtained at days 3, 
6 and 9 with the highest counts obtained at day 6. Also, SI equal to above 3 were 
obtained at these time points with the highest SI of 7 obtained at day 6 with both 
C3H chondrogenic differentiated MSC and DF (Figure 5.17F). 
Taken together, the results showed that both syngeneic and allogeneic chondrogenic 
differentiated MSC and DF equally suppressed one-way MLR. In LTA, allogeneic 




but not syngeneic chondrogenic differentiated MSC and DF cells stimulated Balb/c 
lymphocyte proliferation. 
 
Figure 5.17. Effects of chondrogenic differentiated syngeneic and allogeneic MSC and 
DF on one-way MLR and LTA as measured by 
3
H-thymidine uptake. Mitotically 
inactivated chondrogenic differentiated Balb/c (syngeneic) and C3H (allogeneic) MSC and 
DF (5 x 10
4
 cells per well) were co-cultured in one-way MLR comprising Balb/c and 
mitotically inactivated C3H mononuclear cells (MNC) at a 1:1:1 ratio. One-way MLR 
culture only was used as a control for alloantigen stimulation. LTA comprised co-cultures of 
differentiated Balb/c or C3H MSC and DF with responder Balb/c MNC at 1:1 ratio. Balb/c 
mononuclear cells (MNC) cultured alone or stimulated with Con-A were used as controls for 
non-proliferating and proliferating cells respectively. Cultures were incubated for 3, 6, 9, 12 
and 15 days with medium changes every 3 days and lymphocyte proliferation was measured 
by 
3
H-thymidine uptake. Data  (n=6) was Log10 transformed and analysed by 2-way 
ANOVA followed by calculation of the MSD (p < 0.05) by the T method to determine 
individual differences between test and control cells at each time point. Data was then back-
transformed for presentation and plotted as mean CPM ± 95 % CL for unstimulated controls 
(A), stimulated controls (B), one-way MLR (C) and LTA (D). SI were computed for one-
way MLR (E) and LTA (F). The red line at SI=3 denotes statistical biological positive; SI 
above 3 were considered significant. 
*
 indicates significant differences between one-way 
MLR only and one-way MLR + C3H or Balb/c differentiated MSC and DF  in (C) and 









The purpose of the work carried out in this chapter was aimed at investigating the 
immunological properties of both undifferentiated and chondrogenic differentiated 
allogeneic MSC in light of reported evidence that they possess immunosuppressive 
properties which could potentially be of therapeutic value in clinical procedures such 
as allogeneic transplantation. In addition, MSC have also been reported to be 
immunoprivileged which means that donor allogeneic MSC are not rejected in an 
allogeneic recipient. Therefore, three key questions were investigated in this work, 
firstly whether undifferentiated MSC possessed immunosuppressive properties and if 
so, whether the suppression was sufficient to ameliorate the allogeneic rejection and 
secondly, to test whether MSC were immunoprivileged and incapable of initiating 
allogeneic rejection. The final question was to investigate whether the properties 
exhibited by undifferentiated MSC were retained following chondrogenic 
differentiation. 
To answer the first question, syngeneic Balb/c and allogeneic C3H MSC were co-
cultured with one-way and two-way MLR comprising mismatched Balb/c and C3H 
mononuclear cells. For the second question, Balb/c MSC and C3H MSC were co-
cultured with responder Balb/c mononuclear cells in LTA to test their capacity to 
stimulate lymphocyte proliferation. For the third question, MSC were differentiated 
along the chondrogenic pathway and were similarly tested for their 
immunomodulatory properties and immunogenicity in one-way MLR and LTA 
respectively. 
For undifferentiated cells, both C3H (allogeneic) and Balb/c (syngeneic) MSC 
significantly suppressed one-way MLR with 90 % of the proliferative response 
suppressed at day 6. Similarly, both types of MSC suppressed two-way MLR with 
Balb/c MSC showing 14 % more suppression compared to C3H MSC when cultured 
at a 1:1:1 ratio. These findings supported a growing pool of evidence from other in 
vitro studies which used mouse MSC (Djouad et al., 2003; Glennie et al., 2005; 
Sudres et al., 2006; Xu et al., 2007; Han et al., 2010), human (Di Nicola et al., 2002; 
Le Blanc et al., 2003c; Klyushnenkova et al., 2005), primate (Bartholomew et al., 
2002) and other animal models. Despite using different adaptations of the MLR such 
as culture period, cell ratios and stimulator cells (3
rd
 party MSC in human studies) 




and unseparated or purified responder lymphocytes, the in vitro inhibitory potency of 
allogeneic MSC to controls has been demonstrated to range between 60 – 95 %. 
Unlike in other previous studies using mouse models, the MLR in this study were 
carried out for a total of 15 days (compared to an average of 5 days) accompanied by 
medium replacement (discussed in Section 4.3.2). This modification resulted in 
lymphocyte proliferation as represented by increasing 
3
H-thymidine uptake, peaking 
at day 6 in control cultures for the MLR. The SI for the these cultures were above 3 
at all the time points except at day 15, which suggested that the Balb/c mononuclear 
cell allogeneic response to C3H mononuclear cells was detected up to 12 days in 
culture. Therefore, MSC mediated suppression was sustained for the duration of the 
cultures. The fact that syngeneic and allogeneic MSC were equally suppressive in 
one-way MLR suggested that the mechanisms involved were independent of MHC 
differences. This was previously reported in similar studies which used human MSC 
(Le Blanc et al., 2003c). 
The exact mechanisms behind MSC mediated immunosuppression in MLR remain 
largely unresolved. It is thought that MSC are able to exert their immunosuppression 
by a combination of mechanisms which includes secretion of a milieu of suppressive 
chemicals and cytokines in addition to cell to cell contact mechanisms. 
Immunosuppressive factors such NO, IDO, PGE2 and TGF have been implicated 
but some of the evidence is contradictory since some of the factors are not 
constitutively expressed by all MSC resulting in huge variations across studies (Tse 
et al., 2003; Meisel et al., 2004; Aggarwal & Pittenger, 2005). This study did not 
focus on investigating secreted molecules from MLR cultures because the evidence 
in the literature suggests that of all the secreted immunosuppressive molecules 
known to be produced by MSC to date, such as IDO, PGE2 and TGF none has been 
found to be indispensable as discussed in Section 1.8.2.1. In fact, it is widely 
accepted across the stem cell field that experimental conditions and factors such as 
age and passage number of the MSC and the source of the MSC play a key part in 
the behaviour exhibited by MSC in vitro. Therefore, this study focused on 
investigating how different MLR parameters such as incubation period and medium 
changes affected the course of MSC mediated immunosuppression. 




With regard to whether allogeneic MSC were immunoprivileged or immunogenic, 
LTAs were carried out and extended from the usual 5 days to 15 days accompanied 
by medium changes every 3 day period. Con-A stimulated and unstimulated Balb/c 
mononuclear cells were used as controls for proliferating and non-proliferating cells 
respectively. For any response to be deemed stimulatory, the counts would have to be 
significantly different from those of the control unstimulated Balb/c mononuclear 
cells as well as the SI having to be above 3. The results showed that C3H MSC 
(allogeneic) but not Balb/c (syngeneic) MSC significantly stimulated Balb/c 
responder mononuclear cells using MSC that had and had not been mitotically 
inactivated. Though the stimulation by C3H MSC peaked at day 6, it was also 
detected at days 9 and 12. These findings suggested that allogeneic MSC were 
immunogenic under these experimental conditions and thus contradicted other in 
vitro studies that have reported that allogeneic MSC were immunoprivileged and 
failed to stimulate allogeneic lymphocytes. Some of these studies did not use the SI 
as a measure of immunogenicity and therefore based their findings in terms of the 
counts alone. This approach is not inaccurate but it is based on high counts having to 
be achieved for a positive stimulatory response. For instance, the counts obtained 
when Balb/c mononuclear cells were stimulated by C3H mononuclear cells (one-way 
MLR), were high. The counts obtained when Balb/c mononuclear cells were 
stimulated with C3H MSC were lower in comparison.  
In a study that used human MSC, it was reported that allogeneic MSC were not 
immunogenic when co-cultured with purified lymphocytes but when they were 
cultured with unseparated PBMC, the 
3
H-thymidine counts were significantly higher 
than for PBMCs cultured alone which suggested that the allogeneic MSC were 
stimulatory at day 8 but this observation has been largely overlooked in the literature 
(Klyushnenkova et al., 2005). Due to the inherent hypo-immunogenicity of MSC 
discussed in Section 1.8.1 (low expression of MHC I and lack of surface MHC II and 
co-stimulatory molecules CD80 and CD86), it is probable that they will not be able 
to stimulate lymphocytes by the direct pathway. However, when PBMC were used, it 
is also possible that allo-antigens from the allogeneic MSC could be presented to 
lymphocytes by the APC present in PBMC via the indirect and semi-direct pathways. 
Therefore, LTA tested within 3-4 days may not capture the indirect and semi-direct 
pathways. 




It is important to note that the stimulatory response shown by C3H MSC was 
obtained after numerous experiments in which they failed to stimulate Balb/c 
mononuclear cells. Initially, when the LTA were carried out without medium 
changes for a 7-day culture period, no stimulatory response was observed. Similar 
findings were also observed when surface-coated plates were used (Nunc
™
 ). 
Stimulatory responses were only observed when medium changes and uncoated 
plates were used. Also, some of the experiments were affected by inconsistent counts 
particularly for unstimulated control cells which in some cases were too high such 
that SI, including for Con-A stimulated controls, were drastically reduced. This 
problem has been reported previously in similar studies using mouse mononuclear 
cells. Therefore, as discussed in Section 4.4, it was necessary to define the most 
appropriate conditions for performing the LTA and MLR. 
Another important consideration for the LTA was the ratio between the responder 
Balb/c mononuclear cells and the stimulator C3H MSC. Since allogeneic MSC were 
stimulatory at a 1:1 ratio, it was necessary to investigate whether increasing the 
stimulator cell ratio in the LTA would lead to an improved allogeneic response. 
Thus, LTA were prepared in which the ratio of responder Balb/c mononuclear cells 
to stimulator MSC was increased from 1:1 to 1:5. It was found that 
3
H-thymidine 
counts decreased with increasing stimulator cell ratio when C3H MSC were used as 
stimulators. Similarly, SI values decreased with increasing proportion of allogeneic 
MSC at all the time points. In previous studies, it was also shown that increasing the 
numbers of MSC inhibited lymphocyte proliferation in a dose-dependent manner (Le 
Blanc et al., 2003c; Nauta et al., 2006; Sudres et al., 2006; Jones et al., 2007). Thus, 
since allogeneic MSC stimulated lymphocyte proliferation at 1:1 ratio, increasing the 
MSC ratio reduced 
3
H-thymidine uptake. Therefore, this suggested that at specific 
cell ratios, allogeneic MSC fail to stimulate lymphocyte proliferation. In a study by 
Le Blanc and co-workers, it was suggested that at low numbers, allogeneic MSC 
stimulated lymphocyte proliferation as opposed to suppression observed with higher 
doses (Le Blanc et al., 2003c). Despite this finding, the authors did not investigate 
further as to why the MSC were stimulatory at low ratios. This further illustrates how 
variations in experimental conditions contribute to conflicting conclusions. Most 
studies in which high ratios of allogeneic MSC were used resulted in MSC failing to 
stimulate allogeneic lymphocytes (Nauta et al., 2006; Jones et al., 2007).  




Studies that have tested allogeneic MSC in vitro and in vivo using mouse models 
have also shown allogeneic MSC to be immunogenic in vivo despite failing to 
stimulate allogeneic lymphocytes in vitro (Eliopoulos et al., 2005; Nauta et al., 2006; 
Sudres et al., 2006). This could be due to the fact that high MSC to lymphocyte cell 
ratios were used in vitro, but such MSC doses are less likely to be replicated in vivo 
and therefore allogeneic MSC become stimulatory leading to rejection.  
DF were chosen as controls to test whether the properties exhibited by MSC were 
unique to stem cells or were shared by other cells of mesenchymal origins. Thus, DF 
were tested in the same way described for MSC. With regard to the one-way MLR, 
both allogeneic and syngeneic DF suppressed responder Balb/c mononuclear cell 
response to allogeneic C3H mononuclear cells. Similarly, in the two-way MLR, both 
C3H and Balb/c DF suppressed lymphocyte proliferation. The suppression exhibited 
by DF (75 %) though less than exhibited by MSC (90 %) was significant with SI 
falling below 3.  
Slight differences in SI trends between MSC and DF mediated suppression of one 
and two-way MLR were noticed. When Balb/c and C3H MSC were cultured with 
one-way and two-way MLR, SI above 3 were obtained at day 3 but dropped below 3 
at day 6 onwards. With DF however, SI values were below 3 at day 3 but values 
above 3 were obtained at day 9. This could suggest that despite both MSC and DF 
exhibiting immunosuppressive properties, the mechanisms by which they achieve 
suppression might be different. It has been recently suggested that MSC exhibited 
anti-inflammatory properties in vitro which were absent in DF (Blasi et al., 2011); 
such differences may potentially affect the mechanisms by which they achieve 
immunosuppression.  
In the last two decades, studies using allogeneic human gingival and corneal 
fibroblasts have reported their immunosuppressive properties (Shimabukuro et al., 
1992; Donnelly et al., 1993). More recently, human primary articular chondrocytes, 
synovial and dermal fibroblasts have been reported to exhibit dose-dependent 
lymphocyte inhibitory effects comparable to MSC (Bocelli‐Tyndall et al., 2006; 
Haniffa et al., 2007; Jones et al., 2007). Together with their ability to undergo tri-
lineage differentiation and similar phenotype to MSC (discussed in Chapter 3), this 
study has shown that mouse DF possessed comparable immunosuppressive 




properties to MSC. Thus, the ability to suppress lymphocyte proliferation may be a 
property shared by other cells of the mesenchymal lineage.  
When DF were tested in LTA, both C3H (allogeneic) and Balb/c (syngeneic) DF 
failed to stimulate Balb/c mononuclear cells. Unlike allogeneic MSC, allogeneic DF 
were not immunogenic; with counts obtained not significantly different from those 
for control cultures and the SI below 3 in all the experiments carried out. Recently, 
there has been a growing interest in the study of the immunomodulatory properties of 
DF particularly as more evidence about their similarities to MSC is accumulating. To 
date, there are a few studies that have investigated the immunoregulatory properties 
of allogeneic human DF (Haniffa et al., 2007) but none has tested allogeneic DF in 
LTA to test their immunogenicity. Due to their similarities with MSC, DF and other 
fibroblasts are now receiving more attention as was reviewed in detail by Haniffa and 
co-workers (Haniffa et al., 2009) and their potential in tissue engineering and 
regenerative medicine has not been explored.  
The data obtained from MLR and LTA carried out in uncoated U-bottom and V-
bottom plates demonstrated that both were equally effective in supporting these 
experiments unlike the Nunc  surface coated plates as previously described in 
Section 5.3.4. Although the counts obtained in the control experiments were 
marginally higher in U-bottom than in V-bottom plates, there were no significant 
differences between the two. Importantly, this experiment demonstrated the 
reproducibility of the assays particularly the stimulation of Balb/c mononuclear cells 
by allogeneic C3H MSC. Moreover, the counts and overall lymphocyte stimulatory 
(Con-A control, MLR control and C3H MSC in LTA) and suppressive (Balb/c and 
C3H MSC and DF in MLR) trends obtained from this experiment were comparable 
to those obtained in Section 5.3.1 and Section 5.3.2. 
When one-way MLR and LTA using Balb/c and C3H MSC and DF were carried out 
in culture medium supplemented with 2 % (v/v) Balb/c serum (syngeneic to the 
responder lymphocytes), 
3
H-thymidine uptake was inhibited in all reactions 
(including the one-way MLR) except in the Con-A stimulated control. As was 
observed with commercial mouse serum in Section 4.3.4, these findings suggested 
that mouse serum contains a factor or factors thought to be lipoproteins that suppress 
lymphocyte proliferation stimulation as previously discussed in Section 4.4. 




With regard to the commercial mouse serum used previously, it was found out from 
the suppliers that the serum was a mixture of sera obtained from several mouse 
strains. Therefore, it was thought that using freshly prepared syngeneic Balb/c serum 
would favour Balb/c lymphocyte proliferation but this was not the case. Since 
alloantigen stimulation was achieved in culture medium supplemented with 10 % 
(v/v) FCS, it is possible to speculate that since FCS has been reported to contain 
several poorly defined factors such as endotoxins, antigenic peptides, glucocorticoids 
and other hormones that can influence immune cells such as macrophages, DC and 
T-lymphocytes (Eske et al., 2009). Therefore, FCS may have the capacity to polarise 
lymphocytes to proliferate as a result of stimulation from ―by-stander‖ antigens 
derived from the serum. Importantly, commercial FCS composition varies from 
batch-to-batch and the variations in some cases have been reported to be significant 
(Bryan et al., 2011). This could explain in part why variability between different 
experiments particularly 
3
H-thymidine counts was in some cases high. This made 
reproducibility of the experiments very challenging. In some cases, high 
3
H-
thymidine counts were often obtained in negative control experiments which 
comprised unstimulated cells. In the end, the FCS used in most of the experiments 
presented in this thesis was obtained from a single batch which had been tested and 
shown to be non-stimulatory towards negative controls. The problem of lack of 
reproducibility in mouse MLR and LTA experiments which use FCS for medium 
supplementation is a widely reported phenomenon and presents major challenges in 
research. 
In a study that used mouse sera obtained from non-pregnant and pregnant mice at 
different stages of gestation showed that serum obtained from mid-gestation mice 
significantly suppressed MLR and was accompanied by a notably reduced expression 
of MHC II molecules on stimulator DC (Shojaeian et al., 2007). This study also 
reported reduced IFN and elevated IL-4 and IL-10 secretion by responder T-cells 
and implicated progesterone as a potential immunosuppressive factor in the serum 
since it had been previously shown to inhibit IFN secretion (Piccinni et al., 1995). 
In a different study however, progesterone was shown to promote DC maturation and 
MHC II expression (Liang et al., 2006) thus making the evidence in inconclusive. 




Another study described the existence of immunosuppressive mouse serum factor(s) 
which were eluted in the gamma-globulin fraction following Sepharose 6B gel 
filtration chromatography with molecular weights between 100 and 150 kDa which 
act by blocking IL-2 receptors after internalisation by T-lymphocytes (Lindqvist et 
al., 1992). It has also been argued that the presence of the hormone leptin in the 
serum promotes in vitro lymphocyte proliferation but its absence led to suppression 
(Lord et al., 1998).  
This is particularly interesting since leptin has been reported to increase the secretion 
of lipoprotein lipase in human macrophages (Maingrette & Renier, 2003). It is 
therefore possible to hypothesize that since lipoprotein lipase is required for the 
metabolism of lipoproteins which have been implicated as potential 
immunosuppressive factors in mouse serum (Section 4.4), the absence of leptin in 
serum probably due to heat inactivation, could potentially result in the presence of 
immunosuppressive levels of lipoproteins. It is also interesting to investigate the role 
of IL-6 in serum-induced immunosuppression since it has been reported to resemble 
leptin (Fantuzzi & Faggioni, 2000). 
Another important component in mouse lymphocyte culture medium is the presence 
of 50 M of -mercaptoethanol. The necessity of this component was tested during 
the initial stages of this study and it was found that stimulation of Balb/c 
mononuclear cells with PHA in the absence of or in the presence of amounts less 
than 50 M of -mercaptoethanol was unsuccessful. The role of -mercaptoethanol 
in lymphocyte stimulation is unknown but due to its known function as a powerful 
reducing agent, it is possible to hypothesize that it may be involved in the breaking 
of disulphide bonds of complex sulphur containing proteins which may aid nutrient 
uptake or lymphocyte proliferation. 
Importantly, it was necessary to investigate the immunosuppressive properties and 
immunogenicity of chondrogenic differentiated MSC and DF in order to determine 
whether they retained similar properties to those exhibited by undifferentiated cells. 
As has been mentioned throughout this study, undifferentiated and in some cases 
terminally differentiated allogeneic MSC have been reported throughout the 
literature to be immunosuppressive and immunoprivileged. Crucially, the potential 




application of MSC in tissue engineering procedures for tissue repair and 
replacement requires the use of MSC differentiated into specific lineages. 
Theoretically, once terminally differentiated, MSC would lose their immunological 
and ‗stem‘ properties as they would assume a different morphology and function 
punctuated by expression of lineage specific proteins and molecules. Thus, the 
hypothesis for this experiment was that MSC would lose their immunomodulatory 
properties once they undergo terminal differentiation. Therefore, Balb/c and C3H 
MSC and DF were differentiated along the chondrogenic lineage and their 
immunomodulatory properties were tested using the one-way MLR and LTA 
respectively. 
Chondrogenic differentiation of Balb/c and C3H MSC and DF was confirmed by 
alcian blue staining after 21 days of pellet culture as was previously demonstrated in 
Chapter 3. This assay is the only functional assay to date that clearly demonstrates 
successful chondrogenic differentiation of stem cells. Complete disaggregation of the 
pellets required incubation with 0.01 % (v/v) collagenase. The cells were seeded in 
uncoated V-bottom plates overnight before the one-way MLR and LTA cultures 
were set up to allow the cells to aggregate into micro-pellets. In Section 5.3.4, V-
bottom plates were compared to U-bottom plates in one-way MLR and LTA and 
both types of plates were found to be equally suitable based on the comparable 
3
H-
thymidine uptake counts obtained. Therefore, V-bottom plates were preferred to U-
bottom plates as they were thought to be more suitable for the culture of 
chondrogenic micro-pellets. 
With regard to immunosuppressive properties, both chondrogenic differentiated 
Balb/c and C3H MSC and DF exhibited comparable suppression of the one-way 
MLR, causing a 50 % reduction in 
3
H-thymidine uptake in one-way MLR at day 6 
whereas in experiments which used undifferentiated MSC and DF, suppression of 90 
% and 75 % respectively were obtained. Although the experiments using 
chondrogenic differentiated MSC and DF and those using undifferentiated MSC and 
DF were not carried out at the same time, the results appeared to suggest that 
chondrogenic differentiated MSC and DF suppression of the one-way MLR was less 
compared to that for undifferentiated MSC and DF. These results concurred with 
similar findings in a recent study in which mouse MSC differentiated into osteoblasts 




were reported to have lost their immunosuppressive capacity. This loss of was 
attributed to decreased secretion of IL-10 and TGF (Liu et al., 2012). Passage 
number and ‗age‘ of MSC is also thought to lead to loss of MSC immunosuppressive 
capacity. During differentiation of MSC, the fractions of cells that successfully 
undergo terminal differentiation vary as a result of the cell ‗age‘. Therefore, the 
properties exhibited by MSC cultures at different stages of culture are variable; with 
long term cultures associated with the gradual loss of differentiation potential and 
other ‗stem‘ properties (Kretlow et al., 2008). In contrast, other studies have 
suggested that the immunosuppressive properties displayed by MSC are also inherent 
in other differentiated cells including chondrocytes (Jones et al., 2007). However, 
there is little evidence in the literature on the immunosuppressive properties of 
differentiated MSC. It is probable that the conflicting findings across studies could 
be accounted for by the variations in the quality or quantity of the cells used. Also, as 
shown in Section 5.3.3 and in another study (Le Blanc et al., 2003c), the ratio of 
responding lymphocytes to stimulator MSC could play a part in determining whether 
they exhibit an inhibitory or stimulatory response in vitro.  
With regard to the immunogenicity of the chondrogenic differentiated MSC and DF 
in LTA, it was shown that allogeneic but not syngeneic chondrogenic differentiated 
MSC and DF stimulated Balb/c lymphocyte proliferation. Previously, allogeneic 
C3H MSC, but not DF, stimulated Balb/c lymphocyte proliferation. In this case 
however, chondrogenic differentiated DF were also found to be immunogenic. There 
is evidence in the literature that rat MSC differentiation into chondrocytes but not 
adipocytes and osteocytes resulted in the expression of the co-stimulatory molecules 
CD80 and CD86 which were partly responsible for the rejection of chondrogenic 
differentiated MSC following allogeneic transplantation (Chen et al., 2007). In a 
separate study, MSC differentiation led to surface expression of MHC II and elevated 
MHC I which led to rejection by allogeneic lymphocytes (Huang et al., 2010). 
Conflicting results were obtained when osteogenic differentiated MSC were reported 
to have retained their immunoprivileged status (Liu et al., 2006). It was also reported 
that human MSC differentiated into chondrocytes, adipocytes and osteocytes failed 
to stimulate allogeneic lymphocytes in vitro (Le Blanc et al., 2003b). 
It is likely that during differentiation, specific pathways are switched on depending 
on the specific properties the cells have to acquire in order to assume new functions. 




These pathways could lead to previously immunoprivileged cells becoming 
immunogenic. This is demonstrated throughout the mammalian developmental 
process in which immunoprivileged pluripotent stem cells such as ESC, undergo 
multi-differentiation pathways which lead to immunogenic progeny. 
Chondrocytes from various animals, including mice in particular have been reported 
to constitutively express CD80 and CD86 which potentially could contribute to their 
immunogenicity (Yuan et al., 2003). This notion was directly contradicted in a report 
that allogeneic rat cartilage-derived chondrocytes did not constitutively express 
CD80 and CD86 and were immunoprivileged (Adkisson et al., 2010). 
With regard to DF, there are no studies to date that have investigated the 
immunogenicity of DF using LTA. In general, evidence on the immunomodulatory 
properties of DF is limited although there is growing interest in this field. These 
results showed that chondrogenic differentiation of allogeneic MSC and DF resulted 
in reduced immunosuppressive potency. Both chondrogenic differentiated allogeneic 
MSC and DF were immunogenic.  
In summary, the findings in this chapter have shown that undifferentiated mouse 
MSC and DF were immunosuppressive in one-way and two-way MLR regardless of 
histocompatibility differences. Following chondrogenic differentiation both 
syngeneic and allogeneic MSC and DF were immunosuppressive in one-way MLR 
although the potency of suppression appeared to be less than that shown by 
undifferentiated cells. In LTA however, undifferentiated allogeneic MSC (C3H) but 
not syngeneic MSC stimulated Balb/c responder lymphocytes whilst both allogeneic 
and syngeneic DF failed to stimulate lymphocyte proliferation. This suggested that 
despite their immunosuppressive properties, undifferentiated allogeneic MSC may 
not be immunoprivileged. Following chondrogenic differentiation however, both 
allogeneic MSC and DF were immunogenic. The failure by undifferentiated DF to 
stimulate allogeneic lymphocyte proliferation was surprising and would warrant 
future investigations. Importantly, the properties exhibited by both undifferentiated 
and chondrogenic differentiated DF suggested that the immunomodulatory properties 
are shared by other cells of the mesenchymal lineage and this may have implications 
in research and potential clinical applications in the future. 
 




6. CHAPTER SIX: FINAL DISCUSSION 
6.1. Overview 
The work carried out in this study was aimed at investigating the immunological 
properties of allogeneic MSC, namely their immunosuppressive properties and 
immunoprivileged status, which have been reported in some studies. Other studies 
however, have reported conflicting results with regard to the immunogenicity of 
allogeneic MSC particularly in light of their potential in tissue engineering and 
regenerative medicine. An allogeneic mouse model was used in which Balb/c 
(responder) and C3H (stimulator) MSC were tested for their immunosuppressive 
properties using adaptations of the one-way MLR while their immunoprivileged 
status was tested using the LTA. MSC were isolated from mouse bone marrow and 
characterised using flow cytometry. The phenotype of the MSC was found to be 
consistent with that widely regarded as representative of MSC. Both Balb/c and C3H 
MSC underwent tri-lineage differentiation into adipocytes, chondrocytes and 
osteocytes which is currently the only functional test for MSC.  
It is widely thought that the immunoprivileged status of MSC stems from their 
phenotype which is characterised by the absence of MHC II and co-stimulatory 
molecules CD80 and CD86 which play an important role in allorecognition. Thus, in 
most in vitro studies, MSC have been reported to be immunoprivileged on the basis 
of their failure to stimulate allogeneic lymphocytes in vitro. The hypothesis for this 
study however, speculated that despite their phenotype or hypoimmunogenicity, 
MSC would stimulate allogeneic lymphocytes via the indirect and semi-direct 
pathways of allorecognition if cultured for longer than the standard 5 day period used 
in most studies. Therefore, by allowing for longer incubation under favourable 
conditions, allogeneic MSC, like all allogeneic cells, would be immunogenic. 
In order to perform the one-way MLR and LTA, a significant amount of time was 
dedicated to defining the most appropriate conditions for performing these assays so 
that they would capture the indirect and semi-direct responses. Unlike in most 
studies, the MLR and LTA assays in this study were performed over a 15 day period. 
A strategy to replace half the culture medium each 3 days as described in Section 
4.2.3 was introduced in order to ensure the availability of nutrients and removal of 




metabolic by-products during the longer incubation period. This strategy was shown 
to significantly increase the late incorporation of 
3
H-thymidine in cultures stimulated 
with Con-A in comparison to cultures in which culture medium was unchanged. Peak 
3
H-thymidine uptake and stimulation was obtained at day 6 and day 3 in cultures 
with and without medium changes respectively. This strategy was then used in all the 
MLR and LTA which included MSC. There are currently no reported studies in 
which medium changes have been carried out in MLR and LTA. 
It is widely acknowledged throughout the stem cell field that the major contributing 
factor to conflicting results is the variability in conditions between studies. 
Therefore, an effort was made in this study to ensure that the parameters for MLR 
and LTA were thoroughly tested. One of the key parameters tested was the 
concentration of mitomycin C (10 g.ml-1) used to induce mitotic arrest in stimulator 
cells. A wide range of concentrations (5 - 100 g.ml-1) have been used in various 
studies. Despite the toxicity of mitomycin C however, none of the studies in the 
literature have provided evidence for testing the viability of the stimulator cells 
following treatment. It was found that a balance between maintenance of viability 
and mitotic inactivation was necessary. Concentrations of mitomycin C above 10 
g.ml-1 drastically reduced cell viability whereas concentrations below 10 g.ml-1 
maintained viability but did not effect complete arrest of lymphocyte proliferation 
upon stimulation. Mitotic inactivation and maintenance of cell viability are crucial 
factors in MLR and LTA as insufficient inactivation would result in stimulator cells 
capable of dividing while low cell viability would result in non-viable stimulator 
cells. Using non-viable stimulator cells may yet provide stimulation of responder 
lymphocytes via the indirect and semi-direct pathways of allorecognition as 
discussed in Section 1.7.2.2 and Section 1.7.2.3 respectively as a result of antigenic 
cell debris being presented to responder lymphocytes by responder APC. There is a 
possibility that some studies in the literature may have used non-viable stimulator 
cells in their experiments. 
Another important factor that warranted investigation was the feasibility of using 
mouse serum instead of the commonly used FCS for supplementing culture medium. 
Both commercially sourced mouse serum and Balb/c serum extracted from Balb/c 
mice blood in the laboratory, were tested at different concentrations in MLR and 




LTA. In both cases, both mouse serum and Balb/c serum failed to support Balb/c 
lymphocyte stimulation by allogeneic C3H mononuclear cells in control one-way 
MLR despite showing positive results in Con-A stimulated cultures. In Con-A 
stimulated Balb/c mononuclear cells, mouse serum appeared to inhibit lymphocyte 
proliferation in a dose-dependent manner. Although similar observations have been 
noted in the literature and various inhibitory molecules and mechanisms proposed to 
be the cause as discussed in Section 4.4 and Section 5.4, the exact mechanisms 
remain unknown to date. With FCS however, lymphocyte proliferation was observed 
in all one-way MLR and mitogen stimulated controls with increasing FCS 
concentration resulting in increased 
3
H-thymidne utilisation which peaked at 10 % 
(v/v). Although it is possible to speculate that xenogeneic antigenic epitopes in the 
FCS may have had a stimulatory effect on mouse responder lymphocytes, this was 
unlikely in the experiments presented in this thesis since control cultures of 
mononuclear cells alone did not show a proliferative response in FSC supplemented 
medium. However, as previously discussed in Section 4.4, this notion cannot be 
discounted in general terms since there were experiments in which unstimulated 
mononuclear cells produced unusually high counts.  
Following the establishment of appropriate conditions for performing MLR and 
LTA, the immunosuppressive properties of MSC were determined using one-way 
and two-way MLR at a 1:1:1 cell ratio. Both mitotically inactivated allogeneic (C3H) 
and syngeneic (Balb/c) MSC significantly suppressed one-way MLR with similar 
potency. The same was observed when either Balb/c or C3H MSC were tested in 
two-way MLR. Importantly, the suppression was maintained throughout the 15 day 
culture period. These findings showed that MSC-mediated immunosuppression is 
non-specific with regard to the differences in MHC and were in agreement with most 
studies in the literature. When the MSC were differentiated into chondrocytes and 
then tested for their immunosuppressive properties however, it was found that their 
suppressive properties decreased following differentiation although it must be 
stressed that this was observed in separate experiments. For instance, the day 6 SI for 
the one-way MLR controls were 36 and 18 for the experiments involving 
undifferentiated MSC and chondrogenic differentiated MSC respectively. However, 
in cultures with syngeneic and allogeneic undifferentiated MSC and chondrogenic 




differentiated MSC respectively, the SI were reduced to 4 in the former and 10 in the 
latter.  
With regard to the immunoprivileged status of MSC, mitotically inactivated or not 
allogeneic (C3H) and syngeneic (Balb/c) MSC, the findings showed that allogeneic 
but not syngeneic MSC significantly stimulated Balb/c lymphocytes. It was observed 
that the stimulation was at its peak at day 6. This evidence suggested that allogeneic 
MSC were immunogenic and were therefore not immunoprivileged. These findings 
therefore, contradicted most of the studies in the literature in which allogeneic MSC 
have been reported to be immunoprivileged. When the stimulator cell (allogeneic 
MSC) ratio was increased however, the level of stimulation decreased suggesting 
that high doses of allogeneic MSC relative to the responding lymphocytes would 
result in allogeneic MSC appearing to be non-immunogenic. Thus, these findings 
emphasized the importance of cell ratios in these assays. Following chondrogenic 
differentiation of the MSC, allogeneic but not syngeneic chondrocytes stimulated 
Balb/c lymphocyte proliferation.  
DF were used as controls to test whether the immunomodulatory properties of MSC 
were unique to stem cells or were shared by other cells of mesenchymal origin. MSC 
and fibroblasts have been widely reported as sharing morphological and phenotypical 
similarities and have been suggested to be indistinguishable (Blasi et al., 2011). 
Thus, DF isolated from Balb/c and C3H mice were tested similarly to MSC. 
Phenotypic characterisation showed that DF did not express CD90.2, CD105 and 
CD44 which were expressed by MSC. Following tri-lineage differentiation, DF 
successfully differentiated into adipocytes, chondrocytes and osteocytes. When 
tested in one-way MLR, both allogeneic and syngeneic DF suppressed lymphocyte 
proliferation. Similar suppression was observed when DF were tested in two-way 
MLR. These findings suggested that, like MSC, DF possessed immunosuppressive 
properties. However, following chondrogenic differentiation, both allogeneic and 
syngeneic differentiated DF appeared to have reduced immunosuppressive potency. 
Interestingly, when DF were tested in LTA to determine their immunogenicity, both 
allogeneic (C3H) and syngeneic (Balb/c) DF failed to stimulate Balb/c lymphocyte 
proliferation. This was also observed when the ratio of stimulator DF to responder 
cells was increased from 1:1 to 1:5. These results were not expected since allogeneic 




MSC had been found to be immunogenic. When the DF were differentiated into 
chondrocytes however, allogeneic but not syngeneic differentiated DF, stimulated 
Balb/c lymphocyte proliferation.  
In summary, the results obtained in this study showed that both allogeneic and 
syngeneic MSC were immunosuppressive in one-way MLR. The immunosuppressive 
properties were also displayed by DF. When tested for their immunoprivileged 
statuses, allogeneic but not syngeneic MSC, were immunogenic. Surprisingly, 
allogeneic DF were non-immunogenic under the same conditions used for testing 
MSC. Following chondrogenic differentiation however, both allogeneic and 
syngeneic MSC and DF appeared to lose some of their immunosuppressive potency. 
Both chondrogenic differentiated allogeneic MSC and DF were immunogenic. 
Therefore, undifferentiated MSC may have utility as immunosuppressive therapies. 
However, the clinical application of both undifferentiated and differentiated 
allogeneic MSC may be limited by their immunogenicity. There is need to 
investigate the potential utility of DF as an alternative for MSC in clinical 
applications. 
It must be emphasized however that these findings were obtained after numerous 
experiments were carried out in order to create the conditions that were eventually 
used to obtain the reported findings. Initially, the MLR and LTA produced variable 
results which were not reproducible. This has been widely reported in studies of this 
nature using mouse cells. Therefore, during the course of this study, a great deal of 
effort was invested in testing for the most appropriate conditions for obtaining 
repeatable experiments. Thus, further experiments discussed in Section 7.5 which 
could have been carried out were not completed during the time available.    
6.2. Implications of findings 
Since the last decade, autologous adult stem cells, particularly bone marrow-derived 
and adipose-derived MSC, have become widely used as they are affected by neither 
the ethical obstacles that affect ESC nor the immunological barriers that hinder the 
use of allogeneic MSC as discussed broadly in Chapter 1. The most important 
feature of autologous MSC is the absence of any immunological risk following 
application. Since 2008 to date, there have been up to 85 clinical trials (on-going, 




completed and currently recruiting) of autologous MSC for the treatment of a wide 
range of ailments including Parkinson‘s disease, diabetes mellitus and osteoarthritis 
(http://clinicaltrials.gov/ct2/home).  
Current tissue engineering approaches that utilise autologous MSC have seen some 
clinical success. In a pioneering case of large organ replacement, autologous MSC 
obtained from a patient with end-stage bronchomalacia were expanded ex vivo and 
differentiated into chondrocytes which together with epithelial cells, were seeded 
onto an allogeneic decellularised trachea and developed into a functional organ 
which was successfully used in the patient (Macchiarini et al., 2008). Importantly, 
this procedure was characterised by a time lag between harvesting the cells, ex vivo 
expansion and differentiation and bioreactor culture prior to implantation. This delay 
was not a major problem as in this case, airway replacement is not regarded as an 
acute life-saving procedure (Grillo, 2002). In acute life threatening conditions 
however, autologous MSC based approaches, would be unfavourable. Allogeneic 
MSC would solve this problem as they can be obtained from healthy donors and used 
to make ―off–the-shelf‖ products either in their differentiated forms in tissue 
engineered products or in their undifferentiated state as cell therapies with huge 
commercial benefits for industry as discussed in Chapter 1. Allogeneic MSC, as is 
the case with ESC, face the risk of immunological rejection.  
The work carried out in this study therefore sought to investigate the immunological 
properties of allogeneic MSC in light of recent reports in which allogeneic MSC 
have been described as possessing immunosuppressive properties in addition to 
having an immunoprivileged status (Bartholomew et al., 2002; Tse et al., 2003; Ryan 
et al., 2005; Uccelli et al., 2006). These claims, if true, would enable the application 
of allogeneic MSC without the risk of immune rejection. The immunosuppressive 
properties of MSC could be used in the treatment of conditions such as GvHD 
following HSC transplantation (Toubai et al., 2009) or inflammatory conditions such 
as Crohn‘s disease (Newman et al., 2009). The immunoprivileged status would 
enable the safe application of MSC therapies without immunological risks. Other 
studies using different in vitro and in vivo animal models have reported conflicting 
evidence with regard to the immunoprivilege status of allogeneic MSC (Eliopoulos et 
al., 2005; Poncelet et al., 2007).  




One of the problems that potentially contributed to the conflicting reports with regard 
to the immunological status of MSC stems from the lack of a universal definition for 
them. As was discussed previously in Section 1.3, the lack of definitive markers for 
MSC has led to inconsistencies in MSC phenotype. Although the phenotype 
expressed by the MSC in this study was consistent with that obtained from other 
studies (Nadri & Soleimani, 2007a; Sung et al., 2008), there were variations with 
other studies in terms of the expressed markers and the expression levels of specific 
markers within the MSC cultures. It has been argued that all MSC cultures, including 
those obtained from single clones, are intrinsically heterogeneous with varying levels 
of replicative potential (Atala et al., 2009). In both mouse (Kretlow et al., 2008) and 
human (Stolzing et al., 2008) MSC, it has been demonstrated that MSC ―fitness‖ 
declined with donor age and passage. These observations, although focused on tri-
lineage potential (Kretlow et al., 2008), could have further implications in other 
aspects of the cells including their immunological properties. Since different studies 
used MSC obtained from different sources, age and passage, it is conceivable that 
conflicting findings with regard to the immunological properties of these cells are 
possible.  
In this study, although both early passage and late passage Balb/c and C3H MSC 
expressed similar phenotypic markers, there were notable differences in the levels of 
expression for CD105, CD29 and CD90.2 which increased from intermediate to high 
levels from p3 to p12. These phenotypic variations however, were not further 
investigated. It was also observed in the literature that attention was not paid to the 
subtle variations within MSC populations. In light of the potential therapeutic 
application of MSC, it is important that administered cells are well characterised in 
terms of their phenotype and potency in order to determine the effective therapeutic 
doses. 
The heterogeneity of MSC cultures also presents a major challenge with regard to the 
potential application of undifferentiated MSC as cell therapies. As with all 
therapeutic agents, the potency or dosage of the therapy should be determined using 
standard tests in order to ensure that effective dosage is administered to bring about 
the desired effects. With MSC however, it is difficult to determine the relative 
therapeutic contribution of each cell in culture in light of evidence that MSC potency 
decreases with age and passage (Kretlow et al., 2008) as well as the existence of 




different sub-populations of cells within MSC cultures which exhibit different 
properties (Crigler et al., 2006; Phinney, 2007). Some of the reported sub-
populations derived from MSC cultures include MAPC which were described as 
pluripotent (Schwartz et al., 2002; Jiang et al., 2002a) and the so-called unrestricted 
somatic stem cells (USSC) which have also been reported to possess differentiation 
potential beyond the mesodermal lineages (Kögler et al., 2004). Therefore, with 
regard to the immunosuppressive properties of MSC, it can be argued that the 
immunosuppressive properties exhibited by different MSC cultures are always varied 
due to the types and amounts of immunomodulatory molecules secreted by the 
different sub-populations thus making potency assays difficult to develop.  
In some cases, phenotypic differences have not been found to influence the overall 





 MAPC were found to exhibit a similar dose-dependent 
immunosuppressive effect on allogeneic T and dendritic cells both in vitro and in 
vivo (Luyckx et al., 2011). Oct4 is widely used as a marker for ESC and its presence 
is thought to indicate pluripotency as previosuly mentioned (Jiang et al., 2002a). 
However, most human MSC isolates are Oct4
-
 and therefore these findings showed 
that some differences in marker expression may not alter the immunomodulatory 
properties of the cells. It is important to note that although similar 
immunosuppressive potency was observed, the immunogencicity of these cells was 
not tested. 
To date, the exact mechanisms that control MSC immunomodulation are not known 
which makes it difficult for commercial companies providing ―off-the-shelf‖ 
therapies based on undifferentiated MSC to define the therapeutic mechanisms which 
would be important for product description. It is not known also whether the 
therapeutic properties of MSC cultures are a result of the ―typical‖ MSC or the non-
MSC sub-populations or interactions among the different sub-populations. Judging 
from the evidence, it appears the term MSC is an oversimplification of an otherwise 
diverse and heterogeneous group of progenitor cells. It is possible therefore, to 
speculate that commercial companies developing products based on undifferentiated 
MSC (cell-based) are likely to face more challenges compared to companies making 
products based on differentiated MSC (tissue engineering-based).   




The tri-lineage differentiation assay is often viewed as the gold standard test for 
distinguishing MSC from other cells which bear phenotypic and morphological 
resemblance to MSC. This ability had been thought to be a unique feature of stem 
cells and generally cells that fail this test are not regarded as such (Pittenger et al., 
1999). In this study however, DF demonstrated tri-lineage potency similar to bone 
marrow-derived MSC. During the early stages of this study, this development was 
not expected as it was thought that only stem cells had the capacity for tri-lineage 
differentiation. Unlike MSC, the evidence for DF differentiation is controversial. In a 
study that compared MSC and other cells of mesenchymal origin including primary 
articular chondrocytes, DF and synovial fibroblasts, only DF, failed to undergo 
adipogenic and osteogenic differentiation (Jones et al., 2007). Other previous studies 
had demonstrated DF differentiation into either one or two (French et al., 2004; 
Wagner et al., 2005; Lorenz et al., 2008) but not all the three cell lineages. More 
recent studies however, have demonstrated the tri-lineage differentiation capacity of 
human DF (Junker et al., 2010). This development is particularly interesting as it 
suggests that DF and other mesenchymal stromal cells may possess similar utility to 
MSC. 
An interesting point to note during differentiation was that the protocols used in this 
study did not include BMP2 for osteogenic differentiation or TGF3 for 
chondrogenic differentiation. These growth factors have been reported to be essential 
in stimulating differentiation of MSC and have been used in many MSC 
differentiation studies. The fact that differentiation was achieved without these 
factors is particularly interesting. It would have been interesting to determine the 
extent of differentiation with and without these factors in order to ascertain their 
necessity as culture medium supplements. 
The distinction between MSC and fibroblasts has been a long-standing debate since 
the discovery of MSC by Friedenstein almost 50 years ago (Friedenstein et al., 
1974). In fact, it is still unclear whether fibroblasts can be described as terminally 
differentiated or precursor cells (Haniffa et al., 2009). Morphologically and 
phenotypically, MSC and fibroblasts have been reported to be indistinguishable, 
although in this study MSC but not DF were positive for CD90.2, CD105 and CD44. 
Although these markers could arguably be used to distinguish mouse MSC from DF 
in this study, the evidence from other studies suggests that the expression of these 




markers in MSC is inconsistent particularly between MSC populations obtained from 
different sources (Wagner & Ho, 2007). Although DF have been found to express 
CD90.2, CD105 and CD44 in other studies (Haniffa et al., 2007; Blasi et al., 2011), 
it is interesting that phenotypic differences have also been found in DF obtained from 
different body sites (Nolte et al., 2008). Thus, the evidence from the literature clearly 
demonstrates that our current understanding of the differences between MSC and DF 
is limited. Thus, despite the subtle differences in phenotype between MSC and DF 
observed in this study, the morphological and tri-lineage capacity demonstrated by 
both types of cells suggested that these cells may share similar functional 
characteristics which potentially could be exploited in the development of clinical 
therapies. 
6.3. Allogeneic and syngeneic MSC and DF are immunosuppressive 
Both syngeneic and allogeneic MSC and DF demonstrated significant suppression of 
the one-way MLR when introduced at the beginning of culture. Similar findings have 
been reported in a wide range of studies which used human and animal models as 
discussed in Section 5.4. Studies using transwell cultures have demonstrated that the 
mechanism of suppression involves the secretion of molecules such as IDO, PGE2, 
IL-2 and TGF and cell to cell contact (Aggarwal & Pittenger, 2005; Uccelli et al., 
2006) although the exact mechanisms are yet to be elucidated. Supernatants of MSC 
cultured alone have been reported to exhibit similar suppression of MLR (Di Nicola 
et al., 2002; Tse et al., 2003; Liu et al., 2012). This could imply that allogeneic MSC 
supernatants could be used as potential immunosuppressive therapies. The same 
cannot be said of DF since it has been demonstrated that supernatants from DF 
cultures had negligible amounts of immunosuppressive molecules. In fact, cell to cell 
contact has been shown to be critical for fibroblast-mediated immunosuppression 
(Sato et al., 1997). Despite differences in the possible mechanisms by which they 
achieve immunosuppression, this study clearly demonstrated that both allogeneic 
MSC and DF are immunosuppressive. 
The reduced suppressive potency following chondrogenic differentiation however, 
could suggest that the suppressive properties were dependent on the undifferentiated 
state. This raises the question whether the chemical supplements used in 
chondrogenic differentiation medium or that the differentiation process itself 




diminished the ability of the cells to suppress lymphocyte proliferation. The latter 
appears more probable given that the differentiation process changes the cell function 
and phenotype. This notion was supported by Chen and co-workers who showed that 
rat MSC partially lost their in vitro immunosuppressive properties following 
chondrogenic differentiation (Chen et al., 2007). Liu and co-workers, using a rabbit 
skin transplantation model, demonstrated the loss of immunosuppressive potency of 
autologous osteogenic differentiated MSC in vivo (Liu et al., 2006).     
Le Blanc and co-workers however, had argued that MSC differentiated into 
adipocytes, chondrocytes and osteocytes were more potent suppressors of the MLR 
in comparison to undifferentiated MSC (Le Blanc et al., 2003b). However, their 
results were highly variable. In some experiments they found that chondrogenic 
differentiated MSC failed to suppress MLR with lymphocyte proliferation higher 
than in control MLR (114 %) while in some cases up to 40 % suppression of MLR 
was observed. Similar variation was also observed in MLR co-cultured with 
undifferentiated MSC. Although such variation is uncommon, it can be argued that 
there was need for optimising the experimental conditions in order to minimise 
inconsistent results as was done in this study. It can be argued therefore, that their 
conclusion that differentiated MSC are potent immunosuppressors does not fully 
represent their findings. In this study, suppression of MLR by both syngeneic and 
allogeneic differentiated MSC was approximately 50 % whereas with 
undifferentiated MSC it was 90 % which suggested that differentiated MSC lost 
nearly half of their suppressive potency compared to undifferentiated MSC. This 
further emphasises the point that differences in experimental conditions may produce 
conflicting results. The problem of conflicting findings is one of the major challenges 
affecting stem cell biology and its translation into clinical therapies. 
6.4. Allogeneic MSC are not immunoprivileged 
Despite the demonstrated capacity of MSC to suppress MLR, the potential clinical 
utility of allogeneic MSC is dependent on their immunogenicity. This study showed 
that allogeneic MSC were immunogenic. This is in contrast with many reports in the 
literature which suggested that they are immunoprivileged (Klyushnenkova et al., 
2005; Ryan et al., 2005; Le Blanc & Ringden, 2007; Poncelet et al., 2007; Uccelli et 
al., 2008; Sensebé et al., 2010).  




The basis of MSC immunoprivilege is thought to be due to their lack of MHC II and 
co-stimulatory molecules CD80 and CD86 as previously discussed in Section 1.8.1 
and Section 5.4. This study however, argued that despite their phenotype, allogeneic 
MSC would be rejected via the indirect and semi-direct pathways of allorecognition 
which do not require the stimulator cells to express MHC II or co-stimulatory 
molecules as discussed in Section 1.7.2. In order to capture the indirect and semi-
direct response in vitro, longer incubation periods and culture medium changes 
would be required. Therefore, medium changes each 3 day period and longer 
incubations up to 15 days were introduced in this study. To date, this strategy has not 
been used in any study in the literature. Given that most of the in vitro LTA in the 
literature have been carried out within 5 days without medium changes, it is probable 
that such conditions did not capture the indirect and semi-direct responses. It is 
therefore possible to speculate that the discrepancies between in vitro and in vivo 
experiments in which allogeneic MSC have been reported to be immunoprivileged in 
the former but immunogenic in the latter (Nauta et al., 2006; Sudres et al., 2006) 
could have been partly due to the shorter incubation periods and nutrient depletion 
encountered in vitro.  
The importance of experimental conditions was highlighted in this study particularly 
the effect of changing culture medium. As mentioned previously, experiments in 
which medium was not changed did not result in notable stimulation of Balb/c 
lymphocytes by allogeneic C3H MSC. Given that MSC cultured alone have been 
previously reported to constitutively secrete immunosuppressive molecules (Di 
Nicola et al., 2002; Liu et al., 2012), it can be argued that when MSC are co-cultured 
with allogeneic lymphocytes, these immunosuppressive molecules may inhibit 
allogeneic responses. Without medium changes, an accumulation of inhibitory 
molecules would therefore quench lymphocyte proliferation in the presence of 
allogeneic MSC. With medium changes however, the inhibitory molecules would be 
diluted which would result in the capture of the allogeneic response.  
Chondrogenic differentiated C3H allogeneic MSC also stimulated Balb/c 
mononuclear cells. This was supported by several recent studies in the literature (Liu 
et al., 2006; Chen et al., 2007; Huang et al., 2010; Technau et al., 2011). Chen and 
co-workers showed that rat MSC expressed the co-stimulatory molecules CD80 and 
CD86 in addition to elevated levels of MHC I following chondrogenic 




differentiation. They argued that CD80 and CD86 may act as an alternative to MHC 
II and elicit immune rejection (Chen et al., 2007). In their experiments, chondrogenic 
differentiated MSC, but not undifferentiated MSC stimulated human PBMC. They 
also found that CD83 (marker for DC maturation) expression on human DC was 
elevated in the presence of the chondrogenic differentiated rat MSC. After blocking 
CD80 and CD86 on the chondrogenic differentiated rat MSC using monoclonal 
antibodies, CD83 expression on the human DC was significantly reduced. Although 
this was a xenogeneic model, which is different from the allogeneic model used in 
this study, they found that removing the DC from the cultures led to a significant 
reduction in human lymphocyte proliferation. This demonstrated the importance of 
APC in the stimulation of responding lymphocytes. Despite the authors not 
mentioning it, this potentially demonstrated the role of the indirect and semi-direct 
responses in the xenogeneic response. The use of unseparated mononuclear cells in 
this study allowed the presence of APC to facilitate the rejection of allogeneic MSC. 
Although an experiment to demonstrate the role of APC was not carried out during 
this study, Klyushnenkova and co-workers showed that undifferentiated human 





proliferation but stimulated allogeneic PBMCs (Klyushnenkova et al., 2005).  
Allogeneic C3H DF failed to stimulate responder Balb/c mononuclear cells under the 
same conditions in which C3H MSC stimulated Balb/c lymphocyte proliferation. 
This suggested that allogeneic DF are immunoprivileged whilst allogeneic MSC are 
not. Although DF have been widely used as control cells in MSC studies (Jones et 
al., 2007), the evidence with regard to their immunogenicity is equally controversial 
as that for MSC. In previous studies, human DF failed to stimulate a proliferative 
response in allogeneic lymphocyte whereas allogeneic smooth muscle, endothelial 
and epidermal cells stimulated significant response (Theobald et al., 1993). Similar 
findings had been observed using mouse allogeneic DF in earlier studies (Wagner & 
Wyss, 1973). 
 Interestingly, this was contradicted in in vivo studies in which mouse DF transfected 
with viral proteins directly induced CD8 lymphocytes in lymphoid organs in the 
absence of professional APC suggesting that allogeneic DF are capable of initiating 
allogeneic immune responses (Kundig et al., 1995). Also, in mouse skin 
transplantation studies in which allogeneic DF were used as feeder cells for 




supporting autologous grafts it was shown that allogeneic DF initiated inflammatory 
responses that led to delayed breakdown of grafts (Hultman et al., 1996). This 
evidence demonstrated that allogeneic DF are immunogenic. Phenotypic difference 
between MSC and DF were observed in this study as described in Section 3.4 and 
Section 6.1. In addition, MSC cultured alone have been reported to constitutively 
express immunomodulatory molecules (Liu et al., 2012) whereas DF did not (Sato et 
al., 1997). These differences could imply that MSC and DF use distinct mechanisms 
to interact with other cells. Chondrogenic differentiated C3H DF however, like 
chondrogenic differentiated C3H MSC, stimulated Balb/c mononuclear cells.  
In a study using human foreskin derived fibroblasts and MSC, it was shown that the 
immunosuppressive mechanisms employed by these fibroblasts was different from 
those used by MSC. Unlike the MSC, the fibroblasts were incapable of osteogenic 
and adipogenic differentiation and did not secrete IDO and NO when co-cultured 
with PBMC. They however strongly expressed IFN which suggested that this 
molecule may be involved in the fibroblast immunosuppressive mechanisms (Wada 
et al., 2010). This supported earlier findings by Sato and co-workers (Sato et al., 
1997) and provided strong evidence that fibroblasts employ different 
immunomodulatory mechanisms to MSC.  
Importantly, the DF used in this study had a shorter ex vivo culture period in 
comparison to MSC due to their fastidious growth and slow growth of MSC. This 
could potentially have implications to the findings obtained. It is known that 
prolonged culture periods has affects the properties of ex vivo cultured cells. Thus it 
is possible to speculate that the undifferentiated DF used had less time in culture and 
hence failed to stimulate allogeneic lymphocytes whereas MSC did. However, 
following chondrogenic differentiation, which allowed for longer ex vivo culture, DF 
stimulated allogeneic lymphocytes. 
6.5. Future studies 
This study investigated the immunogenicity of allogeneic MSC in light of their 
reported immunoprivilege. Although both undifferentiated and chondrogenic 
differentiated MSC were found to be immunogenic, further investigations are 
necessary in order to fully understand the basis of their immunogenicity. 




With regard to MSC and DF characterisation, it would be important to quantify the 
extent of differentiation. For instance, adipogenesis can be quantified by using a 
simple spectroscopic method to determine the amount of ORO dye taken up by 
differentiated MSC cultures or computer image analysis which use densitometry to 
determine the amount of dye taken up by differentiated MSC (Szczepaniak et al., 
1999; Chen and Farese, 2002; Foster et al., 2005; Gorjup et al., 2009). Monitoring  
of calcein intake can be used to quantify the extent of mineralisation during 
osteogenic differentiation (Uchimura et al., 2003). Quantification of GAGs can be 
used to determine the extent of chondrogenic differentiation (Lü et al., 2012). 
Measurement of differentiation would enable systematic analysis of the 
immunomodulatory properties of MSC during differentiation and can provide 
important insights on the implications of MSC differentiation in clinical applications. 
It would be of interest to investigate the mechanisms that underline the interaction of 
allogeneic MSC and mononuclear cells. In line with the hypothesis of this study, the 




 lymphocytes in the 
presence and absence of APC such as DC would provide further insights with regard 
to the role of the indirect and semi-direct pathways of allorecognition. CD3 specific 




 lymphocytes which could 
then be co-cultured with allogeneic MSC. This would show whether APC are 
required for the allogeneic response. The absence of APC in MLR and LTA only 
measures the direct pathways and therefore can be used to determine whether the 
indirect or semi-direct mechanisms are involved in MSC immunomodulation since 
APC are required for these pathways. Another approach may involve the co-culture 
of MSC and MHC I blocked (using specific antibody) CD4
+
 allogeneic lymphocytes. 
Since MSC lack MHC II, this experiment would show whether the indirect pathway 
is involved in allorecognition as the MSC will be incapable of initiating an immune 
response via the direct pathway. 
Use of the antibiotic cerulenin (Falo et al., 1987), or the endoprotease cathepsin S 
(Riese et al., 1998) which have been reported to inhibit antigen processing and 
presentation by mouse and human APC, would also enable the determination of the 
indirect and semi-direct pathways. Since these pathways rely on antigen processing 
and presentation by responder APC, inhibition of APC activity would exclude the 
indirect and semi-direct pathways and therefore allow for stimulation to occur only 




by the direct pathway. This would allow for the investigation of the immunogenicity 
of MSC and the role of APC.   






 T-regs and MSC remains unknown 
although it is thought that MSC may promote T-regs proliferation and activation. T-
regs can be isolated from mononuclear cell populations using flow cytometry. This 
could allow experiments such as MLR and LTA to be carried out with and without 
T-regs in order to determine their role in MSC immunomodulation.  
Another approach would involve the detection and measurement of secreted 
cytokines and other immunomodulatory molecules during LTA particularly before 
and at the time when lymphocyte proliferation is detected. Although previous studies 
have implicated several cytokines such as TGF, IDO, PGE2 and NO as having an 
immunosuppressive role, none of these molecules has been found to be indispensable 
nor have they been found to play a part in conferring an immunoprivilege status to 
MSC. In addition, MSC have been reported to constitutively secrete these molecules 
in monocultures. By measuring their quantities, it would be interesting to investigate 
whether the allogeneic response is detected with and without medium changes. MSC 
secretion of TGFis particularly interesting since it has been reported to mediate 
estradiol inhibition of antigen presentation in rat APC. Studies using MSC have 
shown that TGFmay also be involved in the inhibition of myeloid DC, CD4+, CD8+ 
and B cells (Uccelli et al., 2008). IL-10 has been shown to inhibit the antigen 
presenting capacity of macrophages (Möttönen et al., 1998). Since MSC are known 
to constitutively secrete IL-10, it would be of interest to investigate whether IL-10 
secretion by MSC plays any role in modulating the allogeneic response. 
For chondrogenic differentiated allogeneic MSC, it would be necessary to investigate 
whether the differentiation process results in the expression of co-stimulatory 
molecules CD80 and CD86 as has been previously reported (Chen et al., 2007). 
Whether the expression of these molecules alone confers immunogenicity or the 
presence of APC in mononuclear cells facilitates allorecognition via the indirect and 
semi-direct pathways warrants further investigation in order to fully understand the 
mechanisms behind the immunogenicity of differentiated MSC.  




With regard to the reduction in immunosuppressive potency of chondrogenic 
differentiated MSC; measurement of cytokine expression at various stages of MLR 
may shed more light on the role of the cytokines in mediating allogeneic suppression. 
Long term in vivo studies to investigate the implications of transplanted allogeneic 
MSC could be carried out using immunocompetent mice. Both differentiated and 
undifferentiated allogeneic MSC could be tested. 
In light of the failure by C3H DF to stimulate Balb/c mononuclear cells, the 
immunogenicity of allogeneic DF requires further investigation. Fibroblasts (Boots et 
al., 1994), but not MSC have been reported to express MHC II and function as APC 
when exposed to IFN. This would provide further insights into the possible 
differences between MSC and DF mediated immunomodulation.  
The distinction between MSC and DF requires further investigation. The phenotypic 
differences observed in this study require further investigation. This could provide 
the markers that can be used to distinguish MSC from fibroblasts. Currently, the 
distinction between MSC and fibroblasts is vague and mostly based on the source 
which the cells are obtained from. In terms of function, phenotype and morphology, 
there are more similarities than differences between the two types of cells (Haniffa et 
al., 2009; Blasi et al., 2011). Given the findings of this study, like MSC, DF could 
potentially be exploited in tissue engineering and regenerative medicine given the 
ease by which they can be obtained.  
6.6. The future of MSC therapies  
The prospect of commercial MSC products reaching the market is growing as the 
understanding of MSC biology improves. However, there is no evidence to date that 
conclusively show that allogeneic MSC are immunoprivileged and safe to use either 
as undifferentiated MSC therapies or differentiated MSC tissue engineered products 
in immunocompetent patients. 
Pluristem Theraupetics Inc, a company based in Israel claimed that its allogeneic 
MSC product PLX-1 aimed at addressing the global shortfall of matched tissue or 
bone marrow transplantation, was immunoprivileged (Prather, 2008). However, the 
testing has not completed the clinical trial phase and to date no evidence of the 




efficacy of these cells is known. It was claimed in May 2012 that intramuscular 
injection of these cells successfully treated a patient with bone marrow aplasia for 
whom previous allogeneic MSC transplantation procedures had failed. Due to the 
absence of functional immune cells in the patient, the use of allogeneic MSC was 
safe but did not prove whether these cells were immunoprivileged. 
Prochymal
®
, an allogeneic MSC based product developed by Osiris Inc for the 
treatment of severe GvHD (Le Blanc et al., 2008; Wolf & Wolf, 2008) and acute 
myocardial infarction showed promising results in phase I and II trials but phase III 
and IV studies failed. Also, phase II trials of the same product for Crohn‘s disease 
were discontinued by the company after patients taking placebo fared better than 
patients treated with the product (Allison, 2009). Despite the failures, Prochymal
®
 
was recently registered in May 2012 in Canada as the first ―off-the-shelf‖ allogeneic 
MSC product for the treatment of severe GvHD in children subject to post clinical 
studies (http://www.stemcelldigest.net, 2012).  
Cephalon Inc, a company based in USA announced its investment of US$1.7 billion 
in Mesoblast Inc, an Australian company, for the development and 
commercialisation rights for its allogeneic MSC product Revascor
®
 which is 
currently under trials for the treatment of congestive heart failure. The product has 
shown promising phase I and II results (http://www.mesoblast.com, 2012). Recently, 
TEVA Ltd acquired Cephalon Inc to give the company a value of US$20 billion. 
This demonstrates the huge commercial investments that are being put into the 
development of ―off-the-shelf‖ MSC products. 
Despite the increased interest in MSC therapies, allogeneic rejection has remained 
the major challenge with regard to the use of allogeneic MSC. No predictive assays 
for MSC treatment have been developed to date. This means that the actual 
performance of MSC therapies cannot be determined. Due to their heterogeneity, the 
clinical application of undifferentiated MSC faces major challenges. For instance, 
Mesoblast Inc define their Revascor
®




 (Kocher et al., 2001) 
whereas Cephalon Inc‘s Prochymal® are defined as cells expressing more than 90 % 
of CD73, CD90 and CD105 while being negative for CD34, CD45, CD14 and CD3 
(Wolf & Wolf, 2008). The lack of standardisation within the stem cell industry will 




continue to hamper progress until MSC are fully defined and the problem of 
heterogeneity addressed. 
6.7. Concluding remarks 
Development of autologous MSC therapies as immunosuppressors for treatment of 
autoimmune diseases is promising. Tissue engineering solutions that utilise 
autologous MSC, though practically and commercially unfavourable, provide the 
safest method for tissue repair and regeneration. Despite the practical advantages of 
allogeneic MSC over autologous MSC and their commercial appeal, their clinical 
application is hampered by their immunogenicity. Due to the huge investments in 
MSC research, the immunogenicity of allogeneic MSC will be resolved in the near 
future. Also, the potential of DF warrants further research into their application in 
tissue engineering and cell based therapies. 
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8. APPENDIX  
8.1. General equipment 
The equipment listed in Table 8.1 was used throughout the study 
Table 8.1. Equipment used with manufacturer/supplier and model 
Equipment Model/size Source 
Analytical balance  AE50 Mettler Toledo, Leicester, UK 
Cell counting chamber improved 
Neubauer 




 Perkin Elmer, Boston, USA. 
Cell sieves  100 m Sigma-Aldrich Company Ltd, Dorset, 
UK 
Centrifuge Harrier 15/80 SANYO Europe BV, Biomedical 
Division, Loughborough, UK 
Centrifuge Microcentaur MSE Ltd, London, UK 
CO2 Incubator  MCO-20AIC SANYO Biomedical Europe BV, 
Amsterdam, Holland 
CO2 Incubator MCO-17A SANYO Biomedical Europe BV, 
Amsterdam, Holland 
Cryo-freezing container Nalgene ―Mr. 
Frosty‖ 5100   






Integra Biosciences, Zurich, 
Switzerland. 
Digital camera Evolution MP Media Cybernetics, Berkshire, UK. 
Digital scale GR-200-EC A&D Scales, Devon, UK 
Flow cytometer BD-
FACSCalibur™ 
Becton Dickinson, San Jose, USA. 
Flow cytometer BD-LSRFortessa™ Becton Dickinson, San Jose, USA. 
Flow cytometer Partec PAS III  Cronus Technologies, Hampshire, UK 
Fridge Electrolux 
ER8817C 
Jencons PLC, Bedfordshire, UK. 
Freezer (-20 ºC)  Electrolux 3000 Jencons PLC, Bedfordshire, UK. 
Freezer (-80 ºC) MDF U74V VIP™ SANYO Europe BV, Biomedical 
Division, Loughborough, UK 
Hot air oven  OMT225.XX2.C Weiss-Gallenkemp, Loughborough, 
UK 
Incubator - Laboratory and Electrical Engineering 
Company, Nottingham, UK 
Inverted microscope Olympus, IX71 Olympus optical Co. Ltd., Southall, 
UK 




Light microscope Olympus CK40-
SLP 
Olympus optical Co. Ltd., Southall, 
UK 
Liquid nitrogen Dewar  BIO65 Jencons PLC, Bedfordshire, UK. 






Perkin Elmer, Boston, USA. 
Orbital microplate 
shaker  
IKA KS130 VWR-Jencons, Leicestershire, UK 
pH Meter  3020 Jenway Ltd, Dumor, UK 
Gilson pipettes  Gilson P2, P20, 
P200, P1000 
Gilson Inc., Middleton, USA 
Pipettes PIPETBOY acu Integra Biosciences AG, Switzerland 
Refrigerated centrifuge Harrier 18/80 SANYO Europe BV, Biomedical 
Division, Loughborough, UK 
Refrigerated centrifuge 5418 Eppendorf, Cambridge, UK 
Water bath Clifton Scientific Laboratory Supplies, 
Nottingham, UK 
 
8.2. General consumables 
Disposable and consumable items used in the study are listed in Table 8.2. 
Table 8.2. Disposable laboratory consumables used with suppliers 
Item Source 
BD FACSFlow Becton Dickinson, Oxford, UK 
Benchkote  protection paper Scientific Laboratory Suppliers, Nottingham, UK 





Scientific Laboratory Suppliers, Nottingham, UK 
Glass coverslips MIC3228 Scientific Laboratory Suppliers, Nottingham, UK 
Liquid nitrogen gas BOC Ltd, West Sussex, UK 
Ministat 0.2 μm syringe filters Sartorius Ltd, Surrey, UK. 
Nitrile powder free gloves STARLAB Ltd., Milton Keynes, UK 
Parafilm M Scientific Laboratory Suppliers, Nottingham, UK 
Pasteur pipettes Alpha Laboratories Ltd, Hampshire, UK. 
Scalpel blades size 22 Thermo Fisher Scientific, Loughborough, UK 
Sheath fluid for flow cytometer Becton Dickinson, Oxford, UK 
Sterile scalpel blades #22 Thermo Fisher Scientific, Loughborough, UK. 
18G x 1‖ hypodermic syringe 
needles 
Terumo Medical Corporation, New Jersey, USA 




Trigene Scientific Laboratory Suppliers, Nottingham, UK 
TopSeal™-A self-adhesive for 
96-well plates 
Perkin Elmer, Berkshire, UK. 
Virkon Bios Europe Ltd, Lancashire, UK 
 
8.3. Plastic ware 
Plastic ware used in the study is listed in Table 8.3. 
Table 8.3. Disposable plastic ware used with sizes and suppliers 











Thermo Fisher Scientific, 
Loughborough, UK. 
96-well glass filter 
bottomed plates for 
TopCount™ 
UniFilter™ GF/B 96 Perkin-Elmer, Berkshire, UK. 




Perkin-Elmer, Berkshire, UK 
96-well plates U-bottom, Nunclon™ 
surface 




U-bottom, Uncoated Sterilin Ltd, Staffordshire, UK. 
96-well plates V-bottom, Nunclon™ 
surface 




V-bottom, Uncoated Sterilin Ltd, Staffordshire, UK. 
Bijous 5 ml  Scientific Laboratory Suppliers, 
Nottingham, UK 





 and 125 cm
2
 
Thermo Fisher Scientific, 
Loughborough, UK. 
Centrifuge tubes Corning™ 15 ml and 20 
ml 
Thermo Fisher Scientific, 
Loughborough, UK. 




Stripette™ 1 ml, 2 ml, 5 
ml, 10 ml, 25 ml 
Sigma-Aldrich, Surrey, UK. 
Disposable plastic 
pippetes (sterile) 
1 ml, 2 ml, 5 ml, 10 ml, 25 
ml 
Corning Costar Ltd., High 
Wycombe, UK. 
Lids for 96-well 
Sterilin plates (-
irradiated) 
- Sterilin Ltd, Staffordshire, UK. 




Microfuge tubes Eppendorf™ 1.5 ml VWR international, West Chester, 
UK. 
Petri-dishes 50 mm (dia) x 12 mm (H) 
100 mm (dia) x 15 mm (H) 




2 l, 10 l, 20 l, 200 l 
and 100 l 
STARLAB Ltd., Milton Keynes, 
UK 
Pipette tips (sterile 
endotoxin free) 
2 l, 10 l, 20 l, 200 l 
and 100 l 
STARLAB Ltd., Milton Keynes, 
UK 
Plastic syringes 2 ml, 5 ml, 10 ml and 20 
ml 
Scientific Laboratory Suppliers, 
Nottingham, UK 
Plastic syringes  2 ml, 5 ml, 10 ml and 20 
ml 
Terumo Medical Corporation, 
New Jersey, USA 
Specimen pots  60 ml, 150 ml and 250 ml Scientific Laboratory Suppliers, 
Nottingham, UK 
Test tubes 10 ml Scientific Laboratory Suppliers, 
Nottingham, UK. 
Universal tubes  25 ml Scientific Laboratory Suppliers, 
Nottingham, UK 
[dia; diameter. H; height. ml; millilitre. l; microlitre. mm; millimetre. cm2; square 
centimetre] 
 
8.4. Reagents and chemicals 
Reagents and chemicals used in the study are listed in Table 8.4; 
Table 8.4. Reagents and chemicals used with suppliers 
Item Source 
Alcian blue stain Sigma-Aldrich, Surrey, UK. 
Alcian blue stain (1 % v/v) in acetic acid Biostain Ready Reagents, Manchester, 
UK. 
Alizarin red S dye Sigma-Aldrich, Surrey, UK. 
Ascorbate -2-phosphate Sigma-Aldrich, Surrey, UK. 
Ammonium hydroxide  Sigma-Aldrich, Surrey, UK. 
ATPLite™ assay kits Perkin-Elmer, Boston, USA. 
-glycerophosphate Sigma-Aldrich, Surrey, UK. 
-mercaptoethanol Sigma-Aldrich, Surrey, UK. 
Camptothecin  Sigma-Aldrich, Surrey, UK. 
 CFSE Sigma-Aldrich, Surrey, UK. 
Collagenase 1A Sigma-Aldrich, Surrey, UK. 
CountBright™ fluorescent counting beads Life Technologies Inc, Paisley, UK. 




for flow cytometry; (excitation, UV– 635 
nm; emission, 385–800 nm) 
Dexamethasone Sigma-Aldrich, Surrey, UK. 
Dimethyl sulphoxide (DMSO) Life Technologies Inc, Paisley, UK. 
Dispase II Sigma-Aldrich, Surrey, UK. 




Lonza, Slough, UK. 




Life Technologies Inc, Paisley, UK. 
Ethanol (100%) Thermo Fisher Scientific, 
Loughborough, UK. 
Foetal calf serum (FCS) Lonza, Slough, UK. 
Hank‘s balanced salt solution (HBSS) Life Technologies Inc, Paisley, UK. 
HEPES buffer Lonza, Slough, UK. 
Hy-Q-Tase™ cell dissociation solution Thermo Fisher Scientific, 
Loughborough, UK. 
IBMX (3-isobutyl-1-methylxanthine) Sigma-Aldrich, Surrey, UK. 
Indomethacin  Sigma-Aldrich, Surrey, UK. 
Insulin (10 mg.ml
-1
) solution Sigma-Aldrich, Surrey, UK. 
Insulin-Transferrin-Selenium-X supplement 
(ITS) 
Life Technologies Inc, Paisley, UK. 
Isopropanol Thermo Fisher Scientific, 
Loughborough, UK. 
L-glutamine Life Technologies Inc, Paisley, UK. 
Lymphoprep™ density gradient medium Axis-Shield, Kimbolton, UK. 
MesenCult™  mesenchymal stem cell basal 
medium  
STEMCELL Technologies, Manchester, 
UK. 
MesenCult™ mesenchymal stem cell 
medium stimulatory supplements 
STEMCELL Technologies, Manchester, 
UK. 
Methanol (100%) Merck, Middlesex, UK. 
Microscint-20™ scintillation fluid Perkin-Elmer, Berkshire, UK. 
Minimum essential medium (-MEM) Lonza, Slough, UK. 
Mitomycin C Sigma-Aldrich, Surrey, UK. 
Mouse serum Autogen Bioclear 
Neutral buffered formalin (10 % v/v) Sigma-Aldrich, Surrey, UK 
Oil red O dye Sigma-Aldrich, Surrey, UK. 
Penicillin-Streptomycin mixture Lonza, Slough, UK. 
Phosphate buffered saline (PBS) solution Lonza, Slough, UK. 
Phytohaemagglutinin (PHA) Sigma-Aldrich, Surrey, UK. 




Purelab Option distilled water ELGA LabWater, High Wycombe, UK. 
RPMI-1640 medium without L-glutamine Lonza, Slough, UK. 
StemXVivo™ human and mouse MSC 
medium 
R&D Systems, Oxford, UK 
Sodium chloride  Merck, Middlesex, UK. 
Sodium pyruvate  Helena Biosciences, Gateshead, UK 
Trichloroacetic acid (TCA) Thermo Fisher Scientific, 
Loughborough, UK. 




H) thymidine (Low activity) 
NET027001MC 
Perkin-Elmer, Berkshire, UK. 
Trypan blue (0.4%) dye solution Sigma-Aldrich, Surrey, UK. 
Trypsin 0.5% with EDTA (10x) Life Technologies Inc, Paisley, UK. 
Via-Probe™ 7-amino actinomycin-D (7-
AAD) cell viability probe  
BD Bioscience, Oxford, UK 
[EDTA; Ethylenediaminetetraacetic acid. HEPES; N-(2-hydroxyethyl) piperazine 
N;-(2-ethansulphonic acid. RPMI-1640; Rosslyn Park Memorial Institute. DMEM; 
Dulbecco‘s modified Eagles medium. CFSE; Carboxyfluorescein succinimidyl ester] 
 
